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ABSTRACT
Inflammation is a normally beneficial, complex interplay of events that occur in
response to tissue injury or infection. Granulocytes are rapidly recruited to the
inflammatory site, however, the activity of these cells must be carefully regulated as
uncontrolled release of cytotoxic cell contents into the surrounding milieu may result
in excessive tissue damage. In order to avoid this undesirable and inappropriate
response, granulocytes undergo a regulated process of programmed cell death or
apoptosis, allowing shutdown of secretory capacity and phagocytic removal of intact
effete cells by a mechanism that does not incite an inflammatory response.
Although the apoptotic programme in granulocytes is an intrinsic cell process, the
rate of apoptosis can be altered dramatically by a number of agents. We have shown
that elevation of the second messenger cyclic AMP and glucocorticoids, profoundly
delay constitutive neutrophil apoptosis. Further investigations demonstrated that
cyclic AMP inhibits loss of mitochondrial membrane potential occurring during
constitutive neutrophil apoptosis. Moreover, cyclic AMP was found to delay caspase
activation in these inflammatory cells. Investigations were undertaken to examine the
cyclic AMP signal transduction pathway responsible for delay of neutrophil
apoptosis. Despite increasing protein kinase A (PKA) activity, this kinase is unlikely
to mediate the effects of cyclic AMP in apoptosis since blockade of PKA activation
did not influence the survival effects of cyclic AMP. Furthermore, cyclic AMP
mediated delay of neutrophil apoptosis is independent of PI-3 kinase and MAP
kinase activation. Our results suggest cyclic AMP delays neutrophil apoptosis via a
novel, reversible and transcriptionally-independent mechanism. We show that
proteasome activity in the neutrophil is vitally involved in this process and suggest
that a balance of pro-apoptotic and anti-apoptotic proteins plays a key role in the
powerful ability of cyclic AMP to delay neutrophil death.
Additional studies were aimed at elucidating the underlying mechanisms of
glucocorticoid regulation of granulocyte apoptosis. Glucocorticoids were found to
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exert diametrically opposed effects on eosinophils and neutrophils, causing induction
of apoptosis in eosinophils while delaying neutrophil cell death. Granulocytes were
found to express the glucocorticoid receptor (GR), however the nature of isoforms
expressed remains undefined. Examination of the glucocorticoid signal transduction
cascade suggested the requirement for hsp90 in glucocorticoid regulation of
granulocyte apoptosis. Further studies were undertaken to establish the involvement
of transcriptional transactivation or repression in glucocorticoid signalling pathway
regulating granulocyte cell death.
In summary, there is good evidence implicating glucocorticoids and cyclic AMP in
the regulation of granulocyte apoptosis. A greater understanding of the signalling
mechanisms by which these mediators regulate granulocyte death could potentially
lead to the development of novel strategies to therapeutically induce apoptosis for the
resolution of inflammation.
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1 INTRODUCTION
1.1 INTRODUCTION LAYOUT
The introduction summarises the knowledge to date on the generation, structure and
function of granulocytes and describes the surface phenotype and mediator release
involved in the phagocytic capacity of these cells, following migration into tissues.
The following section describes the role of neutrophils and eosinophils in disease
highlighting the differences in the structure and phenotype of granulocytes, which
may lead to the differential involvement of these cells in many cellular processes.
The process of apoptosis is then described and the mechanisms involved in
molecular and genetic control of apoptosis are discussed.
Finally the introduction ends with a summary of the current knowledge of the
mechanisms involved in granulocyte apoptosis and the potential implications of
manipulation of granulocyte apoptosis for therapeutic treatment of inflammatory
disease.
1
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1.2 THE ROLE OF NEUTROPHILS IN INFLAMMATION
1.2.1 GENERATION OF NEUTROPHILS
Neutrophils are the most abundant leukocytes in the blood and are derived from
pluripotent stem cells located in the bone marrow. During their development
pluripotent stem cells undergo proliferation and differentiation under the influence of
three major haematopoietic cytokines G-CSF, GM-CSF and IL-3 (Metcalf and
Nicola, 1983; Metcalf et al., 1986; Bot et al., 1988) allowing them to differentiate
and mature into fully functional neutrophils. There appear to be several recognisable
morphological stages including myeloblast, primary myeloblast, myelocyte, and
metamyelocyte stages with subsequent formation of non-segmented (band)
neutrophils before fully functional segmented neutrophils are formed (Zajicek et al.,
1984). During the developmental process neutrophils acquire their characteristic
primary (azurophil), secondary (specific), and tertiary granules. The mature
neutrophil is distinguished also by a lobulated chromatin dense nucleus.
Neutrophils are released from the bone marrow into the circulation in the healthy
adult, at a rate of 10u neutrophils per day (Cannistra and Griffin, 1988). During
acute inflammation, release of neutrophils from the bone marrow is thought to
i j
increase to more than 10 per day (Cannistra and Griffin, 1988). Neutrophils are
short lived cells and in the circulation have an estimated half life of only 4 - 6 h.
Neutrophils may also exist in marginated pools in the liver, spleen and lung, where
they can live for 1 to 2 days (Bicknell et al., 1994; Peters, 1998). A dynamic
equilibrium exists between the circulating pools and marginated pools, allowing
exchange with each other (Berkow and Dodson, 1987).
1.2.2 NEUTROPHIL MORPHOLOGY
Neutrophils have a mean diameter of ~7 pm and are characterised by a multilobed
chromatin-dense nucleus and a large number of intracellular granules. Initially
neutrophil granules were simply divided into two categories namely peroxidase
2
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positive (azurophil or primary) and peroxidase negative (specific or secondary).
However it appears that there are in addition two further granule subgroups namely
tertiary/gelatinase granules and secretory vesicles (Borregaard et al., 1993). Each
category of granule can be distinguished by differences in morphology and
biochemical constituents (For a recent review see Borregaard and Cowland, 1997).
The importance of neutrophil granules is demonstrated in Chediak-Higashi syndrome
in which an apparent inability to mount a proper inflammatory response leads to a
congenital abnormality in neutrophil granule formation (Davis and Douglas, 1972).
The azurophil or primary granules vary in size and have an oval or round
morphology (Bainton, 1975). They contain a wide variety of agents believed to be
involved in bacterial killing and are primarily released into the phagolysosomal
compartment during phagocytosis. Regulated secretion of granule contents is
required to avoid detrimental pathology to host tissue. Among the many
antimicrobial constituents of azurophil granules, one of the most important for
effective bactericidal killing is myeloperoxidase (MPO) (For a recent review see
Klebanoff, 1999). The enzymatic activity of MPO is responsible for the conversion
of hydrogen peroxide to hypochlorous acid, providing the neutrophil with a highly
effective microbicidal capacity. Azurophil granules also contain antimicrobial
peptides called defensins, which form a large proportion of the proteins contained in
azurophil granules (Chertov et al., 2000). These small antimicrobicidal peptides are
highly toxic to a wide variety of bacteria, fungi and some viruses. Other important
constituents include serine proteases such as elastase and cathepsin G which are
involved in hydrolytic degradation of many substrates including bacterial cell walls
(Chertov et al., 2000).
The second category of granules are specific granules which are round, oval or
elongated in shape and are slightly larger than gelatinase granules. In contrast to
azurophil granules, it is thought that specific granules release their contents
extracellularly. They characteristically contain the iron sequestering protein
lactoferrin, important for preventing the growth of ingested bacteria by depriving
them of this vital growth nutrient (Spitznagel et al., 1974). Specific granules are also
3
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a source of cytoplasmic receptors for the small complement fragment iC3b (Berger et
al., 1984), laminin (Yoon et al., 1987) and fMLP (Sengelov et al., 1994). It is not
clear if these receptors are fully functional when translocated to the plasma
membrane. A further important constituent of specific granules is cytochrome b558,
a component of the NADPH oxidase, responsible for the generation of superoxide
anion (Borregaard, 1985).
Gelatinase (or tertiary) granules are smaller than specific granules and are principally
composed of the protease gelatinase, which may be involved in digestion of the
vascular basement membrane, allowing the extravasation of neutrophils (Murphy et
al., 1980; Dewald et al., 1982). Similarly to specific granules, gelatinase granules
contain cytochrome b558 and several acid hydrolases but do not contain lactoferrin.
The fourth category of granules namely secretory vesicles contain alkaline
phosphatase and are characterised by their ability to be rapidly mobilised to the
plasma membrane of neutrophils (Borregaard et al., 1990). The possible importance
of this ability to translocate is suggested by the presence of several receptors, which
may be important for neutrophil adhesion and chemotaxis such as CD lib/CD 18
(Mac-1) (Calafat et al., 1993), and the fMLP receptor (Sengelov et al., 1994).
Furthermore, secretory granules may also contain CD 16 (Fey receptor III) (Tosi and
Zakem, 1992), CD 14 (Detmers et al., 1995) and cytochrome b558 (Calafat et al.,
1993).
1.2.3 NEUTROPHIL RECRUITMENT AT SITES OF INFLAMMATION
The neutrophil is key in first line defence against invading micro-organisms and is
the first type of leukocyte summoned from the blood to sites of infection or injury.
The rapid mobilisation of neutrophils relies on the ability of these cells to respond to
chemotactic agents and adhere to endothelial cells. Initial interactions between
neutrophils and the endothelium involves selectins, which allow the neutrophil to roll
along the endothelium via transient contacts (Picker et al., 1991; Lawrence and
Springer, 1991; Lawrence and Springer, 1993). Involvement of each of the main
4
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selectins (L-, P-, and E-selectin) has now been described (For a recent review see
Gonzalez-Amaro and Sanchez-Madrid, 1999). Following activation by
chemoattractant agents such as IL-8 or PAF, the neutrophil upregulates adhesion
receptors such as CDllb/CD18. Consequently, firm adhesion to the endothelium is
secured via binding through CD11/CD18 with endothelial cell ligands such as
intercellular adhesion molecule-1 (ICAM-1) (Carlos and Harlan, 1994; Springer,
1994; Ley, 1992; Smith et al., 1989). Transmigration of neutrophils across the
endothelial barrier involves an interaction between leukocyte integrins and
endothelial ICAM, and between glycosylated aminoglycans on the neutrophil plasma
membrane and CD31, localised in the intercellular junctions of endothelial cells
(Muller et al., 1993). Diapedesis of neutrophils through the endothelium is then
followed by migration to the site of infection along a chemotactic gradient (Figure
1.1). The invading microorganism may produce chemoattractants such as fMLP,
involved in recruiting neutrophils to the site of infection. Other chemotactic agents
such as IL-8 may be released from the phagocytes themselves following initial
interactions with infectious agents (Hachicha et al., 1998). This allows an
amplification of the preliminary inflammatory response, initiating a second wave of
neutrophil recruitment.
1.2.4 REGULATION OF NEUTROPHIL FUNCTION
It is well recognised that there are complex regulatory mechanisms in place to allow
neutrophils to respond rapidly to infection when required. The magnitude of
neutrophil responsiveness to infection or tissue injury may be influenced by several
agents which may allow dormant neutrophils to acquire a state of preactivation,
allowing enhanced responsiveness to microbial infection. This regulatory mechanism
ofpriming is vitally important for generating a more rapid and powerful neutrophil
response, following the initial microbial insult (For a recent review see Condliffe et
al., 1998). Priming agents include cytokines such as GM-CSF, G-CSF and TNFa
and bacterial products such as LPS (Guthrie et al., 1984). As a consequence,
neutrophil functions such as agonist (e.g fMLP, C5a) induced degranulation
(Fittschen et al., 1988), the respiratory burst (Guthrie et al., 1984) and production
5
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Figure 1.1 Schematic representation of the mechanisms involved in neutrophil
recruitment. Initial interactions involve reversible binding to the endothelium through
selectins on the endothelium and their carbohydrate ligands on the PMNs, which allows
rolling of the leukocyte along the endothelial cell surface. Stronger binding is mediated
through CD1 la:CD18, CDllb:CD18 and ICAM-1. Tight binding arrests the rolling and
allows the neutrophil to transmigrate across the endothelium and enter the site of
infection. Finally the neutrophil migrates along a concentration gradient of chemokines
secreted by the cells at the site of infection.
6
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of lipid mediators (Doerfler et al., 1989; Doerfler et al., 1994) is greatly enhanced. It
has become increasingly apparent that regulation of neutrophil function is also
determined by the ability of neutrophils to produce a variety of mediators, which can
influence neutrophil activity in an autocrine manner. This is in contrast to previously
held beliefs that neutrophils already possess all mediators necessary to participate in
the inflammatory response and have little synthetic capacity. However neutrophils
are now known to be capable of producing a large variety of inflammatory mediators
such as bioactive lipids and cytokines which can participate and influence the
inflammatory response.
Through metabolism of arachadonic acid, neutrophils produce leukotrienes and
prostaglandins such as LTB4 (McColl et al., 1991) and PGE2 (Tolone et al., 1977).
Furthermore they can secrete a wide variety of cytokines such as IL-8 (Cassatella et
al., 1992; Bazzoni et al., 1991), IL-6 (Cicco et al., 1990), TNFa (Dubravec et al.,
1990; Djeu et al., 1990) and IL-1 (Tiku et al., 1986; Lindemann et al., 1988, for a
recent review see Scapini et al., 2000). Thus the role of the neutrophil is not only
determined by their ability to respond to agents in the extracellular milieu, but also
by their capacity to direct and influence the inflammatory response.
1.2.5 NEUTROPHIL FUNCTIONS AND ROLE IN DISEASE
Once a neutrophil has migrated into the tissue, its primary purpose is to recognise
and destroy pathogens. Phagocytosis is a process utilised by neutrophils to ingest
and clear large particles (> 0.5 (iM), including infectious agents and cellular debris.
Neutrophils may phagocytose microbes through direct binding of lectins (Ofek et al.,
1995). However, in many instances effective phagocytosis and clearance of
infectious agents additionally requires the availability of opsonins, to facilitate the
adherence of the bacteria and other microbes to opsonin receptors on the surface of
the neutrophil. Opsonisation prior to phagocytosis may be mediated for example
through Fc receptor binding to Fc portion of antibodies deposited on the bacterial or
7
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viral cell surface or via complement receptors binding to C3b (Scribner and Fahrney,
1976) (Figure 1.2).
Following recognition and pathogen binding, a phagosome forms containing
engulfed micro-organisms. This then fuses with the intracellular granules, allowing
the neutrophil to release a variety of antimicrobial agents into a contained
microenvironment. It appears that both specific and azurophil granule products are
released into the phagosome, while some specific granule products, together with
products from secretory vesicles, are released extracellularly. During phagocytosis a
substantial increase in oxygen consumption is observed, called the respiratory burst
(For a recent review see Wientjes and Segal, 1995). Activation of respiratory burst
activity occurs upon translocation and assembly of the cytosolic components of the
NADPH oxidase enzyme system (\)A5ph"x, p67phox, p21rac) with membrane-bound
flavocytochrome, cytochrome bssg. This process, through the reduction of oxygen by
NADPH oxidase, allows the generation of toxic reactive oxygen intermediates (ROI)
such as superoxide anions and hydrogen peroxide. Further reduction leads to the
production ofmore toxic oxygen radicals such hydroxyl radical (OH*) from H2O2, in
a reaction catalysed by Fe2+ or the production of hypochlorous acid, through the
action of MPO. These substances have highly powerful antimicrobial activities; the
importance of which is illustrated in chronic granulomatous disease (CGD). In CGD,
absence of a proper respiratory burst due to an abnormality in the NADPH oxidase
system, manifests in children as an inability to fight bacterial infection (Hohn and
Lehrer, 1975; Klebanoff, 1975).
The neutrophil plays an essential role in host defence however there is accumulating
evidence that dysregulation of neutrophil function can result in injury to healthy
tissue and is associated with the pathogenesis of a large number of inflammatory
conditions. In many diseases such as rheumatoid arthritis, vasculitis, and
glomerulonephritis, the neutrophil is thought to contribute to disease progression
(Weissmann and Korchak, 1984; Weissmann, 1989; Heinzelmann et al., 1999). In
8
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Figure 1.2. Fc and complement receptor mediated neutrophil phagocytosis.
9
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
acute respiratory distress syndrome (ARDS), neutrophils may cause injury through
enhanced production of reactive oxygen species (McGuire et al., 1982). Influx of
neutrophils and subsequent activation is also thought to be involved in ischemia-
reperfusion injury (Jordan et al., 1999).
1.3 ROLE OF EOSINOPHILS IN INFLAMMATION
1.3.1 GENERATION OF EOSINOPHILS
The eosinophil, like the neutrophil, is a terminally differentiated cell derived by
differentiation from pluripotent stem cells in the bone marrow. In contrast to
neutrophils, the development of eosinophils is specifically promoted by GM-CSF,
IL-3 and IL-5 (Bot et al., 1988; Metcalf et al., 1986; Campbell et al., 1987), allowing
the pluripotent stem cells to differentiate and mature into fully functional eosinophils
over a period of 2-6 days. The eosinophil resides predominantly in the tissues and is
mainly found in the epithelium of the respiratory and gastrointestinal tract. The
eosinophil appears to be long-lived compared to the neutrophil. In the presence of
growth factors such as IL-5, GM-CSF and IL-3, the eosinophil can survive in vitro
culture for more than 7 days (Tai et al., 1991). The half life of the eosinophil in the
circulation is 18 h. However, as large numbers can be found in tissues even when the
blood count is low, it is presumed they are able to reside in the tissues for several
days (Weller, 1991).
1.3.2 EOSINOPHIL MORPHOLOGY
Eosinophils have a mean diameter of 8 pm, a bilobed chromatin-dense nucleus and a
large number of distinctive intracellular granules (Sokol et al., 1987). The
characteristic identifying feature of eosinophils is the presence of large specific
ellipsoid granules containing crystalline cores. These contain a wide variety of agents
that are believed to be involved in host defence such as major basic protein (MBP),
eosinophil cationic protein (ECP), eosinophil derived neurotoxin (EDN) and
eosinophil peroxidase (EPO) (Gleich et al., 1976; Egesten et al., 1986; Peters et al.,
10
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1986). MBP is contained in the crystalline core whereas ECP, EDN and EPO are
found in the surrounding matrix. These distinct cationic proteins contribute to
varying degrees in defence against helminth parasites but have the potential to be
involved in host tissue damage. Large specific granules also contain hydrolytic
lysosomal enzymes and histaminase. In addition, the eosinophil possesses other so-
called small granules which in contrast lack a crystalline core and contain aryl
sulphatase and acid phosphatase. Although both eosinophil and neutrophil granules
contain potent antimicrobial agents and toxins, granule contents may be discharged
in very different ways by each cell. Whereas the neutrophil releases granule contents
primarily into contained phagolysosome, eosinophil granules may be released onto
extracellular parasites.
1.3.3 EOSINOPHIL RECRUITMENT AT SITES OF INFLAMMATION
Similarly to neutrophils, eosinophils will respond to chemotactic stimuli following
tissue injury and will marginate and diapedese into the tissues, travelling towards the
inflammatory focus along a chemotactic gradient (Resnick and Weller, 1993).
Although the process of neutrophil and eosinophil recruitment are broadly similar at
a molecular level, selectivity in recruitment of granulocytes is achieved through
several regulatory mechanisms. For example differential expression of adhesion
molecules may determine the type of granulocyte selectively recruited to the site of
injury. In this regard, expression of (3j integrin VLA-4 and P7 integrin OC4P7 by
eosinophils but not neutrophils may allow the specific accumulation of eosinophils at
an inflammatory site (Weller et al., 1991). The chemotactic agents present during the
inflammatory response may determine further selectivity in recruitment. For example
the presence of IL-8 may favour selective neutrophil accumulation whereas the
presence of eotaxin, MCP-3 and RANTES may result in preferential recruitment of
eosinophils (Leonard et al., 1990; Griffiths-Johnson et al., 1993; Ponath et al., 1996;
Dahinden et al., 1994; Kameyoshi et al., 1992; Rot et al., 1992).
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1.3.4 REGULATION OF EOSINOPHIL FUNCTION
Eosinophil function is also regulated by the ability of eosinophils to respond to local
mediators during the inflammatory response and also by the capacity of eosinophils
to synthesise and secrete mediators, which may in turn, govern and refine the
subsequent immune response.
Eosinophils are capable of producing a number of cytokines that may be involved in
various aspects of the inflammatory response such as IL-la (Weller et al., 1993), IL-
4 (Moqbel et al., 1995; Nonaka et al., 1995), IL-6 (Elamid et al., 1992; Melani et al.,
1993), IL-8 (Braun et al., 1993; Kita et al., 1995), TNFa (Costa et al.,
1993), RANTES (Lim et al., 1995) and TGF(3 (Wong et al., 1991; Ohno et al.,
1992). Furthermore they also produce GM-CSF (Weller, 1992), IL-3 (Kita et al.,
1991a; Fujisawa et al., 1994) and IL-5 (Broide et al., 1992; Dubucquoi et al., 1994)
which may serve as autocrine growth factors. In addition, eosinophils secrete lipid
mediators such as PAF (Lee et al., 1984) and LTC4 (Verhagen et al., 1984) which
alter permeability of the microvasculature and also cause bronchoconstriction and
enhance the secretion ofmucus (Henderson, Jr., 1991).
1.3.5 EOSINOPHIL FUNCTIONS AND ROLE IN DISEASE
The eosinophil is thought to play an important and specialised role in the adaptive
immune response most notably against helminthic parasite worms (Butterworth et
al., 1975; Gleich and Adolphson, 1986). These large multicellular organisms cannot
be phagocytosed and eosinophils instead defend against such parasites through
release of helminthotoxins such as MBP and ECP, by extracellular release of
eosinophil granule contents.
Although the eosinophil may potentially have an important role in host defence
against helminthic parasites, there is a wide consensus that the eosinophil and its
derived products may be important contributors in the pathogenesis ofmany allergic
and asthmatic diseases. Extracellular release of granule products in an uncontrolled
12
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
manner may have detrimental consequences to host tissue. Many eosinophil products
such as MBP are known to be toxic to mammalian cells and may produce
pathological changes through alteration of lipid membranes (Kroegel et al., 1987).
Airway inflammation is a distinctive feature of asthma and is characterised by a large
inflammatory cell infiltrate with a notable abundance of eosinophils (Bousquet et al.,
1990; Djukanovic et al., 1990). There is significant evidence that eosinophils and
their derived mediators play a central role in the pathogenesis of this disease
(Bousquet et al., 1990; Martin et al., 1996; Smith, 1992; Kay, 1991a; Wardlaw et al.,
1995). There appears to be a positive correlation between the severity of airway
hyperreactivity and numbers of eosinophils found in the BAL fluid and peripheral
blood of patients with asthma (Bousquet et al., 1990; Bradley et al., 1991). Persistent
accumulation of eosinophils and the release of cytokines such as IL-4 and IL-5 from
Th2 lymphocytes, may be in part be responsible for tissue accumulation of
eosinophils in this disease (Kay, 1991b). It has been shown that IL-5 administration
to the airways of asthmatic subjects is associated with peripheral blood eosinophilia,
airway eosinophilia, and brochial hyperresponsiveness (Shi et al., 1998; Shi et al.,
1999). It is believed that activation of eosinophils in the bronchial mucosa with
subsequent release of cytokines and eosinophil granule proteins may not only be
cytotoxic to the bronchial epithelium but may also increase bronchial responsiveness
and amplify the asthmatic hyperreactivity.
The role of the eosinophil in the pathogenesis of asthma has however recently come
into question in light of clinical reports that suggest reduction of eosinophil numbers
has limited effects on airway hyperreponsiveness and the late asthmatic reaction.
Leckie and colleagues report that monoclonal anti-IL-5 blocking antibodies, which
substantially decrease allergen induced blood and sputum eosinophilia, fail to
influence the late asthmatic reponse or alleviate airway hyperresponsiveness to
histamine (Leckie et al., 2000). From this particular report, it may be difficult to
refute the idea of an important role for eosinophils, due to the very small sample size
of this study. However, a recent study by van Rensen et al. suggests aerosol
administration of IL-5 to mild asthmatics does not induce eosinophilic inflammation
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or bronchial hyperresponsiveness, although there may be potential systemic effects
of IL-5 on the bone marrow (van Rensen et al., 2001). In a further study, the
cytokine IL-12 was tested for its ability to suppress allergic and eosinophilic
inflammation (Bryan et al., 2000). IL-12 is key in regulating the balance between
Thl and Th2 cells. It is believed that allergic inflammation involves Th2 responses,
which may favour eosinophil accumulation and enhance IgE synthesis. Animal
studies have suggested treatment with IL-12 reduces airway hyperresponsiveness
following antigen challenge (Kips et al., 1996; Schwarze et al., 1998). However,
human studies by Bryan et al demonstrate that while IL-12 administration causes
significant reduction of blood and sputum eosinophils, the late asthmatic response
and airway hyperresponsiveness are unaffected (Bryan et al., 2000). It is conceivable
that approaches to suppress eosinophilic mediated inflammation by blocking a single
mediator of eosinophil accumulation, may be ineffective, as only a small number of
residual eosinophils capable of eliciting cytotoxic mediators, could potentially still
orchestrate a detrimental inflammatory response. Furthermore, numbers of tissue
dwelling eosinophils, which may be fundamentally involved in the asthmatic
response, may not be effectively lowered in these studies. It will be interesting to
observe if future studies demonstrate changes in the numbers of eosinophils in
tissues of the airways following treatment with blocking antibodies to IL-5.
Furthermore as many other mediators, in addition to IL-5, are involved in
accumulation of eosinophils, a combinatorial approach to blocking eosinophil
inflammation may be required for effective reduction in eosinophil accumulation and
responsiveness. Verification or confirmation of the central role of the eosinophil in
allergic inflammation, will therefore await future studies.
The eosinophil may also be involved in the pathogenesis of many other diseases
including the development of fibrosis. In Hodgkin's disease, as in certain other
malignancies, there appears to be elevated numbers of eosinophils in the circulation
and tissues, which may contribute to the development of fibrosis through production
of TGF-p (Kadin et al., 1993).
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It appears that in many chronic inflammatory diseases and distinctive cancers
outlined above, the normal control mechanisms regulating eosinophil function are
perturbed leading to detrimental sequelae for the host. The reasons for eosinophil
dysregulation in these conditions are not fully understood however insight can be
gained by examining divergence from the normal regulatory control mechanisms,
which under normal physiological conditions, limit the potentially deleterious
capacity of these inflammatory cells to damage host tissue. Increased production of
anti-inflammatory mediators, a reduction in the effective concentrations of pro¬
inflammatory mediators and cellular and tissue desensitisation may all be involved.
Perhaps most importantly, controlled death or apoptosis of cells, concomitant with
their safe and effective removal may be essential for successful resolution of
inflammation.
1.4 APOPTOSIS
1.4.1 MORPHOLOGY OF APOPTOSIS
Cell death is known to occur by two distinct mechanisms namely necrosis or
apoptosis (programmed cell death). For many years it was assumed that all cells died
by a process of necrosis, in which disintegration of the cell membrane ultimately
leads to the uncontrolled release of cell contents (Trump et al., 1981a; 1981b). A
distinctive feature of necrosis is dysregulation of osmotic pressure as a consequence
of plasma membrane damage by environmental insults such as physical or chemical
trauma. This induces the swelling and rupturing of the plasma membrane, leading to
dysregulated release of intracellular contents. As a consequence of increased cell
membrane permeability, necrosis can often be measured by the ability of cells to take
up dyes such as trypan blue. One could envisage that disintegration of a cell by
necrosis, with particular regard to the granulocyte, could provoke undesirable
inflammation that may prove deleterious to the host.
Apoptosis, in contrast to necrosis, represents a "physiological" form of cell death in
which the cell dies in a highly regulated manner that importantly does not incite an
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inflammatory response. There is wide consensus that apoptosis is involved in many
physiological and homeostatic processes such as regulating cell numbers during
embryonic development (Granerus et al., 1995). Apoptosis may also allow the
controlled removal of cells that could represent a threat to the integrity of the host i.e.
those with DNA damage (Williams, 1991) or those infected with viruses (Vaux et
al., 1994).
Apoptosis was initially described with respect to a succession of morphological
changes that contrasted to molecular events observed in necrosis (Wyllie et al.,
1980). Although apoptosis may be differentially regulated in different cell types,
there are many common morphological and biochemical changes during apoptosis.
Major cell surface changes such as plasma membrane ruffling, together with loss of
microvilli is often evident. Furthermore, there may be exposure of
phosphatidylserine on the outer leaflet of the plasmalemma, often used as an
indicator of apoptotic onset. Commonly, apoptotic cells display cell shrinkage due to
cytoplasmic condensation through fluid loss. The most striking changes, however,
are observed in the nucleus. Condensation of chromatin forms crescent shaped
aggregates around the nuclear envelope, which may coalesce into one or two dense
'pyknotic' spheres when the nucleus is multilobular. This is accompanied by
activation of endogenous endonucleases resulting in internucleosomal cleavage of
chromatin and the characteristic 'ladder' pattern of fragmented DNA subunits
(Wyllie, 1980). Throughout this process the plasma membrane integrity is preserved
and cells maintain their osmotic gradients. Cells may remain as intact apoptotic cells
or may eventually form small membrane-bound apoptotic bodies that enclose the
intracellular contents of the cells (Arends and Wyllie, 1991; Cohen, 1993). In either
case, the apoptotic cells or bodies are rapidly phagocytosed and degraded by
macrophages preventing the release of cellular contents into the extracellular milieu
and limiting the inflammatory response.
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1.4.2 CASPASES
A common feature in the series of events underlying apoptosis regulation is the
activation of a group of cysteine proteases termed the caspases (cytosolic aspartate-
specific cysteine proteases). These death proteases, which are highly conserved
through evolution, are thought to be responsible for most of the morphological
changes observed in apoptosis and are thus viewed as the central executioners of cell
death (Budihardjo et al., 1999; Cikala et al., 1999; Thornberry, 1997; Cohen, 1997;
Cohen, 1997; Martin and Green, 1995; Kothakota et al., 1997; Rao et al., 1996;
Enari et al., 1998).
Understanding the mechanisms of apoptosis and the involvement of caspase
activation has benefited from insight gained from genetic studies in nematode
Caenorhabditis elegans (C.elegans) (Ellis and Horvitz, 1991; Hengartner and
Horvitz, 1994). The C.elegans gene, ced-3 is required for apoptosis in the nematode
and was found to have similarity to the interleukin-1 [3 (IL-1 [3)-converting enzyme
(ICE)-like protease (Miura et al., 1993; Thornberry et al., 1992; Yuan et al., 1993).
Since this discovery, enormous progress has been made in the identification and
elucidation of the role of caspases in progression of cell death.
Caspases are synthesised as inactive pro-enzymes, which are activated by cleavage
after aspartic acid residues, a process that initiates the subsequent cleavage of the
next caspase in the pathway, thus stimulating a cascade of caspase activation (Harvey
and Kumar, 1998; Thornberry, 1997). It is this caspase cascade which is thought to
be responsible for the cleavage of cellular proteins which bring about the visible
changes characteristic of apoptotic cell death (Martin and Green, 1995). The mature
caspase zymogens are composed of an N-terminal prodomain and the p20 and plO
domains (Cohen, 1997). Although many caspase substrates have been identified, it is
widely believed that caspases recognise and cleave a limited set of target proteins
(Nicholson, 1999). Substrates include enzymes involved in DNA repair such as
DNA-dependent protein kinase (DNA-PK) (Casciola-Rosen et al., 1995) and
poly(ADP-ribose) polymerase (PARP) (Lazebnik et al., 1994), structural proteins of
17
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
the nuclear envelope such as lamins A and B (Lazebnik et al., 1995; Neamati et al.,
1995; Orth et al., 1996; Rao et al., 1996) and cytoskeletal proteins such as gelsolin
and fodrin (Martin and Green, 1995; Kothakota et al., 1997 Buendia et al., 1999).
Caspases can be separated into two distinct groups according to structural and
functional differences (Thornberry and Lazebnik, 1998). The first group such as
caspase 8, -9 and -10 are distinguished by a long prodomain and are involved in the
initiation of the caspase cascade and are appropriately termed 'initiator' caspases. A
further group known as 'effector' caspases which includes caspases 3, -6 and-7, are
distinguished by a relatively short prodomain and are activated upon cleavage by
initiator caspases (Figure 1.3). In general it is assumed that effector caspases become
active when proteolytically cleaved by upstream caspases, usually between the p20
and plO domains. As cleavage occurs after aspartic acid residues, it suggests the
possibility of autocatalysis (Thornberry, 1997). However this mechanism of
activation cannot account for activation of initiator caspases, as being the apical
proteases in the pathway, they are unable to be enzymatically cleaved by upstream
caspases. In view of this, two alternative mechanisms have been proposed to explain
activation of initiator caspases. In the first model, initiator caspases are recruited in
response to death stimuli via adaptor proteins to the ligand-receptor complex,
increasing their local concentration. It is postulated that low intrinsic protease
activity of the zymogen is sufficient to allow transcatalysis and autoproteolytic
processing, thereby fully activating the caspase (Muzio et al., 1998). This simplistic
model of caspase activation by induced proximity has been implicated in the
activation of caspase-8 following ligation of TNFR1 and Fas by their respective
ligands (Muzio et al., 1998). Caspase-2 and -10 may also be activated in this manner
(Salvesen and Dixit, 1999).
A further model of caspase activation has been proposed in which enzymatic
maturity of the caspase is dependent on co-factor association. This mechanism of
activation is used by caspase-9 and is dependent on an essential association with the
cytosolic protein Apaf-1 (Li et al., 1997; Zou et al., 1997). The release of
cytochrome c from mitochondria is believed to induce a conformational change in
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Figure 1.3 Proenzyme organisation of the caspases. Caspases are synthesised as proenzymes
with an N-terminal prodomain (PRO) and a large and small subunit often separated by a linker
peptide. Caspases are subdivided into two structurally and functionally distinct groups,
'initiator' or 'effector', characterised by long and short prodomains respectively. Caspase-8
and -10 contain N-terminal death effector domains (DED) allowing interaction with adaptor
molecules such as FADD. Other caspase such as caspase-9 contain caspase recruitment
domains (CARD), which permits interaction with other caspases or adaptor proteins such as
IAPs.
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Apaf-1, allowing it to form an active complex with caspase-9, which is believed to
be the enzymatically active form of caspase-9 (Rodriguez and Lazebnik, 1999). The
hierarchy of caspase activation, which ultimately may lead to the disassembly and
dismantling of the cell can be separated into two distinct signalling pathways. Which
of these cascades of caspase activation is induced is dependent on the whether
apoptosis is initiated by cell surface 'death' receptor (extrinsic) signalling or by
intracellular stress (intrinsic) signals (Figure 1.4) (For a recent review see Strasser et
al., 2000).
1.5 INITIATION OF APOPTOSIS
1.5.1 APOPTOSIS INITIATED BY EXTRINSIC SIGNALLING
There are two principal pathways by which apoptosis may be initiated. In the first
mechanism, activation of cell death is initiated through the engagement of cell
surface death receptors belonging to the tumour necrosis factor (TNF)/nerve growth
factor (NGF) receptor superfamily. Members of this family include TNFR1,
Fas/APO-l/CD95, DR-3/Apo-3/TRAMP, DR4/TRAIL-R1 and DR5/TRAIL-
R2/TRICK2 (Schmitz et al., 2000; Ashkenazi and Dixit, 1998). The extracellular
domains of these receptors share characteristic cysteine-rich motifs, however, a
subset of this superfamily, including Fas and TNFR1, contain an important 68 amino
acid region of homology in their cytoplasmic tail called the 'death domain' (DD),
which as the name implies is essential for apoptotic signalling (Itoh and Nagata,
1993; Tartaglia et al., 1993; Boldin et al., 1995). Death receptor signalling involves a
well characterised sequence of events commencing with ligand-induced receptor
trimerisation, followed by the recruitment of receptor-associated proteins and finally
initiation of caspase activation. Upon receptor activation, the death domain of the
cell surface death receptor undergoes homotypic interaction with death domain
containing proteins such as TRADD and FADD, recruiting them to the so-called
death inducing signalling complex (DISC) (Chinnaiyan et al., 1995). Death receptor
signalling through Fas involves direct recruitment of FADD to the DISC whereas
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TNFR1 binds FADD indirectly via TRADD. The adaptor protein FADD is essential
for cell death signalling from both receptors and through an N-terminal 'death
effector domain' (DED), allows recruitment of DED containing procaspase-8 and/or
procaspase-10 to the DISC. As a result, procaspase-8 is proteolytically cleaved into
its active form and in turn initiates cleavage of downstream caspases (Muzio et al.,
1996; Srinivasula et al., 1996; Muzio et al., 1998). Caspase-8 may also cleave the
BH3 only protein Bid, allowing its recruitment to the mitochondria, inducing the
release of cytochrome c (Luo et al., 1998). As will be discussed in the next section,
cytochrome c release forms an essential part of cell death mediated by stress-induced
stimuli. There is controversy regarding the importance of mitochondrial perturbation
and cytochrome c release in death receptor signalling. It is likely that death receptors
may initiate differential signalling pathways and depending on cell type may or may
not require mitochondrial release of cytochrome c (Scaffidi et al., 1998). Receptor
activation through TNFR1 complex may also lead to recruitment of the serine-
threonine kinase RIP (Receptor interacting protein) and TRAF2 (TNFR associated
factor 2) through TRADD. RIP and TRAF2 both seem to be involved in NFkB
activation (Liu et al., 1996; Ting et al., 1996). Additionally TRAF2 allows activation
of JNK (Natoli et al., 1997; Reinhard et al., 1997).
It is perhaps not surprising that there are regulatory mechanisms in place to control
and inhibit death receptor signalling when required. There are multiple levels of
regulation, including inhibitory proteins and decoy receptors. The latter bind ligands
such as TRAIL, and Fas ligand but are unable to transduce normal death signals due
to truncated death domains (Marsters et al., 1997; Pitti et al., 1998). Thus, decoy
receptors may prevent normal death stimuli from binding their appropriate receptor,
preventing apoptosis (Pan et al., 1997; Sheridan et al., 1997; Degli-Esposti et al.,
1997). Apoptosis induced by death receptor activation may also be inhibited by
FLICE-like inhibitory proteins (FLIPs) which possess DED domains allowing
interaction with FADD, procaspase-8 and -10, thereby by preventing normal
recruitment of procaspases to the DISC by competitive inhibition (Cryns and Yuan,
1998; Hu etal., 1997a; Thome et al., 1997; Irmler etal., 1997;Tschopp et al., 1998).
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Figure 1.4 Death and non death receptor apoptotic signalling pathways Ligation of
death receptors induces processing of caspase-8 and subsequent activation of effector
caspases. Caspase-8 cleavage of Bid induces release of cytochrome c from the mitochondria.
Stress/chemical induced apoptosis also results in release of cytochrome c causing processing
of caspase-9 within the apoptosome complex.
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It is interesting to note that immune evasion strategies may involve manipulation of
death receptor signalling mechanisms. For example viral proteins such as crmA that
can directly inhibit autocatalysis of procaspase-8 and -10 preventing their activation
and consequently preventing death receptor signals from being transduced (Ray et
al., 1992; Komiyama et al., 1994). Prevention of cell death by inhibiting activation
of the caspase cascade may constitute an important viral counter-measure against
host defence during infection.
1.5.2 APOPTOSIS INITIATED BY INTRINSIC SIGNALLING
An alternative mechanism for apoptosis to that triggered by cell surface death
receptors, may result as a consequence of growth factor withdrawal, chemical
treatment (e.g. staurosporine) or DNA damage to the cell. Activation of this death
pathway in response to internal insults or extracellular cues, is thought to converge
on the mitochondria, which may be the central control point of this pathway. The
first suggestion of mitochondrial involvement in apoptosis, resulted from studies
which demonstrated mitochondria to be required for cytosolic extracts to induce
apoptotic changes in isolated nuclei from Xenopus eggs (Newmeyer et al., 1994).
Further fractionation of cytosolic extracts revealed that cytochrome c, a resident
protein of the mitochondrial intermembrane space, was necessary to activate the
apoptotic effector caspases (Kluck et al., 1997). Since these initial findings there
have been many advances in understanding the extent of mitochondrial involvement
in apoptosis and the molecular events which may converge on the mitochondria,
leading to commitment to cell death.
Cytochrome c forms an important part of a high molecular weight complex termed
the 'apoptosome', which is composed of cytochrome c, Apaf-1 and procaspase-9
(Zou et al., 1999; Cain et al., 1999). Once released from mitochondria, cytochrome c
binds to Apaf-1, which recruits and activates procaspase-9 in the presence of ATP or
dATP (Li et al., 1997; Hu et al., 1999; Zou et al., 1999). Activation of procaspase-9
is mediated by means of conformational change, not proteolysis. As a result,
activation of caspase-9 then processes and activates other caspases to orchestrate the
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biochemical execution of cells (Slee et al., 1999). Apaf-1 shares an 85 amino acid
region of homology to the prodomains of several caspases and functions as a caspase
recruitment domain (CARD) (Hofmann et al., 1997). The central region of Apaf-1
contains a nucleotide-binding domain, which is essential for function (Zou et al.,
1997). This region shows structural and functional homology to the C. elegans death
promoting protein Ced-4 (Zou et ah, 1997). The C-terminal region is made up of
WD-40 repeats which mediate protein-protein interactions. As mitochondrial
cytochrome c is located in the intermembrane space, passage of cytochrome c
through the outer mitochondrial membrane is critical for activation of the caspase
cascade.
In addition to cytochrome c, other mediators involved in regulation of caspase
activation and apoptosis are also released from mitochondria. In some cells,
mitochondria contain a pool of procaspase-3 that is liberated into the cytosol during
induction of apoptosis (Mancini et al., 1998). Another caspase activating protein,
namely 'apoptosis inducing factor' (AIF), can also be released from the
intermembrane space ofmitochondria (Susin et al., 1996; Susin et al., 1997).
The integrity of the outer mitochondrial membrane, appears to be an important
regulator of the release of apoptotic mediators and consequently the control of
induction of apoptosis. In light of this, it is perhaps not surprising there are several
control mechanisms in place to regulate this process, which involve several members
of the Bcl-2 family of proteins.
1.6 REGULATION OF MITOCHONDRIA BY BCL-2 FAMILY
MEMBERS
Members of the expanding family of Bcl-2 like proteins have emerged as important
regulators of programmed cell death. However, until recently the mechanisms by
which Bcl-2 related proteins regulate apoptosis have remained unknown. There are
currently 15 Bcl-2-like proteins identified in mammals (Gross et al., 1999)
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characterised by the presence of a-helical conserved regions termed Bcl-2 homology
domains (BH1-BH4) which allow homo- and heterotypic protein interactions
(Kelekar and Thompson, 1998; Oltvai et al., 1993; Reed et al., 1996). Bcl-2 like
proteins are either anti-apoptotic (e.g. Bcl-2, Bcl-XL) and contain at least three BH
domains or are pro-apoptotic (e.g. Bax, Bak) and contain two or more BH domains
(Chao and Korsmeyer, 1998; Reed, 1998). Some pro-apoptotic members of this
family are more distantly related to Bcl-2 and possess only the BH3 domain (e.g. Bid
and Bad) which is required for both their ability to transduce apoptotic signals and
for their interactions with other family members (Kelekar and Thompson, 1998;
Chao and Korsmeyer, 1998; Reed, 1998). As Bcl-2 family members have the ability
to localise constitutively or inducibly to the outer mitochondrial membrane, it has
been proposed that they regulate apoptosis through an ability to control
mitochondrial compartmentalisation of cytochrome c (Goping et al., 1998;
Antonsson et al., 2000; Antonsson et al., 2001; Gross et al., 1999). It has been shown
that the anti-apoptotic proteins Bcl-2 and Bcl-XL, prevent release of mitochondrial
cytochrome c in response to death stimuli (Yang et al., 1997; Vander Heiden et al.,
1997). In contrast, the pro-apoptotic Bcl-2 family member Bax has been
demonstrated to accelerate programmed cell death (Oltvai et al., 1993) and can
induce release of cytochrome c when added directly to isolated mitochondria
(Jurgensmeier et al., 1998; Eskes et al., 1998). Although members of the Bcl-2
family have been implicated in regulating mitochondrial release of cytochrome c, the
precise biochemical events by which this occurs has not been fully elucidated.
Currently there are three basic models by which Bcl-2 like proteins have been
proposed to regulate cytochrome c release from mitochondria. These are described
below:
1.6.1 FORMATION OF ION CHANNELS BY BCL-2 FAMILY MEMBERS
The structural similarity of Bcl-XL to diphtherial bacterial toxin, which is known to
allow the transport of ions by forming pores in lipid bilayers, suggested Bcl-2
proteins may have similar properties (Muchmore et al., 1996). Subsequently, it has
been demonstrated that Bc1-Xl, tBid and Bax, can form functional ion channels in
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synthetic lipid vesicles and planar bilayers (Minn et al., 1997; Schendel et al., 1997;
Schlesinger et al., 1997; Antonsson et al., 1997). However, there is no evidence that
Bcl-2 family proteins form channels in vivo. Furthermore, it is uncertain whether the
diameter of such channels would be sufficient for proteins such as cytochrome c to
pass through.
1.6.2 FORMATION OF LARGE PROTEIN CHANNELS BY BCL-2 FAMILY
MEMBERS
Bcl-2 family members may also be able to facilitate release of apoptosis-inducing
factors by interacting with other proteins in the outer mitochondrial membrane to
form a large pore. Pro-apoptotic Bcl-2 family members may co-operate with the
voltage dependent anion channel (VDAC) and form a large cytochrome c conducting
channel (Shimizu et al., 1999). It could be envisaged that pro-apoptotic proteins such
as Bax and Bak, may allow opening of the channel, whereas anti-apoptotic proteins
such as Bc1-Xl, may facilitate its closure (Shimizu et al., 1999). It is predicted that
VDAC on its own would be unable to form channels big enough to allow
cytochrome c to pass through. Instead, it is proposed that a conformational change in
VDAC would be required, together with co-operation Bcl-2 family proteins, to allow
formation of a megapore of the appropritate size (Shimizu et al., 2000).
Other studies have suggested that some BH3-only proteins such as Bid alone can act
through a separate undefined pathway, which is sufficient to cause release of
cytochrome c from mitochondria. It remains elusive how BH3-only proteins can
mediate release of cytochrome c, although it is possible that they may associate with
novel proteins in the outer mitochondrial membrane to allow redistribution of
cytochrome c (Wang et al., 1996a; Luo et al., 1998; Li et al., 1998).
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1.6.3 REGULATION OF OUTER MITOCHONDRIAL MEMBRANE
RUPTURE BY BCL-2 FAMILY MEMBERS
A further proposed mechanism to account for cytochrome c redistribution during
apoptosis, may involve the non-specific disruption of the outer mitochondrial
membrane. This disruption could occur following alterations in mitochondrial
physiology as a consequence of apoptotic signalling, allowing the diffusion of
proteins through the lipid bilayer. Non-specific rupture of the outer mitochondrial
membrane may involve the opening of a large conductance channel called the
mitochondrial permeability transition pore (PTP) (Zamzami et al., 1996a; Qian et al.,
1997; Crompton, 1999). Opening of the PTP results in collapse of the mitochondrial
inner transmembrane potential (ATTn) and matrix swelling (Zamzami et al., 1996b).
As a result of organellar swelling, the outer mitochondrial membrane may rupture,
causing the release of apoptosis inducing factors localised within the intermembrane
space (Kroemer et al., 1997). It is possible that Bcl-2 family members could directly
regulate PTP activity (Marzo et al., 1998; Narita et al., 1998). Evidence to support
this model of mitochondrial disruption is implied from the ability of inhibitors of PT
pore opening such as bongkrekic acid and cyclosporin to block apoptosis in some
(Zamzami et al., 1996a), but not all systems (Eskes et al., 1998). At present it is
controversial whether mitochondrial depolarisation as a result of PT pore opening
initiates the induction of apoptosis or if PTP opening is a late event which occurs as a
consequence of apoptosis.
In summary, Bcl-2 family members are important regulators of apoptosis and this
may depend in part on their ability to control mitochondrial release of cytochrome c.
It could be envisaged that regulation of apoptosis by Bcl-2 like proteins involves a
balance of pro-apoptotic and anti-apoptotic signals possibly at the level of the
mitochondria, which may determine cellular fate in many systems.
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1.7 GRANULOCYTE APOPTOSIS
As described in section 1.2.3, granulocytes are recruited to inflammatory sites in
response to infection or tissue injury. In acute inflammation, neutrophils accumulate
in tissues due to targeted influx from the circulation in response to inflammatory
stimuli. However the recruitment of large numbers of inflammatory cells also
increases the potential for tissue damage through liberation of destructive enzymes or
toxic oxygen metabolites. This is exemplified in asthmatic and allergic inflammation
where accumulation of eosinophils in the bronchial mucosa, and subsequent release
of eosinophil granule products may lead to bronchial epithelial cell damage and
contribute to the pathogenesis of asthma (Walsh, 2001). The beneficial contribution
of inflammatory cell recruitment must be balanced by the safe removal and cessation
of cell accumulation when these cells are no longer required.
The majority of circulating granulocytes are eliminated by the reticuloendothelial
system of the liver and spleen. Extravasated granulocytes are not thought to return to
the blood stream (Haslett and Henson, 1988) and instead meet their fate at the
inflammatory site. It was originally assumed granulocytes would die in situ by
cellular necrosis once their contribution to the inflammatory response was complete
(Hurley, 1983). However, death by necrosis results in the release of toxic granule
contents into the extracellular milieu, thereby inciting an exaggerated and potentially
deleterious inflammatory response. Since host tissue damage does not normally arise
following an acute inflammatory response, it is likely that resolution of inflammation
must involve a clearance mechanism in which the cells are removed in a manner that
limits the release of inflammatory mediators and granule contents. It is believed that
termination of the inflammatory role of granulocytes occurs by death by apoptosis
and subsequent clearance of intact cells by tissue macrophages (Savill et al., 1989;
Savill etal., 1990; Savill, 1992).
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1.7.1 MOLECULAR CHANGES IN GRANULOCYTES UNDERGOING
APOPTOSIS AND CLEARANCE
Granulocytes will undergo constitutive apoptosis during in vitro culture and exhibit
classic changes associated with apoptosis including cytoplasmic condensation and
internucleosomal cleavage of DNA by endogenous endonucleases (Savill et al.,
1989). There are several changes to expression of cell surface molecules during
granulocyte apoptosis, some of which may be unique to these cells, such as loss of
CD16 (FcyRIII) expression in neutrophils (Dransfield et al., 1994). Other cell surface
changes such as exposure of phosphatidylserine on the outer leaflet of the
plasmalemma, may be important for phagocytic recognition of apoptotic
granulocytes (Fadok et al., 1992). There is also downregulation of the functional
capacity of granulocytes during apoptosis, with cells having a reduced ability to
generate a respiratory burst, degranulate or undergo chemotaxis in response to
external stimuli (Whyte et al., 1993). This decreased responsiveness and reduced
adhesive capacity, together with exposure of ligands facilitating apoptotic cell
recognition, may serve to limit tissue injury and promote resolution of inflammation.
A variety of studies, including experimental models of glomerulonephritis (Savill et
al., 1992a) and endotoxin induced lung injury (Cox et al., 1995), have given
evidence to support a role for apoptosis in the clearance of apoptotic neutrophils in
vivo. Furthermore, it has been demonstrated in vitro that apoptotic granulocytes are
rapidly recognised and ingested by macrophages (Haslett et al., 1989; Stem et al.,
1992; Savill et al., 1989; Savill, 1992; Meagher et al., 1992), without elicitation of
proinflammatory mediators but importantly with release of anti-inflammatory
mediators such as IL-10 (Voll et al., 1997) and TGF-(3 (Fadok et al., 1998). Thus
removal of apoptotic granulocytes by this manner could be crucial in resolution of
the inflammatory process and in the disposal of effete granulocytes from the sites of
inflammation. Macrophages are the principal cells involved in clearance of apoptotic
granulocytes although semi-professional phagocytes such as fibroblasts and
glomerular mesangial cells may also recognise and ingest apoptotic neutrophils
(Savill et al., 1992a; Hall et al., 1994; Hughes et al., 1997).
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Several molecules have been implicated in apoptotic cell recognition including the
phosphatidylserine receptor (Fadok et al., 2000), the vitronectin receptor avp3
integrin (Savill et al., 1990), CD36 (Savill et al., 1992b), the ATP binding cassette
transporter (ABC1) (Luciani and Chimini, 1996), class A scavenger receptor (Piatt et
al., 1996) and the CD 14 receptor (Devitt et al., 1998). Considering the number of
receptors that have been proposed to be involved, there may be functional
redundancy in the molecular pathways that are used for phagocytic cell clearance.
There may be complex subtleties in the involvement of each of these molecules in
apoptotic cell recognition, perhaps with some molecules engaged in initial
recognition of the apoptotic cell, while others may be preferentially used in
engulfment. It is probable that many phagocyte surface receptors implicated in
apoptotic cell recognition, may act in concert. However, research is still required to
resolve apparent differences in receptor usage between different phagocyte and
apoptotic cell populations and to understand the precise regulatory mechanisms
underlying apoptotic cell clearance.
1.7.2 REGULATION OF GRANULOCYTE APOPTOSIS BY BCL-2 FAMILY
MEMBERS
As previously discussed, members of the Bcl-2 family have been well characterised
as important regulators of apoptosis. It is thought that the relative levels of these pro-
and anti-apoptotic proteins and their molecular interactions, are cmcial in
determining whether a cell will survive or become apoptotic. Mature neutrophils do
not express Bcl-2 (Delia et al., 1992; Hannah et al., 1994) but do express the pro-
apoptotic proteins Bax (Moulding et al., 1998), Bik (Moulding et al., 2001) and Bak
(Bazzoni et al., 1999) and the anti-apoptotic proteins Mcl-1 and Al (Moulding et al.,
1998; Moulding et al., 2001). Eosinophils on the other hand are thought to express
Bc1-Xl (Dibbert et al., 1998) Bax (Druilhe et al., 1998; Dibbert et al., 1998; Dewson
et al., 2001) and in some reports, low levels of Bcl-2 (Druilhe et al., 1998). There
have been some discrepancies in the literature, due to different methods of detection
and variability in levels of expression, perhaps reflecting the maturation and
activation status of the cells being examined. Thus, caution must be taken when
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trying to correlate expression of these family members with granulocyte survival.
Expression of Mcl-1, another Bcl-2 family member, is reportedly decreased prior to
onset of apoptosis in neutrophils but is increased in response to the apoptosis
delaying agents, LPS and GM-CSF (Moulding et al., 1998). Neutrophils also express
mRNA for A1, a further anti-apoptotic member of the Bcl-2 family however reliable
expression of Al at the protein level is yet to be obtained (Chuang et al., 1998;
Moulding et al., 2001). Both Mcl-1 and Al are reported to be expressed in
eosinophils, however, convincing evidence of a correlation between expression of
these proteins and eosinophil apoptosis is yet to be produced (Druilhe et al., 1998;
Dibbert et al., 1998).
1.7.2 REGULATION OF GRANULOCYTE APOPTOSIS BY
EXTRACELLULAR STIMULI
Although granulocytes undergo constitutive apoptosis, it is apparent that this process
is not immutable and it is well established that many inflammatory mediators can
prolong or suppress granulocyte survival by altering the rate of apoptosis (Haslett et
al., 1991) (Figure 1.5). Considering extravasated granulocytes die by apoptosis in
situ at inflammatory foci, the ability of exogenous inflammatory mediators and
cytokines to differentially modulate granulocyte survival, has important
consequences for resolution of the inflammatory response. Thus, the longevity and
resolution of an acute inflammatory response may depend on exogenous stimuli
present at an inflammatory focus. Pro-inflammatory mediators including cytokines
such as GM-CSF, G-CSF, IFN-y, bacterial products such as LPS and chemotactic
peptides such as C5a, delay granulocyte apoptosis (Brach et al., 1992; Colotta et al.,
1992; Stern et al., 1992; Lee et al., 1993). It is important to note that granulocytes
show differential responsiveness to apoptotic stimuli compared with other
leukocytes. Indeed, there appears to be differences in the regulatory mechanisms
controlling apoptosis in neutrophils and eosinophils (Figure 1.5). This may be due to
the presence of distinct receptors on the surface of the eosinophil compared to the
neutrophil. For example IL-5 can profoundly enhance eosinophil survival yet does
not modulate neutrophil apoptosis (Tai et al., 1991; Yamaguchi et al., 1991).
31
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Similarly IL-8 can suppress neutrophil apoptosis but has no effect on eosinophil
longevity (Leuenroth et al., 1998; Kettritz et al., 1998). The situation is further
complicated by the ability of certain cytokines such as TNFa to have bi-phasic
effects; in vitro TNFa will induce neutrophil apoptosis at early time points while at
later time points apoptosis is inhibited by this cytokine (Murray et al., 1997).
Granulocyte apoptosis may also be modulated by stimulation of the Fas signalling
pathway, with reports that both neutrophils and eosinophils are susceptible to
induction of apoptosis by Fas mediated signals (Liles et al., 1996; Renshaw et al.,
2000; Iwai et al., 1994; Brown et al., 1997). Initial findings that neutrophils could
produce and secrete FasL, led to the proposal that Fas/FasL could regulate
spontaneous granulocyte apoptosis (Liles et al., 1996). However this is somewhat
controversial as induction of granulocyte death has been achieved using Fas
activating antibodies but not reproducibly with soluble FasL (Brown et al., 1997;
Renshaw et al., 2000). Moreover, constitutive apoptosis in neutrophils isolated from
FasL (gld)- and Fas (lpr)-deficient mice appears to proceed at a rate comparable to
neutrophils obtained from control mice, arguing against a role for Fas-FasL in the
regulation of constitutive neutrophil death (Fecho and Cohen, 1998; Villunger et al.,
2000).
Other extracellular modulators of granulocyte apoptosis include nitric oxide (NO),
which can promote neutrophil apoptosis (Fortenberry et al., 1998; Fortenberry et al.,
1999; Ward et al., 2000) but delay cell death in eosinophils (Beauvais et al., 1995).
Moreover hypoxia, in contrast to many other cell types, delays neutrophil apoptosis
(Hannah et al., 1995). This may have important implications as neutrophil lifespan
may be increased in the hypoxic environment of the tissues following extravasation
from the circulation during the inflammatory response. As yet, little is known of the
regulatory mechanisms which underlie regulation of apoptosis by these conditions.
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AGENTS WHICH DELAY GRANULOCYTE APOPTOSIS
Figure 1.5 Factors which influence the acceleration or delay of constitutive apoptosis in
granulocytes
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Granulocyte apoptosis in vitro is accelerated by inhibitors of protein synthesis such
as cycloheximide and actinomycin D suggesting that granulocyte survival is
prolonged by the expression of one or more survival proteins (Whyte et al., 1997). It
has also been reported that many agents which delay granulocyte apoptosis require
new protein synthesis for their survival enhancing effects (Brach et al., 1992;
Hachiya et al., 1995; Kato et al., 1995; Cox and Austin, 1997). It is possible that
extracellular modulators of neutrophil survival may achieve their effects through
upregulation of transcription of genes important for survival or alternatively by
postranslational modification of pre-existing proteins, which may alter their cellular
activity.
1.7.3 SIGNALLING PATHWAYS REGULATING GRANULOCYTE
APOPTOSIS
Despite the wide numbers of agents implicated in modulation of granulocyte
apoptosis, surprisingly little has been described of the intracellular signalling
pathways used by these agents to regulate cell death. Dissection of the signalling
pathways leading to granulocyte death have been hindered by the inability of these
cells to be transfected by conventional methods. Elucidation of the signalling
pathways involved has relied principally on pharmacological approaches.
There is evidence that granulocyte apoptosis is regulated by activation of
phosphorylation cascades by extracellular agents through cell surface receptors.
Many studies have implicated a role for the mitogen-activated protein kinase
(MAPK) signal transduction cascade in the regulation of granulocyte apoptosis.
There are three different types of MAP kinases: the p42/p44 extracellular signal-
related protein kinases (ERKs), the c-Jun N-Terminal kinase/stress activated MAPKs
(JNKS/SAPKs) and p38 MAPKs. The role of p38 MAPK in regulation of
granulocyte survival is somewhat controversial. Some reports suggest a role for this
signalling pathway in activation of constitutive neutrophil apoptosis (Aoshiba et al.,
1999) although further studies have not supported these findings (Villunger et al.,
2000; Frasch et al., 1998). Paradoxically, it appears that p38 MAPK is required for
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irradation-induced apoptosis and also in the survival effects of hypoxia (Frasch et al.,
1998; Leuenroth et al., 2000). Thus, at present the exact function of p38 MAPK in
the signalling pathways controlling survival and death of granulocytes is still
uncertain.
Activation of classical p42/p44 ERKs appear important in the regulation of
constitutive granulocyte apoptosis. For example, LPS, IL-8 and GM-CSF stimulate
survival pathways in neutrophils, which are dependent on the activation ofMEK and
presumably therefore ERKs (Nolan et al., 1999; Klein et al., 2000). Additionally,
survival signals stimulated by IL-8 and GM-CSF appear to involve activation of the
phosphoinositide 3-kinase (PI-3K) signalling pathway (Klein et al., 2000). PI-3
kinase has been implicated as an important pathway in apoptotic control through the
ability of PI-3 kinase to activate Akt, which in turn phosphorylates the Bcl-2 family
member, Bad (del Peso et al., 1997; Franke and Cantley, 1997). Phosphorylation of
Bad sequesters Bad from Bc1-Xl resulting in binding to 14-3-3 in the cytosol,
reducing its pro-death properties (Zha et al., 1996). Whether Akt and Bad
phosphorylation are required for the survival pathways stimulated by GM-CSF and
IL-8 has yet to be determined.
The downstream targets of both ERK and PI-3K in neutrophils, are not yet
characterised. However, from other cell systems it is likely that NFkB and other
transcription factors may be involved. Indeed, NFkB has been shown to be an
important survival signal in neutrophils and is involved in the anti-apoptotic effects
of TNFa in these cells (Ward et al., 1999a). Blockade of NFkB activation will
rapidly induce apoptosis in neutrophils (Ward et al., 1999a) which is in contrast to
thymocytes and HL60 cell lines where NFkB activation is required for cell death
(Slater et al., 1995; Hettmann et al., 1999; Boland et al., 2000). However, not all
agents that delay granulocyte apoptosis activate NFkB and it is likely that other
transcriptional regulators may be involved in regulating cell survival (McDonald et
al., 1997).
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Constitutive granulocyte apoptosis may also be regulated through the activity of the
serine/threonine kinase PKC and, in particular, the PKC isoform PKC8 may be
involved in control of neutrophil apoptosis (Pongracz et al., 1999; Khwaja and
Tatton, 1999). Blockade of PKC activity pharmacologically with Ro318220 or using
the non-selective PKC inhibitor staurosporine, induce granulocyte apoptosis although
the downstream substrates of PKC activated by this signalling pathway have not
been fully identified (Cousin et al., 1997).
Second messengers appear to be important regulators of apoptosis in diverse cell
types and it is therefore perhaps unsurprising that these molecules are potent
regulators of apoptosis in granulocytes. In contrast to the induction of apoptosis in
thymocytes (McConkey et al., 1990; Suzuki et al., 1991) and leukaemic cell lines
(Lanotte et al., 1991), elevation of the second messenger cyclic AMP can profoundly
delay cell death in both neutrophils and eosinophils (Rossi et al., 1995; Ottonello et
al., 1998). The intracellular signalling pathway of cyclic AMP is well characterised
but remarkably little is known of the underlying regulatory signal transduction
cascades involved in the ability of cyclic AMP to modulate apoptosis. Manipulation
of cyclic AMP levels, through phosphodiesterase (PDE) inhibition, has been a target
for treatment of chronic airways disease, due to the ability of cyclic AMP to mediate
relaxation of airways smooth muscle and suppress inflammatory cell responsiveness
to secretory agonists (Underwood et al., 1993; Dent and Giembycz, 1996; Lad et al.,
1985; Wada, 1989; Dent et al., 1994). However, the observations that cyclic AMP
may delay granulocyte apoptosis together with reports that cyclic AMP can inhibit
macrophage phagocytosis of apoptotic cells (Rossi et al., 1998) may have important
implication for the potential usefulness of PDE inhibitors in treatment of asthma.
Also applicable to chronic airways disease is the observation that glucocorticoids
exert differential effects on granulocyte apoptosis (Meagher et al., 1996).
Glucocorticoids are known to be potent anti-inflammatory agents and have been
most widely used in the treatment of chronic inflammatory diseases such as
rheumatoid arthritis and asthma (Barnes, 1998). Although glucocorticoids exert
divergent effects on many cell types, the efficacy of steroid treatment in asthma may
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relate in part to their ability to induce eosinophil death. Further, it has been
demonstrated that glucocorticoids in vivo reduce the number of eosinophils in airway
secretions (Woolley et al., 1996). Considering the ability of glucocorticoids to
increase macrophage phagocytosis of apoptotic cells (Liu et al., 1999), the anti¬
inflammatory capacity of glucocorticoids may partially rest in their ability to both
induce apoptosis concomitant with upregulation of normal clearance mechanisms.
Surprisingly very little has been elucidated of the signalling pathways and regulatory
mechanisms involved in the divergent effect on granulocyte apoptosis.
In summary, there is good evidence implicating glucocorticoids and second
messengers such as cyclic AMP in the regulation of apoptosis in granulocytes,
however their mechanisms of action are still obscure. The mechanism by which these
agents may regulate the activation of the members of the caspase family and how this
in turn modulates endonuclease activation and cell death, is not well understood.
Although granulocytes express several members of the Bcl-2 family, it is unclear
how agents which modulate the rate of granulocyte apoptosis, such as cyclic AMP
and glucocorticoids, integrate with the regulatory control mechanisms of Bcl-2
family proteins. Moreover, little progress has been made to understanding why one
signal may induce apoptosis in eosinophils yet inhibit or delay neutrophil cell death.
Understanding these complex interactions in the apoptotic cascades regulating
granulocyte death could lead to development of novel strategies to therapeutically
induce apoptosis for the resolution of inflammation. Furthermore, as there appear to
be significant differences in apoptotic regulation between granulocytes and other
immune cells and additionally between neutrophils and eosinophils, there may be the
opportunity to induce apoptosis in inflammatory cell types selectively, for
therapeutic gain.
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1.8 AIMS OF THESIS
The principal aims of this thesis were to determine the signalling mechanisms
involved in cyclic AMP and glucocorticoid regulation of human granulocyte
apoptosis.
• Preliminary studies established that elevation of cyclic AMP caused a marked
enhancement of neutrophil and eosinophil longevity by inhibiting apoptosis.
Studies were undertaken to investigate the influence of cyclic AMP on key
cellular events such as caspase activation and dissipation of mitochondrial
transmembrane potential, which may regulate constitutive granulocyte apoptosis
• Subsequent experiments, designed to further assess the involvement of this
second messenger in the regulation of granulocyte apoptosis, investigated the
cyclic AMP signalling transduction pathway directly and examined the
involvement of transcriptional regulation in cyclic AMP mediated control of
granulocyte cell death. As cyclic AMP delays apoptosis in both neutrophils and
eosinophils, studies of the signalling pathways involved were performed
primarily in neutrophils.
• It was also established that glucocorticoids differentially regulate granulocyte
apoptosis; promoting eosinophil apoptosis while delaying neutrophil cell death.
Studies were undertaken to elucidate the glucocorticoid signal transduction
pathways involved in regulation of apoptosis in both cell types. The involvement
of transactivation and transrepression of gene transcription in both glucocorticoid
mediated enhancement of neutrophil longevity, and glucocorticoid promotion of
eosinophil cell death, were also examined.
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2 MATERIALS AND METHODS
2.1 MATERIALS AND BUFFERS
All materials were purchased from Sigma (Poole, Dorset) unless otherwise indicated:
Blocking Buffer
TBS with 0.1% Tween-20 and 5% Milk powder (Marvel). Made fresh.
ELISA Blocking Buffer
TBS containing 0.1% bovine serum albumin (BSA). Made fresh.
ELISA Wash Buffer
TBS containing 0.1% Tween-20. Kept at room temperature.
ELISA Substrate Buffer
Sodium acetate-citrate 100 mM pH 4.9 (80 ml 0.1M sodium acetate with 17 ml 0.1M
citric acid, dH20 up to 100 ml). Made fresh.
ELISA Substrate solution
100 pi TMB ((3,3'.5,5'-Tetramethylbenzidine) dissolved at 10 mg/ml in DMSO -
stored in dark for up to 2 weeks) added to 10 ml ELISA substrate buffer with 5 pi
H2O2 (30%) added just prior to use. Made up fresh.
FACS Annexin V binding buffer
500 ml Hanks Balanced Salt Solution (Gibco, Paisley, UK, H9394) with 5 pM CaCl2
(final). Kept at 4°C.
Methanol Based Transfer Buffer
14.6 g Glycine, 2.9 g Tris-HCl, 200 ml methanol, dH20 up to 1000 ml. Made fresh.
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NP-40 Cytoplasmic Lysis Bufferforprotease sensitiveproteins (cLBPSP)
10 mM HEPES pH 7.8, 10 mM KC1, 2 mM MgCl2, 0.1 mM EDTA, 0.5 mM ABSEF,
10 |!g/ml aprotinin, 2 mM levamisole, 10 jig/ml leupeptin, ImM sodium
orthovanadate, 0.5 mM benzamidine, 10 mM (^-glycerophosphate, 10 |ig/ml
pepstatin A, 1 mM phenanthroline, 1 mM PMSF. Made up fresh.
NP-40 Nuclear Lysis Bufferforprotease sensitive proteins (nLBPSP)
50 mM HEPES pH 7.8, 50 mM KC1, 300 mM NaCl, 0.1 mM EDTA, 10 % glycerol,
0.5 mM ABSEF, 10 pg/ml aprotinin, 2 mM levamisole, 10 pg/ml leupeptin, 1 mM
sodium orthovanadate, 0.5 mM benzamidine, 10 mM (^-glycerophosphate, 10 (ig/'ml
pepstatinA, 1 mM phenanthroline, 1 mM PMSF. Made up fresh
PKA Extraction Buffer
25 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 10 mM beta-
mercaptoethanol, 1 pg/ml leupeptin, 1 pg/ml aprotinin, 1 mM PMSF and 1% Triton
X-100. Made up fresh.
Sample buffer (x3)
1 ml stacking gel buffer, 1 ml 20 % SDS, 500 p.1 (3-mercaptoethanol, 1 ml glycerol,
bromophenol blue. Store at 4°C.
SDS-Tris Glycine Electrophoresis Buffer (xlO)
250 mM Tris-HCl, 1.92 M Glycine, 1% SDS. Kept at room temperature.
Separating Gel Buffer
36.30 g Tris-HCl, 0.8 g SDS, dH20 up to 100 ml pH 8.9
Stacking Gel Buffer
5.1 g Tris-HCl, 0.4 g SDS, dH20 up to 100 ml pH 6.7
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StandardNP40 cytoplasmic lysis buffer
50 mM sodium fluoride, 5 mM tetra sodium pyrophosphate, 1 mM sodium
orthovanadate, 10 mM ^-glycerophosphate, 0.5% NP40, 2 mM EDTA, 20 mM
Na2HP04, 20 mM NaH2P04, 1 protease inhibitor tablet. Stored at -20°C.
StandardNP40 nuclear lysis buffer
50 mM sodium fluoride, 5 mM tetra sodium pyrophosphate, 1 mM sodium
orthovanadate, 10 mM ^-glycerophosphate, 0.5% NP40, 2 mM EDTA, 20 mM
Na2HPC>4, 20 mM NaPEPC^ 300 mM NaCl, 1 protease inhibitor tablet. Stored at -
20°C.
Tris Buffered Saline (TBS)
Tris-HCl (20 mM) pH 7.4, NaCl (15 mM)
Western Wash Buffer
TBS with 0.1% Tween-20. Kept at room temperature.
Triton X-100 Lysis Buffer
10 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, pH 7.4. and 1
protease inhibitor tablet (1 per 20 ml lysis buffer). Stored at -20°C.
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Further materials were purchased from the following companies:
Affiniti Research Products Ltd, Mamhead, Exeter, UK: z-VAD-ffnk methyl ester,
lactacystin, epoxomicin.
Affinity Bioreagents Inc, Golden, CO, USA: polyclonal rabbit anti-human
glucocorticoid receptor antibody (PA1-511), polyclonal rabbit anti-human
glucocorticoid receptor beta antibody (PA3-514).
Amersham Pharmacia Biotech, UK Ltd, Buckinghamshire, UK: Hybond C
nitrocellulose membrane, horse radish peroxidase-conjugated donkey anti-rabbit
secondary antibody, Phosphorus-33 (370MBq/ml, 10 |ici/ml).
Baxter Healthcare Ltd, Baillieston, Glasgow, Scotland, UK: Diff Quik™ stain.
Solution I (Eosin G in phosphate buffer, pH 6.0), Solution II (Thiazine blue in
phosphate buffer; pH 6.0), saline solution 0.9% (sterile).
Boehringer Mannheim, Germany: Annexin-V-FLUOS
Calbiochem-Novabiochem UK, Nottingham, UK: Rp-8-Br-cAMPS sodium,
trichostatin A Streptomyces sp, dibutyryl-cyclic AMP sodium, H-89 Dihydrochoride,
PD 98059, LY 294002, GGTI-286, geldanamycin
Cell Signalling Technology, Beverly, MA, UK: polyclonal rabbit anti-licBa
antibody
DAKO Ltd Cambridgeshire, UK: Horse radish peroxidase-conjugated, goat anti-
mouse, secondary antibody and rabbit immunoglobulin fraction (normal).
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Dynal UK, Wirral, UK: Dynabeads M-450 sheep anti-mouse IgG. Supplied as 4 x
o
10 beads/ml in PBS pH 7.4 with 0.1% human serum albumin and 0.2% sodium
azide.
Genzyme Diagnostics, Kent, UK: GM-CSF (1000 U/ml in PBS) was stored at -
70°C.
Gibco Life Technologies, Paisley, Scotland, UK: Iscove's Dulbecco's modified
Eagles medium, without supplements with L-glutamine (Iscove's MDM); Hanks
Balanced Salt Solution (HBSS); culture supplements penicillin (50
U/ml)/streptomycin (50 U/ml); L-glutamine (200 mM); 10 % SDS; and 30 % (w/v)
acrylamide/bis solution.
Martindale Pharmaceuticals Ltd, Romford, UK: calcium chloride.
Millipore, Bedford, Mass, USA.: Immobilon-P PVDF
Molecular Probes Inc, Eugene, OR, USA: TO-PRO-3, iodide (642/661), JC-1
[5,5 ',6,6'-tetrachloro-1,1 ',3,3'-tetraethylbenzimidazocarbocyaniniodide].
Organon Laboratories Ltd, Cambridge, UK: Dexamethasone.
Phoenix Pharmaceuticals Ltd, Gloucestershire, UK: Sodium citrate solution
(3.8%).
Promega Corporation, Southampton, UK: SignaTECT™ cAMP-Dependent
Protein Kinase (PKA) Assay System
R&D Systems Europe Ltd, Oxon, UK: TNFa (stock solution 10 pg/ml); mouse
IgGi anti-human IL-8 monoclonal antibody (stock solution 500 (ig/ml), biotinylated
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anti human IL-8 polyclonal antibody (stock solution 50 jj.g/ml), human IL-8 (stock
solution.
Shandon, Pittsburgh, PA, USA: Shandon Filter Cards
Spectrum Companies, Gardena, CA, USA: Spectra/Por Molecular porous
membrane tubing MWCO 3,500
Transduction Laboratories, San Diego, California, USA: Rabbit anti-human
caspase-3 polyclonal antibody, rabbit anti-human Bax polyclonal antibody, mouse
IgG2b PKA Ri antibody, mouse IgG2b PKAc antibody.
TCS Biologicals, Botolph Clayton, Bucks, UK: anti-Fas human clone CH-11
The following reagents were kindly donated as gifts: RU24858 and RU27842 were
obtained from Roussel UCLAF, Romainville, Cedex, France; ZK77945 and
ZK55740 from Schering AG, Berlin, Germany; Clostridium sordelli lethal toxin
from M.R Popoff, Centre National de Reference des Bacteries Anaerobies, Institut
Pasteur, Paris; polyclonal rabbit anti-SLPI antibody from J.M Sallenave, CIR,
University of Edinburgh; NH3 mouse monoclonal antibody from I.Dransfield, CIR,
University of Edinburgh and murine anti-neutrophil antibody 3G8 from Dr J.
Unkeless, Mount Sinai Medical School, New York.
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2.2 CELL ISOLATIONS AND PURIFICATIONS
2.2.1 ISOLATION OF HUMAN GRANULOCYTES FROM PERIPHERAL
BLOOD
Human neutrophils were purified from the peripheral blood of healthy human
volunteers by modification of previously described methods (Haslett et al., 1985;
Dransfield et al., 1994). Neutrophil isolation was performed at room temperature,
under sterile conditions and using endotoxin-free reagents and plasticware (Falcon,
Oxford, UK). Venous blood was collected into 50 ml polypropylene tubes,
anticoagulated (4 ml 3.8% sodium citrate/36 ml blood) and centrifuged (350g, 20
min., room temperature). This gives two layers, an upper layer containing plasma
and platelets, and a lower layer containing a mixture of erthyrocytes and leukocytes.
The platelet-rich plasma (PRP) was aspirated and used to prepare autologous serum
in glass tubes by the addition of CaCL (220 pi of 1 M CaCl2 added to 10 ml PRP) at
37°C. To sediment the erythrocytes, 5 ml of 6% dextran (T500 pre-warmed to 37°C)
was added to the pelleted cells and the volume made up to 50 ml with 0.9 % saline
(pre-warmed to 37°C). The tubes were mixed gently and the cells allowed to
sediment for ~30 min at room temperature resulting in formation of two
distinguishable layers; a bottom layer containing mainly sedimented erythrocytes and
an upper leukocyte-rich layer. The leukocyte-rich layer was aspirated, centrifuged
(350g, 6 min) and the supernatant discarded. The resulting leukocyte pellet was
resuspended in 2.5ml of 55% isotonic Percoll (9:1 v/v Percoll: 10 x PBS) in 1 x PBS
without divalent cations. Discontinous Percoll gradients were prepared by overlaying
2.5ml of 68% Percoll onto 2.5ml of 79% isotonic Percoll in a 15 ml Falcon tube.
Leukocytes were then resuspended in 55% Percoll and overlayed to form the final
layer of the gradient. The gradients were centrifuged (720g, 20 min) and
polymorphonuclear cells harvested from the 68%/79% Percoll interface.
Mononuclear cells sedimented at the 55%/68% Percoll interface. Purified cells were
washed sequentially in PBS twice and cell yield assessed using a haemocytometer.
Although the above density gradient centrifugation method does not separate
neutrophilic from eosinophilic or basophilic granulocytes, however harvested
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polymorphonuclear cells generally consisted of<3% eosinophils, and basophils were
rarely seen. Preparations of granulocytes containing >5% eosinophils were used for
preparation and study of eosinophils as described in section 2.2.2. Cell viability was
assessed by trypan blue exclusion and was routinely >99%. The typical yield for this
isolation method was 100 x 106 polymorphonuclear cells/40 ml whole blood. Cells
were minimally activated by the methods used for cell preparation as outlined above.
2.2.2 PREPARATION OF HUMAN EOSINOPHILS FROM PERIPHERAL
BLOOD
Eosinophils were prepared from polymorphonuclear cells, isolated as described
above (Section 2.2.1). Separation of eosinophils from neutrophils was achieved
through negative selection by immunomagnetic separation using the murine anti-
neutrophil antibody 3G8 (anti-CD 16)-coated sheep anti-mouse IgG-Dynabeads.
CD 16-Dynabeads were prepared under sterile conditions by combining 3G8
supernatants with Dynal M450 sheep anti-mouse dynabeads (10 ml supernatant:
500pl beads), in a 15ml falcon tube. The antibody/bead mixture was rotated at 4°C
for at least 20 mins to allow antibody binding. The coated beads were then
sequentially washed 4 times in PBS without divalent cations (4°C) and the beads
retrieved using a stationary contact (3 min) with a magnet (Dynal Magnetic Particle
concentrator, MPC-1).
Granulocytes, isolated as in Section 2.2.1 were incubated with washed 3G8-
Dynabeads at a bead : granulocyte ratio of 3:2 on a rotary mix at 4°C for 10 min and
the beads with attached neutrophils were magnetically separated by stationary
contact (3 min) with a magnet. This procedure was repeated once. Purity was
assessed by light microscopy of cyto-centrifugated cells, stained with Diff-Quik™.
Purified eosinophils (> 98%) were washed and centrifuged (220g, 5 min) twice in
PBS without divalent cations, before cell yield was assessed by haemacytometer
counts.
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2.2.3 SEPARATION OF APOPTOTIC NEUTROPHILS FROM NON
APOPTOTIC NEUTROPHILS
Purification of apoptotic neutrophils from a mixed population of aged neutrophils
was performed according to the method of Dransfield et al., (1994). Non-apoptotic
neutrophils were removed using immunomagnetic separation with sheep anti mouse
IgG-Dynabeads (Dynabeads M-450, Dynal, Merseyside, United Kingdom) coated
with the murine anti-neutrophil antibody 3G8 (anti-CD 16; a gift from Dr J. Unkeless,
Mount Sinai Medical School, New York). Cells were mixed with washed antibody-
coated magnetic beads on a rotary mixer at 4 °C for 20 minutes, and the beads
removed magnetically by two 3 minute stationary magnetic contacts (Dynal




Unless otherwise stated, freshly isolated neutrophils and eosinophils were routinely
suspended at a density of 5 x 106/ml or 2.5 x 106/ml respectively in Iscove's DMEM
supplemented with 10% autologous serum, 50 U/ml penicillin, and 50 U/ml
streptomycin. Cells were cultured in a final volume of 150 jal in flat-bottomed 96-
well Falcon flexiwell plates (Becton-Dickinson, UK) at 37°C in a humidified, 5%
CO2 atmosphere for the time periods indicated. Cells showed minimal activation and
remained non-adherant during the culture period, making this in vitro culture system
a good model for examining constitutive granulocyte apoptosis. Reagents to be
examined in this assay system were diluted to 10 x the final concentration required in
Iscove's DMEM before addition of 15 (il of each reagent to be investigated.
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2.4 ASSESSMENT OF APOPTOSIS
2.4.1 ASSESSMENT OF APOPTOSIS BY MORPHOLOGICAL CRITERIA
Neutrophil apoptosis was assessed morphologically according to the method of
Savill et al (Savill et al., 1989). Cells were gently resuspended and 100 pi of cell
suspension (approximately 5 x 103 neutrophils) harvested from each well,
cytocentrifuged (300 rpm, 3 min) and the resulting slide preparations air dried, fixed
in methanol and stained with Diff-Quik™ and cells were counted using oil
immersion light microscopy. Cell recovery was measured in parallel using a
haemocytometer and cell viability assessed by trypan blue exclusion. Apoptotic cells
were defined as those containing one or more darkly stained pyknotic nuclei (see
Sections 3.1 and 4.1). At least 500 cells were counted over five fields of view, with
slides prepared in triplicate per well and the observer blinded to the experimental
conditions.
2.4.2 ASSESSMENT OF APOPTOSIS BY ANNEXIN V BINDING
In addition, apoptosis was assessed by flow cytometry using FITC-labelled
recombinant human Annexin V that binds to phosphatidylserine exposed on the
surface of apoptotic cells. A working solution of Annexin V was made from stock
Annexin V (Annexin-V-FLUOS, Boeringer), diluted 1:3000 with Annexin V binding
buffer (see buffers). Neutrophils (20 pi of 5 x 106/ml) were added to 200 pi of the
working solution of Annexin V-FLUOS before being assessed by flow cytometry on
a FACSCalibur (Becton Dickinson, Oxford, UK) and analysed on associated
CellQuest (Becton Dickinson) software. All experiments were performed at least
three times unless otherwise indicated.
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2.5 MEASUREMENT OF MITOCHONDRIAL DISSIPATION
Changes in mitochondrial potential were measured in neutrophils following
stimulation using JC-1 [5,5',6,6'-tetrachloro-l,r,3,3'-tetra-ethyl-benzimidazocarbo-
cyaniniodide] (Molecular Probes), a cationic dye which exhibits potential dependent
accumulation in mitochondria indicated by a fluorescence emission shift from green
(525 nm) to red (590 nm). Mitochondrial depolarisation is indicated therefore by a
decrease in the red/green fluorescence intensity ratio. JC-1 (10 |Llg/ml) was diluted in
PBS from stock JC1 (5 mg/ml in DMSO) and added to neutrophils (1 x 106/ml) for
10 min at 37°C. Neutrophil mitochondria labelled with JC-1, were examined by
confocal fluorescent microscopy together with TO-PRO-3 (1 pM) (Molecular
Probes) to assess neutrophils with necrotic morphology. Alternatively neutrophils
labelled with JC-1 were assessed by flow cytometric analysis using FACSCalibur
(Becton Dickinson, Oxford, UK) and analysed on associated CellQuest (Becton
Dickinson) software.
2.6 ENZYME LINKED IMMUNOSORBANT ASSAY (ELISA)
Interleukin-8 (IL-8) secretion was analysed by detecting soluble protein in aliquots of
supematants collected from granulocyte cultures at 24 h. Reagents for IL-8 detection
and standards were purchased from R&D systems (Oxon, UK). Briefly, anti-
cytokine capture antibodies were diluted to 4 pg/ml in PBS. 100 pi of diluted
capture antibody was added to the wells of enhanced protein binding ELISA plates
(Coming, NY, USA). The plates were sealed and incubated overnight at 37°C.
Capture antibody was removed, and wells were washed 3 times with ELISA wash
buffer, 200 pl/well. 100 pi of ELISA blocking buffer was added to each well and the
plates incubated at 37°C for 1 h. Wells were washed 3 times with ELISA wash
buffer (200 pl/well) and 100 pi of standards and samples were added to the wells
(appropriately diluted in ELISA wash buffer). Plates were sealed and incubated for 1
h at 37°C. Wells were washed 3 times with 200 pi ELISA wash buffer and 100 pi of
20 ng/ml biotinylated detection antibody diluted in ELISA blocking buffer was
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added to each well. Plates were incubated for 1 h at room temperature after which
wells were washed 3 times with 200|ll1 ELISA wash buffer and lOOpl of 1 in 2000
diluted Streptavidin-HRP (Amersham Life Sciences, Amersham, U.K.) was added to
the wells and incubated for 20 mins at room temperature. Wells were washed 3
times with ELISA wash buffer and 100 pi of substrate solution was then added.
Plates were placed in the dark for development before the reaction was stopped by
the addition of 50 pi H2SO4 to each well and read on a Microplate Reader 450
(BioRad Laboratories, Hemel Hempstead, U.K.) and associated software.
2.7 SIGNALLING
2.7.1 MEASUREMENT OF PKA ACTIVITY
PKA activity was measured using Promega's SignaTECT™ cAMP-Dependent
Protein Kinase (PKA) Assay System which utilises biotinylated Kemptide
(LRRASLG), a peptide substrate derived from the in vivo substrate pyruvate kinase.
Unless otherwise stated, neutrophils (5 x 106 cells) were pre-incubated with control
buffer or 10 pM H89 (Calbiochem, Nottingham, UK) for 1 h in PBS with Ca2+/Mg2+
at 37 °C before being stimulated with 0.2 mM dbcAMP or 1 pM PGE2, for 30 min at
37 °C. Following one wash in ice cold PBS, neutrophils were resuspended in 0.5 ml
of cold PKA extraction buffer. The lysates were centrifuged (5 min; 4 °C; 14,000 g)
and the supematants retained. The PKA reaction mix consisting of 5 pi of 5 x PKA
Assay Buffer, 5 pi of cyclic AMP (0.025 mM), 5 pi of PKA Biotinylated Peptide
Substrate (0.5 mM), 5 pi [gamma-33P]ATP mix (5 pi 0.5 mM ATP and 0.05 pi
[gamma- PJATP (3,000Ci/mmol) lOpCi/pl) was mixed gently and pre-incubated at
30 °C for 5 min. A control reaction without substrate was performed to determine
background counts. The PKA activity reaction was initiated by adding 5 pi of the
lysates to the reactants and incubated at 30°C for 5 min. The reaction was terminated
by adding 12.5 pi of Termination buffer to each sample (Promega, Southampton,
UK). Aliquots (10 pi) from each terminated reaction sample were spotted onto
prenumbered SAM2™
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Membrane squares (Promega, Southampton, UK). The SAM2™ Membrane squares
containing the spotted samples were then washed 1 x 30 seconds with 200 ml 2 M
NaCl (Sigma, Poole, Dorset, UK) followed by 3 x washes for 2 min of 200 ml 2 M
NaCl then 4 x washes for 2 min of 200 ml 2 M NaCl in 1% H3PO4. Finally the
Membrane squares were quickly washed in deionized water before being allowed to
dry. PKA activity was measured by scintillation counting.
2.7.2 WESTERN BLOTTING
A number of lysis methods were employed to extract neutrophil proteins as
inconsistent results and glucocorticoid receptor (GR) proteolysis were found when
standard lysis methods were utilised (Figures 2.1 and 2.2). These problems occurred
despite inclusion of a broad spectrum of protease inhibitors and may reflect the major
protease content of neutrophils.
2.7.2.1 Extraction of proteins from neutrophils using Triton X-100 lysis buffer
200 pi of Triton X-100 lysis buffer (see buffers) was added to the PBS washed,
pelleted (10 x 106) neutrophils and the cells thoroughly resuspended by repeat
pipetting. The samples were then incubated on ice for 10 min before being
centrifuged (20000g, 4°C, 10 min). The resulting supernatants were stored at -80°C
prior to analysis. Prior to electrophoresis, 15 pi of 3 x sample buffer was added to 30
pi of lysate and samples boiled for 2 min, 95°C.
2.7.2.2 Extraction of proteins from neutrophils using boiling sample buffer
Washed cell pellets were resuspended in 40 pi of lx sample buffer, preheated to
95°C. Samples were then vortexed and sonicated before being stored at 4°C.
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2.7.2.3 Extraction of proteins from neutrophils using NP40 lysis buffer
100 pi of cytoplasmic NP40 lysis buffer (see buffers) was added to the washed,
pelleted neutrophils and the cells thoroughly resuspended by repeat pipetting. The
samples were then incubated on ice for 10 min before being centrifuged (4300g, 4°C,
10 min). Supematants were harvested and stored at -80°C prior to analysis. To the
remaining pellet, 50 pi of nuclear NP40 lysis buffer was added and the samples
incubated on ice for 10 min before being centrifuged (23100g, 4°C 10 min).
Supematants were saved and stored at -80°C prior to analysis
2.7.2.4 Extraction of proteins from neutrophils using NP40 lysis buffer for
proteins sensitive to proteases (PSP)
100 pi of cytoplasmic NP-40 lysis buffer (cLBPSP) (see buffers) was added to the
washed, pelleted neutrophils and the cells thoroughly resuspended by repeat
pipetting. The samples were incubated on ice for 10 min to help aid neutralisation of
surfaces proteases. Following the 10 min incubation time, 10 pi ofNP-40 was added,
the sample flick-mixed, before being centrifuged (4300g, 10 min). Supematants were
harvested and immediately added to 50pl of 3 x sample buffer, before being boiled
for 2 min, 95°C. The remaining cell pellet was resuspended in 50 pi of nuclear NP-
40 lysis buffer (nLBPSP) (see buffers) and the samples placed at 4°C with constant
shaking, to solubilise nuclear proteins. After 20 min incubation the samples were
centrifuged (23100g, 10 min) and the supematants added to 25pl of 3 x sample
buffer before being boiled for 2 min, 95°C.
2.7.3 ASSESSMENT OF PROTEIN CONCENTRATIONS
Protein concentrations were quantified using a BCA protein assay (Pierce, IL, USA).
This assay is based on the ability of protein present in the test samples to cause a
reduction of Cu2+ to Cu+ and bicinchoninic acid (BCA) to chelate Cu+ forming a
purple compound which can be measured using spectrophotometry (562 nm) (Smith
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et al., 1985). Samples were diluted 1 in 10 in dH20 and 10 |il incubated with 200 fil
of test solution (30 min, 37°C) in 96 well plates prior to analysis using an automated
plate reader (MR5000, Dynatech, UK). Samples were assayed in triplicate and
standard curves formed using pre-made BSA standards.
2.7.4 SEPARATION OF PROTEIN EXTRACTS BY POLYACRYLAMIDE
GEL ELECROPHORESIS (PAGE)
Protein extracts (50 pg protein) were subject to SDS-PAGE on polyacrylamide gels.
Samples were electrophoresed at 150 Volts using SDS-Tris-Glycine electrophoresis
buffer (Mini Protean II apparatus, Biorad, CA) for one hour beside pre-stained
molecular weight markers (Gibco BRL, Paisley, U.K.). Unless otherwise stated,
proteins were transferred to nitrocellulose (Hybond C, Amersham Pharmacia
Biotech, Amersham, U.K.) using methanol based transfer buffer at 60 Volts for 1 hr.
Non-specific protein binding sites on the nitrocellulose membrane were blocked by
incubation of the membranes in 50 ml of blocking buffer for one hour at 37°C.
Membranes were then incubated at 4°C overnight in 3 ml blocking buffer containing
the appropriate primary antibodies with constant shaking. This was followed by 3
sequential washes (5 min, 25°C) in Western wash buffer. Membranes were then
incubated with the appropriate horse-radish peroxidase (HRP)-conjugated secondary
antibodies either (a) HRP-Goat anti mouse Ig (Dako Corporation, Cambridege, UK)
or (b) HRP-donkey anti rabbit Ig (Amersham) diluted 1 in 2000 in blocking buffer
for one hour at room temperature with gentle shaking. Membranes were washed a
further 3 times with 50 ml wash buffer before 1 min incubation with ECL reagent
(Amersham). Excess ECL reagent was removed and the membrane placed under
BioMax MS-1 X-ray sensitive film. Films were processed through an X-ray
developer (X-Ograph Imaging Systems, Wilts, U.K.) at various exposure time points
(lmin, 3min, 5 min and 10 mins).
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2.7.5 WESTERN BLOTTING FOR THE GLUCOCORTICOID RECEPTOR
(GR)
When neutrophil lysates, prepared using a standard Triton X-100 based lysis buffer
(section 2.7.2.1), were separated with SDS-PAGE and the Western blots developed
using an anti-GR antibody, several bands were observed (Figure 2.1A), suggesting
non-specific binding of the rabbit polyclonal antibody or severe protein degradation
during the neutrophil lysis. A similar result was observed when neutrophil lysates
were prepared by direct lysis of neutrophils using boiling Laemelli buffer (Section
2.7.2.2, Figure 2.IB). Furthermore neutrophil lysates prepared using a standard NP-
40 lysis buffer, failed to produce a band of the appropriate molecular weight for GR
(Section 2.7.2.3, Figure 2.2A). To investigate if problems in western blotting for GR
were due to poor antibody binding, anti-GR antibody was tested against pre-prepared
human epidermal A431 cell line lysates from Santa Cruz and A431 and neutrophil
cytoplasmic extracts prepared by a standard NP40 lysis buffer (Section 2.7.2.3,
Figure 2.2Aand 2.2B). Figure 2.2A shows a Western blot of neutrophil proteins
prepared using by a standard NP-40 lysis buffer in which neutrophils do not appear
to express GR. Expression of GR was found in A431 cytoplasmic lysates prepared
by the same lysis method or in pre-prepared A431 lysates from Santa Cruz (Figure
2.3). Neutrophil cytoplasmic extracts could be successfully immunoblotted for actin
(NH3) indicating that extraction method was sufficient for detecting high abundance
proteins in neutrophils (Figure 2.2B). From this result it would appear that anti-GR
antibody does recognise GR in A431 cells yet cannot detect GR expression in
neutrophils. This suggests that difficulty in detection of GR in neutrophils is not due
to poor antibody binding but may instead reflect either a low expression level of GR
in neutrophils or degradation of GR in these cells, despite inclusion of a broad range
of protease inhibitors in the lysis buffer. To investigate if difficulty in detection of
GR in granulocytes was due to proteolytic degradation of GR in these cells, we
further optimised a standard NP40 lysis protocol (Section 2.7.2.4) to include a high
protease inhibitor content lysis buffer and incubation of granulocytes with protease
inhibitors before lysis to neutralise surface proteolytic activity. Using this lysis
method, a band of the appropriate molecular weight to GR could be consistently
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detected in neutrophils (See Figures 4.4.1A and 4.4.1B). This suggests that protease
activity of granulocytes is a major problem for successful immunoblotting and
consequently, this optimised NP40 lysis protocol was used for all other
immunoblotting.
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97kDa —►
Figure 2.1 Immunoblotting for GR in neutrophil lysates. Neutrophil lysates were
prepared using a standard Triton X-100 lysis buffer (A) or by direct addition of boiling
Laemelli buffer (B). Cell lysates were prepared and immunoblotted as described under
"Materials and Methods". Lysates were prepared from equivalent numbers of cells and
subjected to SDS-PAGE/immunoblot analysis using a 8.5 % polyacrylamide gel and
membranes probed with a rabbit anti-human GR antibody (PA 1-511). The gels are
representative of 3 experiments.
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GRa (PA1-511)
I NEUTROPHILS 1 A431 A431




NEUTROPHILS 1 A431 A431
CYT CYT NUC NUC CYT WC
Figure 2.2. Western blot analysis for GRa in neutrophils. Neutrophil and A431
cytoplasmic (CYT) and nuclear (NUC) lysates were prepared using standard NP40 lysis
buffer and immunoblotted as described under "Materials and Methods". Lysates were
prepared from equivalent numbers of cells and subjected to SDS-PAGE/immunoblot
analysis using antibodies against either GRa (PA 1-511) (A) or actin (NH3) (B). As a
positive control the last lane contains a whole cell lysate (WC) supplied by Santa Cruz
made from A431 cell lines.
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2.7.6 WESTERN BLOTTING FOR SECRETORY LEUKOCYTE
PROTEINASE INHIBITOR (SLPI)
Neutrophils and eosinophils were cultured at 5 x 106/ml or 2.5 x 106/ml respectively
in Iscove's DMEM supplemented with 10% autologous serum, 50 U/ml penicillin,
and 50 U/ml streptomycin. Cells were cultured for 20 h in the presence or absence of
appropriate concentrations of dexamethasone. The supernatants were then harvested
and dialysed overnight using dialysis tubing (MWCO 3,500) to remove excess salts
from the medium. Supematants were run on a 15 % polyacrylaminde gel and
Western blotting was performed as in Section 2.7.4 using a rabbit anti-human SLPI
antibody (gift from J.Sallenave).
2.8 STATISTICAL ANALYSIS
Results are reported either as pooled data from a series of n separate experiments
(mean ± S.E.) or as individual representative experiments (mean ± SD, 3
replicates/condition). Statistical significance was assessed by the students t-test or,
by one way analysis of variance with comparisons between groups made using the
Newman-Keuls procedure.
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3 CYCLIC AMP REGULATION OF GRANULOCYTE
APOPTOSIS
Cyclic AMP is a key second messenger that plays a central role in regulating a
multitude of cellular processes. It is widely recognised that cyclic AMP is involved
in the control of many cellular events occurring in the immune system such as
proliferation, differentiation and chemotaxis. For example, cyclic AMP induces
eosinophilic differentiation of human leukaemia cell line Eol-1 (Jung et al., 1994)
and potentiates granulocytic differentiation of retinoid induced maturation of human
myeloid leukaemia cells (Olsson and Breitman, 1982). Cyclic AMP is also able to
influence development of the immune system through its ability to affect T cell
effector function. Elevation of cyclic AMP has been shown to both inhibit
lymphocyte proliferation (Estes et al., 1971; Skalhegg et al., 1992; Bauman et al.,
1994; Bryce et al., 1999) and regulate mononuclear cell production of cytokines
influencing T cell polarisation. For example, elevation of cyclic AMP has been
shown to inhibit secretion of IFN y and IL-2 (Betz and Fox, 1991; Snijdewint et al.,
1993) but enhance production of IL-5 (Lacour et al., 1994), IL-10 (Platzer et al.,
1995) and IL-l-(3 (Lorenz et al., 1995). The ability of cyclic AMP to inhibit Thl
type cytokine production lead to the proposal that cyclic AMP favoured development
of a Th2 phenotype (Gajewski et al., 1990; Betz and Fox, 1991) however the finding
that cyclic AMP also inhibited IL-4 secretion (Borger et al., 1996; Sottile et al.,
1996) has put this into question.
In addition to influencing adaptive immune responses, cyclic AMP plays an
important role in regulating innate immune cell function. (32-adrenoceptor agonists
have been found to be very effective in the treatment of inflammatory diseases such
as asthma (Barnes, 1999). It is postulated that this relates partly to the ability of (32-
adrenoceptor agonists to stimulate increases in cyclic AMP, leading to suppression of
inflammatory cell function (Hallsworth et al., 2001). For example, elevation of cyclic
AMP is known to inhibit directly many granulocyte functions such as superoxide
anion release (Schudt et al., 1991; Lad et al., 1985), degranulation (Kita et al.,
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1991b), enzyme secretion (Wada, 1989) and the induction of the respiratory burst
(Dent et al., 1994). Cyclic AMP will also inhibit indirectly inflammatory cell
activity by suppressing release of many proinflammatory mediators such as
eicosanoids (Ham et al., 1983), LTC4 (Tenor et al., 1996), thromboxane A2 (Zheng et
al., 1991) and eosinophil activating cytokines such as GM-CSF, RANTES and
eotaxin (Hallsworth et al., 2001). The effect of cyclic AMP on neutrophil chemotaxis
however is somewhat more controversial with reports that [^-adrenoceptor agonist
suppression of LTB4 induced chemotaxis does not relate to its ability to elevate
cyclic AMP (Harvath et al., 1991). Forskolin, a more effective elevator of cAMP,
also was found to be ineffectual at inhibiting LTB4 induced chemotaxis in this cell
type (Harvath et al., 1991) suggesting that intracellular concentration of cyclic AMP
is not the key determinant in suppression of neutrophil chemotaxis. In light of these
findings it appears cyclic AMP suppresses certain responses in neutrophils such as
release of PAF and superoxide anions yet fails to affect other neutrophil responses
such as priming, chemotaxis and transmigration (Daniels et al., 1993; Armstrong,
1995)
The mechanism by which cyclic AMP regulates control of various cellular processes
involves a well-characterised signalling pathway initiated by the specific ligation of
appropriate G protein coupled receptors (Figure 3). Following conformational
changes induced by ligand binding, Gs composed of 0Cs and (3y subunits, becomes
activated causing the 0Cs subunit to dissociate from the Gs complex, exposing a
binding site for adenylate cyclase. Binding of the Os subunit to adenylate cyclase, of
which there are at least nine membrane isoforms, leads to the formation of cyclic
AMP from ATP (Hanoune and Defer, 2001). Cyclic AMP signalling is typically
transient, with formation of cyclic AMP in the cell being balanced by progressive
degradation by cyclic nucleotide phosphodiesterases (PDEs). There have been at
least 10 different isoenzyme classes of PDEs described in mammalian cells (PDE1-
PDE10) with this superfamily being further subdivided due to the presence of
multiple splice variants (Houslay and Milligan, 1997). In inflammatory cells, the
predominant PDEs expressed are type III and IV, with granulocytes reported to
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contain only PDE IV (Dent et al., 1991). The formation of cyclic AMP by adenylate
cyclase initiates cyclic AMP binding to cytoplasmic protein kinase A; a tetrameric
structure composed of two regulatory (R) and two catalytic (C) subunits which exists
as an inactive holoenzyme complex in the absence of cyclic AMP (Daniel et al.,
1998). There are two isoforms of PKA identified, namely PKA-I and PKA-II, which
are differentiated on the basis of their regulatory subunits (RI and RII) (Rubin, 1994;
Beebe, 1994) Expression of a particular isoform of PKA regulatory subunits has
important consequences for the subcellular localisation of PKA. For example, it has
been found that a family of proteins called A-kinase anchoring proteins (AKAPs)
will interact with RII subunits of PKA when inactive, sequestering PKA at specific
locations within the cell (Rubin, 1994). AKAPs do not appear to bind RI subunits of
PKA, thus cyclic AMP dependent signalling may vary as a consequence of which
PKA isoforms are present in a particular cell (Rubin, 1994; Scott and McCartney,
1994). There is also some evidence that cyclic AMP signalling may be further
compartmentalised. Caveolae membrane microdomains have been found to contain
many components involved in cyclic AMP signalling. Furthermore, caveolinl has
been shown to be capable of abrogating cyclic AMP signalling (Razani et al., 1999).
The consequences of compartmentalisation on downstream signalling events of
cyclic AMP have still to be elucidated.
Activation of PKA by cyclic AMP results in the translocation of the catalytic
subunits to the nucleus, allowing phosphorylation of specific cellular substrates such
as transcription factors. These include cyclic AMP responsive element binding
protein (CREB), cyclic AMP responsive element modulator (CREM) and activating
transcription factor 1 (ATF1) (Sassone-Corsi, 1995). These transcription factors bind
as dimers to the cyclic AMP consensus sequence TGACGTXA, known as the cyclic
AMP responsive element (CRE) (Sassone-Corsi, 1995). Binding of transcription
factors to CRE is thought to allow cyclic AMP stimulated signals to subsequently
affect gene transcription (Sassone-Corsi, 1995). Transcription of CRE regulated
genes may be augmented by interaction with CBP (CREB binding protein) which
bridges CREB with the basal transcriptional machinery (Goldman et al., 1997). CBP
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CYCLIC AMP SIGNAL TRANSDUCTION CASCADE
Figure 3 Cyclic AMP signalling cascade. Ligand binding to G-coupled receptors activates
a stimulatory G-protein (Gs). This activates adenylate cyclase (AC) leading to formation of
cyclic AMP from ATP. Active PKA catalytic subunits are released following cyclic AMP
binding to PKA regulatory subunits. The C subunits phosphorylate targets in the cytoplasm
(e.g. Bad, Rapl) and in the nucleus (e.g. cyclic AMP response element binding protein
(CREB)).
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is believed to have a more universal role and may also allow integration of signals
from other transcription factors such as AP-1 (Kamei et al., 1996). Other
transcription factors regulated by and responsive to the activation of the cyclic AMP
signalling pathway include NFkB (Chen and Rothenberg, 1994; Satriano and
Schlondorff, 1994) and nuclear receptors (Darwish et al., 1993).
It is important to note that PKA has been reported to act independently of cyclic
AMP in some circumstances. It has been demonstrated that PKA is capable of
regulating NFkB transcription by phosphorylating p65 and initiating the degradation
of IkB (Zhong et al., 1997), in a ligand independent manner. Furthermore it has been
reported that PKA can form part of an inactive complex with NFkB/IkB (Zhong et
al., 1997) and is thought to be responsible for regulating glucocorticoid-mediated
suppression ofNFkB independently of cyclic AMP (Doucas et al., 2000).
Until recently it was assumed that cyclic AMP exerted its physiological functions
almost solely through activation of PKA. However this appears to not be the case
with the discovery of a new family of cyclic AMP binding proteins which have close
sequence similarity to PKA (Kawasaki et al., 1998; de Rooij et al., 2000). These
cyclic AMP binding proteins termed cyclic AMP specific guanine nucleotide
exchange factors (cAMP-GEFs) contain a guanine nucleotide exchange factor (GEF)
domain and a cyclic AMP binding domain which closely resemble the cyclic AMP
binding sites of PKA (de Rooij et al., 2000; Kawasaki et al., 1998). There have been
two cAMP-GEFs identified, namely cAMP-GEFI (or Epac) and cAMP-GEFII (de
Rooij et al., 2000; Kawasaki et al., 1998). Binding of cyclic AMP to cAMP-GEFs
results in the activation of the small Ras like GTPase, Rap-1 (de Rooij et al., 2000).
The functional consequences of activation of Rap 1 have not been fully established,
however Rap-1 is postulated to have a role in platelet aggregation (Bos, 1998), cell
differentiation (York et al., 1998), cell proliferation (Altschuler and Ribeiro-Neto,
1998) and T cell anergy (Boussiotis et al., 1997). The downstream signalling cascade
of Rapl is poorly defined, however there have been suggestions that Rapl may
antagonise Ras signalling (Cook et al., 1993; Hu et al., 1997b). This has recently
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been disputed with the finding that ERK activation ofRap 1 fails to interfere with Ras
effector signalling (Zwartkruis et al., 1998). The localisation of Rapl may however
give clues as to its function as it has been shown to be present in the mid Golgi, early
and late endocytic vesicles and lysosomes whereas Ras is mainly localised in the
plasma membrane (Pizon et al., 1994).
Many of the molecular mechanisms underlying cyclic AMP regulation of cellular
events are well characterised. However, the ability of this ubiquitous second
messenger to regulate one aspect of cellular function remains poorly defined. Cyclic
AMP can powerfully and differentially modulate apoptosis in a wide variety of cell
types yet little is known of the molecular mechanisms controlling this process. It has
recently come to light that cyclic AMP is involved in the regulation of the pro-
apoptotic Bcl-2 family member Bad (Harada et al., 1999). Bad is found to be
associated with Bc1-Xl at the mitochondrial outer membrane (Zha et al., 1997). It has
been proposed that following cyclic AMP mediated activation of PKA there is
phosphorylation of key serine residues on Bad, allows the dissociation of Bad from
Bcl-XL(Harada et al., 1999). Bad is then thought to be sequestered in the cytoplasm
by 14-3-3 resulting in abrogation of its pro-apoptotic properties, allowing cell
survival (Zha et al., 1996). The physiological importance of this pathway has yet to
be determined however it is unlikely that this is the universal mechanism controlling
cyclic AMP regulated apoptosis, considering the divergent effects cyclic AMP has
on cell death in different cell types.
The importance of understanding the signalling pathways mediated by cyclic AMP,
in the control of apoptosis, is exemplified by the wide variety of cells in which cyclic
AMP determines cell fate. For example, elevation of cyclic AMP induces apoptosis
in thymocytes (McConkey et al., 1990; Suzuki et al., 1991), primary granulosa cells
(Aharoni et al., 1995), myeloid cell lines (Lanotte et al., 1991) and WEHI7.2 murine
lymphocytes (Dowd et al., 1992). The signalling mechanisms used by cyclic AMP to
control these events are likely to be complex and cell type specific. For example, in
contrast to the profound induction of apoptosis in the cell types above, evidence has
emerged demonstrating that cyclic AMP can provide protection from cell death in
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many cell types. Cyclic AMP inhibits apoptosis in pancreatic cancer cells (Boucher
et al., 2001), protects human osteoblasts from NO induced apoptosis (Chae et al.,
2001) and promotes neuronal survival (Deckwerth and Johnson, Jr., 1993; D'Mello et
al., 1993; De et al., 1994; Li et al., 2000a). There has been recent interest in the
finding that cyclic AMP can also regulate granulocyte apoptosis. Elevation of cyclic
AMP using either analogues of cyclic AMP (Rossi et al., 1995) or receptor directed
prostaglandins (Rossi et al., 1995; Ottonello et al., 1998) has been reported to
profoundly delay neutrophil apoptosis. Various studies have described similar
findings in eosinophils yet little is known of the signalling mechanism by which
cyclic AMP appears to regulate this cell function (Chang et al., 2000; Peacock et al.,
1999; Hallsworth et al., 1996). We have previously highlighted the importance of
regulated granulocyte apoptosis, as a vital process for ensuring the successful
resolution of an inflammatory response (Savill, 1992; Stem et al., 1992). The
obvious consequence of the knowledge that cyclic AMP can protect against
granulocyte apoptosis, is the chance to promote apoptosis indirectly by blocking the
influence of this survival factor and augment phagocytic removal of these cells.
Since the mechanisms by which cyclic AMP influences granulocyte apoptosis and
the signalling pathways involved in regulating granulocyte cell death remain ill
defined, our aim was to investigate the underlying molecular mechanism and
establish a greater understanding of the control of neutrophil cell death.
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3.1 ELEVATION OF CYCLIC AMP DELAYS CONSTITUTIVE
NEUTROPHIL APOPTOSIS
To examine the effects of cyclic AMP on constitutive neutrophil apoptosis,
neutrophils (5 x 106/ml) cultured in serum supplemented Iscove's DMEM, were
exposed to dibutyryl cyclic AMP (dbcAMP), a membrane-permeant cyclic AMP
analogue and the receptor directed stimulus prostaglandin E2 (PGE2), for 20 h. Both
dbcAMP and PGE2 delay morphological changes characteristic of constitutive
neutrophil apoptosis, such as cytoplasmic shrinkage and nuclear condensation
(Figure 3.1.1). DbcAMP and PGE2 also delay cell membrane changes associated
with apoptosis such as the exposure of phosphatidylserine measured by Annexin V
binding (Figures 3.1.2 and 3.1.3). Figure 3.1.2 illustrates the percentage of cells
within the Annexin V "high" gate was reduced by dbcAMP treatment from 63% (B;
control) to 34% (C). It is interesting to note that maximal concentrations of dbcAMP,
established previously as 0.2 mM (Rossi et al., 1995), are more effective at delaying
neutrophil apoptosis compared to maximal concentrations of PGE2 (10 jiM) (Figure
3.1.3). Assessment of cell viability by trypan blue exclusion demonstrated that
dbcAMP or PGE2 did not alter this parameter (data not shown).
Cyclic AMP mediated delay of neutrophil apoptosis was also measured by loss of
cell surface CD16 (FcyRIII), a process that has been characterised as a further marker
of spontaneous neutrophil death (Dransfield et al., 1994). The marked inhibition of
apoptosis induced by dbcAMP (as determined by CD 16 shedding) is exemplified by
the representative flow cytometric analysis depicted in Figure 3.1.4. The CD16 " low
peak" in the control 24 h cells represents apoptotic cells that have shed their cell
surface CD 16; the percentage cells with "low" CD 16 was markedly reduced when
compared to cells that have been treated with dbcAMP whereas the corresponding
CD 16 "high" peak was increased. Together these results demonstrate morphological
and surface alterations that accompany apoptosis are inhibited by elevators of cyclic
AMP.
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SUMMARY
• Elevation of cyclic AMP by dbcAMP and PGE2 delays morphological changes
that occur during neutrophil apoptosis.
• Elevation of cyclic AMP delays expression of phosphatidylserine and inhibits
cell surface loss ofCD16 (FCRylll) that occur during neutrophil apoptosis.
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Figure 3.1.1 Neutrophil apoptosis is delayed by elevation of cyclic AMP. Human
neutrophils (5 x 106/ml) were cultured in Iscove's DMEM containing 10% autologous
serum at 37 °C, with or without dbcAMP (0.2mM). After 20 h, cells were harvested and
assessed morphologically for apoptosis. The upper panel indicates control neutrophils
after 20 h in culture. The bottom panel indicates neutrophils treated with dbcAMP for 20
h.
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Figure 3.1.2 Cyclic AMP elevation delays neutrophil apoptosis. (A) represents a
typical flow cytometric scatter plot for neutrophils. (B) represents control neutrophils
after 20h in culture incubated with FITC-labelled recombinant human Annexin-V to
determine phosphatidylserine expression. Similarly (C) represents neutrophils
stimulated with dbcAMP for 20 h before incubation with FITC-labelled recombinant
human Annexin-V to determine phosphatidylserine exposure.
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control PGE2 dbcAMP
Figure 3.1.3 Cyclic AMP elevation delays neutrophil apoptosis as assessed by
Annexin V binding. Human neutrophils (5 x 106/ml) were cultured at 37 °C in Iscove's
DMEM containing 10% autologous serum and treated with dbcAMP (0.2 mM) or PGE2
(10 |iM). After 20 h, the cells were incubated with FITC-labelled recombinant human
Annexin-V to determine phosphatidylserine exposure. All values represent mean ± S. E.
of n = 5 - 8 experiments, each performed in duplicate where significant difference from
control is represented by * PO.OOl and #P<0.05. Similar results were found by
morphological assessment of apoptosis (data not shown).
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Figure 3.1.4 Cyclic AMP elevation delays neutrophil apoptosis as assessed by CD16
shedding. Human neutrophils (5 x 106/ml) were cultured at 37 °C in Iscove's DMEM
containing 10% autologous serum and treated with or without dbcAMP (0.2 mM). After
24 h, the cells were measured for CD 16 expression as outlined in the "Methods" section
before being analysed on FACS Calibur and the CellQuest associated software. Data
presented is of one representative experiment.
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3.2 CYCLIC AMP ELEVATION INHIBITS CASPASE-3
EXPRESSION DURING CONSTITUTIVE NEUTROPHIL
APOPTOSIS
In light of the findings that cyclic AMP elevating agents delay neutrophil apoptosis,
we were interested in investigating the point at which cyclic AMP influenced the
apoptotic signalling cascade. It is widely believed that caspases act as the main
executioners of apoptosis, with their activation resulting in chromatin condensation
and DNA fragmentation. Whether cyclic AMP delays constitutive neutrophil
apoptosis by directly suppressing caspase activation in these cells has not been
examined. We therefore investigated the effect of cyclic AMP on activation of
caspase-3 during constitutive neutrophil apoptosis. Cytoplasmic extracts were
obtained from neutrophils which had been treated with control buffer or dbcAMP
(0.2 mM) over a time course of 20 h. Lysates were prepared from equivalent
numbers of cells and were subject to SDS-PAGE/immunoblot analysis using a rabbit
polyclonal antibody specific for caspase-3. The caspase-3 antibody recognizes both
the 32 kD pro-caspase-3 and the 17 kD subunit of active caspase-3. Neutrophils
began to express active caspase-3 (17kD) at 8 h and by 20 h there was significant
caspase-3 activity (17kD) which could be inhibited by dbcAMP (Figure 3.2.1.). We
also found that expression of caspase-3 correlated with the phosphatidylserine
exposure that occurs during constitutive neutrophil apoptosis (Figure 3.2.2). The
appearance of some caspase-3 activity in the presence of dbcAMP at 20 h probably
reflects the presence of some apoptotic cells in the population (Figure 3.2.2). The
intriguing nature of the results illustrated above raised the possibility that cyclic
AMP mediated delay of neutrophil apoptosis is due to suppression of caspase
activation. We therefore studied the effect of co-culturing dbcAMP and the pan
caspase inhibitor z-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) on the rate of
neutrophil apoptosis. Figure 3.2.3 shows that when neutrophils are co-cultured in the
presence of both dbcAMP and zVAD-fmk their individual effects are less than
additive suggesting that these reagents delay neutrophil apoptosis by a common
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Figure 3.2.1 Time course for the effect of dbcAMP on caspase-3 expression during
human neutrophil apoptosis Western blot of cytoplasmic extracts from neutrophils
treated with control buffer or dbcAMP (0.2 mM) for the time points indicated. Cell
lysates were prepared and immunoblotted as described under "Materials and Methods".
Lysates were prepared from equivalent numbers of cells and subjected to SDS-
PAGE/immunoblot analysis. A 12.5% gel was used. The rabbit polyclonal antibody to
caspase-3 antibody recognizes both the 32 kDa pro-caspase-3 and the 17 kDa subunit of
active caspase-3. The 17 kD caspase-3 cleavage product is faintly visible in control
lysates at 8 h becoming more apparent by 20 h. The gel is representative of 3
experiments.
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Figure 3.2.2 Time course for phosphatidylserine exposure during overnight
neutrophil culture. Human neutrophils were treated with or without dbeAMP (0.2 mM)
for the time points indicated under equivalent culture conditions as the cells used for
caspase-3 expression assessment above. Cells were assessed for apoptosis by
measurement of phosphatidylserine expression using Annexin-V FITC. All values
represent mean ± S.E. of n = 3 experiments, each performed in duplicate where
significant difference from control is represented by * P<0.001.
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inhibitory mechanism. However further experiments involving much wider
concentration ranges of both reagents are necessary to make any firm conclusions
regarding this data. It is intriguing that elevation of cyclic AMP delayed neutrophil
apoptosis more effectively than blockade of caspase activation by zVAD-fmk. This
suggests either that cyclic AMP elevation more effectively inhibits caspase activation
than zVAD-fmk or alternatively cyclic AMP may act partially through a mechanism
not involving inhibition of caspase activation, in order to suppress neutrophil
apoptosis.
It is interesting that blockade of caspase activation by zVAD-fmk does not fully
suppress neutrophil apoptosis. This is unlikely to be due to poor cell permeability, as
zVAD-fmk will effectively block TNFoc induced apoptosis in neutrophils (Ward et
al., 1999a). It is however possible that zVAD-fmk may be degraded during overnight
culture and therefore caspase activity may not be effectively blocked during the 20 h
culture period. Although this may be possible, a further and more interesting
interpretation of the data would be that constitutive neutrophil apoptosis occurs
partially independently of caspase activation.
SUMMARY
• Constitutive neutrophil apoptosis is accompanied by expression of active
caspase-3.
• Elevation of cyclic AMP delays expression of caspase-3 during constitutive
neutrophil apoptosis.
• Studies with zVAD-fmk suggest constitutive neutrophil apoptosis may occur
partially through a caspase-independent mechanism.
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Figure 3.2.3 Comparison of the effects of dbcAMP and zVAD-fmk on neutrophil
apoptosis. Human neutrophils (5 x 10 6/ml) were cultured at 37 °C in Iscove's DMEM
containing 10% autologous serum and treated with dbcAMP (0.2 mM) or zVAD-fmk (100
pM). After 20 h, the cells were incubated with FITC-labelled recombinant human
Annexin-V to determine phosphatidylserine expression. All values represent mean ± S. E.
of n = 3 experiments, each performed in duplicate where significance from control is
represented by *P<0.001 or #P<0.01 and significance from dbcAMP alone is represented
by ±P<0.05.
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3.3 CYCLIC AMP INHIBITS LOSS OF MITOCHONDRIAL
POTENTIAL OCCURRING DURING CONSTITUTIVE
NEUTROPHIL APOPTOSIS
3.3.1 DETERMINATION OF WHETHER NEUTROPHILS CONTAIN
MITOCHONDRIA
In many cell models, apoptosis is accompanied by an early dissipation of the
mitochondrial transmembrane potential (AThn) (Zamzami et al., 1995). Previous data
have indicated that neutrophils do not respire and it was thought unlikely that they
contained many, if any mitochondria (Simon, 2001). To investigate whether cyclic
AMP mediated delay of neutrophil apoptosis involves regulating changes in
mitochondrial membrane potential we firstly examined if changes in mitochondrial
membrane potential occur during constitutive neutrophil apoptosis. Using confocal
microscopy and flow cytometry we have been able to demonstrate that neutrophils
do contain mitochondria (orange), which during overnight culture exhibit loss of
mitochondrial potential, as indicated by an increase in green fluorescence using the
mitochondrial specific dye JC-1 (Reers et al., 1991) (Figure 3.3.1). Cells displaying
necrotic morphology were distinguished from the rest of the cell population by using
the impermeant nucleic acid dead-cell stain TOPRO-3 (van Hooijdonk et al., 1994).
We found that >99% of neutrophils were viable as assessed by exclusion of TOPRO-
3.
3.3.2 EFFECT OF CYCLIC AMP ON DISSIPATION OF MITOCHONDRIAL
TRANSMEMBRANE POTENTIAL DURING NEUTROPHIL APOPTOSIS
To investigate if cyclic AMP delays neutrophil apoptosis by affecting mitochondrial
membrane potential, cells were cultured in the presence or absence of dbcAMP for
20 h, before measurement ofmitochondrial membrane potential by JC-1. Our studies
reveal that dbcAMP inhibits changes in mitochondrial potential associated with
constitutive neutrophil apoptosis (Figure 3.3.2 A & B). As the number of cells
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Figure 3.3.1 Demonstration of mitochondria within neutrophils. Human neutrophils (1
x 106/ml) were cultured at 37 °C in Iscove's DMEM containing 10% autologous serum.
Neutrophils were labelled with JC-1, a mitochondrial specific dye, and examined by
confocal fluorescent microscopy as described under "Materials and Methods". Bottom
panels show TO-PRO-3 staining for neutrophils with necrotic morphology (blue).
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showing loss of mitochondrial potential appeared to correlate with the number of
apoptotic cells measured by Annexin-V positivity (Figure 3.3.2 C), we wanted to
examine directly if loss in mitochondrial potential occurs in those neutrophils
undergoing apoptosis. By using conjugated anti-CD 16 magnetic beads we were able
to perform immunodepletion of non-apoptotic neutrophils. We confirmed that the
remaining cells following immunodepletion were apoptotic by Annexin-V binding
(Figure 3.3.2 E). Furthermore, we found that the remaining apoptotic neutrophils
were indeed positive for loss of mitochondrial potential, indicating that dissipation of
mitochondrial membrane potential occurs in neutrophils undergoing programmed
cell death (Figure 3.3.2 D). It has been previously shown that inhibitors of the
mitochondrial respiratory chain do not affect constitutive neutrophil apoptosis,
raising the question of the source of their AHhn (Mecklenburgh, 1999). It may be the
case that the neutrophil maintains a transmembrane gradient by a functional F1 Fo
ATPase, however this has to be investigated in more detail. We have demonstrated
that cyclic AMP mediated delay of neutrophil apoptosis appears to suppress both
caspase activation and changes in mitochondrial potential. We next investigated the
cyclic AMP signal transduction pathway responsible for this suppression of
neutrophil apoptosis and attempted to establish how it is coupled to controlling
components of the molecular machinery for cell death as described above.
SUMMARY
• Neutrophils contain a small number ofmitochondria.
• There is dissipation of mitochondria transmembrane potential in neutrophils
undergoing apoptosis.
• Elevation of cyclic AMP inhibits loss of mitochondrial membrane potential,
during constitutive neutrophil apoptosis.
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Figure 3.3.2 Effect of cyclic AMP on dissipation of mitochondrial transmembrane
potential during human neutrophil apoptosis. Human neutrophils (5 x 106/ml) were
cultured for 20 h at 37°C in Iscoves's DMEM containing 10% autologous serum with or
without dbcAMP (0.2 mM). Cells were then labelled with the mitochondrial specific dye
JC-1 as described under 'Materials and Methods' before flow cytometric analysis of
mitochondrial membrane potential (A, B & D). Apoptosis was assessed by incubation of
cells with FITC labelled recombinant human Annexin-V to determine the
phosphatidylserine exposure (C & E). Non-apoptotic neutrophils were removed by anti-
CD 16 immunodepletion before the remaining cells were labelled with either Annexin-V
FITC or JC-1. Shown as one representative experiment.
80
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
3.4 CYCLIC AMP REGULATION OF NEUTROPHIL
APOPTOSIS OCCURS INDEPENDENTLY OF PKA
3.4.1 CYCLIC AMP ELEVATION STIMULATES PKA ACTIVATION IN
NEUTROPHILS, AN EFFECT THAT IS BLOCKED BY
PHARMACOLOGICAL INHIBITORS
The major intracellular receptor for cyclic AMP is the regulatory (R) subunits of
protein kinase A (PKA) (Daniel et al., 1998). Binding of cyclic AMP to the R
subunits releases catalytic C subunits, which consequently phosphorylate target
proteins such as cyclic AMP response element binding protein (CREB) (Daniel et
al., 1998). It has been proposed that the increase of intracellular cyclic AMP
resulting in PKA activation is essential for neutrophil survival (Rossi et al., 1995;
Parvathenani et al., 1998; Tortorella et al., 1998a). To further investigate this we
examined the effects of cyclic AMP elevation on endogenous PKA activation (Figure
3.4.1). PKA activity was assessed in neutrophils by measuring the phosphorylation
of a biotinylated peptide substrate kemptide, which is highly specific for PKA (See
Materials & Methods). The transfer of a labelled phosphate to kemptide in neutrophil
lysates containing PKA activity, was measured by capture of the labelled substrate
on a streptavadin matrix, followed by scintillation counting. We found rapid
activation of PKA when cells were stimulated with both dbcAMP and PGE2 (Figure
3.4.1). Furthermore preincubating for 30 minutes with the pharmacological PKA
inhibitor H-89 (Chijiwa et al., 1990) blocked activation of PKA upon stimulation of
neutrophils with cyclic AMP elevators (Figure 3.4.1).
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Figure 3.4.1. Measurement of PKA activation by elevators of cyclic AMP in human
neutrophils. Human neutrophils (5 x 106/ml) were pre-incubated with 10 pM H-89 for 1
h before being stimulated with dbcAMP (0.2 mM) or PGE2 (1 pM) for 30 minutes at 37
°C. PKA activity was measured as described under "Materials and Methods". All values
represent mean ± S. E. of n = 3 experiments where significant difference from control
values is represented by *P<0.05. Significant difference from dbcAMP alone is
represented by P<0.01 and significant difference from PGE2 alone is represented by
*P<0.01.
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3.4.2 ACTIVATION OF THE PKA PATHWAY DOES NOT ACCOUNT FOR
CYCLIC AMP MEDIATED PROTECTION AGAINST APOPTOSIS.
To investigate if PKA activation by cyclic AMP was necessary for cyclic AMP
mediated delay of apoptosis, neutrophils were incubated with the PKA inhibitor H-
89 before being stimulated with dbcAMP and assessed for apoptosis. To our surprise
although pre-treatment with H-89 prevented activation of PKA, it did not prevent
inhibition of apoptosis by dbcAMP (Figure 3.4.2). Additionally other
pharmacological inhibitors of PKA such as the highly specific inhibitor Rp-8-
BrcAMPS (Gjertsen et al., 1995) also failed to block dbcAMP inhibition of
neutrophil apoptosis (Figure 3.4.3). This demonstrates that cyclic AMP elevation
stimulates PKA activity but PKA does not play a major role in the anti-apoptotic
effect of cyclic AMP elevation in neutrophils.
Moreover it is interesting that inhibition of PKA activity by H-89 suppresses basal
activation of PKA compared to control yet H-89 does not alter the rate of apoptosis
in neutrophils (Figure 3.4.1 and Figure 3.4.2). This suggests that basal turnover of
cyclic AMP and subsequent activation of PKA may not be an important factor in
regulating constitutive neutrophil apoptosis. The ability of H-89 to block PKA
activity, as shown by direct measurement of kinase activity, suggests a lack of
involvement ofPKA in the anti-apoptotic effect of cyclic AMP in neutrophils. It was
therefore important to determine whether H-89 could block PKA activity for the full
overnight culture period and under identical culture conditions that we use for our
apoptosis assay. Neutrophils were cultured in serum supplemented Iscove's DMEM
for 19 h in the presence or absence of H-89 before stimulation with PGE2 for 1 h.
PKA activity was then measured as described in the Materials and Methods. We
found that H-89 could still block PGE2 stimulated PKA activity at 20 h (Figure
3.4.4). This is very important as it demonstrates that the inability of H-89 to reverse
cyclic AMP mediated delay of neutrophil apoptosis is not due to degradation ofH-89
during the overnight culture period. Furthermore it also demonstrates that H-89 is not
inactivated by autologous serum which is used in our apoptosis assay.
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SUMMARY
• Elevation of cyclic AMP by dbcAMP and PGE2 stimulate PKA activity in
neutrophils.
• PKA stimulated activity is blocked by the pharmacological inhibitor H-89.
• Cyclic AMP mediated delay of neutrophil apoptosis is not reversed by the PKA
inhibitors H-89 and Rp-8-Br-cAMPS.
• Failure of H-89 and Rp-8-Br-cAMPS to reverse cyclic AMP mediated delay of
neutrophil apoptosis is not due to inactivation by autologous serum or
degradation of the inhibitors during overnight culture.
• Cyclic AMP mediated delay of neutrophil apoptosis likely occurs via a PKA
independent mechanism.
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Figure 3.4.2. The effect of pharmacological blockade of PKA activity on dbcAMP
mediated delay of neutrophil apoptosis. Human neutrophils (5 xl06/ml) cultured in
Iscove's DMEM containing 10% autologous serum at 37 °C, were pre-incubated for 30
min with H-89 (1 or 10 pM) before stimulation with dbcAMP (0.2 mM). After a further
20 h in culture, the cells were incubated with FITC-labelled recombinant human Annexin-
V to determine phosphatidylserine expression. All values represent mean ± S.E. of n = 3
experiments, each performed in duplicate where significant difference from control is
represented by *P<0.001. Similar results were found when cells were assessed for
apoptosis by morphological examination (data not shown).
85
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
80 i
control dbcAMP Rp-8-Br-cAMPS dbcAMP +
Rp-8-Br-cAMPS
Figure 3.4.3 The effect of pharmacological blockade of PKA activity on dbcAMP
mediated delay of neutrophil apoptosis. Human neutrophils (5 xl06/ml) cultured in
Iscove's DMEM containing 10% autologous serum at 37 °C, were pre-incubated for 30
min with Rp-8-Br-cAMPS (100 pM) before stimulation with dbcAMP (0.2 mM). After a
further 20 h in culture, the cells were incubated with FITC-labelled recombinant human
Annexin-V to determine phosphatidylserine expression. All values represent mean ± S. E.
of n = 3 experiments, each performed in duplicate where significant difference from
control is represented by *P<0.001. Similar results were found when cells were assessed
for apoptosis by morphological examination (data not shown).
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Figure 3.4.4. Measurement of PKA activation by elevators of cyclic AMP in human
neutrophils. Human neutrophils (5 x 106 /ml) were cultured in serum supplemented
Iscove's DMEM and were pre-incubated with 10 pM H-89 for 19 h before being
stimulated with PGE2 (1 pM) for 1 h at 37 °C. PKA activity was measured as described
under "Materials and Methods". Significant difference from PGE2 alone is represented by
><0.01.
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3.5 ACTIVATION OF AKT/PI-3 KINASE PATHWAY DOES NOT
ACCOUNT FOR CYCLIC AMP MEDIATED DELAY OF
NEUTROPHIL APOPTOSIS
In light of the surprising finding that cyclic AMP mediated delay of neutrophil
apoptosis was independent of PKA, we sought to investigate the involvement of
other signalling molecules which may act downstream of cyclic AMP to suppress
neutrophil apoptosis. The phosphoinositide-3 kinase/Akt pathway plays an essential
role in cell survival in various cell types (Datta et al., 1997). Activation of PI 3-
kinase leads to activation of downstream signalling molecules such as Akt/PKB
(Franke et al., 1995; Burgering and Coffer, 1995). It has been proposed that PI-3
kinase may regulate apoptosis through the serine phosphorylation of Bad, a pro-
apoptotic protein of Bcl-2 family (Datta et al., 1997). Furthermore, PI-3 kinase may
be involved in cyclic AMP signalling cascade in a variety of cells. For example, it
has been reported that cyclic AMP requires PI-3 kinase activation for DNA synthesis
induced by IGF-I in FRTL-5 cells (Nedachi et al., 2000), and is involved in the
ability of cyclic AMP to attenuate chemoattractant induced respiratory burst in
neutrophils (Ahmed et al., 1995). Therefore we examined if PI-3 kinase was
involved in the signalling pathway mediating the protective effect of cyclic AMP on
neutrophil survival. Cells were pre-incubated with the specific PI-3 kinase inhibitor
LY294002 (Vlahos et al., 1994) prior to exposing them to dbcAMP or GM-CSF. We
found that the PI-3 kinase inhibitor suppressed GM-CSF mediated delay of
neutrophil apoptosis, which has been previously reported (Klein et al., 2000), yet had
no effect on suppression of apoptosis by dbcAMP (Figure 3.5.1). This suggests
cyclic AMP mediated delay of neutrophil apoptosis does not require PI-3 kinase
activation.
SUMMARY
• The PI-3 kinase inhibitor LY294002 suppresses GM-CSF but not dbcAMP
mediated delay of neutrophil apoptosis
• Cyclic AMP mediated delay of neutrophil apoptosis occurs independently of PI-3
kinase activity.
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Figure 3.5.1. Effect of PI-3 kinase inhibition on cyclic AMP and GM-CSF mediated
delay of neutrophil apoptosis. Human neutrophils (5 xl06/ml) cultured in Iscove's
DMEM containing 10% autologous serum at 37 °C were treated with LY294002 (10 |iM)
for 30 minutes prior to stimulation by dbcAMP (0.2 mM) or GM-CSF (50 U/ml). After a
further 20 h in culture, cells were incubated with FITC-labelled recombinant human
Annexin-V to determine phosphatidylserine expression. All values represent mean ± S. E.
of n = 3 experiments, each performed in duplicate where significant difference from
control is represented by *P<0.001 and significant difference from GM-CSF alone is
represented by #P<0.01.
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3.6 CYCLIC AMP MEDIATED DELAY OF NEUTROPHIL
APOPTOSIS DOES NOT INVOLVE ACTIVATION OF
EXTRACELLULAR SIGNAL REGULATED KINASES
We also investigated if cyclic AMP could act through the extracellular signal
regulated kinases (ERK) signalling pathway to inhibit neutrophil apoptosis.
Activation of ERK has been implicated in a number of systems to contribute as a
negative regulator of apoptosis (Tran et al., 2001; Xia et al., 1995). Increasing cyclic
AMP levels are also known to either inhibit or activate ERK in a cell type- and
stimulus-specific manner. The mechanism by which cyclic AMP activates ERK is
unclear at present, however it has been proposed that cyclic AMP may activate ERK
through small GTPases such as Ras and Rap-1 (Busca et al., 2000; Altschuler et al.,
1995). The physiological role of Rap-1 has yet to be elucidated but has been
postulated to antagonise Ras dependent signalling (Kitayama et al., 1989; Cook et
al., 1993; Boussiotis et al., 1997) although this has recently been disputed
(Zwartkruis et al., 1998). We decided to investigate if activation of Rap-1 or Ras and
subsequently ERK signalling by cyclic AMP, was important for cyclic AMP
mediated suppression of apoptosis.
As an approach to investigating the role of small GTP-binding proteins of the Ras
family, we used Clostridium sordellii lethal toxin (LT), which has been reported to
specifically inhibit the small GTPases Ras, Rap-1 and Rac (Popoff et al., 1996). We
found that blockade of the activity of these small GTPases by LT did not reverse
cyclic AMP mediated delay of neutrophil apoptosis (Figure 3.6.1 A). Replacing
autologous serum with 0.1% BSA in our culture system resulted in the induction of
neutrophil apoptosis by LT (Figure 3.6.LB). This induction of apoptosis was
partially inhibited by cyclic AMP. Thus it appears that a component of autologous
serum suppresses or inactivates the activity of LT. From this data it is difficult to
establish whether blockade of Rap-1 and Ras by Clostridium sordellii lethal toxin
can reverse cyclic AMP mediated delay of apoptosis. At concentrations of LT which
do not cause induction of apoptosis, which have been reported to cause effective
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blockade of small GTPases (Busca et al., 2000), there was no reversal of cyclic AMP
mediated delay of neutrophil apoptosis. However at higher concentrations of LT
which cause induction of neutrophil apoptosis, cyclic AMP mediated suppression of
apoptosis was lost. From this data, it is unlikely that Rap-1 and other small GTPases
such as Ras play a vital role in cyclic AMP mediated delay of apoptosis. However,
activity of small GTPases may be important in regulating constitutive neutrophil
apoptosis.
Further evidence that Rap-1 is not involved in the anti-apoptotic effect of cyclic
AMP was suggested by studies in which Rap-1 processing was inhibited by the
geranylgeranyltransferase inhibitor GGTI-286. Activation of Rap-1 requires post-
translational modifications that facilitate its attachment to the inner surface of the
plasma membrane. Geranylgeranylation is thought to be required for Rap-1 to mature
into its biologically active form (Lerner et al., 1995). Neutrophils were cultured
overnight in serum supplemented Iscove's DMEM in the presence or absence of
GGTI-286. We found that blockade of Rap-1 processing by GGTI-286 did not
reverse cyclic AMP mediated suppression of neutrophil apoptosis (Figure 3.6.2).
Similar results were found when autologous serum was replaced by 0.1% BSA in the
culture system (data not shown). This result further suggests that activation of Rap-1
is not important for cyclic AMP suppression of apoptosis.
Lastly we investigated whether ERK activation was required for cyclic AMP
mediated delay of neutrophil apoptosis. The protective effect of cAMP-elevating
agents does not appear to act through the ERK pathway in our system. This is
suggested by the finding that the p42/p44 MAPK kinase inhibitor PD98059 (Dudley
et al., 1995) had no effect on the anti-apoptotic functions of cyclic AMP in
neutrophils yet can reverse the anti-apoptotic functions of GM-CSF treatment in
neutrophils which has been also shown recently by Klein et al (Figure 3.6.3).
Similarly the p38 MAPK inhibitor SB203580 could not reverse dbcAMP mediated
delay ofneutrophil apoptosis (data not shown).
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SUMMARY
• Cyclic AMP mediated delay of neutrophil apoptosis is not reversed by :
Clostridium sordellii lethal toxin
Geranylgeranyltransferase inhibitor GGTI286
p42/p44 MAP kinase inhibitor PD 98059.
p38 MAP kinase inhibitor SB 203580
• It is unlikely that cyclic AMP mediated delay of neutrophil apoptosis involves
Rapl signalling or MAP kinase activation.
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Figure 3.6.1. Effect of Clostridium sordellii lethal toxin on dbcAMP mediated delay
of neutrophil apoptosis. Human neutrophils (5 xl06/ml) cultured in Iscove's DMEM
containing 10% autologous serum (A) or 0.1% BSA (B) at 37 °C were treated with the
indicated concentrations of Clostridium sordellii lethal toxin (LT) alone (pg/ml) and LT
plus dbcAMP (0.2 mM). After 20 h in culture, the cells were incubated with FITC-
labelled recombinant human Annexin-V to determine phosphatidylserine expression. All
values represent mean ± S.E. of n = 3 experiments, each performed in duplicate where
significant difference control is represented by *P<0.01
93
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP






Figure 3.6.2. Blockade of geranylgeranyltransferase activity does not affect cyclic
AMP mediated delay of neutrophil apoptosis Human neutrophils (5 xl06/ml) cultured
in Iscove's DMEM containing 10% autologous serum at 37 °C were treated with GGTI-
286 for 10 minutes prior to stimulation by dbcAMP (0.2 mM). After a further 20 h in
culture, the cells were incubated with FITC-labelled recombinant human Annexin-V to
determine phosphatidylserine expression. All values represent mean ± S.E. of n = 4 - 6
experiments, each performed in duplicate where significant difference from control is
represented by *P<0.001.
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Figure 3.6.3. Effect of MAP kinase inhibition on dbcAMP and GM-CSF mediated
delay of neutrophil apoptosis. Human neutrophils (5 x 106/ml) cultured in Iscove's
DMEM containing 10% autologous serum at 37 °C were treated with PD98059 (10 |lM)
for 30 minutes prior to stimulation by dbcAMP (0.2 mM) or GM-CSF (50 U/ml). After a
further 20 h in culture, the cells were incubated with FITC-labelled recombinant human
Annexin-V to determine phosphatidylserine expression. All values represent mean ± S. E.
of n = 3 experiments, each performed in duplicate where significant difference from
control is represented by *P<0.001 and significant difference from GM-CSF alone is
represented by #P<0.01.
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3.7 CYCLIC AMP MEDIATED DELAY OF NEUTROPHIL
APOPTOSIS OCCURS VIA A TRANSCRIPTIONALLY
INDEPENDENT AND REVERSIBLE SIGNALLING PATHWAY
3.7.1 CYCLIC AMP MEDIATED SUPPRESSION OF NEUTROPHIL
APOPTOSIS DOES NOT REQUIRE NEW PROTEIN SYNTHESIS
Our results suggest cyclic AMP elevation suppresses neutrophil apoptosis via a
previously uncharacterised signalling mechanism. In order to investigate the
fundamental nature of this signalling mechanism, it was important to establish if
cyclic AMP stimulated a novel signalling pathway which would require
transcriptional activation to suppress neutrophil apoptosis.
Cycloheximide, used to block protein synthesis, was titrated to low concentrations to
minimise the induction of neutrophil apoptosis by this compound on its own (Whyte
et al., 1997). Following overnight culture of neutrophils with dbcAMP and
cycloheximide, apoptosis was assessed by standard morphological criteria and
exposure of phosphatidylserine by Annexin-V binding. It was found that
cycloheximide was unable to reverse the suppression of apoptosis by dbcAMP
(Figure 3.7.1). Cycloheximide however blocked glucocorticoid-mediated suppression
of neutrophil apoptosis at these concentrations (see Figure 4.3.1). These data suggest
that gene transcription is not necessary for suppression of neutrophil apoptosis by
cyclic AMP.
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Figure 3.7.1 Effect of protein synthesis inhibition by cycloheximide on cyclic AMP
mediated delay of neutrophil apoptosis. Human neutrophils (5 x 106/ml) cultured in
Iscove's DMEM containing 10% autologous serum at 37 °C, and treated with the
indicated concentrations of cycloheximide (pg /ml) with or without dbcAMP (0.2mM).
After 20 h, cells were harvested and assessed morphologically for apoptosis. All values
represent mean ± S.E. of n = 10 experiments, each performed in triplicate. Similar results
were found when cells were assessed for apoptosis by Annexin-V binding (data not
shown). Significance from control is represented by *P<0.001 or #P<0.01
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3.7.2 CYCLIC AMP MEDIATED DELAY OF NEUTROPHIL APOPTOSIS IS
DEPENDENT ON CONTINUOUS STIMULATION
As we had eliminated the requirement for gene transcription for the ability of cyclic
AMP to delay neutrophil apoptosis, we examined if cyclic AMP could activate a
rapid and direct signalling pathway instead of stimulating new protein synthesis,
which would occur over several hours. Evidence that this was indeed the case was
implied from experiments in which neutrophils were cultured in the presence of
dbcAMP for the time points indicated (i.e. 0.5, 1, 2, 4 h) before dbcAMP was
removed from culture by gently washing in PBS and the cells returned to normal
culture conditions (Figure 3.7.2). DbcAMP was required to be continually present in
the culture medium in order to suppress neutrophil apoptosis suggesting again that
cyclic AMP does not stimulate production of a survival protein in order to enhance
neutrophil survival (Figure 3.7.2).
3.7.3 CYCLIC AMP ELEVATION CAN RESCUE NEUTROPHILS FROM
APOPTOSIS WHEN ADDED AFTER ONSET OF CULTURE
The results above suggest cyclic AMP activates a rapid signalling pathway in
neutrophils to delay neutrophil apoptosis. We wished to examine if cyclic AMP was
capable of rescuing neutrophils from constitutive cell death by adding cyclic AMP
late after onset of culture. We found that dbcAMP could rescue neutrophils from
apoptosis when added at time points after onset of culture (Figure 3.7.3). It was
striking that cyclic AMP was still able to suppress neutrophil apoptosis even after 8
hours in culture to levels comparable with a full 24 h incubation with cyclic AMP. It
has previously been demonstrated that early measurable signs of neutrophil apoptosis
can occur by 8 hours (Ward et al., 1999a) and so one could assume that the apoptotic
signalling machinery would presumably already be activated in these cells at this
time point. Together these results suggest that cyclic AMP is capable of a powerful
direct signalling mechanism independent of new protein synthesis in order
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Figure 3.7.2. Loss of cyclic AMP mediated delay of neutrophil apoptosis by washing.
Human neutrophils (5 x 106/ml) cultured in Iscove's DMEM containing 10 % autologous
serum at 37 °C were treated with or without dbcAMP (0.2 mM) for the time points
indicated before the cells were washed x 2 in PBS to remove dbcAMP and returned to
culture. Cells were cultured in Iscove's DMEM containing 10 % autologous serum until
20 h when the cells were resuspended and incubated with FITC-labelled recombinant
human Annexin-V to determine phosphatidylserine expression. All values represent mean
± S.E. of n = 3 experiments, each performed in duplicate where significant difference
from control is renresented bv *P<0.001.
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Figure 3.7.3 Rescue of cultured neutrophils from apoptosis by delayed addition of
dbcAMP. Human neutrophils (5 x 106/ml) cultured in Iscove's DMEM containing 10%
autologous serum at 37°C for the time points indicated before addition of dbcAMP (0.2
mM). At 20 h, cells were resuspended and incubated with FITC-labelled recombinant
human Annexin V to determine phosphatidylserine expression. All values represent mean
± S. E. of n = 3 experiments, each performed in duplicate and were significantly different
from control *P<0.01
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to suppress neutrophil apoptosis and that this suppression is rapidly lost when cyclic
AMP is removed from culture. It is likely therefore that cyclic AMP is exerting its
effects via post-translational modifications within the neutrophil.
SUMMARY
• Cyclic AMP mediated delay of neutrophil apoptosis is not reversed by
cycloheximide.
• Suppression of neutrophil apoptosis by cyclic AMP is rapidly lost in "wash-out"
experiments.
• Cyclic AMP will rescue neutrophils from apoptosis up to at least 8 hours after
onset of culture.
• Cyclic AMP may be acting independently of protein synthesis, via a direct and
rapid signalling pathway to delay neutrophil apoptosis.
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3.8 PROTEASOME INHIBITORS ARE ABLE TO REVERSE
SUPPRESSION OF NEUTROPHIL APOPTOSIS BY CYCLIC
AMP
It has been postulated that cell fate may depend on the balance in the cell between
pro-apoptotic and anti-apoptotic proteins (Ward et al., 1999b; Akgul et al., 2001). It
has been shown that neutrophils contain death regulator proteins such as Bax and
Bad and also express some anti-apoptotic Bcl-2 family proteins such as Mcl-1 and
Bc1-Xl but not Bcl-2 (Ward et al., 1999b; Akgul et al., 2001). It has been proposed
that neutrophils may prolong their longevity by a mechanism whereby they
synthesise anti-apoptotic proteins such as Mcl-1 (Ward et al., 1999b; Akgul et al.,
2001). It is unlikely however that cyclic AMP mediated delay of neutrophil apoptosis
involves such a mechanism as we have demonstrated that cyclic AMP mediated
survival does not require gene transcription. We decided to examine if cyclic AMP
could be accelerating the degradation or modification of pro-death proteins within
the neutrophil to promote survival. Proteasomes are thought to have a major role in
the degradation and disposal of intracellular proteins (Rock et al., 1994) however it is
becoming apparent that these organelles play a vital role in the regulation of many
other cellular processes. Proteasomes are now known to selectively degrade many
proteins involved in cell regulation and thus are directly or indirectly involved in
many cell functions including apoptosis (Orlowski, 1999). Recent findings suggest
that proteasomes can modulate the balance between Bcl-2 family members and thus
activity of the proteasome may determine cellular fate (Breitschopf et al., 2000;
Marshansky et al., 2001). For example, it has been shown that blockade of
proteasome activity in Jurkat T cells allows accumulation of Bax and subsequently
induced cytochome c dependent apoptosis (Li and Dou, 2000). To investigate if
cyclic AMP causes targeted degradation of apoptotic proteins in the neutrophil to
promote survival, we blocked proteasome activity with the irreversible proteasome
inhibitors lactacystin and epoxomicin for 20 h. Lactacystin, a Streptomyces
metabolite, is a specific inhibitor of the proteasome, which modifies irreversibly the
amino terminal threonine residue of the mammalian 20S proteasome subunit X,
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which is required for proteolysis (Fenteany et al., 1995). Epoxomicin covalently
modifies 4 catalytic subunits of the 20S proteasome and is thought to have greater
specificity than all other available proteasome inhibitors (Meng et al., 1999). We
found that both lactacystin and epoxomicin could eliminate suppression of neutrophil
apoptosis by dbcAMP thus suggesting cyclic AMP mediated suppression of
neutrophil apoptosis requires the degradation of unknown protein(s) to confer a pro-
survival signal on the cell (Figure 3.8.1 & 3.8.2).
SUMMARY
• Proteasome inhibitors lactacystin and epoxomicin reverse cyclic AMP mediated
delay of neutrophil apoptosis.
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Figure 3.8.1 Effects of lactacystin on dbcAMP mediated delay of neutrophil
apoptosis. Human neutrophils (5 xl06/ml) cultured in Iscove's DMEM containing 10 %
autologous serum at 37 °C, and treated with lactacystin (10 liM) with or without dbcAMP
(0.2 mM). After 20 h in culture, the cells were incubated with FITC-labelled recombinant
human Annexin V to determine phosphatidylserine expression. All values represent mean
± S.E. of n = 3 experiments, each performed in duplicate where significant difference
from control is represented by *P<0.001. Significant difference from dbcAMP alone
represented by f<0.001.
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control dbcAMP epoxomicin dbcAMP +
epoxomicin
Figure 3.8.2 Effects of epoxomicin on dbcAMP mediated delay of neutrophil
apoptosis. Human neutrophils (5 xl06/ml) cultured in Iscove's DMEM containing 10 %
autologous serum at 37 °C, and treated with epoxomicin (10 pM) with or without
dbcAMP (0.2 mM). After 20 h in culture, the cells were incubated with FITC-labelled
recombinant human Annexin V to determine phosphatidylserine expression. All values
represent mean ± S.E. of n=3 experiments, each performed in duplicate where significant
difference from control is represented by *P<0.001. Significant difference from dbcAMP
alone represented by P<0.01.
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3.9 EFFECT OF CYCLIC AMP ON "DEATH PROTEIN"
EFFECTOR EXPRESSION IN NEUTROPHILS
In light of the previous findings, we decided to examine the effect of cyclic AMP on
expression of possible "death" proteins in neutrophils by Western blotting.
Neutrophils were incubated with dbcAMP for various time points over a 20 hour
period from which whole cell lysates were prepared. Neutrophils have been
demonstrated to contain the pro-apoptotic protein Bax. As shown in Figure 3.9.1, we
found that levels of Bax remain unchanged over the 20 hour time course and are not
altered by dbcAMP treatment. Moreover, neutrophils have also been reported to
contain the pro-apoptotic protein Bad, however difficulty in achieving reproducible
blots for Bad in neutrophils has meant that a role for Bad in cyclic AMP-mediated
delay of neutrophil apoptosis has yet to be fully elucidated (data not shown).
It has been demonstrated in neuronal cell lines that exposure to forskolin, a direct
activator of adenylyl cyclase, results in a decrease in the levels of the catalytic and
regulatory subunits ofPKA (Boundy et al., 1998). Further, this process was shown to
be independent of gene transcription and involves proteasome mediated degradation
(Boundy et al., 1998). We therefore investigated the possibility that cyclic AMP
could be targeting the degradation ofPKA, in order to suppress neutrophil apoptosis.
Immunoblotting revealed that in neutrophils, expression of both PKA regulatory and
catalytic subunits remain unchanged during neutrophil apoptosis (Figure 3.9.2).
Furthermore, treatment of neutrophils with dbcAMP does not alter protein levels of
the PKA subunits tested. We also investigated if cyclic AMP could alter the
expression of iKBa, an inhibitor of NFkB in order to delay neutrophil apoptosis.
NFkB has been shown to be an important survival factor in neutrophils (Ward et al.,
1999a) and activation ofNFkB is dependent on the degradation of IkBoc, which as a
consequence allows NFkB translocation to the nucleus (Chen et al., 1995). As
degradation of IKBa is mediated by proteasomes (Chen et al., 1995) it was pertinent
to examine the possibility that cyclic AMP may cause
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Figure 3.9.1 Time course for the effect of dbcAMP on Bax expression during human
neutrophil apoptosis Western blot of cytoplasmic extracts from neutrophils treated with
control buffer or dbcAMP (0.2 mM) for the time points indicated. Cell lysates were
prepared and immunoblotted as described under "Materials and Methods". Lysates were
prepared from equivalent numbers of cells and subjected to SDS-PAGE/immunoblot
analysis using a rabbit polyclonal antibody specific for Bax. The gel is representative of 3
experiments.
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Figure 3.9.2 Time course for the effect of dbcAMP on PKA catalytic (C) and
regulatory (RI) subunit expression during human neutrophil apoptosis Western blot
of cytoplasmic extracts from neutrophils treated with control buffer or dbcAMP (0.2 mM)
for the time points indicated. Cell lysates were prepared and immunoblotted as described
under "Materials and Methods". Lysates were prepared from equivalent numbers of cells
and subjected to SDS-PAGE/immunoblot analysis using mouse IgG2b monoclonal
antibodies specific for PKA catalytic (C) and PKA regulatory (RI) subunit. The gels are
representative of 3 experiments.
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degradation of IkBoc, allowing activation of NFkB which has been demonstrated to
favour neutrophil survival. This appeared unlikely to be the case, as cyclic AMP does
not alter IicBa expression (Figure 3.9.3). As a positive control we were able to
demonstrate that unlike cyclic AMP, TNFa does cause degradation of IkBoc.
Furthermore cyclic AMP stimulation did not alter TNFa mediated degradation of
iKBa.
SUMMARY
• Cyclic AMP does not appear to alter protein expression of Bax, PKA regulatory
and catalytic subunits and IicB-a
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Figure 3.9.3 Time course for the effect of dbcAMP on iKB-a expression during
human neutrophil culture. Western blot of cytoplasmic extracts from neutrophils treated
with control buffer, dbcAMP (0.2 mM) or TNFa (12.5 ng/ml) for the time points
indicated. Cell lysates were prepared and immunoblotted as described under "Materials
and Methods". Lysates were prepared from equivalent numbers of cells and subjected to
SDS-PAGE/immunoblot analysis using a rabbit polyclonal antibody to IKB-a. The gels
are representative of 3 experiments.
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3.10 REGULATION OF DEATH RECEPTOR SIGNALLING IN
GRANULOCYTES BY CYCLIC AMP
We have demonstrated that cyclic AMP plays an important role in the regulation of
constitutive neutrophil apoptosis. We wished to further our studies to investigate the
role of cyclic AMP in regulating death receptor signalling pathways in the
neutrophil. The pathways regulating constitutive neutrophil apoptosis may be very
different from the death receptor signalling mechanisms mediated by the tumour
necrosis factor receptor (TNFR)/nerve growth factor family. Curiously TNFa has
been found to exert both pro-and antiapoptotic effects on the neutrophil (Murray et
al., 1997). A second member of the TNF receptor family, Fas can also transduce
death signals in the granulocyte (Liles et al., 1996). The precise role of Fas and the
natural ligand for Fas, FasL in controlling neutrophil apoptosis is however not yet
clear (Liles et al., 1996; Fecho and Cohen, 1998; Tortorella et al., 1998b). We
decided to establish whether elevation of cyclic AMP could inhibit death receptor
mediated apoptosis and the mechanisms by which this may occur.
3.10.1 SUPPRESSION OF TNFa INDUCED DEATH IN NEUTROPHILS BY
CYCLIC AMP
To examine the effects of cyclic AMP on death receptor mediated apoptosis, we
firstly assessed the ability of cyclic AMP to modulate TNFa induced apoptosis in
neutrophils. TNFa has been shown to induce apoptosis at early time points during
neutrophil culture but inhibits neutrophil apoptosis at later time points (Murray et al.,
1997). To assess if cyclic AMP can modulate TNFa induced apoptosis in
neutrophils, cells were pre-incubated for 10 minutes with dbcAMP prior to
stimulation with TNFa for 6 hours. As previously described, we found that TNFa,
will cause a modest induction of apoptosis at 6 hours (Figure 3.10.1). Furthermore it
appears that elevation of cyclic AMP will block the pro-apoptotic effect of
TNFa (Figure 3.10.1).
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Figure 3.10.1 Suppression of TNFa induced apoptosis by cyclic AMP elevation.
Human neutrophils (5 xl06/ml) were cultured in phosphate buffered saline and pre-
incubated at 37 °C, with dbcAMP (0.2 mM) for 10 min before addition of TNFa (12.5
ng/ml). After 6 h in culture, the cells were incubated with FITC-labelled recombinant
human Annexin V to determine phosphatidylserine expression. All values represent mean
± S.E. of n - 3 experiments, each performed in duplicate where significant difference
from control is represented by *P<0.05. Significant difference from TNFa alone
represented by "P<0.05.
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3.10.2 SUPPRESSION OF FAS INDUCED DEATH IN NEUTROPHILS BY
CYCLIC AMP
As cyclic AMP has the ability to inhibit TNFa induced apoptosis in neutrophils it
was important to ascertain if cyclic AMP could also inhibit other death receptor
signalling pathways. Thus we examined the ability of cyclic AMP to modulate Fas
induced apoptosis in neutrophils. As mentioned previously there is some controversy
as regards the role of the Fas signalling pathway in the regulation of neutrophil
apoptosis. Nevertheless it was important to establish if cyclic AMP could modulate
Fas induction of apoptosis using the current tools available for investigating this
signalling pathway.
Neutrophils were incubated with CH-11, an anti Fas activating antibody (Alderson et
al., 1994), in the presence or absence of dbcAMP for the time points indicated. At 4
hours, CH-11 significantly induced apoptosis compared to control (Figure 3.10.2.A).
Furthermore it appeared that CH-11 induced apoptosis was inhibited by elevation of
cyclic AMP (Figure 3.10.2.A). Additionally, an even greater induction of apoptosis
by CH-11 at 6 hours (Figure 3.10.2.B) which was also inhibited by elevation of
cyclic AMP. It is interesting to note however that dbcAMP does not completely
block CH-11 induced killing in neutrophils observed at 6 hours whereas at 4 hours it
appeared that dbcAMP inhibited CH-11 induced apoptosis to levels comparable with
the control rate of apoptosis. One possibility is that cyclic AMP is not be able to
prevent death receptor induced apoptosis when a greater number of cells are induced
to die. Unfortunately we were unable to test whether the same is true of cyclic AMP
mediated inhibition of TNFa induced apoptosis due to the biphasic effect of TNFa
on neutrophil apoptosis.
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SUMMARY
• Cyclic AMP inhibits TNFa induction ofneutrophil apoptosis
• Cyclic AMP partially inhibits CH-11 induction of neutrophil apoptosis
• Cyclic AMP may inhibit death receptor mediated neutrophil apoptosis however
induction of cell death by a powerful death stimulus may overwhelm the capacity
of cyclic AMP to offer protection against apoptosis.
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Figure 3.10.2 Suppression of CH-11 induced apoptosis by cyclic AMP elevation.
Human neutrophils (5 xl06/ml) were cultured in phosphate buffered saline with divalent
cations and pre-incubated at 37 °C, with dbcAMP (0.2 mM) for 10 min before addition
of CH-11 (500ng/ml). After the indicated time points (4 h A and 6 h B), the cells were
incubated with FITC-labelled recombinant human Annexin V to determine
phosphatidylserine expression. All values represent mean ± S.E. of n = 4 experiments,
each performed in duplicate where significant difference from control is represented by
*P<0.001. Significant difference from CH-11 alone is represented by "P<0.01 or
^<0.05.
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3 DISCUSSION
Human neutrophils undergo apoptosis, a process that is centrally important in the
resolution of inflammation. It has been shown previously that cyclic AMP is an
important regulator of neutrophil apoptosis (Rossi et al., 1995; Parvathenani et al.,
1998; Ottonello et al., 1998; Tortorella et al., 1998a; Tortorella et al., 1998a) yet
little is known of the signalling mechanism by which by cyclic AMP controls
neutrophil cell death. The studies herein have established that cyclic AMP acts
upstream of caspase-3 activation to inhibit the apoptotic pathway in neutrophils. This
finding suggests that cyclic AMP delays neutrophil apoptosis before the main phase
of apoptotic execution. In mammalian cells, execution of apoptosis is thought to
involve either direct activation of procaspase-3 by caspase-8 (Stennicke et al., 1998)
or indirect activation of procaspase-3 through release of apoptosis inducing agents
such as cytochrome c and apoptosis inducing factor (AIF) from the mitochondria
(Kuwana et al., 1998). As cyclic AMP is able to delay the appearance of active
caspase-3 in neutrophils, it suggests that cyclic AMP is acting upstream of at least
the execution step of caspase activation. We have not been able to establish if cyclic
AMP is able to prevent the activation of procaspase-9, regarded as the initial caspase
in the intrinsic (stress and genomic) pathway (Li et al., 1997; Slee et al., 1999).
Immunoblotting for caspase-9 was technically difficult, perhaps due to low levels of
this protein in neutrophils. It would be interesting to establish if cyclic AMP delayed
neutrophil apoptosis by a mechanism which prevented the activity of this apical
caspase perhaps through use of specific caspase inhibitors.
It is unclear at present if cyclic AMP is also able to prevent expression of caspase-8,
considered to be the apical caspase of the extrinsic (death receptor) pathway (Muzio
et al., 1996; Peter and Krammer, 1998). This would be of particular relevance in
understanding the nature of cyclic AMP mediated regulation of death receptor
pathways. We have found that cyclic AMP can inhibit but not prevent death receptor
induction of apoptosis in neutrophils. It would be pertinent therefore to establish
whether cyclic AMP is able to delay expression of active caspase-8 or indeed assess
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the ability of cyclic AMP to delay death receptor induction of apoptosis if caspase-8
has already been activated. This would help ascertain the "point of no return" at
which cyclic AMP is no longer able to delay apoptosis and establish a better picture
of the hierarchy of signalling involving cyclic AMP which determines cellular fate.
Novel interactions between caspases and the cyclic AMP signalling pathway have
been demonstrated in studies by Huston et al who report that cyclic AMP specific
phosphodiesterase PDE4A5 is cleaved by caspase-3 during apoptosis in Rat-1 cells
(Huston et al., 2000). PDE4A5 was found to be cleaved downstream of its SH3
interaction domain, causing a decrease in its catalytic activity. It is suggested
therefore that cleavage by caspase-3 may influence the intracellular targeting of
PDE45 and thus affect its activity and ability to regulate levels of cyclic AMP within
cells. As elevation of cyclic AMP in Rat-1 cells by forskolin and the PDE4 inhibitor
rolipram induces apoptosis, cleavage of PDE4A5 which decreases its ability to
breakdown cyclic AMP may consequently contribute to the regulation of apoptosis in
Rat-1 cells. It would be interesting to investigate if PDE4 is cleaved during
neutrophil apoptosis. Potentially such a mechanism could either upregulate or
downregulate the activity of PDE4A5, changing the levels of cyclic AMP, and
possibly act as a feedback mechanism influencing the rate of neutrophil apoptosis.
For the first time, we have demonstrated that neutrophils contain a small but
significant number ofmitochondria, which exhibit loss of membrane potential during
constitutive apoptosis. We are currently investigating if this process occurs before
other indices of apoptosis in neutrophils, such as phosphatidylserine exposure and
nuclear condensation. This would help ascertain whether loss of mitochondrial
potential, shown to trigger apoptosis in other cell types, has a similar function in
neutrophils. We have also demonstrated that dissipation of mitochondrial membrane
potential can be inhibited by elevation of cyclic AMP. It will be important to
establish if cyclic AMP can directly affect changes in mitochondrial membrane
potential and if this is key to cyclic AMP mediated delay of neutrophil apoptosis.
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A very recent report has highlighted the involvement of mitochondria in eosinophil
apoptosis (Peachman et al., 2001). Similarly to neutrophils, it appears that
eosinophils contain a small number of mitochondria which appear to provide
insignificant respiration yet play a vital role in initiation of apoptosis. There is
evidence to suggest that in neutrophils mitochondria respiratory chain inhibitors do
not cause induction of apoptosis (Mecklenburgh, 1999) indicating that progression of
neutrophil apoptosis does not requires an intact respiratory chain. It will be important
to examine if neutrophils generate changes in mitochondrial membrane potential
from hydrolysis of ATP rather than from respiration and whether blockade of this
activity will cause induction of neutrophil apoptosis. This will help determine
whether mitochondria directly play a functional role in the regulation and initiation
of apoptosis in neutrophils. This also holds importance for the elucidation of the role
of Bcl-2 family members in regulating neutrophil apoptosis. Many of these proteins
are known to associate with the mitochondria and some such as Bax, undergo
conformational changes when associated with these organelles, leading to release of
apoptosis inducing factors such as cytochrome c (Wolter et al., 1997; Zamzami et al.,
1998; Jurgensmeier et al., 1998). Although there is indirect evidence that Bcl-2
family members play a role in neutrophil apoptosis (Chuang et al., 1998; Moulding
et al., 1998) it is unclear whether they require association with mitochondria to
mediate their effects. Indeed it has not yet been established if release of cytochrome c
from mitochondria is an absolute requirement for induction of apoptosis in
neutrophils due to difficulties in detection of this molecule in this cell type.
Establishing the subcellular location and possible association of various Bcl-2 family
members proteins with these organelles in neutrophils, will give a clearer indication
ifmitochondria play a key role in regulating neutrophil apoptosis, as has been shown
in other cell types.
It has been suggested that PKA plays an important role in cyclic AMP-mediated
delay of neutrophil apoptosis (Rossi et al., 1995; Parvathenani et al., 1998; Ottonello
et al., 1998). It has been demonstrated that cyclic AMP analogues, which selectively
activate type I PKA, attenuate neutrophil apoptosis, compared to analogues that
preferentially activate type II PKA suggesting that type I PKA is necessary and
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sufficient to mediate the cyclic AMP induced delay of neutrophil apoptosis
(Parvathenani et al., 1998). We suggest, alternatively, that PKA activation by cyclic
AMP is not responsible for the major apoptosis-retarding influences of cyclic AMP
in neutrophils. Indeed, we have demonstrated directly that cyclic AMP elevation in
neutrophils stimulates an increase in PKA activity, which is blocked by
pharmacological inhibitors. Importantly however, blockade of PKA was not
sufficient to reverse the anti-apoptotic effect of cyclic AMP, implying that this
molecule has little or no role in the cyclic AMP signalling pathway responsible for
the delay of neutrophil apoptosis.
Previous publications have implicated a role for PKA in cyclic AMP regulation of
neutrophil apoptosis using concentrations of H-89 greater than 10 pM (Rossi et al.,
1995; Parvathenani et al., 1998). The specificity of H-89 at these concentrations is
questionable and it has been published that H-89 may inhibit several other kinases,
some with potency similar to, or greater than that for PKA (Davies et al., 2000). We
propose that failure to directly measure PKA activity together with the use of high
and possibly non-specific concentrations ofH-89, could have led to misinterpretation
of previous data. We have demonstrated that 10 pM H-89 is sufficient to block PKA
activity for extended culture periods and is active in the presence of autologous
serum. The failure therefore of both H-89 and Rp-8-Br-cAMPS, a highly specific
inhibitor of PKA, to reverse cyclic AMP mediated delay of neutrophil apoptosis,
point to a novel signaling pathway used by cyclic AMP to inhibit neutrophil
apoptosis, which is independent ofPKA activation.
There have been a few studies reporting PKA independent effects of cyclic AMP.
For example in contradiction to previous findings (Skalhegg et al., 1992; Bauman et
al., 1994), it has been reported recently that cyclic AMP suppression of T cell
proliferation and inhibition of release of T cell cytokines proceeds in a PKA
independent manner (Bryce et al., 1999). Furthermore cyclic AMP mediated
suppression of TNFa mediated apoptosis in primary hepatocytes has been found to
be only partially reversed by the PKA inhibitor KT5720 (Li et al., 2000b). Other
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PKA independent effects include cyclic AMP stimulated Akt phosphorylation and
membrane ruffling in thyroid cells (Cass et al., 1999).
Although these recent studies have suggested cyclic AMP is capable of mediating
effects independently of PKA, there has been little elucidated of the alternative
signalling pathways involved. Pharmacological blockade of the MAP kinase and PI-3
kinase signalling cascades in this study suggest that neither of these signalling
pathways are likely to be important in the cyclic AMP mediated delay of neutrophil
apoptosis. There has been interest in the discovery that cyclic AMP can bind
specifically to and activate small guanine nucleotide exchange factors (GEFs) which
will activate the small Ras like GTPase, Rapl (de Rooij et al., 1998; Kawasaki et al.,
1998). The biological function of Rapl is still unclear but it has been proposed that
activation of this small GTPase may feed into MAPK signaling pathways (Bos,
1998). It was important to investigate if Rapl was involved in cyclic AMP mediated
protection of neutrophil cell death, as Rapl has been found to be highly expressed in
neutrophils (Quilliam et al., 1991; M'Rabet et al., 1998). Furthermore, activation of
Rapl has been shown to occur in neutrophils in response to fMLP, PAF, GM-CSF
and IgG coated particles (M'Rabet et al., 1998). As an approach to establishing if
Rapl has a role in cyclic AMP mediated delay of neutrophil apoptosis, we blocked
Rapl activity using the Clostridium sordellii lethal toxin (LT), which has been
reported to specifically inhibit the small GTPases Rapl, Ras and Rac (Popoff et al.,
1996). Furthermore we tested GGTI-286, a geranylgeranyltransferase inhibitor,
which blocks geranylgeranylation required by Rapl to achieve its mature,
biologically active form (Lerner et al., 1995). Our preliminary experiments have
suggested that Rapl is not involved in cyclic AMP mediated delay of neutrophil
apoptosis. However due to the lack of specificity of both Clostridium sordellii lethal
toxin and GGTI-286 as inhibitors ofRapl, it is difficult to rule out completely a role
for this small GTPase in cyclic AMP mediated neutrophil survival. It would be
interesting to measure Rapl activity directly to ascertain if treatment of neutrophils
with elevators of cyclic AMP results in activation of Rapl. Without the ability to
"knock-out" the activity of Rapl in neutrophils either with a specific
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pharmacological inhibitor or by other means, it is difficult to directly prove the
involvement ofRap 1 in cyclic AMP mediated effects on apoptosis at this time.
Our studies are in accord with very recent publications, which demonstrate that
cyclic AMP can mediate effects independently of all currently known downstream
substrates. For example, cyclic AMP-dependent inhibition of IL-5 from human T
lymphocytes was found not to be mediated by PKA or by the Rapl signalling
pathways (Staples et al., 2001) and in melanocytes, cyclic AMP was found to
activate Ras and B-Raf independently of PKA, the Ras exchange factor, Son of
sevenless (SOS) and Epac (Busca et al., 2000). This reveals the possibility that there
may be an as yet undiscovered downstream substrate(s) for cyclic AMP, which may
mediate the effects of this second messenger in not only neutrophil apoptosis but also
a whole host of other cellular responses. The challenge will be to ascertain the
identity of novel signalling molecules involved in cyclic AMP regulation and contest
the current dogma that cyclic AMP exerts is physiological functions almost entirely
through activation ofPKA.
Regulation of neutrophil apoptosis is thought to depend on the balance between pro-
apoptotic and anti-apoptotic death factors expressed in the cell (Ward et al., 1999b;
Akgul et al., 2001). Neutrophils contain death regulator proteins, including Bax and
Bad, and also express some anti-apoptotic Bcl-2 family proteins such as Mcl-1 and
Bcl-xL but not Bcl-2 (Ward et al., 1999b; Akgul et al., 2001). It has been proposed
that neutrophil longevity may be prolonged by the synthesis of anti-apoptotic
proteins such as Mcl-1 (Moulding et al., 1998). However, it is unlikely that cyclic
AMP effects are mediated by such a mechanism since we have demonstrated that
cyclic AMP-mediated delay of neutrophil apoptosis does not require gene
transcription. Furthermore, "wash out" experiments have revealed that retardation of
neutrophil apoptosis is rapidly lost when dbcAMP is removed from culture, even
after incubation periods that should permit new protein synthesis.
Together, these data suggest a mechanism whereby cyclic AMP does not stimulate
production of a survival protein but may alternatively induce post-translational
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modifications in the neutrophil to promote survival. One potential mechanism for
cyclic AMP-mediated retardation of neutrophil apoptosis may involve cyclic AMP
specifically targeting a death protein(s) to the proteasome for degradation. We have
demonstrated that blockade of proteasome activity results in a dramatic loss of the
pro-survival effect of cyclic AMP. We speculate that cyclic AMP may be involved in
the post-translational modification of a death protein, which it may specifically target
to the proteasome. If cyclic AMP stimulation is removed or proteasome activity is
blocked then the accumulation of a death protein(s) would be predicted to permit the
rapid onset of cell death.
There is evidence that in at least other cell types, cyclic AMP is capable of
stimulating proteasomal activity. For example in human embryonic kidney cells
(HK293) elevation of cyclic AMP results in increased proteasomal activity allowing
secretion of a C terminally truncated fragment of the (3 amyloid precursor protein
(Marambaud et al., 1996). Furthermore, inducible cAMP early repressor (ICER), a
member of the CREB/ATF family of transcription factors, has been shown to be
degraded by the ubiquitin-proteasome pathway (Folco and Koren, 1997), allowing
regulation of its transcriptional activity. There is also evidence that treatment of cells
with proteasomal inhibitors can result in the accumulation of apoptotic regulatory
proteins such as the accumulation of Bax and Bik in Jurkat T cells (Li and Dou,
2000; Marshansky et al., 2001).
To investigate whether cyclic AMP elevation targets the specific degradation of
death protein(s) in neutrophils, we have tried to examine individually possible
"death" proteins that may be degraded by cyclic AMP. We were not able to detect
any changes in the levels of protein expression of Bax, PKA regulatory and catalytic
subunits and IicBa. We did however observe alterations in proteins levels of caspase-
3 with cyclic AMP treatment (Figure 3.2.1). This, we assumed, reflected the ability
of cyclic AMP to delay neutrophil apoptosis and thus decreased expression of active
caspase-3 was likely to be due to a decreased number of apoptotic cells in the
population compared to control. However, it has recently been published that X-
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linked inhibitor of apoptosis (XIAP) promotes degradation of caspase-3 due to its
ubiquitin-ligase activity (Suzuki et al., 2001). The anti-apoptotic activity of XIAP is
thought to be due to the ability of XIAP to promote degradation of caspase-3. It is
possible that a more exciting inference for the ability of cyclic AMP to inhibit
caspase-3 expression is that cyclic AMP is actively causing the specific degradation
of active caspase-3 thus decreasing its expression, delaying apoptosis. In future
experiments it would be interesting to establish if XIAP is present in human
neutrophils and if it has any role to play in cyclic AMP mediated delay of neutrophil
apoptosis.
There is of course the possibility that cyclic AMP is targeting the degradation of a
protein which, is as yet, unidentified. We have also tried to examine the effects of
cyclic AMP in neutrophils by investigating global changes in protein expression by
two-dimensional electrophoresis. However, due to time constraints and difficulty in
identifying new proteins, particularly those expressed at low levels, has meant that
identification of novel targets of cyclic AMP by this method, will await future
studies. It would also be interesting to measure proteasome activity directly and so
further characterise the interplay between the activity of the proteasome and
signalling stimulated by cyclic AMP, in the regulation of neutrophil apoptosis.
We have demonstrated that cyclic AMP can dramatically modulate the rate of
constitutive neutrophil apoptosis via a novel signalling pathway involving
proteasomal regulation. We have also shown in preliminary experiments that cyclic
AMP may regulate apoptosis induced in neutrophils by a variety of death receptor
stimuli. We have found that cyclic AMP inhibits the pro-apoptotic effect of TNFa in
neutrophils. Cyclic AMP is also able to inhibit apoptosis induced by the Fas
activating antibody CH-11, at time points of 4 and 6 hours. It is important to note
however that cyclic AMP does not appear to be as proficient at inhibiting CH-11
induced apoptosis at 6 hours compared to 4 hours when the percentage of cells
induced to die is more modest. It is possible that cyclic AMP is more effective at
inhibiting death receptor mediated apoptosis when induction of cell death is
moderate. Cyclic AMP may not be able confer pro-survival effects in the presence of
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a more powerful death stimulus. Our results are similar to findings made by
Parvathenani et al. in which elevation of cyclic AMP inhibited CH-11 induced
apoptosis better at the early time point of 2 h compared to 8 h where inhibition was
minimal (Parvathenani et al., 1998). Consistent with this suggestion, Tortorella et al.
have reported that dbcAMP could not inhibit CH-11 induced death in neutrophils at
12 h, when the death stimulus is more potent (Tortorella et al., 1998b).
Further support for this hypothesis, is our observation that cyclic AMP is not able to
inhibit induction of cell death in neutrophils by the NFkB inhibitor, gliotoxin or in
the synchronous death during temperature re-warming of neutrophils from 15°C to
37°C (data not shown). In both gliotoxin and temperature shift mediated neutrophil
death, 80-90% of cells are apoptotic after 2 h (Ward et al., 1999a; Pryde et al., 2000).
In both systems, there is a rapid onset of neutrophil apoptosis yet pre-incubation with
elevators of cyclic AMP fails to inhibit induction of neutrophil apoptosis.
We have demonstrated that during constitutive neutrophil apoptosis, cyclic AMP is
able to rescue neutrophils from cell death up to 8 h after the onset of culture.
However we have yet to establish if cyclic AMP is able to rescue cells at time points
after 8 h when we know there is an exponential increase in the rate of cell death. It
would be very interesting to investigate if cyclic AMP continues to delay neutrophil
apoptosis at these later time points or if during this phase of culture, there is a point
at which cyclic AMP is no longer effective. Interpretation of data from these types of
experiments is difficult, as the neutrophils are not dying in a synchronous fashion.
However in experimental systems such as death receptor mediated death or
temperature re-warming, apoptosis is more synchronous and it is in these instances
that we have found cyclic AMP to be unable to effectively mediate protection.
Collectively it appears possible that cyclic AMP powerfully delays neutrophil
apoptosis in circumstances when the cells are constantly stimulated by cyclic AMP
before onset of apoptosis. If cyclic AMP is removed, normal onset of apoptosis is
resumed. Furthermore, if neutrophils are induced to die by a very powerful death
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stimulus, cyclic AMP may no longer be effective at mediating its pro-survival
effects.
Our hypothesis is supported by finding of Niwa et al who show that elevation of
cyclic AMP inhibits neutrophil apoptosis induced by a combination of TNFa and
cycloheximide (Niwa et al., 1999). In this paper it is suggested that cyclic AMP is
only able to suppress apoptosis if elevators of cyclic AMP were added to the
neutrophils before treatment with TNFa. It appears that once the apoptotic signalling
cascade is activated by TNFa, cyclic AMP can no longer inhibit cell death. It is
possible that cyclic AMP may no longer prevent apoptosis once a particular
component of the death pathway becomes engaged and it is tempting to speculate the
identity of such a protein. During neutrophil temperature rewarming, there is an
exponential increase in cell death associated with Bax insertion into the
mitochondrial membrane (Pryde et al., 2000). Failure of cyclic AMP to prevent
apoptosis induced by temperature rewarming may therefore be due to the inability of
this second messenger to inhibit cell death once this death protein is inserted into the
mitochondrial membrane. However, as we have not directly measured the effect of
cyclic AMP on insertion of Bax during temperature rewarming, we can only
hypothesise that this may be the point at which cyclic AMP may no longer be able to
inhibit apoptosis. Furthermore, due to the difficulty at present to 'knock-out' the
effects of Bax and other proteins in neutrophils, one cannot conclude whether
involvement of Bax or other Bcl-2 family proteins in induction of granulocyte death
is associative or causative.
Further research into the mechansims behind the ability of cyclic AMP to influence
neutrophil apoptosis is vital as these findings have potentially important implications
for the role of cyclic AMP in controlling inflammatory cell function in vivo. In
particular, in situations where cyclic AMP may be artificially elevated, such as the
treatment of inflammatory diseases by (32 agonists or selective phosphodiesterase
(PDE) inhibitors. There have been widespread interest in the potential usefulness of
PDE inhibitors for the treatment of inflammatory diseases (Torphy et al., 1992;
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Giembycz and Dent, 1992; Nicholson and Shahid, 1994). Studies have shown that
selective PDE inhibitors through elevation of cyclic AMP, suppress a variety of
inflammatory cell functions such as degranulation and secretion of granule proteins
(Nourshargh and Hoult, 1986; Dent et al., 1991). Rolipram, a PDEIV inhibitor, has
been shown to inhibit allergen induced eosinophil and neutrophil accumulation into
the lungs of ovalbumin sensitised Brown-Norway rats (Elwood et al., 1995).
Furthermore (32 agonists are used as first line therapy in the treatment of asthma and
this is may reflect in part their ability to suppress inflammatory cell functions such as
superoxide anion release through elevation of cyclic AMP. However, our results
point to enhanced neutrophil longevity in the presence of elevated cyclic AMP which
may be deleterious in chronic inflammatory conditions. Given that elevated cyclic
AMP has also been shown to inhibit macrophage phagocytosis of apoptotic cells
(Rossi et al., 1998) it could be predicted that prolonged elevation of cyclic AMP may
lead to both enhanced granulocyte survival and ineffective clearance, exacerbating
rather than alleviating chronic inflammatory conditions. It is possible that PDE
inhibitors although possessing the ability to suppress the inflammatory potential of
granulocytes (Nourshargh and Hoult, 1986; Dent et al., 1991), may also antagonise
the successful clearance and resolution of inflammation by enhancing granulocyte
survival.
There have been intriguing results regarding the influence of cyclic AMP in the
presence of pro-inflammatory cytokines on granulocyte survival. It has been reported
that elevation of cyclic AMP will favour survival of neutrophils but will reduce the
anti-apoptotic effects ofGMCSF (Tortorella et al., 1998a). Similarly in eosinophils it
has been demonstrated that elevation of cyclic AMP enhances survival but reduces
the anti-apoptotic effects ofGMCSF (Hallsworth et al., 1996) and IL-5 (Chang et al.,
2000). Thus there is the possibility that during inflammation, when cytokines such as
GM-CSF may be in abundance, cyclic AMP suppresses inflammation by both
dampening down inflammatory cell function and reducing the survival influencing
effects of GM-CSF. One could envisage a scenario in which once the inflammation
had subsided and activation of various cytokines had decreased, elevation of cyclic
AMP by PDE inhibition for example could be deleterious, as elevation of cyclic
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AMP alone would likely prevent apoptosis and decrease phagocytic clearance by
macrophages.
In summary, our findings have suggested that elevation of cyclic AMP delays
constitutive neutrophil apoptosis via a novel, rapid and transcriptionally independent
signalling pathway. We believe that protection from apoptosis afforded by cyclic
AMP appears to be upstream of changes in mitochondrial potential and executioner
caspases. Although elevation of cyclic AMP is very powerful at delaying constitutive
neutrophil apoptosis, preliminary experiments indicate that the pro-survival effects of
this second messenger may not be as effective when neutrophils are induced to die
by powerful death stimuli. It is yet to be established in vivo, the relative importance
of the ability of cyclic AMP to influence granulocyte apoptosis in the multitude of
cellular processes influenced by this powerful second messenger.
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4 GLUCOCORTICOID REGULATION OF
GRANULOCYTE APOPTOSIS
Glucocorticoids are highly effective in the control of many inflammatory and
immune diseases. Glucocorticoids have been employed therapeutically to treat
diseases such as asthma and rheumatoid arthritis, however, their use is often limited
by systemic side effects. Considering glucocorticoids are widely used in controlling
many inflammatory conditions, it is perhaps surprising how little is known of their
mechanism of action. Elucidating the underlying signalling pathways of
glucocorticoids could be key in the development ofmore selective anti-inflammatory
steroids with fewer side effects.
Glucocorticoids exert their action by diffusing passively through the cell membrane
where they bind to glucocorticoid receptors (GRs) located in the cytoplasm of target
cells (Levinson et al., 1972; Giannopoulos, 1975). The glucocorticoid receptor
belongs to the steroid hormone receptor superfamily whose members include
cytosolic receptors for other steroid hormones such as progesterone and oestrogen
(Carson-Jurica et al., 1990). Unoccupied glucocorticoid receptors form part of a
large heteromeric complex in the cytoplasm that includes proteins such as heat shock
protein 90 (hsp90). These act as molecular chaperones, preventing the nuclear
translocation of glucocorticoid receptors in the absence of steroid (Bresnick et al.,
1989; Bresnick et al., 1988; Pratt et al., 1989). Hsp90, hsp70 and hsp40 together with
co-chaperones Hop and p23 are believed to be involved in the assembly of
glucocorticoid receptors in a conformation receptive for binding (Rajapandi et al.,
2000; Morishima et al., 2000a; Morishima et al., 2000b). It is believed that a
conformational change ensues following glucocorticoid binding to GR, allowing GR
to dissociate from hsp90 and translocate to the nucleus (Pratt et al., 1989; Stancato et
al., 1996).
As the glucocorticoid receptor was one of the first transcription factors to be isolated,
there have been many studies elucidating the structure and function of this protein in
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glucocorticoid mediated effects. Mutagenesis studies have revealed that the steroid
binding domain ofGR is located at the carboxy terminus of the molecule (Giguere et
al., 1986; Danielsen et al., 1987). Additional functions of the C-terminal domain are
thought to include interaction with hsp90, nuclear translocation and transcriptional
transactivation (Picard and Yamamoto, 1987; Dalman et al., 1991; Hollenberg and
Evans, 1988; Webster et al., 1988; Danielian et al., 1992; Webster et al., 1988)
Following glucocorticoid binding to GR, the subsequent step in the glucocorticoid
signal transduction pathway is the rapid translocation of the activated receptor to the
nucleus, where GR binds DNA. The DNA binding domain is situated in a central
region of the receptor comprising of two zinc motifs and two a helical regions that
contact DNA (Luisi et al., 1991; Giguere et al., 1986; Dahlman-Wright et al., 1994;
Danielsen et al., 1986; Green et al., 1988). Formation of each zinc finger is thought
to require four cysteine residues bound to one zinc molecule (Freedman et al., 1988;
Zilliacus et al., 1992). GR is thought to bind to DNA at consensus sites known at
glucocorticoid response elements (GREs) in the 5' upstream promoter region of
glucocorticoid responsive genes (Tsai et al., 1988; Hard et al., 1990; Truss and
Beato, 1993). Transactivation is believed to involve the N-terminal region, which is
the largest of the three major GR protein domains. Situated in this N-terminal region
is a domain called taul (ii) which contains a 41 amino acid core sequence which is
critical for transactivation. Ti may also be involved in binding other transcription
factors (Giguere et al., 1986; Dahlman-Wright et al., 1995). A further transactivation
domain (T2) is also found in human GR and may be important for localisation of GR
to the nucleus (Hollenberg and Evans, 1988). GR is highly phosphorylated
predominantly on serine residues at the N-terminal domain however the definitive
role and consequences of phosphorylation on steroid action remains largely
undetermined (Muller et al., 1991).
Glucocorticoids mediate their effects by activating a signalling pathway in which GR
directly or indirectly regulates transcription of target genes (Beato et al., 1989;
Gronemeyer, 1992) (Figure 4.1).
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Figure 4.1 Schematic representation of the glucocorticoid signal transduction pathway.
Glucocorticoids (GCs) penetrate the cell membrane and bind directly to cytosolic
glucocorticoid receptors (GRs). GRs are held in a large multiprotein complex including
hsp90. Binding of ligand allows GR to dissociate from this complex and translocate to the
nucleus where GR may bind a glucocorticoid recognition sequence (GRE) on the 5'
upstream promoter of glucocorticoid responsive genes, allowing modulation of transcription.
Alternatively activated GR may indirectly modulate transcription by associating with other
transcription factors e.g. AP-1 which may result in mutual repression.
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This is thought to involve transcriptional transactivation by direct DNA binding of
GR followed by transactivation through ti domain (McEwan et al., 1995).
Alternatively GR is thought to control gene expression indirectly through protein-
protein interactions in the nucleus with other transcription factors. The first
mechanism involves the binding of GR to GRE consensus sites on responsive genes,
altering the rate of transcription, resulting in induction or repression of the gene (Tsai
and O'Malley, 1994). The rate of transcription may be influenced by a number of
factors including the number ofGRE consensus sites present and the binding of other
transcription factors in the vicinity ofGRE, which may alter steroid inducibility (Tsai
and O'Malley, 1994; Bastian and Nordeen, 1991; McEwan et al., 1994). There are
several examples of DNA-dependent GR mediated repression such as GR mediated
repression of prolactin and c-fos genes (Sakai et al., 1988; Mittal et al., 1994). GR
has also been proposed to regulate activity of NFkB via GR-GRE induction of
transcription of the gene encoding IkB-oc (Auphan et al., 1995; Scheinman et al.,
1995a). However later studies have shown this mechanism of NFkB regulation by
glucocorticoids to be cell type restricted and is not universally applicable to all cell
types (Brostjan et al., 1996). It has therefore been suggested that GR mediated
transactivation may not represent the principal mechanism of GR mediated
transcriptional regulation. There is now abundant evidence that GR can also function
in a DNA-independent manner, through a transrepression mechanism involving
protein-protein interactions (Karin et al., 1993; Heck et al., 1994; Helmberg et al.,
1995). For example GR mediated repression of collagenase gene induction is thought
to occur independently of GR-DNA binding and instead involves GR forming a
protein-protein complex with AP-1, preventing this transcription factor from
stimulating collagenase activity. GR may also interact directly with other important
transcription factors involved in signal transduction such as NFkB, signal transducers
and activators of transcription (STATs) and cyclic AMP responsive element binding
protein (CREB) (Ray and Prefontaine, 1994; Caldenhoven et al., 1995; Scheinman et
al., 1995b; Stocklin et al., 1996). It has been proposed that GR transcriptional
transrepression mechanisms are important for the anti-inflammatory action of
glucocorticoids. Many of the transcription factors demonstrated to be subject to GR
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transrepression mechanisms such as NFkB and AP-1, are involved in the regulation
of genes centrally involved in inflammation (Barnes and Adcock, 1993).
Glucocorticoids are thought to also regulate gene transcription through effects on
chromatin structure (Figure 4.2). DNA is normally tightly coiled around histone
proteins, which form a repeating array of DNA-protein particles called nucleosomes.
During transcription, histone residues become acetylated, resulting in uncoiling of
DNA, which is wrapped around the histone proteins. This allows increased access of
transcription factors, resulting in enhanced transcriptional activity. Several
transcription factors such as AP-1, STATs and NFkB are thought to bind to co-
activator molecules such as CREB binding protein (CBP) and the related p300
protein (Arias et al., 1994; Kamei et al., 1996; Zhang et al., 1996; Gerritsen et al.,
1997). CBP is thought to regulate transcription through its ability to both associate
with transcription factors and through is possession of intrinsic histone
acetyltransferase (HAT) activity, allowing it to acetylate histone residues and
regulate transcription (Ogryzko et al., 1996). CBP has been shown to associate with
GR via various co-activator proteins such as glucocorticoid receptor interacting
protein-1 (GRIP-1) (Hong et al., 1997) and glucocorticoid receptor coactivator-1
(SRC-1) (Smith et al., 1996) thus linking GR to the basal transcriptional machinery.
It has therefore been suggested that glucocorticoid repression of transcription factors
such as NFkB may be due to competition between GR and NFkB for limiting
amounts of CBP or p300 (Kamei et al., 1996; Sheppard et al., 1998). However, other
studies have suggested that glucocorticoids are capable for repressing NFkB and
other transcription factors independently of the amount of co-activator present in the
cell (De Bosscher et al., 2000; De Bosscher et al., 2001).
During transcriptional repression, deacetylation of histones is thought to occur
resulting in tighter coiling and reduced access of transcription factors to their binding
sites. It has been recently proposed that glucocorticoids in association with co¬
mpressors and proteins with intrinsic histone deacetylation activity may cause
deacetylation of histones, leading to gene repression (Wolffe, 1997).
132
REGULATION OF GRANULOCYTE APOPTOSiS BY GLUCOCORTICOIDS AND CYCLIC AMP
Glucocorticoids are known to be potent anti-inflammatory agents and have been
widely used in the treatment of chronic airways diseases such as asthma (Barnes and
Adcock, 1993; Barnes, 1997). The anti-inflammatory effects of glucocorticoids may
relate, in part, to their ability to downregulate adhesion molecules that may be
required in the recruitment of inflammatory cells to the sites of inflammation.
Glucocorticoids are known to downregulate ICAM-1 and E-selectin via a direct
signalling mechanism (Cronstein et al., 1992; van de et al., 1993). Glucocorticoids
have also been shown to suppress PAF induced upregulation of CD11/CD18 and
downregulation of L selectin, which may have important implications for leukocyte
accumulation (Filep et al., 1997). Glucocorticoids may also suppress inflammation
through enhanced synthesis of anti-inflammatory mediators such as IL-1 receptor
antagonist (IL-lra) (Levine et al., 1996), secretory leukocyte protease inhibitor
(SLPI) (Abbinante-Nissen et al., 1995) and lipocortin-1 (Browning et al., 1990;
Errasfa et al., 1985). Production of lipocortin-1 would presumably decrease the
activity of lipid mediators such as prostaglandins (Fradin et al., 1988) and SLPI may
be involved in anti-inflammatory activity in the airways, through neutralisation of
destructive proteases such as neutrophil elastase (Hochstrasser et al., 1981). The
mechanism by which glucocorticoids upregulate these anti-inflammatory proteins is
thought to be through transcriptional transactivation. Glucocorticoids also suppress
the synthesis of many proinflammatory cytokines from a variety of cells including
macrophages (Martinet et al., 1992; Linden and Brattsand, 1994), T lymphocytes
(Kelso and Munck, 1984), epithelial (Kwon et al., 1994; Kwon et al., 1995; Wang et
al., 1996b) and endothelial cells (Waage et al., 1990; Kemer et al., 1992). Further,
glucocorticoids also suppress the synthesis and effects of many chemokines such as
IL-8 (Kwon et al., 1994), RANTES (Kwon et al., 1995), and eotaxin (Lilly et al.,
1997) potentially abrogating the ability of inflammatory cells to be recruited to the
site of inflammation. As several of these genes do not contain the appropriate GRE
consensus sites in the 5'end region of their promoter region, it is believed
glucocorticoids suppress their production by indirect transrepression of the
transcription factors that regulate their expression.
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Figure 4.2 Effects of glucocorticoids on chromatin structure. Several transcription factors
such as NFkB and CREB bind to the cointegrator molecule CBP/p300 which possesses
intrinsic histone acetyltransferase (HAT) activity. During transcription, acetylation of histone
proteins by CBP, allows DNA that is wrapped around histone proteins to uncoil. This allows
increased accessibility of transcription factors resulting in enhanced transcription.
Glucocorticoids through GR may modulate transcription through association with CBP via
glucocorticoid receptor coactivator-1 (SRC-1). GR may cause gene repression by competing
with other transcription factors for binding to limited amounts ofCBP or instead may disturb
other transcription factors from binding to the basal transcriptional machinery. Alternatively
GR may indirectly deacetylate histones resulting in increased coiling ofDNA around histone
thereby preventing transcription factor binding. BTM, basal transcription machinery, Ac,
acetylated nucleosome.
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The beneficial anti-inflammatory properties of glucocorticoids may also occur
through direct effects on cell function and may relate to the ability of glucocorticoids
to modulate granulocyte function. Glucocorticoids may suppress eosinophilic
inflammation by downregulating the release of eosinophil cytotoxic cell contents.
However, this may not be the universal mechanism by which glucocorticoids
suppress eosinophil activity, as glucocorticoids have been shown to only weakly
suppress eosinophil degranulation and secretion of eosinophil basic proteins (Kita et
al., 1991c). One of the best-described actions attributed to steroids in asthma is a
reduction in the number of circulating eosinophils following glucocorticoid therapy
(Schleimer, 1990). Diminished numbers of eosinophils may be the result of
suppression of eosinophil recruitment through glucocorticoid inhibition of eosinophil
adherence and chemotaxis (Clark et al., 1979; Altman et al., 1981). Furthermore,
glucocorticoids may suppress production of inflammatory mediators and cytokines
involved in recruiting these cells to inflammatory sites. In addition to suppressing
eosinophil influx, a reduction in eosinophil numbers in the airways may be caused by
redistribution of eosinophils to other compartments. However studies by Kawabori et
al have demonstrated that glucocorticoid induced depletion of intestinal eosinophils
does not result in redistribution of eosinophils to the spleen, lymph nodes or
peripheral blood, suggesting that this may not be a major mechanism for
glucocorticoid reduction of eosinophil numbers (Kawabori et al., 1991). There is
accumulating evidence however that glucocorticoid depletion of eosinophils may
instead occur by an important regulatory mechanism, in which glucocorticoids
accelerate eosinophil cell death, allowing engulfment and clearance by macrophages.
To this end, Woolley et al. have reported increased eosinophil apoptosis in the
airways of asthmatics following glucocorticoid treatment. Furthermore, increased
apoptosis has been correlated with clinical improvement and resolution of
eosinophilic inflammation. As it has been demonstrated that activation of
inflammatory cells is reduced when they undergo apoptosis (Whyte et al., 1993),
apoptosis could contribute to the resolution of inflammation by reducing eosinophil
activity and facilitating their safe removal. Furthermore, apoptosis may allow the
shutdown of secretory capacity while maintaining an intact cell membrane thus
preventing leakage of cytotoxic cell contents thereby suppressing any further
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incitement of inflammation. Furthermore, as glucocorticoids have also been
demonstrated to increase the clearance of apoptotic granulocytes (Liu et al., 1999),
the effectiveness of glucocorticoids in treatment of inflammatory diseases such as
asthma may relate in part to their ability to promote apoptosis and clearance of
inflitrating eosinophils.
In contrast to eosinophils, where it has been demonstrated that glucocorticoids
induce apoptosis (Meagher et al., 1996), glucocorticoids have been shown in vitro to
increase the lifespan of the closely related neutrophil (Cox, 1995; Kato et al., 1995),
(Liles et al., 1995; Meagher et al., 1996). Indeed, in comparison to the reduction in
eosinophil numbers observed following systemic treatment with glucocorticoids,
neutrophil numbers in fact show an increase (Schleimer, 1990). Although neutrophil
lifespan appears to be influenced by glucocorticoids, it has generally been assumed
that neutrophils are less sensitive to the influence of glucocorticoids compared to
other white blood cells. Early reports suggested that high concentrations of
glucocorticoids could modulate a variety of neutrophil responses (Levine et al.,
1981; Umeki and Soejima, 1990; Shea and Morse, 1978) however later studies have
reported that physiological concentrations of steroids are unable to suppress a wide
variety of neutrophil functions such as chemotaxis, adhesion, degranulation and
secretion (Schleimer et al., 1989). The inability of glucocorticoids to suppress
neutrophil activity has been proposed to explain the lower efficacy of these drugs in
neutrophilic inflammatory disease. For example the beneficial effect of
glucocorticoids on 'eosinophilic' inflammatory diseases such as asthma and allergy
has not been observed in neutrophil-associated inflammatory diseases such as
chronic obstructive airways disease (Zainudin, 1997). Although ineffectiveness of
glucocorticoids may be partly due to the inability of these drugs to influence
neutrophil responses such as degranulation, it is reasonable to predict that
glucocorticoid enhancement ofneutrophil longevity may also play a part.
The mechanisms by which eosinophil and neutrophil apoptotic responses to
glucocorticoids differ are unknown. It has been proposed that glucocorticoids are
likely to exert their effects on granulocyte apoptosis by regulating the cytokine
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environment that influences the longevity of these cells. Several groups have
reported that glucocorticoids inhibit the effect of cytokines such as GM-CSF in
prolonging eosinophil survival (Her et al., 1991; Lamas et al., 1991; Wallen et al.,
1991; Hallsworth et al., 1992). Furthermore it has also been reported that
glucocorticoids enhance the neutrophil survival properties of GM-CSF (Cox, 1995;
Meagher et al., 1996). As eosinophils and neutrophils when appropriately activated,
are capable of producing GM-CSF (Kita et al., 1991a), it has been proposed that
glucocorticoids exert their influence on granulocyte apoptosis through differential
regulation of the elaboration of GM-CSF. However GM-CSF is undetectable in
ageing granulocyte cultures and excess of blocking anti-GM-CSF Ab fails to affect
modulation of apoptosis caused by glucocorticoids (Meagher et al., 1996). Thus the
direct influence of glucocorticoids on granulocyte apoptosis does not appear to be
mediated by GM-CSF. It is important to note that in vivo, glucocorticoids may
influence secretion of cytokines such as GM-CSF from a variety of cell types, which
may in turn influence granulocyte apoptosis. For example, glucocorticoids have been
reported to suppress GM-CSF production from human bronchial epithelial cells,
which consequently abrogates the survival influence of GM-CSF on eosinophils
(Cox et al., 1991). These findings may have importance for the use of
glucocorticoids in inflammatory conditions, at times where GM-CSF may also be
present. However of equal importance is the direct influence of glucocorticoids on
granulocytes, which we propose may be a major influence in the long observed
divergent response among granulocyte types following glucocorticoid administration
in vivo. Our aim was to try to elucidate the mechanisms by which glucocorticoids can
exert their effects on granulocytes, examining the intracellular signalling pathways
initiated by the binding of glucocorticoids to these cells and investigating the
differential responsiveness of granulocytes that suggest distinct apoptotic control
mechanisms are present in each cell type. Elucidation of the signalling pathways by
which glucocorticoids directly influence granulocyte apoptosis, may contribute to a
greater understanding of the anti-inflammatory action of glucocorticoids in
inflammation.
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4.1 DIFFERENTIAL EFFECT OF GLUCOCORTICOIDS ON
NEUTROPHIL AND EOSINOPHIL APOPTOSIS
Glucocorticoids have been previously reported to exert diametrically opposed effects
upon the rate of granulocyte apoptosis in vitro; promoting eosinophil apoptosis while
inhibiting neutrophil apoptosis (Cox, 1995; Kato et al., 1995; Liles et al., 1995;
Meagher et al., 1996). To confirm this is indeed the case, neutrophils (5 x 106/ml)
and eosinophils (2.5 x 106/ml) were cultured in serum supplemented Iscove's
DMEM and exposed to dexamethasone (1 pM) for 20 h and 40 h respectively. We
found that dexamethasone delayed morphological changes characteristic of
constitutive neutrophil apoptosis, such as cytoplasmic shrinkage and nuclear
condensation (Figure 4.1.1). Dexamethasone also delayed cell membrane changes
associated with apoptosis such as the exposure of phosphatidylserine measured by
Annexin V binding (Figures 4.1.2 and 4.1.3). Figure 4.1.2 illustrates the percentage
of cells within the Annexin V "high" gate was reduced by dexamethasone treatment
of neutrophils from 57% (B; control) to 23% (C; dexamethasone).
In contrast to the effects observed on neutrophils, eosinophils (2.5 x 106/ml) cultured
in serum supplemented Iscove's DMEM showed increased apoptosis in the presence
of 1 pM dexamethasone at 40 h as measured by standard morphological assessment
(Figure 4.1.4). The morphological changes in apoptosis associated with
dexamethasone treatment of eosinophils include nuclear pyknosis and chromatin
condensation together with decreased cell size and cytoplasmic vacuolation (Bottom
panel Figure 4.1.4). Numerous anucleate eosinophils or "ghosts" habitually appeared
on the cytocentrifuge preparations, indicative of nuclear extrusion. The effect of
dexamethasone on eosinophil apoptosis was also examined by Annexin V binding
(Figure 4.1.5 and 4.1.6). Measurement of Annexin-V binding during eosinophil
apoptosis revealed an increase in the percentage of cells showing Annexin V "high
positivity in dexamethasone treated eosinophils (83%) compared to untreated
controls (45%) (Figure 4.1.6).
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Assessment of cell viability demonstrated that dexamethasone did not significantly
alter this parameter (data not shown). Thus we have confirmed the previous
observation that glucocortiocoids exert differential effects on neutrophils and
eosinophils.
SUMMARY
• Dexamethasone delays neutrophil apoptosis as assessed by morphological and
cell membrane changes.
• Dexamethasone induces eosinophil apoptosis as assessed by morphological and
cell membrane changes.
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Figure 4.1.1 Neutrophil apoptosis is delayed by dexamethasone. Human neutrophils (5
xl06/ml) were cultured in Iscove's DMEM containing 10% autologous serum at 37 °C,
with or without dexamethasone (lpM). After 20 h, cells were harvested and assessed
morphologically for apoptosis. The upper panel indicates control neutrophils after 20 h in
culture. The bottom panel indicates neutrophils treated with dexamethasone for 20 h.
Note that the number of cells exhibiting classical apoptotic morphology (i.e. condensed
nuclei) is much less in the dexamethasone treated cells.
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Figure 4.1.2 Dexamethasone mediated delay of neutrophil apoptosis. (A) represents a
typical flow cytometric plot for neutrophils. (B) represents control neutrophils after 20 h
in culture incubated with FITC labelled recombinant human Annexin-V to measure
phosphatidylserine expression. (C) represents neutrophils stimulates with dexamethasone
(1 pM) for 20 h before being incubated with FITC labelled recombinant human Annexin-
V to measure phosphatidylserine expression. The data is of one representative experiment.
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Figure 4.1.3 Dexamethasone delays neutrophil apoptosis. Human neutrophils (5
xl06/ml) were cultured in Iscove's DMEM containing 10 % autologous serum at 37 °C,
and treated with dexamethasone (1 pM). After 20 h in culture, the cells were incubated
with FITC-labelled recombinant human Annexin V to determine phosphatidylserine
expression. All values represent mean ± S.E. of n = 6 experiments, each performed in
duplicate where significance from control is represented by */3<0.001.
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Figure 4.1.4 Dexamethasone induces eosinophil apoptosis. Human eosinophils (2.5
xl06/ml) were cultured in Iscove's DMEM containing 10% autologous serum at 37 °C,
with or without dexamethasone (lpM). After 40 h, cells were harvested and assessed
morphologically for apoptosis. The upper panel indicates control eosinophils after 40 h in
culture. The bottom panel indicates eosinophils treated with dexamethasone for 40 h. Note
that the number of cells exhibiting classical apoptotic morphology (i.e. condensed nuclei)
is much higher in the dexamethasone treated cells.
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Figure 4.1.5 Dexamethasone induction of eosinophil apoptosis. (A) represents a
typical flow cytometric scatter plot for eosinophils. (B) represents control eosinophils
after 40 h in culture incubated with FITC-labelled recombinant human Annexin-V to
determine phosphatidylserine expression. Similarly (C) represents eosinophils stimulated
with dexamethasone (1 pM) for 40 h before incubation with FITC-labelled recombinant
human Annexin-V to determine phosphatidylserine expression. The data above is one
representative experiment.
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Figure 4.1.6 Dexamethasone induces eosinophil apoptosis. Human eosinophils (2.5
xl06/ml) cultured in Iscove's DMEM containing 10 % autologous serum at 37 °C, and
treated with dexamethasone (1 pM). After 40 h in culture, the cells were incubated with
FITC-labelled recombinant human Annexin V to determine phosphatidylserine
expression. All values represent mean ± S.E. of n = 3 experiments, each performed in
duplicate where significance from control is represented by *P<0.001
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4.2 CONCENTRATION DEPENDENCY OF THE EFFECT OF
DEXAMETHASONE ON NEUTROPHIL AND EOSINOPHIL
APOPTOSIS
To determine whether the differential effect of dexamethasone on neutrophil and
eosinophil apoptosis is concentration dependent, we performed the following
experiments. Neutrophils (5 x 106/ml) cultured in serum supplemented Iscove's
DMEM showed decreasing levels of neutrophil apoptosis in the presence of
increasing concentrations of dexamethasone (0.001 - 10 jiM). Furthermore,
eosinophils (2.5 x 106/ml) cultured in serum supplemented Iscove's DMEM showed
increasing levels of apoptosis in the presence of increasing concentrations of
dexamethasone (0.01-10 (iM). It is important to note that neutrophils appear sensitive
to the survival effects of dexamethasone at low concentrations of this glucocorticoid
(10 nM). In comparison, it appears that higher concentrations of dexamethasone are
needed to induce eosinophil apoptosis (0.1-10 pM).
It has been widely suggested that neutrophils are less sensitive to the effects of
glucocorticoids compared to other cell types (Schleimer et al., 1989). The inability of
glucocorticoids to modulate key neutrophil functions such as chemotaxis and
degranulation led to the prevailing notion that these cells are unresponsive to the
effects of glucocorticoids. The data above clearly demonstrates that this is not the
case with regards to the ability of nanomolar concentrations of dexamethasone to
inhibit neutrophil apoptosis. Furthermore, it is interesting that glucocorticoid
induction of eosinophil apoptosis requires higher concentrations of dexamethasone
compared with that required to modulate neutrophil apoptosis.
SUMMARY
• Dexamethasone delays neutrophil apoptosis in a concentration dependent manner
• Dexamethasone induces eosinophil apoptosis in a concentration dependent
manner
• Neutrophils appear more sensitive to the apoptotic regulatory effects of
glucocorticoids compared to eosinophils
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Figure 4.2.1 Dexamethasone delays neutrophil apoptosis in a concentration
dependent manner. Human neutrophils (5 xl06/ml) were cultured in Iscove's DMEM
containing 10 % autologous serum at 37 °C with the indicated concentrations of
dexamethasone (pM). After 20 h in culture, the cells were incubated with FITC-labelled
recombinant human Annexin V to determine phosphatidylserine expression. All values
represent mean + S.E. of n = 3-7 experiments, each performed in duplicate where
significance from control is represented by *P<0.01
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Figure 4.2.2 Dexamethasone induces eosinophil apoptosis in a concentration
dependent manner. Human eosinophils (2.5 xl06/ml) were cultured in Iscove's DMEM
containing 10 % autologous serum at 37 °C with the indicated concentrations of
dexamethasone (pM). After 40 h in culture, the cells were incubated with FITC-labelled
recombinant human Annexin V to determine phosphatidylserine expression. All values
represent mean ± S.E. of n = 3 experiments, each performed in duplicate where
significance from control is represented by TO.01
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4.3 GLUCOCORTICOID REGULATION OF GRANULOCYTE
APOPTOSIS REQUIRES HSP90
Glucocorticoids exert their effects by diffusing passively through the cell membrane
where they bind to glucocorticoid receptors (GRs) located in the cytoplasm of target
cells. Glucocorticoid receptors form part of a large heterocomplex in the cytoplasm
with specific molecular chaperones and other proteins, which prevent unoccupied
glucocorticoid receptors from translocating to the nucleus, in the absence of ligand.
The large protein complex which binds the carboxy terminal of the glucocorticoid
receptor includes two subunits of the heat shock protein hsp90, hsp70 and several
other co-chaperones (Bresnick et al., 1989; Pratt et al., 1989; Morishima et al.,
2000b; Rajapandi et al., 2000). The role of the hsp 90 as a molecular chaperone of
the glucocorticoid receptor is well characterised in many cell systems however
involvement of hsp90 and other molecular chaperones in glucocorticoid regulated
processes in granulocytes has not been described.
To establish if hsp90 in involved in the glucocorticoid signalling mechanisms
controlling cell death in granulocytes we have made use of the hsp90 binding
benzoquinoid ansamycin, geldanamycin (GA). Geldanamycin occupies the
nucleotide-binding site on hsp90 and prevents the switch to its ATP-bound
conformation, which is required for assembly of GR-hsp90 heterocomplexes
receptive to ligand binding (Prodromou et al., 1997; Roe et al., 1999). Neutrophils
were incubated in serum supplemented Iscove's DMEM in the presence of
dexamethasone (1 pM) with or without geldanamycin (10 pM) for 20 h, before
assessment of apoptosis (Figure 4.3.1). We found that dexamethasone mediated
delay ofneutrophil apoptosis is abrogated in the presence of geldanamycin indicating
that hsp90 is required for glucocorticoid inhibition of neutrophil apoptosis.
In parallel studies, eosinophils were incubated for 40 h in the presence of
dexamethasone (1 pM) with or without geldanamycin (10 pM) before assessment of
apoptosis. Dexamethasone treatment of eosinophils induces apoptosis, which we
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found could be significantly inhibited by geldanamycin (Figure 4.3.2), suggesting a
role for hsp90 in glucocorticoid regulation of eosinophil cell death. It is interesting
that geldanamycin causes a small induction of apoptosis on its own in eosinophils
suggesting that hsp90 may be involved in regulation of constitutive eosinophil
apoptosis.
Our results suggest that both glucocorticoid inhibition of neutrophil apoptosis and
glucocorticoid induction of eosinophil cell death require the involvement of hsp90.
As geldanamycin is known to block the formation of steroid binding competent
aporeceptor complexes, our results may suggest that correctly assembled GR-hsp90
complexes are vital for glucocorticoid regulation of granulocyte apoptosis. However
there are as yet no studies demonstrating that GR heterocomplexes form in
granulocytes or are required for glucocorticoid signalling in these cells. Thus
abrogation of glucocorticoid mediated effects in granulocyte apoptosis by
geldanamycin only gives indirect evidence of hsp90 involvement in generating
glucocorticoid receptors of the correct conformation for ligand binding. To further
elucidate the signalling mechanism by which glucocorticoids differentially regulate
granulocyte apoptosis we decided to try to examine the role of GR and its
downstream effector mechanisms which may be participating in this process.
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Figure 4.3.1 Blockade of hsp90 with geldanamycin abrogates dexamethasone
mediated delay of neutrophil apoptosis. Human neutrophils (5 x 106/ml) cultured in
Iscove's DMEM containing 10% autologous serum at 37 °C, and treated with
geldanamycin (10 pM) with or without dexamethasone (1 pM). After 20 h, cells were
incubated with FITC-labelled recombinant human Annexin V to determine
phosphatidylserine expression. All values represent mean ± S.E. of n = 3 experiments,
each performed in duplicate where significant difference from control is represented by
*P<0.001 and difference from dexamethasone alone is represented by #P<0.001.
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Figure 4.3.2 Blockade of hsp90 with geidanamycin abrogates dexamethasone
mediated induction of eosinophil apoptosis. Human eosinophils (2.5 x 106/ml) cultured
in Iscove's DMEM containing 10% autologous serum at 37 °C, and treated with 10 pM
geidanamycin with or without dexamethasone. After 40 h, cells were incubated with
FITC-labelled recombinant human Annexin V to determine phosphatidylserine
expression. All values represent mean ± S.E. of n = 3 experiments, each performed in
duplicate where significant difference from control is represented by *P<0.001 and
significant difference from dexamethasone alone is represented by #P<0.05.
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SUMMARY
• Inhibition of hsp90 by geldanamycin abrogates glucocorticoid mediated delay of
neutrophil apoptosis
• Inhibition of hsp90 by geldanamycin abrogates glucocorticoid mediated
induction of eosinophil apoptosis
• Inhibition of hsp90 by geldanamycin causes a small induction of constitutive
eosinophil apoptosis
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4.4 ROLE OF THE GLUCOCORTICOID RECEPTOR IN
GLUCOCORTICOID REGULATION OF GRANULOCYTE
APOPTOSIS
4.4.1 EXPRESSION OF GLUCOCORTICOID RECEPTOR ISOFORMS IN
GRANULOCYTES
In light of the fact that neutrophils, compared to eosinophils, appear to have both a
differential response and enhanced sensitivity to the apoptotic regulatory influence of
glucocorticoids, we investigated if this was due to differences in the glucocorticoid
signalling pathway at the level of the GR. The human glucocorticoid receptor exists
as two different isoforms, GRa and GR[), which arise from the same gene by
alternative splicing (Hollenberg et al., 1985; Encio and Detera-Wadleigh, 1991). The
two isoforms differ only at their carboxy terminus with the last 50 amino acids of
GRa being replaced by a 15 AA sequence in GR|3, which is thought to lack a steroid
binding domain. As a result, it is believed that GRp is incapable of binding
glucocorticoids and is unable to stimulate gene transcription. Moreover it has been
suggested that GR[) can antagonise the effects ofGRa possibly through formation of
antagonistic GRa/GR(3 heterodimers (Bamberger et al., 1995; de Castro et al., 1996;
Oakley et al., 1996; Oakley et al., 1999).
It has previously been shown that neutrophils and eosinophils exhibit similar
numbers of glucocorticoid receptors (Peterson et al., 1981). The saturable
glucocorticoid binding in human neutrophils is similar to that observed in eosinophils
(Kd = 17.7 ± 0.8 nM in the neutrophil and Kd = 15.3 ± 0.6 nM in the eosinophil)
(Peterson et al., 1981). This would appear to suggest that differences in receptor
number and affinity are not responsible for the differential effect of glucocorticoids
on granulocyte apoptosis. It is currently unknown which isoforms of GR are
expressed in neutrophils and eosinophils and indeed if there are any differences in
the nature of the isoforms expressed in these cell types. Although binding studies
-7
using H-labelled agonists have indicated neutrophils and eosinophils contain similar
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numbers of glucocorticoid receptors, this technique would not be able to take into
account effects mediated by the presence of GR[f, which cannot bind ligand and
whose effects may be independent of this activity. Therefore we decided to examine
if the differential responsiveness and effect of glucocorticoids in granulocytes is due
to differential expression and signalling ofGR isoforms.
Numerous studies have shown that GRa resides mainly in the cytoplasm of cells in
the absence of hormone and translocates to the nucleus in a hormone dependent
manner (Cidlowski et al., 1990; Antakly et al., 1989). In contrast, it has been shown
that GR(3 resides mainly in the nucleus although it is unclear if GR(3 is able to change
its subcellular localisation upon hormone treatment (Oakley et al., 1996). As an
initial approach to attempt to dissect the signalling mechanisms involved in
glucocorticoid regulation of granulocyte apoptosis, we examined GR protein
expression in neutrophils and eosinophils by Western blotting. Protein extracts were
obtained from granulocytes which had been treated with control buffer or
dexamethasone (1 jiM) over a time course of 20 h. Lysates were prepared from
equivalent numbers of cells and subject to SDS-PAGE/immunblot analysis.
Numerous lysis methods and antibodies were tested as we found extreme difficulty
in obtaining successful Western blots for GR using standard techniques. These
problems occurred despite inclusion of a broad spectrum of protease inhibitors and
may reflect the major protease content of these cells. The various lysis methods and
antibodies that were tested are outlined in Chapter 2. Following lengthy optimisation,
GR was detectable as a 97 kDa species upon Western blotting of neutrophil
cytoplasmic extracts (Figure 4.4.1A). Levels of expression ofGR did not alter during
the 4 h time course. Furthermore there was surprisingly no detectable loss of GR
from the cytoplasm upon dexamethasone treatment at all time points tested (Figure
4.4.1A). Moreover, we could not detect expression of GR in neutrophil nuclear
extracts. Similarly to neutrophils, we found that expression of GR in eosinophils
remains unchanged over a time course of 4 h (Figure 4.4.IB). Furthermore there is
no detectable loss of GR from the cytoplasm of eosinophils upon dexamethasone
treatment (Figure 4.4.IB) or expression of GR in nuclear extracts at all time points
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tested (data not shown). An affinity purified rabbit IgG verified that the band
appearing at 97kDa was not as a result of non-specific binding of the rabbit
polyclonal antibody (data not shown).
Western blotting analysis of expression of GRp specifically was performed using a
commercially available rabbit anti-human polyclonal antibody which recognises
specifically the carboxy terminus of GR(3 (PA3-514). In granulocytes,
immunoblotting using this antibody, resulted in the appearance of a ~60 kDa protein
band in lysates from both neutrophils and eosinophils (Figure 4.4.1C & Figure
4.4. ID). There was no evidence of higher molecular weights proteins present in these
immunoblots, even after a long exposure time. The disparity in the molecular weight
of the protein observed and GRp, which is ~94kDa, suggested the antibody was not
recognising GRp specifically. It was found that immunoblotting with an affinity
purified rabbit IgG used at equivalent concentrations, produced a band of the same
molecular weight, suggesting the protein detected is not GRP and is due to non¬
specific binding of rabbit IgG.
SUMMARY
• Neutrophils and eosinophils express GR by Western blotting however the nature
of GR isoforms present in these cells remains undefined.
• Translocation of GR upon dexamethasone treatment could not be detected in
neutrophils and eosinophils
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Figure 4.4.1A Time course for the effect of dexamethasone on GR expression during
human neutrophil apoptosis Western blot of cytoplasmic (CYT) and nuclear extracts
(NUC) from neutrophils treated with control buffer or dexamethasone (1 pM) for the time
points indicated. Cell lysates were prepared and immunoblotted as described under
"Materials and Methods". Lysates were prepared from equivalent numbers of cells and
subjected to SDS-PAGE/immunoblot analysis using a rabbit anti-human polyclonal
antibody (PA 1-511) which recognises all forms of GR. The antibody recognises a 97 kDa
GR protein. The gel is representative of 3 experiments.
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Figure 4.4.1B Time course for the effect of dexamethasone on GR expression in
human eosinophils. Western blot of cytoplasmic extracts from eosinophils treated with
control buffer or dexamethasone (1 pM) for the time points indicated. Cell lysates were
prepared and immunoblotted as described under "Materials and Methods". Lysates were
prepared from equivalent numbers of cells and subjected to SDS-PAGE/immunoblot
analysis using a rabbit anti-human polyclonal antibody (PA 1-511) which recognises all
forms of GR. The antibody recognises a 97 kDa GR protein. The gel is representative of
3 experiments.
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Figure 4.4.1C Time course for the effect of dexamethasone on GRp expression in
human neutrophils. Western blot of cytoplasmic extracts from neutrophils treated with
control buffer or dexamethasone (1 jjM) for the time points indicated. Cell lysates were
prepared and immunoblotted as described under "Materials and Methods". Lysates were
prepared from equivalent numbers of cells and subjected to SDS-PAGE/immunoblot
analysis using a rabbit anti-human polyclonal antibody (PA3-514) which specifically
recognises GRP or as a negative control an affinity purified rabbit IgG. The gel is
representative of 3 experiments
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Figure 4.4.1D Time course for the effect of dexamethasone on GRp expression in
human eosinophils. Western blot of cytoplasmic extracts from eosinophils treated with
control buffer or dexamethasone (1 pM) for the time points indicated. Cell lysates were
prepared and immunoblotted as described under "Materials and Methods". Lysates were
prepared from equivalent numbers of cells and subjected to SDS-PAGE/immunoblot
analysis using a rabbit anti-human polyclonal antibody (PA3-514) which recognises s
GRP specifically or as a negative control an affinity purified rabbit IgG. The gel is
representative of 3 experiments
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4.4.2 EFFECT OF GLUCOCORTICOID ANTAGONIST RU486 ON
DEXAMETHASONE MEDIATED DELAY OF NEUTROPHIL APOPTOSIS
In the previous experiments we could not detect glucocorticoid mediated activation
of the glucocorticoid receptor and did not observe dexamethasone-induced
translocation of GR to the nucleus in either cell type. Although this may be due to
limitations in the techniques used, it was necessary to try to elucidate whether
glucocorticoid regulation of granulocyte apoptosis requires classical glucocorticoid
signalling through GR. As an alternative approach, we therefore examined the effects
of the glucocorticoid and progesterone receptor antagonist RU 486 on glucocorticoid
regulation of granulocyte apoptosis. RU 486 is believed to act as a competitive
antagonist, capable of binding to cytosolic glucocorticoid receptors but unable to
stimulate GR dependent transcription (Moguilewsky and Philibert, 1984; Bourgeois
et al., 1984). Neutrophils were co-cultured with the indicated concentrations of
dexamethasone and RU 486 for 20 h before assessment of apoptosis (Figure 4.4.2A).
10 pM RU 486 was found to fully reverse the delay of neutrophil apoptosis mediated
by 0.01-0.1 pM dexamethasone however only a partial reversal was found in cells
co-cultured in 1 pM dexamethasone and 10 pM RU 486.
It has been suggested that RU 486 has to be in at least 10 fold excess in order to fully
abrogate dexamethasone binding to GR which would explain why only a partial
reversal is found with 10 pM RU486 in the presence of 1 pM dexamethasone. It is
striking however that there appears to be no reversal of dexamethasone inhibition of
neutrophil apoptosis using 1 pM RU 486 when dexamethasone is titrated to
concentrations as low at 0.01 pM.
To establish if glucocorticoid induction of eosinophil apoptosis required the
involvement of the glucocorticoid receptor, eosinophils were co-cultured with the
indicated concentrations of dexamethasone and RU 486 for 40 h, before assessment
of apoptosis (Figure 4.4.2B). As previously shown in Figure 4.1.4, dexamethasone
induces eosinophil apoptosis at concentrations of 0.1 pM and above. It appears that
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RU 486 may act as a partial agonist with regards to the induction of eosinophil
apoptosis. RU 486 at 10 pM will cause a small induction of apoptosis in eosinophils
yet appears to also act as a competitive antagonist and will compete with
dexamethasone for binding to GR resulting in partial abrogation of dexamethasone
mediated eosinophil death. RU 486 was effective at reversing dexamethasone
induction of eosinophil apoptosis when used at a concentration of 10 pM but again
was ineffective at concentrations below this.
It is perhaps surprising that such high concentrations of RU 486 are needed to
abrogate the apoptosis influencing effects of glucocorticoids in granulocytes. In
particular it is remarkable that glucocorticoids can influence neutrophil apoptosis at
nanomolar concentrations yet, 10 pM RU486 is required to abrogate this effect.
These findings may suggest that glucocorticoids regulate neutrophil apoptosis via a
mechanism other than classical signalling through GR. Although we have not been
able to demonstrate the presence of GR(3 in granulocytes due to poor antibody
specificity it is possible that some of the effects of glucocorticoids could be mediated
by GR(3 which may not be antagonised be RU 486 (Oakley et al., 1996).
SUMMARY
• Dexamethasone inhibition of neutrophil apoptosis is partially abrogated by RU
486 (>10pM) but not at lower concentrations.
• Dexamethasone induction of eosinophil apoptosis is partially abrogated by
RU486 (>10pM) but not at lower concentrations.
• RU486 may also act as a partial agonist and induce apoptosis in eosinophils.
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Figure 4.4.2A Effect of glucocorticoid antagonist RXJ486 on dexamethasone mediated
delay of neutrophil apoptosis. Human neutrophils (5 x 106/ml) cultured in Iscove's
DMEM containing 10 % autologous serum at 37 °C, and treated with the indicated
concentrations of RU486 (|iM) with or without dexamethasone. After 20 h, cells were
incubated with FITC-labelled recombinant human Annexin V to determine
phosphatidylserine expression. All values represent mean ± S.E. of n = 3 experiments,
each performed in duplicate where significant difference from control is represented by
*P<0.01 and significant difference from dexamethasone alone is represented by # P<0.01.
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Figure 4.4.2B Effect of glucocorticoid antagonist RU486 on dexamethasone mediated
induction of eosinophil apoptosis. Human eosinophils (5 x 106/ml) cultured in Iscove's
DMEM containing 10 % autologous serum at 37 °C, and treated with the indicated
concentrations of RU486 (pM) with or without dexamethasone. After 40 h, cells were
incubated with FITC-labelled recombinant human Annexin V to determine
phosphatidylserine expression. All values represent mean ± S.E. of n = 3 - 4 experiments,
each performed in duplicate where significant difference from control is represented by
*P<0.05 and significant difference from dexamethasone alone (0.1 pM) by **P<0.01.
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4.5 REQUIREMENT FOR PROTEIN SYNTHESIS IN
GLUCOCORTICOID MEDIATED INHIBITION OF
NEUTROPHIL APOPTOSIS
In light of the difficulties in establishing direct GR involvement in glucocorticoid
regulation of granulocyte apoptosis, an alternative approach was sought to dissect the
mechanism behind the differential effect of glucocorticoids on granulocytes.
Glucocorticoids produce their effects on responsive cells by activating GR to directly
or indirectly regulate the transcription of target genes. It has been highly
controversial whether glucocorticoid regulation of apoptosis is a consequence of
DNA-binding dependent transcriptional activation or transrepression. It has been
previously shown that DNA binding of GR is a prerequisite for glucocorticoid
mediated thymocyte apoptosis (Reichardt et al., 1998). Similarly, Chapman et al
have reported that transcription transactivation by GR is required for glucocorticoid
induction of apoptosis in murine thymoma cells (Chapman et al., 1996). In contrast,
Helmberg et al have demonstrated that transrepression by GR is involved in
glucocorticoid induction of apoptosis in human leukemic cells (Helmberg et al.,
1995). A key question we wished to address therefore was whether glucocorticoid
regulation of granulocyte apoptosis required the direct effects of glucocorticoids
through GR-DNA binding or instead involved transcriptional repression via GR
association with other transcription factors. We also wished to ascertain if divergence
in the mechanisms regulating glucocorticoid stimulated transcriptional activity, was
responsible for the differential responsiveness of eosinophils and neutrophils to
apoptotic regulation by glucocorticoids.
As an initial approach to verify the necessity of gene transcription for glucocorticoid
modulation of apoptosis in granulocytes, cells were co-cultured with the protein
synthesis inhibitor, cycloheximide. This compound was titrated to low concentrations
to minimise the induction of apoptosis that has been reported to occur by this
compound on its own. We first tested if glucocorticoid inhibition of neutrophil
apoptosis required gene transcription. Neutrophils were cultured in serum-
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supplemented Iscove's DMEM in the presence of dexamethasone (1 |iM) together
with the indictaed concentrations of cycloheximide. After 20 h, apoptosis was
assessed by standard morphological criteria and exposure of phosphatidylserine by
Annexin V binding. We found that cycloheximide blocked glucocorticoid-mediated
suppression of neutrophil apoptosis at these concentrations (Figure 4.5.1) suggesting
glucocorticoids are required to stimulate gene transcription in order to delay
neutrophil apoptosis.
Similar experiments were performed to establish if glucocorticoid induction of
eosinophil cell death required gene transcription. However interpretation was
difficult as eosinophils are particularly sensitive to induction of apoptosis by
cycloheximide thus masking any changes that may occur to glucocorticoid mediated
induction of eosinophil apoptosis when gene transcription is blocked (data not
shown). However this data does suggest that transcriptional events may be involved
in prolonging eosinophil survival as cycloheximide will rapidly induce eosinophil
apoptosis.
SUMMARY
• Cycloheximide reverses glucocorticoid mediated delay ofneutrophil apoptosis
• Cycloheximide induces apoptosis in both neutrophils and eosinophils
• The requirement of gene transcription in glucocorticoid mediated induction of
eosinophil apoptosis could not be determined due to the sensitivity of eosinophils
to the apoptosis inducing properties of cycloheximide
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Figure 4.5.1 Effect of protein synthesis inhibition by cycloheximide on
dexamethasone mediated delay of neutrophil apoptosis. Human neutrophils (5
xl06/ml) cultured in Iscove's DMEM containing 10% autologous serum at 37 °C, and
treated with the indicated concentrations of cycloheximide (pg/ml) with or without
dexamethasone (lpM). After 20 h, cells were harvested and assessed morphologically for
apoptosis. All values represent mean ± S.E. of n = 5 experiments, each performed in
triplicate. Similar results were found when cells were assessed for apoptosis by Annexin-
V binding (data not shown). Significant difference from control is represented by #P<0.01
and significant difference from dexamethasone alone is represented by **P<0.01 or
***P<0.001
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4.6 INVOLVEMENT OF GENE TRANSACTIVATION AND
TRANSREPRESSION IN GLUCOCORTICOID REGULATION
OF GRANULOCYTE APOPTOSIS.
As transcriptional regulation by glucocorticoids likely plays a role in glucocorticoid
mediated modulation of granulocyte apoptosis, we sought to determine the
mechanism by which glucocorticoids affect transcriptional activity in order to
influence apoptosis and in particular, if different mechanisms of transcriptional
control are involved in the ability of glucocorticoids to differentially affect apoptosis
in these cells. Firstly, we investigated whether glucocorticoids stimulate
transcriptional induction through GRE mediated stimulation of steroid responsive
genes. As a measurement of GR-mediated transactivation we examined
glucocorticoid stimulation of secretory leukocyte protease inhibitor (SLPI)
production by Western blotting. Glucocorticoids have been shown to increase the
transcription of SLPI through direct DNA binding of GR the promoter region of the
SLPI gene (Abbinante-Nissen et al., 1995). SLPI is an important antiprotease found
in the upper airways during pulmonary inflammation and may serve to counteract the
effects of inflammatory enzymes. Further SLPI is a major leukocyte elastase
inhibitor and has been shown to be present in human neutrophils (Sallenave et al.,
1997).
Neutrophils (5 x 106/ml) and eosinophils (2.5 x 106 /ml) were cultured in serum
supplemented Iscove's DMEM in the presence of dexamethasone (0.01-1 pM) for 20
h before supematants were harvested. The supematants were then dialysed to remove
excess salts contained in culture medium before SDS-PAGE/immunblot analysis
using a rabbit polyclonal antibody specific for human SLPI. Surprisingly we found
that dexamethasone did not increase SLPI production in either neutrophils or
eosinophils (Figure 4.6.1 & Figure 4.6.2). Moreover, in neutrophils, dexamethasone
may even downregulate SLPI production compared to unstimulated cells (Figure
4.6.1) although this was not always reproducible. Phorbol myristate acetate (PMA)
was used as our positive control and was found to upregulate SLPI production.
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Figure 4.6.1 Effect of dexamethasone on SLPI expression in neutrophils. Western
blot of supernatants from neutrophils treated with the indicated concentrations of
dexamethasone (pM) or PMA (lOOnM) for 20 h. Supernatants were prepared and
immunoblotted as described under "Materials and Methods" and subjected to SDS-
PAGE/immunoblot analysis using a rabbit polyclonal antibody specific for SLPI. The
SLPI antibody recognizes a 14kDa protein. The gel is of a representative experiment.
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Figure 4.6.2 Effect of dexamethasone on SLPI expression in eosinophils. Western
blot of supernatants from eosinophils treated with the indicated concentrations of
dexamethasone (pM) or PMA (lOOnM) for 20 h. Supematants were prepared and
immunoblotted as described under "Materials and Methods" and subjected to SDS-
PAGE/immunoblot analysis using a rabbit polyclonal antibody specific for SLPI. The
SLPI antibody recognizes a 14kDa protein. The gel is of a representative experiment.
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We also examined if glucocorticoids could also transrepress gene transcription in
granulocytes. Many studies examining the anti-inflammatory action of
glucocorticoids have focussed on glucocorticoid transrepression of NFkB, as NFkB
binding sites are found in the promoter regions of many cytokines known to be
downregulated by glucocorticoids. As NFkB has been demonstrated to be an
important regulator of neutrophil apoptosis (Ward et al., 1999a) we decided to study
if glucocorticoids transrepress NFkB activation in neutrophils and eosinophils as a
measurement of glucocorticoid transrepression in these cells. NFKB-mediated
transcription was assessed by measuring the influence of glucocorticoids on LPS
stimulated IL-8 production by ELISA. NFkB is believed to be essential for
transcription of IL-8 although other transcription factors may also be important for
the regulation of this gene such as AP-1 (Mukaida et al., 1994a). Furthermore NFkB
has been shown to be the target in glucocorticoid regulation of IL-8 secretion
(Mukaida et al., 1994b).
Neutrophils (5 x 106 cells/ml) and eosinophils (1 x 106 cells/ml) were cultured in
serum supplemented Iscove's DMEM together with LPS (100 ng/ml) in the presence
or absence of the indicated concentrations of dexamethasone. After 20 h the
supematants were saved and IL-8 was measured by IL-8 sandwich ELISA.
Dexamethasone concentration dependently suppresses basal and LPS stimulated IL-8
production in neutrophils (Figure 4.6.3). As there is donor variation in basal and
stimulated IL-8 production between experiments the data are represented as two
typical experiments together with the averaged data of several experiments to show
the similarity in individual trends, although there is variation in baseline IL-8
production. This data confirms that concentrations of dexamethasone which
transrepress NFkB regulated IL-8 production in neutrophils are capable of delaying
neutrophil apoptosis. In eosinophils there was greater donor variation however
dexamethasone tended to suppress basal IL-8 production (Figure 4.6.4). Although
dexamethasone (0.1 pM) could suppress LPS stimulated IL-8 production, high
concentrations of dexamethasone (1 pM) did not significantly inhibit LPS stimulated
IL-8 secretion.
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SUMMARY
• Dexamethasone does not upregulate GRE-mediated SLPI production in
neutrophils and eosinophils measured by Western blotting.
• Dexamethasone concentration dependently suppresses NFkB regulated IL-8
production in neutrophils
• Dexamethasone (0.1 pM) suppresses NFkB regulated IL-8 production in
eosinophils but not at higher concentrations (1 pM).
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Figure 4.6.3 Effect of dexamethasone on LPS stimulated IL-8 production in
neutrophils. Human neutrophils (5 x 106/ml) were cultured in Iscove's DMEM
containing 10 % autologous serum at 37 °C, and treated with indicated concentrations of
dexamethasone with or without LPS (100 ng/ml). After 20 h, supernatants were saved and
IL-8 production was measured by ELISA. Graphs A and B represent results from two
different individual donors. Graph C represents mean ± S.E. of n = 13 experiments, each
performed in duplicate where significant difference from control is represented by
*"P<0.001, "P<0.01 or *P<0.05 and significant difference from LPS alone is represented
by ***P<0.001 or" PO.01.
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Figure 4.6.4 Effect of dexamethasone on LPS stimulated IL-8 production in
eosinophils. Human eosinophils (1 x 106/ml) were cultured in Iscove's DMEM containing
10 % autologous serum at 37 °C, and treated with indicated concentrations of
dexamethasone with or without LPS (100 ng/ml). After 20 h, supernatants were saved and
IL-8 production was measured by ELISA. Graphs A and B represent results from two
different individual donors. Graph C represents mean ± S.E. of n = 4-6 experiments, each
performed in duplicate where significant difference from control is represented by
*P<0.05.
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4.7 EFFECT OF DISSOCIATED GLUCOCORTICOIDS ON
GRANULOCYTE APOPTOSIS
In neutrophils it appears that glucocorticoids are capable of regulating gene
expression by a mechanism of transrepression. On the other hand glucocorticoids
appear incapable of transactivation through direct DNA binding to GRE consensus
sites in these cells as measured by glucocorticoid effects on production of SLPI. We
have also found that concentrations of dexamethasone, capable of transrepressing
NFkB regulated IL-8 production, are also able to delay neutrophil apoptosis. This
does not directly prove however that transrepression is required for the anti-apoptotic
effect of glucocorticoids in neutrophils. In eosinophils, glucocorticoids may not act
through transcriptional transactivation, as measured by SLPI production.
Glucocorticoids were found to transrepress IL-8 secretion but not at the
concentrations which most effectively induce eosinophil apoptosis.
In order to elucidate directly if glucocorticoid transactivation or transrepression are
directly required for glucocorticoid regulation of granulocyte apoptosis, we took
advantage of the availability of dissociated glucocorticoids which have been
published to distinguish between transactivation and repression. We tested these
compounds for their ability to affect apoptosis in neutrophils and eosinophils, in
comparison to the classical glucocorticoid dexamethasone. The dissociated
glucocorticoids used in these experiments differ from classic glucocorticoids, as they
have been designed to be either defective in transactivation but retain the ability to
transrepress or vice-versa, unlike classical glucocorticoids which are thought capable
of acting via both mechanisms to a greater or lesser extent. The first set of
compounds from Hoechst Marion Roussel Pharmaceutical Corp, RU24782 and
RU24858, have been demonstrated to be only weakly capable of transactivation as
measured by a GR reporter gene (Vayssiere et al., 1997). These compounds have
been shown to be capable of transrepressing AP-1 by measurement of the activation
of c-Jun activated collagenase promoter-Cat reporter gene (Vayssiere et al., 1997). A
further set of steroids were obtained from Schering AG, namely ZK55740 and
ZK77945. These compounds have been reported to transactivate transcription of
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metallothionein Iia in HeLa cells, though they were not as efficient as
dexamethasone (Heck et al., 1997). Importantly, ZK55740 and ZK77945 were only
weakly capable of transrepressing AP-1 regulated collagenase 1 activity unlike
dexamethasone which efficiently suppressed collagenase 1 (Heck et al., 1997).
4.7.1 EFFECT OF DISSOCIATED GLUCOCORTICOIDS ON NEUTROPHIL
APOPTOSIS
To investigate if transactivation is required for glucocorticoid mediated delay of
neutrophil apoptosis neutrophils were cultured in serum supplemented Iscove's
DMEM in the presence of the indicated concentrations of dexamethasone, ZK55740
or ZK77945. After 20 h cells were assessed for apoptosis by measurement of
Annexin V binding. We found that ZK77945 significantly inhibited neutrophil
apoptosis (0.1 - 10 |iM) as did ZK55740 albeit only at high concentrations (1-10
(iM) (Figure 4.7.1A). In comparison to dexamethasone however, ZK77945 and
ZK55740 did not inhibit neutrophil apoptosis as efficiently (Figure 4.7.1A).
To test whether glucocorticoids require the ability to transrepress gene expression in
order to delay neutrophil apoptosis, neutrophils were incubated in serum
supplemented Iscove's DMEM in the presence of the indicated concentrations of
dexamethasone, RU24858 or RU24782. After 20 h apoptosis was assessed by
measurement of Annexin V binding. We found that RU24858 and RU24782 both
significantly inhibit neutrophil apoptosis (0.01-10 |iM) with RU24858 being more
effective at lower concentrations than RU24782 (Figure 4.7.IB). Moreover,
dexamethasone appears to be more efficient at delaying neutrophil apoptosis
compared to either compound (Figure 4.7.IB). It is important to note however that at
low concentrations (0.01 pM), both RU24858 and RU24782 significantly delay
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Figure 4.7.1A Effect of ZK transactivating compounds compared to dexamethasone
on neutrophil apoptosis. Human neutrophils (5 x 106/ml) cultured in Iscove's DMEM
containing 10% autologous serum at 37 °C, and treated with the indicated concentrations
of ZK55740, ZK77945 or dexamethasone. After 20 h, cells were incubated with FITC-
labelled recombinant human Annexin V to determine phosphatidylserine expression. All
values represent mean ± S.E. of n = 3-6 experiments, each performed in duplicate where
significant difference from control is represented by ***P<0.001, **P<0.01 and *P<0.05.
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Figure 4.7.IB Effect of RU transrepressing compounds compared to
dexamethasone on neutrophil apoptosis. Human neutrophils (5 x 106/ml) cultured
in Iscove's DMEM containing 10% autologous serum at 37 °C, and treated with the
indicated concentrations of RU24782, RU24858 or dexamethasone. After 20 h, cells
were incubated with FITC-labelled recombinant human Annexin V to determine
phosphatidylserine expression. All values represent mean ± S.E. of n = 4-5
experiments, each performed in duplicate where significant difference from control
is represented by ***P<0.001, **P<0.01 and *P<0.05.
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neutrophil apoptosis whereas the transrepressing compounds ZK77945 and ZK55740
are ineffective (Figure 4.7.IB & Figure 4.7.IB). The ability of high concentrations of
ZK transactivating compounds to delay neutrophil apoptosis, could be argued to be
due to a residual albeit impaired ability to transrepress, which is more noticeable at
these concentrations. However as dexamethasone is more efficient at delaying
neutrophil apoptosis compared to either set of dissociated glucocorticoids and is
known to retain the ability to both transactivate and transrepress, it is possible that
both transactivation and transrepression to some degree are involved in
glucocorticoid regulation of neutrophil apoptosis.
SUMMARY
• ZK55740 and ZK77945 significantly delay neutrophil apoptosis.
• ZK55740 will delay neutrophil apoptosis only at high concentrations (1-10 pM)
whereas ZK77945 is slightly more effective delaying neutrophil apoptosis
between (0.1-10 pM).
• ZK55740 and ZK77945 are less efficient at inhibiting neutrophil apoptosis
compared to dexamethasone
• RU24858 and RU24782 significantly delay neutrophil apoptosis (0.01-10 pM)
• RU24858 and RU24782 are less efficient at inhibiting neutrophil apoptosis
compared to dexamethasone
• RU transrepressing compounds appear more efficient at delaying neutrophil
apoptosis compared to transactivating ZK compounds
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4.7.2 EFFECT OF DISSOCIATED GLUCOCORTICOIDS ON EOSINOPHIL
APOPTOSIS
To assess the involvement of transactivation by glucocorticoids in the induction of
eosinophil apoptosis, eosinophils were cultured in serum supplemented Iscove's
DMEM in the presence of dexamethasone (1 pM), ZK77945 (1 pM) or ZK55740 (1
pM). After 40 h apoptosis was assessed by Annexin V binding. We found that
ZK77945 could significantly induce eosinophil apoptosis albeit less effectively than
dexamethasone. ZK57740 was unable to induce eosinophil apoptosis.
To assess the requirement of transrepression in glucocorticoid induction of
eosinophil apoptosis, cells were cultured for 40 h in the presence of RU24858 (1
pM), RU24782 (1 pM) or dexamethasone (1 pM) before assessment of apoptosis.
We found that RU24858 could significantly induce eosinophil apoptosis unlike
RU24782, which had little effect. Again dexamethasone was more efficient at
inducing eosinophil cell death than either RU compounds.
Our results suggest that dissociated glucocorticoids, defective in either their ability to
transactivate or transrepress transcriptional activity, are less efficient at inducing
eosinophil apoptosis compared to dexamethasone, which is capable of performing
both these functions. As we have used reasonably high concentrations of dissociated
steroids in these experiments (1 pM) and a full concentration response curve has not
yet been performed, it is difficult to conclude if either transactivation or
transrepression are absolutely necessary for glucocorticoid mediated induction of
apoptosis. At these concentrations, any residual ability to either transrepress in the
case of the ZK transactivating compounds or the ability to transactivate in the RU
transrepressing compounds, may have important effects. It would be useful to
perform a full concentration response curve to further elucidate the mechanisms of
glucocorticoid mediated transcriptional regulation during induction of eosinophil
apoptosis.
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Figure 4.7.2A Effect of ZK transactivating compounds compared to dexamethasone
on eosinophil apoptosis. Human neutrophils (2.5 x 106/ml) cultured in Iscove's DMEM
containing 10% autologous serum at 37°C, and treated with ZK57740, ZK77945 or
dexamethasone (lpM). After 40 h, cells were incubated with FITC-labelled recombinant
human Annexin V to determine phosphatidylserine expression. All values represent mean
± S.E. of n = 4 experiments, each performed in duplicate where significant difference
from control values is represented by ***P<0.001 and * P<0.05
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Figure 4.7.2B Effect of RU transrepressing compounds compared to dexamethasone
on eosinophil apoptosis. Human neutrophils (2.5 x 106/ml) cultured in Iscove's DMEM
containing 10% autologous serum at 37 °C, and treated with RU 24858, RU24782 or
dexamethasone (lp.M). After 40 h, cells were incubated with FITC-labelled recombinant
human Annexin V to determine phosphatidylserine expression. All values represent mean
± S.E. of n = 4 experiments, each performed in duplicate where significant difference
from control values is represented by ***P<0.001 and *P<0.05.
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SUMMARY
• ZK77945 significantly induces eosinophil apoptosis however ZK55740 was
found to be ineffective.
• Dexamethasone was more efficient at inducing eosinophil apoptosis compared to
ZK77945
• RU24858 significantly induces eosinophil apoptosis however RU24782 was
found to be ineffective
• Dexamethasone was more efficient at inducing eosinophil apoptosis compared to
RU24858.
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4.8 ROLE OF HISTONE DEACETYLATION IN
GLUCOCORTICOID REGULATION OF GRANULOCYTE
APOPTOSIS
We have attempted to explore the potential mechanisms used by glucocorticoids to
govern transcriptional regulation in granulocytes and ascertain the importance of
these mechanisms in glucocorticoid mediated control of granulocyte apoptosis. A
further aspect of glucocorticoid transcriptional control is related to the recently
suggested ability of glucocorticoids to affect chromatin structure.
During activation of transcription, access of transcription factors to DNA is thought
to be increased by the unwinding ofDNA wrapped around histone proteins following
the acetylation of histone residues. During transcriptional repression, deacetylation of
histones is thought to occur resulting in tighter coiling and reduced access of
transcription factors to their binding sites. It has been recently proposed that
glucocorticoids in association with co-repressors and proteins with intrinsic histone
deacetylation activity may cause deacetylation of histone leading to gene repression
(Wolffe, 1997). There is no evidence as yet that glucocorticoid-mediated regulation
of apoptosis involves changes in chromatin structure.
To investigate if glucocorticoid regulation of granulocyte apoptosis involves
chromatin remodelling, we made use of a pharmacological inhibitor called
trichostatin A, a potent histone deacetylation inhibitor (Yoshida et ai, 1990).
Neutrophils (5 x 106/ml) and eosinophils (2.5 x 106/ml) were cultured in serum
supplemented Iscove's DMEM in the presence of dexamethasone (1 pM) with or
without the indicated concentrations of trichostatin A (TSA) for 20h and 40h
respectively. Apoptosis was then assessed by measurement of phosphatidylserine
exposure by Annexin V binding and morphological examination. We found that
blockade of histone deacetylation did not significantly reverse dexamethasone
mediated delay of neutrophil apoptosis. Trichostatin A has been reported to block
histone deacetylation at low concentrations (Ki 3.4 nM) (Yoshida et al., 1990)
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however we found that equivalent concentrations and above did not appear to
modulate dexamethasone inhibition ofneutrophil apoptosis.
In further studies we observed that concentrations of TSA greater than or equal to 0.1
pM, cause induction of constitutive eosinophil apoptosis. Although this was not
statistically significant due to donor variation, it is possible that acetylation of
histones may be important in regulating the progress of constitutive eosinophil cell
death. Importantly, it appears that dexamethasone mediated induction of eosinophil
apoptosis does not require histone deacetylation activity. At concentrations of TSA
which do not modulate basal eosinophil apoptosis, there was no reversal of
dexamethasone mediated acceleration of eosinophil apoptosis. Furthermore, at higher
concentrations ofTSA which do cause induction of constitutive eosinophil apoptosis,
there was no amplification of dexamethasone mediated modulation of apoptosis. It
would be interesting to measure histone acetylation directly to investigate if
dexamethasone induced hyperacetylation is involved in the ability of glucocorticoids
to induce eosinophil apoptosis. From these experiments it is difficult to draw
conclusions and it would be necessary to perform a titration of dexamethasone
against TSA to establish if they are acting through a similar mechanism.
SUMMARY
• TSA does not reverse dexamethasone mediated delay ofneutrophil apoptosis
• Constitutive eosinophil apoptosis appears to be accelerated by TSA > 0.1 (iM
while constitutive neutrophil apoptosis is unaffected.
• TSA does not modulate dexamethasone mediated induction of eosinophil
apoptosis
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Figure 4.8.1 Effect of trichostatin A on dexamethasone mediated delay of
neutrophil apoptosis. Human neutrophils (5 x 106/ml) cultured in Iscove's
DMEM containing 10% autologous serum at 37 °C, and treated with the indicated
concentrations of trichostatin A (TSA) (pM) or without dexamethasone (1 pM).
After 20 h, cells were harvested and assessed for apoptosis by Annexin V binding.
All values represent mean ± S.E. of n = 4-6 experiments, each performed in
duplicate where significant difference from control is represented by *P<0.001.
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Figure 4.8.2 Effect of trichostatin A on dexamethasone mediated induction of
eosinophil apoptosis. Human eosinophils (2.5 x 106/ml) cultured in Iscove's DMEM
containing 10% autologous serum at 37 °C, and treated with the indicated concentrations
of trichostatin A (TSA) (|xM) or without dexamethasone (1 (xM). After 40 h, cells were
harvested and assessed for apoptosis by Annexin V binding. All values represent mean ±
S.E. of n = 3-4 experiments, each performed in duplicate where significant difference
from control is represented by *P<0.01.
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4 DISCUSSION
The studies herein have sought to elucidate the mechanisms by which
glucocorticoids regulate granulocyte apoptosis. Neutrophils and eosinophils are
closely related myeloid cells, which arise from a common precursor in the bone
marrow. Granulocyte apoptosis can be modulated by a variety of inflammatory
mediators and cytokines, which commonly elicit similar effects in both eosinophils
and neutrophils. However, it has long been observed that glucocorticoids cause a
rapid and dramatic reduction in eosinophil numbers in vivo yet neutrophil numbers in
contrast, are often elevated following glucocorticoid treatment (Schleimer, 1990).
We propose that the direct influence of glucocorticoids to differentially modulate
granulocyte apoptosis, may be a major factor in the production of this effect.
We have confirmed previous reports that glucocorticoids exert diametrically opposed
effects upon the rate of apoptosis in neutrophilic and eosinophilic granulocytes in
vitro; promoting eosinophil apoptosis while inhibiting neutrophil cell death (Kato et
al., 1995; Cox, 1995; Liles et al., 1995; Meagher et al., 1996). It has been widely
assumed that neutrophils are unresponsive to the effects of glucocorticoids
(Schleimer et al., 1989). Indeed many groups have ignored any possible influence of
glucocorticoids on neutrophil behaviour due to reports that functions such as
secretion, degranulation and chemotaxis, fail to be suppressed by glucocorticoid
treatment (Schleimer et al., 1989). Our results demonstrate that neutrophil longevity
is remarkably sensitive to the survival influence of glucocorticoids, with neutrophil
apoptosis capable of being delayed by low concentrations of glucocorticoids.
Importantly, it appears neutrophils are more sensitive to apoptotic influence of
glucocorticoids than eosinophils, with induction of cell death in eosinophils requiring
higher concentrations of glucocorticoids compared to those needed to delay
neutrophil death. These findings suggest that glucocorticoid regulation of neutrophil
behaviour should not be overlooked. The relative inability of glucocorticoids to
resolve neutrophilic inflammation has been proposed to relate to the
'unresponsiveness' of neutrophils to glucocorticoid treatment. However, we would
suggest that the influence of glucocorticoids in enhancing neutrophil survival plays
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an important part in prolonging neutrophilic inflammation. Moreover, differences in
the concentrations of glucocorticoid required to modulate apoptosis in neutrophils
compared to eosinophils further emphasise the distinct regulatory mechanisms by
which these cells respond to apoptotic modulating stimuli.
The glucocorticoid signal transduction cascade and the molecular mechanisms by
which glucocorticoids regulate transcriptional activity have been well characterised.
However, divergent responses of various cell types to glucocorticoid treatment, not
only in terms of their ability to differentially modulate apoptosis, but through their
differential actions on secretion and adhesion, make it highly unlikely that a
universal mechanism of glucocorticoid action exists. Little is known of the
underlying signalling mechanisms that allow glucocorticoids to exert divergent
actions on various cell types. Indeed many of the molecules characterised in
glucocorticoid signal transduction studies have yet to be implicated in various
glucocorticoid effector functions and pertinent to this study, in glucocorticoid
regulation of granulocyte cell death.
Glucocorticoids exert their effects by diffusing passively through the cell membrane
where they bind to cytoplasmic glucocorticoid receptors (GRs). Glucocorticoid
receptors are associated with specific molecular chaperones and other proteins,
which prevent them from translocating to the nucleus in the absence of ligand (Pratt
et al., 1989; Morishima et al., 2000b). Of the number of molecular chaperones and
proteins involved in preventing nuclear localisation of unoccupied GR, hsp90
appears to play a major role. By making use of the hsp90 binding benzoquinoid
ansamycin, geldanamycin (GA), we have been able to demonstrate that functional
hsp90 is required for both glucocorticoid-mediated delay of neutrophil apoptosis and
glucocorticoid induction of eosinophil death. Interestingly, geldanamycin appears to
induce constitutive eosinophil apoptosis. Although this was not statistically
significant, the data perhaps imply a role for hsp90 in regulating basal eosinophil
apoptosis.
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Insight into the processes involved in heat shock protein assembly of stable
cytoplasmic GR heterocomplexes receptive to ligand binding, has recently been
gained through elegant studies by Rajapandi et al and Morishima et al. It appears
hsp70 and hsp90 are required sequentially to activate hormone binding to
glucocorticoid receptor with co-chaperones Hop hsp40 and p23 enhancing
heterocomplex formation and assembly (Rajapandi et al., 2000; Morishima et al.,
2000b). Hsps may also perform a similar role in the nucleus, assembling recycled
receptors into hormone binding competent heterotrimeric complexes (Liu and
DeFranco, 1999). It would be interesting to investigate if similar molecules, in
addition to hsp90, are involved in formation of conformationally mature
glucocorticoid receptors in granulocytes.
The requirement of hsp90 activity in both glucocorticoid induction of eosinophil
apoptosis and delay of neutrophil death is presumably to allow formation of
competent steroid binding glucocorticoid receptors, allowing glucocorticoid signal
transduction to follow. However, it has recently come to light that in addition to
binding GR, Hsp90 forms complexes with various kinases and transcription factors,
assisting their transport within the cell and/or stabilising their conformation required
for functional maturity (Pratt, 1998; Mayer and Bukau, 1999). Thus chaperones such
as hsp90 may be key regulators of signal transduction cascades through selective
transport or segregation of signalling components. Indeed a recent study has reported
the direct association of hsp90 with components of the apoptotic signalling pathway.
Hsp90 has been shown to bind Apaf-1, preventing the participation of Apaf-1 in
forming an active complex with caspase-9, thus inhibiting downstream caspase
activation, delaying apoptosis (Pandey et al., 2000). It would be interesting to
investigate if glucocorticoid delay of neutrophil apoptosis involves targeted binding
of hsp90 to Apaf-1, preventing apoptosome formation and thus inhibiting apoptosis.
However, if such a mechanism were also to be implicated in glucocorticoid induction
of eosinophil apoptosis, dexamethasone mediated abrogation of hsp90 binding to
Apaf-1 would be required to induce cell death.
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To elucidate further the mechanisms controlling glucocorticoid modulation of
granulocyte apoptosis, we sought to determine GR expression in granulocytes and
the glucocorticoid signal transduction cascade activated following ligand binding.
Although it has been presumed that glucocorticoid modulation of granulocyte
apoptosis requires competent ligand binding receptors, this has not been shown
•3
directly. Binding studies using H-labelled agonists have indicated that neutrophils
and eosinophils exhibit similar numbers of glucocorticoid receptors, with similar
affinity for glucocorticoid binding (Peterson et al., 1981). This suggests that
differences in receptor number and affinity cannot be responsible for the differential
effect of glucocorticoids on granulocyte apoptosis. We wished to investigate if
divergence in responsiveness to glucocorticoids among granulocyte types was
instead due to differential expression of glucocorticoid receptor isoforms. From
binding studies, granulocytes appear to express a single class of glucocorticoid
receptor however as GR(3 is not thought capable of binding glucocorticoid, the
influence of this isoform would not have been taken into account, in these studies
(Peterson et al., 1981; Bamberger et al., 1995). GR(3 is thought to influence
glucocorticoid signalling and transcription through formation of heterodimers with
steroid binding GRa (Oakley et al., 1999), which may reduce the transcriptional
activity of GRa by denying access to GREs (Oakley et al., 1996). By Western
blotting, we have shown GR is expressed in the cytoplasm of both neutrophils and
eosinophils. Successful immunoblotting required extensive optimisation of standard
protein extraction protocols suggesting GR may be particularly sensitive to
proteolytic degradation by granulocyte proteases such as elastase (Distelhorst et al.,
1987). Attempts to establish the isoforms of GR expressed in each cell type were
hampered due to non-specific binding of available GR(3 specific antibodies.
Curiously, we did not observe any translocation of GR to the nucleus following
treatment of granulocytes with dexamethasone.
A recent report has suggested that neutrophils contain high constitutive expression of
GRf3, which it is postulated, allows neutrophils to escape glucocorticoid induced cell
death (Strickland et al., 2001). Immunofluorescence studies by Strickland et al
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propose neutrophils contain higher levels of GRa and GRP in comparison to
PBMCs. Furthermore, IL-8 is demonstrated to synergise with dexamethasone to
decrease neutrophil apoptosis in vitro, a response associated with an increase in the
ratio ofGRP to GRa. The argument is further strengthened by transfection ofmouse
neutrophils with GR(3, resulting in a small reduction in the rate of apoptosis in
response to dexamethasone. In contrast to previous reports, it is suggested that GRP
is located mainly in the cytoplasm of cells. Curiously, there is no demonstration of
ligand dependent accumulation of GR in the nucleus upon dexamethasone treatment,
particularly regarding GRa isoform.
The hypothesis that in neutrophils an alternative mode of action of GR exists, which
allows neutrophils to reduce their rate of spontaneous apoptosis in response to
glucocorticoid, is an attractive one. Strickland et al., argue that glucocorticoid
induction of apoptosis proceeds through GRa homodimer transcription via GRE
mediated transactivation. In neutrophils, an increase in the ratio of GR(3 to GRa in
neutrophils, favours the formation of responsive heterodimers, preventing normal
GRa homodimer GRE mediated transcription, thereby delaying apoptosis. In
contrast PBMCs, shown to have a higher ratio of GRa to GR(3, favouring GRa
homodimer formation, are sensitive to apoptosis induction by dexamethasone. It
would be extremely useful to examine the ratio of GR isoform expression in
neutrophils compared to eosinophils, to test if acceleration of apoptosis by
glucocorticoids in this cell type is due to a higher ratio of GRa to GR(3. It is further
proposed by Strickland et al that IL-8 enhances neutrophil survival by increasing
GRP expression, however it is not revealed whether GR isoform expression in
PBMC is also affected by IL-8 treatment. This control would be useful to rule out the
possibility that IL-8 non-specifically upregulates GRP expression in many cell types
and would help establish if increased GRP in neutrophils by IL-8, is specifically
responsible for mediating enhanced neutrophil survival in the presence of
glucocorticoids.
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Our own studies of GR expression in granulocytes and those by Strickland et al do
not directly demonstrate the necessity for GR activation as an essential requirement
for glucocorticoid modulation of apoptosis. Although there may be limitations in the
techniques we have used, we could not detect translocation of the glucocorticoid
receptor from the cytoplasm to the nucleus following glucocorticoid treatment.
Further, Strickland et al., do not reveal in their immunofluorescence studies if GR
activation occurs in response to dexamethasone in neutrophils. To address this issue,
we elected for an alternative approach, making use of the glucocorticoid receptor
antagonist RU 486. While we found that 10 (iM RU 486 partially abrogated
dexamethasone mediated modulation of both neutrophil and eosinophil apoptosis,
lower concentrations of this compound had no effect, even when in significant
excess. This may suggest that the antagonist binds to granulocytes with low affinity
compared to the agonist or that glucocorticoid modulation of granulocyte apoptosis
may not occur through the classical glucocorticoid signal transduction pathway.
However, as RU 486 is unable to bind and therefore antagonise GRfl, glucocorticoid
modulation of granulocyte apoptosis may still proceed through GR(3. It will be
interesting if future studies ascertain if indeed differential GR isoform expression
relates to diverging responses to the apoptotic influences of glucocorticoids in these
cells.
Glucocorticoid signal transduction, regardless of being mediated via classical GRa
homodimers or formation of antagonistic GRa/GRp heterodimers, is thought to
ultimately lead to regulation of transcription of target genes in responsive cells. We
found that dexamethasone induced suppression of neutrophil cell death was
abrogated upon co-treatment with cycloheximide, confirming gene transcription to
be essential for glucocorticoid inhibition of neutrophil apoptosis. One could
hypothesise that glucocorticoids therefore delay neutrophil apoptosis through
enhanced production of a survival protein(s) or by switching off production of a
putative death factor(s) in these cells. If the latter were true, one would expect that
treatment of neutrophils with protein synthesis inhibitors would delay constitutive
neutrophil apoptosis. However this has been shown not to be the case and in contrast,
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protein synthesis inhibitors rapidly accelerate apoptosis in granulocytes (Whyte et
al., 1997; Cox and Austin, 1997). This suggests granulocyte cell death may normally
held in check by the constant production of inhibitor protein(s). It is possible that
glucocorticoids could influence granulocyte apoptosis through differential regulation
of possible inhibitor protein(s) however dissection of the mechanisms involved using
inhibitors of transcription and translation are inherently problematic due to fact that
synthesis of as yet unidentified proteins, appear intrinsically important in regulating
constitutive apoptosis. Thus it is difficult to separate the influence of these
compounds on glucocorticoid regulation from their additional effects on constitutive
cell death. This is particularly pertinent to examination of transcriptional mechanisms
involved in glucocorticoid induction of eosinophil apoptosis, as inhibitors of protein
synthesis even when titrated to low levels, rapidly accelerate apoptosis in these cells
(data not shown).
To examine more specifically the molecular basis of glucocorticoid modulation of
granulocyte apoptosis, we investigated whether glucocorticoids regulate transcription
via direct GRE mediated transactivation or indirect transrepression in these cells.
Further we sought to determine if either of these mechanisms was involved in
glucocorticoid regulation of apoptosis. Commonly, GRE mediated transcriptional
transactivation is measured by the ability of glucocorticoids to enhance the activity
of a glucocorticoid responsive luciferase reporter construct, transfected into cells of
interest e.g. the GR responsive mouse mammary tumour virus (MMTV) reporter
gene. However experimental transfection protocols of this nature cannot be
performed in granulocytes due to the limited lifespan of these cells. For this reason,
measurement of glucocorticoid transactivation was investigated by examining the
effects of glucocorticoids on endogenous proteins whose expression and synthesis
can be modulated through GRE mediated transactivation. One such protein appears
to be the antiprotease, secretory leukocyte proteinase inhibitor (SLPI), a potent
inhibitor of elastase, shown to be present in a variety of cells including human
neutrophils (Abbinante-Nissen et al., 1995; Sallenave et al., 1997).
194
REGULATION OF' GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
We found that treatment of both neutrophils and eosinophils with dexamethasone
does not result in any detectable upregulation of SLPI. Moreover, in neutrophils,
SLPI expression may in fact be downregulated in response to glucocorticoids in
neutrophils, although this was not always reproducible. These preliminary results
question whether glucocorticoids exert their influence on granulocyte apoptosis
through GRE-mediated transactivation of steroid responsive genes. It must be noted
however that measurement of SLPI production by Western blotting may not be
optimal for detection of quantitative changes in expression of this protein.
Development of an ELISA based detection procedure may help more accurately
determine and quantitate changes in expression of SLPI. In addition it may have been
more pertinent to examine glucocorticoid transcriptional transactivation by looking at
glucocorticoid induced changes in levels of gene expression rather than changes in
protein expression. Analysis of glucocorticoid induced alterations in a variety of
genes using techniques such as real-time PCR or microarray technology may have
been more useful in determining whether glucocorticoids modulate granulocyte
apoptosis via transcriptional transactivation or repression.
The discovery that many genes down-regulated by glucocorticoids do not contain
appropriate GRE sequences or any other GR binding sites, suggested that
glucocorticoids may mediate effects on transcription, independent of direct GR DNA
binding. Indeed, it has been proposed that many of the anti-inflammatory effects of
glucocorticoids involve indirect modulation of gene expression by transcriptional
transrepression instead of transactivation of steroid responsive genes. One of the
main transcription factors thought to be targeted by GR is NFkB (Scheinman et al.,
1995b; Scheinman et al., 1995a). It has been proposed that the anti-inflammatory
potential of glucocorticoids resides in their ability to interfere with the activity of this
important transcription factor (Caldenhoven et al., 1995). Our studies have shown
that glucocorticoids suppressed LPS induced IL-8 secretion in neutrophils in a
concentration dependent manner. In contrast, not all concentrations of
dexamethasone, shown to modulate eosinophil apoptosis, could down-regulate LPS
stimulated IL-8 production in eosinophils. Together these results suggest
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glucocorticoid suppression of NFkB activation may be involved in glucocorticoid
inhibition of neutrophil apoptosis but may not be essential to glucocorticoid
modulation of eosinophil cell death. However, these results should be interpreted
with caution due to donor variability in these experiments. Although we have
demonstrated glucocorticoids down-regulate the synthesis of an NFkB regulated
protein in granulocytes, it does not necessarily follow that glucocorticoids exert their
apoptotic influence via this mechanism. Indeed, if glucocorticoids do regulate
granulocyte apoptosis via transcriptional transrepression, many other transcription
factors in addition to NFkB could potentially be involved.
To directly assess the necessity of glucocorticoid transactivation or transrepression of
gene transcription for glucocorticoid regulation of granulocyte apoptosis, we made
use of a novel set of synthetic glucocorticoids, which have been published to
discriminate between transactivation and transrepression (Vayssiere et al., 1997;
Heck et al., 1997). Compared to dexamethasone, transactivating compounds
ZK77945 and ZK55740 and transrepressing compounds RU24858 and RU24782
were less effective at modulating granulocyte apoptosis. In neutrophils,
transrepressing compounds delayed apoptosis at concentrations similar to
dexamethasone whereas higher concentrations of the transactivating compounds,
were required to delay neutrophil cell death. In eosinophils, transactivating ZK77945
and transrepressing RU24858 could induce eosinophil death, but again neither
compound was effective at accelerating eosinophil apoptosis as dexamethasone.
Thus, dissociated glucocorticoids, in which either transrepressing or transactivating
ability is deficient, are able to modulate granulocyte apoptosis, though not to as an
extent as the classical glucocorticoid, dexamethasone. It has previously been shown
that both transactivating and transrepressing capabilities are fully intact in responses
mediated by dexamethasone. It would be interesting to test whether combinations of
the two types of dissociated steroids could restore the ability of these glucocorticoids
to modulate granulocyte apoptosis to levels comparable with dexamethasone.
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Interpretation of the results from these experiments must be viewed with a degree of
caution. Firstly, it is likely that dissociated glucocorticoids such as the
transrepressing compounds RU24858 and RU24782, retain some ability to
transactivate. The converse may be true of the transactivating compounds ZK7745
and ZK55740. This may confuse and obscure the responses elicited by
transrepression or transactivation alone and must be taken into consideration when
viewing these results. Secondly, although these compounds have been demonstrated
to discriminate between transactivation and transrepression, we have yet to
demonstrate separation of these activities in our system. The necessity of such
experiments is illustrated in recent findings by Vanden Berghe et al who report
RU24782 displays similar transactivating ability as dexamethasone, measured by
GRE dependent reporter gene expression, in mouse fibroblast cells (Vanden Berghe
et al., 1999). This is in contrast to the original studies in which RU24782 exerted
strong AP-1 inhibition, but only weakly activated the GRE based reporter gene
(Heck et al., 1997). This illustrates that there may be divergent potencies of
dissociated steroids in stimulating GRE dependent transactivation in different cell
types. Using these reagents to draw conclusions regarding the mechanism of
glucocorticoid transcriptional regulation, requires experiments to test their ability to
stimulate GRE mediated transcription in granulocytes and further investigate their
capacity to interfere with gene activation driven by a variety of transcription factors
such as NFkB and AP-1. Experiments of this kind would elucidate ifmechanisms of
glucocorticoid transcriptional regulation, examined mainly through overexpression
studies in other cell types, were applicable to the mechanisms of glucocorticoid
regulation in primary cells such as granulocytes.
In summary, limitations of the prototypic dissociated glucocorticoids as tools to
dissect glucocorticoid regulation of transcription must be taken into consideration
when elucidating the mechanism of glucocorticoid regulation of granulocyte
apoptosis. The development of these compounds as novel glucocorticoids with
improved therapeutic benefit is perhaps questionable. Recent findings by Belvisi et
al have suggested transrepressing glucocorticoids exhibit comparable anti¬
inflammatory activity to classical glucocorticoids such as budesonide, however they
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were also found to have equally potent systemic effects (Belvisi et al., 2001). This
suggests that in vitro separation of transrepression from transactivation may not be
reflected in whole animal physiological studies or that side effects of glucocorticoids,
previously attributed to transactivation only, may also be a consequence of
transrepression.
Finally, we have examined whether glucocorticoid regulation of granulocyte
apoptosis involves changes in gene transcription, through chromatin remodelling. It
is thought that actively transcribed genes are associated with acetylation of specific
lysine residues on histone proteins, resulting in unwinding of DNA, allowing
increased accessibility of transcription factors to nearby promoter sequences. Thus
histone acetylation is thought to be correlate with increased transcription (Beato et
al., 1996; Wolffe, 1997) in contrast to histone deacetylation, which has been
correlated with transcriptional repression and gene silencing (Wolffe, 1997; Ura et
al., 1997). GR has been shown to form part of the basal transcriptional machinery
through interaction with large co-activator molecules such as CBP (Sheppard et al.,
1998). Hormone activated GR may bind to CBP and/or associated molecules,
enhancing local histone acetyltransferase activity and increasing gene transcription.
Alternatively, GR may reduce gene transcription via deacetylation of histones,
causing a tightening of the chromatin structure, reducing the access of transcription
factors such as NFkB to their DNA binding sites, thereby transrepressing
proinflammatory gene expression. It is possible that firstly, competition between GR
and other transcription factors for binding to CBP, could reduce the availability of
the CBP associated HAT activity required for transcriptional activation by these
transcription factors (Kamei et al., 1996). Alternatively, GR may recruit proteins
with histone deacetyltransferase activity to repress histone acetylation, again
resulting in transcriptional repression (Ito et al., 2000). Indeed recruitment of
HDAC2 by GR has been reported to be essential for maximal transrepression of
NFkB stimulated HAT activity by glucocorticoids and may be vitally important for
glucocorticoid exertion of their anti-inflammatory effects (Ito et al., 2000; Ito et al.,
2001).
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Our studies suggest changes in acetylation of histone proteins may be important for
regulation of constitutive granulocyte apoptosis. TSA, a potent histone deacetylation
inhibitor, at high concentrations could induce eosinophil apoptosis yet could not
reverse or enhance glucocorticoid acceleration of apoptosis in these cells. It is
possible that histone hyperacetylation and therefore activation of transcription, may
be important for induction of eosinophil apoptosis. Indeed, it has been shown in
A549 cells, that dexamethasone alone can induce histone acetylation in a
concentration dependent manner (Ito et al., 2001). Curiously, in these same studies,
low concentrations of dexamethasone repress IL-lp p65-associated histone
acetylation which, it is proposed, is due to recruitment of HDAC2 to the p65-HAT
complex. Indeed, in the presence of IL-lp, dexamethasone is shown to induce
HDAC expression (Ito et al., 2001). It was argued that glucocorticoid transrepression
of proinflammatory transcription factors, involves recruitment of proteins with
histone deacetyltransferase activity. In eosinophils, we found that low concentrations
of dexamethasone could effectively transrepress NFkB regulated IL-8 expression,
yet high concentrations, which modulate eosinophil apoptosis, had no effect. It is
possible that in eosinophils, dexamethasone may repress NFkB at low concentrations
through HDAC expression but more importantly, at high concentrations which are
required to modulate eosinophil apoptosis, dexamethasone may itself induces histone
acetylation and therefore can no longer inhibit NFkB stimulated histone acetylation.
Measurement of histone acetylation directly would help ascertain the extent of the
involvement, if any, of chromatin remodelling in glucocorticoid control of eosinophil
death.
In neutrophils, dexamethasone delays neutrophil apoptosis over a wide concentration
range, which are also able to repress NFkB stimulated IL-8 secretion. However, as
TSA does not reverse dexamethasone-mediated delay of neutrophil apoptosis,
histone deacetylation and therefore transrepression may not be essential for
glucocorticoid modulation of neutrophil cell death. It is important to note however,
that high concentrations of dexamethasone (l|iM) were used in these experiments
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and a full titration of dexamethasone against TSA would be required to rule out the
possibility of glucocorticoid associated HDAC activity in the mechanism by which
glucocorticoids delay neutrophil apoptosis.
In summary, it is unclear at present if glucocorticoid regulation of granulocyte
apoptosis requires glucocorticoid stimulated changes in histone
acetylation/deacetylation. Experiments measuring histone acetylation and
deacetylation in granulocytes in response to glucocorticoid treatment, will be
necessary to provide direct evidence of the existence of such mechanism of
glucocorticoid action in these cells. Furthermore, additional investigations would be
required to elucidate if changes in histone acetylation correlate with transactivation
and histone deacetylation with repression, before implicating either mechanism in
glucocorticoid regulation of granulocyte apoptosis. There is some evidence to
suggest that hyperacetylation of histones may suppress or be ineffectual in
stimulating gene transcription at some promoters (Van Lint et al., 1996; Mizuguchi
et al., 2001). Moreover, recent findings by Sheldon et al, investigating glucocorticoid
regulation of the mouse mammary tumor virus (MMTV) promoter, demonstrate high
levels of acetylation when the promoter is inactive, which decreases during hormone
activation through histone deacetylation (Sheldon et al., 2001). Therefore it is likely
that regulation of gene transcription through changes in histone acetylation may vary
between different genes.
Finally, there may be novel mechansims of transcriptional regulation by
glucocorticoids, which may be important for the ability of these compounds to
modulate granulocyte apoptosis. For example Wallace et al., have recently suggested
that transcriptional activation by glucocorticoids may be regulated by proteasome
mediated degradation of GR, which may provide a mechanism to terminate
glucocorticoid responses (Wallace and Cidlowski., 2001). Whether the ubquitin-
proteasome pathway or other novel regulatory mechanisms are involved in
glucocorticoid regulation of granulocyte apoptosis is yet to be assessed.
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In conclusion, there may be several mechanisms by which glucocorticoids regulate
transcriptional activation and future studies should help unravel which of these
processes are key in eliciting the potent anti-inflammatory effects of these
compounds. At present, little is known of the mechanisms of transcriptional
regulation involved in glucocorticoid-mediated control of apoptosis and how
glucocorticoids differentially regulate transcriptional activation to exert diverging
responses on apoptosis in different cell types. A greater understanding of the
signalling mechanisms, by which glucocorticoids differentially regulate granulocyte
apoptosis, could potentially lead to the development of novel glucocorticoids with a
greater selectivity of action. This could only be achieved through further
characterisation of glucocorticoid transcriptional regulation in granulocytes and
investigations into how glucocorticoids control of components of the apoptotic signal
transduction cascade, to differentially modulate the rate of cell death in these cells.
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5 CONCLUSIONS
Apoptosis, concomitant with efficient recognition and clearance by phagocytes, has
been proposed as a major mechanism involved in the removal of excess or effete
granulocytes from an inflammatory focus. Although granulocytes appear to be 'pre¬
programmed' or committed to death via apoptosis, it is clear that the life span and
functional longevity of these cells can be modulated significantly by a number of
inflammatory mediators and cytokines. As a consequence, there is the potential to
regulate granulocyte longevity by altering the balance between pro- and anti-
apoptotic stimuli at the inflammatory site. The therapeutic induction of apoptosis as
an anti-inflammatory strategy may be successful if developed in parallel with
upregulation of mechanisms that drive efficient clearance of apoptotic cells.
Although closely related in ontogeny, there are major differences in the apoptotic
control mechanisms of neutrophils and eosinophils, which may additionally provide
the opportunity to induce apoptosis selectively in these inflammatory cells.
The work presented in this thesis has sought to further define the signalling
mechanisms by which glucocorticoids and cyclic AMP regulate granulocyte
apoptosis. We have observed that elevation of cyclic AMP profoundly delays
constitutive neutrophil apoptosis and are the first to demonstrate that cyclic AMP
delays apoptosis through initiation of a novel signal transduction mechanism, which
contrary to expectations is independent of PKA activation. Further, we have shown
that cyclic AMP exerts control of signalling components which may be key to
initiation and execution of apoptosis in these cells. We are the first to report that
dissipation of mitochondrial transmembrane potential occurs during constitutive
neutrophil apoptosis. Furthermore, protection from apoptosis, afforded by cyclic
AMP, appears to be upstream of the changes in mitochondrial transmembrane
potential. Mitochondria play an integral role in apoptotic signal transduction and
activation of apoptosis in response to internal insults or extracellular cues is thought
to converge on the mitochondria, leading to commitment to death. It has yet to be
demonstrated whether mitochondria perform a similar regulatory role to control
granulocyte apoptosis and furthermore whether early dissipation of mitochondrial
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transmembrane potential is indicative of granulocyte irreversible commitment to cell
death. We have also demonstrated that cyclic AMP delays neutrophil apoptosis
upstream of activation of executioner caspases. The mechanisms by which this
second messenger exerts influence over the apoptotic signal transduction machinery,
to delay granulocyte apoptosis, have still to be fully defined.
To our surprise, cyclic AMP acts independently of PKA activation to delay
constitutive neutrophil apoptosis. Furthermore, PI-3 kinase and MAP kinase
activation do not appear to be required for the survival effects of cyclic AMP. Our
work suggests that cyclic AMP delays neutrophil cell death via initiation of a rapid,
reversible and transcriptionally independent signalling pathway. We have
demonstrated that proteasome activity in the neutrophil is vitally involved in the
powerful ability of cyclic AMP to delay constitutive neutrophil apoptosis and
together our data suggests cyclic AMP may induce post-translational modifications
of a previously uncharacterised protein(s), to promote survival. Alteration of the
balance between pro- and anti-apoptotic proteins may be a key mechanism by which
cyclic AMP modulates neutrophil death. We have also shown that cyclic AMP
inhibits acceleration of neutrophil apoptosis induced by a variety of death receptor
stimuli. Intriguingly however, powerful death stimuli may eventually overwhelm the
capacity of cyclic AMP to inhibit neutrophil apoptosis. Future identification of novel
targets of cyclic AMP regulation and elucidation of the point at which cyclic AMP
can no longer rescue cells from irreversible commitment to death, may lead to a
better understanding of the signalling mechanism by which this second messenger
modulates granulocyte cell death.
The work in this thesis has also given novel insight into the signal transduction
pathways by which glucocorticoids modulate granulocyte apoptosis. Glucocorticoids
exert differential effects on granulocyte apoptosis; causing induction of apoptosis in
eosinophils while delaying neutrophil cell death. In contrast to previous reports, we
have demonstrated that neutrophils are not unresponsive to the effects of
glucocorticoids. Indeed, we have shown that neutrophil longevity is remarkably
sensitive to the inhibitory influence of glucocorticoids which may have important
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implications for the use of glucocorticoids in treatment of chronic inflammatory
conditions associated with neutrophilic infiltration. Interestingly, it appears that
eosinophils are less responsive to the apoptotic influence of glucocorticoids and this
further emphasises the distinct signalling mechanisms by which glucocorticoids
modulate apoptotic regulation in these closely related cells. We are the first to report
the requirement for hsp90 in both glucocorticoid induction of eosinophil apoptosis
and delay of neutrophil death. The requirement of hsp90 as a molecular chaperone
for GR, to allow the formation of competent steroid binding receptors in
granulocytes, awaits future confirmation. We have attempted to further characterise
the glucocorticoid signal transduction pathway controlling apoptosis in granulocytes
by examining GR isoform expression and activation following glucocorticoid
treatment. Although we have shown GR to be present in both neutrophils and
eosinophils, problems in immunoblotting with isoform specific antibodies meant we
were not able to characterise if differential expression of GR isoforms in
granulocytes, relates to the divergent effect of glucocorticoids in modulating
apoptosis in these cells. It has been suggested that glucocorticoid delay of neutrophil
apoptosis may be as a result of preferential expression of GRP, allowing neutrophils
to escape from glucocorticoid induction of apoptosis. However, it has not yet been
demonstrated whether eosinophils, sensitive to induction of apoptosis by
glucocorticoids, exhibit, lower expression of GRP compared to neutrophils or indeed
whether acceleration of apoptosis by glucocorticoids in this cell type, requires
GRa homodimer transactivation. Future studies, using specific antibodies or
quantitative PCR, involving a direct comparison of GR isoform expression in
neutrophils compared to eosinophils, would help ascertain whether the outcome of
glucocorticoid treatment on granulocyte apoptosis specifically correlates to
differential expression of GR isoforms in these cells.
Studies were undertaken to dissect the complex transcriptional regulatory
mechanisms that may be involved in glucocorticoid modulation of granulocyte
apoptosis. We have demonstrated that glucocorticoids transrepress NFkB regulated
IL-8 production in granulocytes. Furthermore, glucocorticoids appear not to be
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capable of transcriptional transactivation, however due to the limitations in our
ability to measure GRE-mediated transactivation in granulocytes, these results
should be viewed with caution. Considering the implication ofNFkB as an important
survival factor in granulocytes, it is possible that in eosinophils, glucocorticoids
block the synthesis of a NFkB regulated survival protein by transrepression to induce
apoptosis. Obviously the same mechanism could not apply to neutrophils as
dexamethasone, although transrepressing NFkB regulated IL-8 production in
neutrophils, enhances cell survival. Through the use of dissociated glucocorticoids,
we have shown that transactivating and transrepressing glucocorticoids can both
induce eosinophil apoptosis and delay neutrophil cell death. Importantly however,
neither set of compounds appear as efficient as dexamethasone in modulating
granulocyte apoptosis. This suggests both transactivation and repression by
glucocorticoids to some extent, may be implicated in glucocorticoid regulation of
granulocyte apoptosis. Further research investigating the complex mechanisms of
transcriptional regulation by glucocorticoids, including the involvement of chromatin
remodelling, is required to fully elucidate the aspects of transcriptional regulation
important for glucocorticoid modulation of apoptosis. The development of more
selective reagents leading to a greater understanding of the glucocorticoid signal
transduction cascade in granulocytes, may help ascertain if differential
responsiveness to glucocorticoids in neutrophils and eosinophils, results from
divergence in transcriptional regulation by glucocorticoids, in each cell type.
There is accumulating evidence of the importance of apoptosis as a major means of
eliminating extravasated granulocytes from inflamed sites. It has been proposed that
persistent inflammatory responses may arise from failure or inefficiency in the
phagocytic clearance mechanisms to remove apoptotic cells, which as a consequence
undergo secondary necrosis, releasing toxic cell contents thus amplifying
inflammation. The majority of evidence supporting the hypothesis that granulocyte
apoptosis provides a mechansim for resolution of inflammation, has mainly come
from in vitro experimentation. In a recent report, Erjefalt et al. have questioned the in
vivo relevance of apoptosis as a tissue-injury limiting mechanism during
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inflammation, particularly with regard to the role of eosinophil apoptosis in
regulation and resolution of lung inflammation (Erjefalt and Persson, 2000; Uller et
al., 2001). Ejefalt et al suggest eosinophil apoptosis may occur as a secondary event
following eosinophil extrusion into the airway lumen from the lung tissue.
Furthermore, they argue that lack of evidence of apoptosis of airway tissue-residing
eosinophils, suggests that an alternative pathway of luminal extrusion may be
involved in clearance of eosinophils during lung inflammation. The difficulty in
obtaining biopsy and tissue samples, with particular regard to human studies, has
meant that it has been difficult to directly demonstrate apoptosis and subsequent
clearance of tissue dwelling granulocytes during the inflammatory response.
Furthermore, in vitro data suggests engulfment of apoptotic cells usually occurs
within minutes of contact, thus it may be difficult to visualise the extent of this
process occuring in tissue samples, due to the rapid kinetics of phagocytosis. Many
of the in vivo studies of apoptotic cell clearance during inflammation have numbers
of apoptotic cells obtained from BAL fluid or sputum samples. In a model of acute
lung injury, Cox et al. report the appearance of apoptotic neutrophils and
macrophage engulfment in BAL fluid to be temporally correlated with the resolution
of pulmonary inflammation (Cox et al., 1995). Wedi et al report that eosinophils
derived from patients with inhalent allergy and atopic dermatitis have a reduced rate
of apoptosis compared to nonatopic subjects (Wedi et al., 1997). As mentioned
previously, Woolley et al have demonstrated that glucocorticoid treatment of
asthmatic patients is associated with an increase in the number of apoptotic
eosinophils in the airways and eosinophil products inside macrophages (Woolley et
al., 1996). In addition, it has been demonstrated that administration of an anti-Fas
antibody to the lungs following allergen induced eosinophilia, caused a marked
reduction in the number of eosinophils in the airways (Tsuyuki et al., 1995).
Furthermore human airways inflammation has been shown to be associated with
ingestion of apoptotic neutrophils by macrophages through measurement of apoptotic
cells and macrophages in BAL fluid from neonates (Grigg et al., 1991). There are
also a small number of studies which present in vivo evidence that apoptosis in tissue
granulocytes may provide an important mechanism for limitation of the
inflammatory response. For example, Ying et al. report association of granulocyte
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apoptosis and clearance by macrophages with resolution of allergen induced
cutaneous late phase response (Ying et al., 1997). In addition, Kawabori et al have
demonstrated increased eosinophil apoptosis and phagocytosis in corticosteroid
treated intestine (Kawabori et al., 1991) and Davidsson et al report apoptosis of
tissue dwelling eosinophils and their engulfment by macrophages, in sinonasal
polyps (Davidsson et al., 2000). Furthermore, Vignola et al. have demonstrated an
inverse correlation between the number of apoptotic eosinophils and clinical severity
of asthma in mucosal biopsy specimins (Vignola et al., 1999). In a murine model,
adminstration of anti-Fas antibody induced apoptosis of infiltrated eosinophils and
abolished the augmentation of airway hyperresponsiveness in response to ovalbumin
sensitisation (Ohta et al., 2001). Furthermore, Kodama et al report increased
apoptosis in the lung, following ovalbumin challenge in a murine model of allergic
airway inflammation (Kodama et al., 1998) It is not unlikely that apoptosis and
removal by macrophages and other phagocytes is an injury limiting disposal
mechanism for the extravasated neutrophil. With the development of sophisticated
imaging techniques, it may in the future be possible to track the migration of
granulocytes into the tissues and therefore ultimately determine the fate of these cells
and their removal, during the resolution of inflammation.
The in vitro data presented in this thesis suggests that the rate of granulocyte
apoptosis may be powerfully modulated by glucocorticoids and cyclic AMP. These
findings may have potentially important implications for the effectiveness of existing
anti-inflammatory treatments or the development of new intervention strategies
which favour the resolution of inflammation. Given that selective phosphodiesterase
(PDE) inhibitors and (32 adrenoceptor agonists may exert their anti-inflammatory
effects through elevation of cyclic AMP, there is the potential that in some instances
inflammation may not resolve due to enhanced granulocyte longevity and inhibited
macrophage clearance mechanisms in such treatments. Furthermore, given the ability
cyclic AMP to interfere with the signal transduction pathways of inflammatory
cytokines such as GM-CSF, cyclic AMP may have opposing effects depending on
the influence of other mediators at an inflammatory focus. Further exploration of
possible cross-talk between the cyclic AMP signal transduction cascade and other
207
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
signalling pathways, may give a greater comprehension of the potential outcomes of
elevation of this second messenger in vivo. In addition, a better understanding of the
mechanisms which underlie differential steroid responsivenss in granulocytes, could
potentially be exploited for the development of novel approaches for treatment of
allergic inflammation. Currently, there is little known of the mechansims by which
glucocorticoids integrate with the apoptotic signal transduction machinery to
differentially modulate granulocyte apoptosis. Further definition of the signalling
mechanims involved in glucocorticoid responsivenss may be useful not only for the
development of novel glucocorticoids which have the ability induce apoptosis in
selective cell populations, but may aid production of glucocorticoids with fewer
systemic side effects, that currently limits their use.
208
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
PUBLICATIONS
Martin M. C., Dransfield, I., Haslett, C and Rossi, A.G. (2001)
Cyclic AMP regulation of neutrophil apoptosis occurs via a novel PKA independent
pathway. J. Bio Chem. 276. 45041-45050
ABSTRACTS
Martin, M. C., Dransfield, I., Haslett, C., Rossi, A. G. (2001) The cell permeable
cAMP analog dibutyryl cAMP delays neutrophil apoptosis using a protein kinase A-
independent mechanism. Molecular Mechanism of Apoptosis, Keystone Symposia.,
Jan 16-22.
Martin, M. C., Dransfield, I., Haslett, C., Rossi, A. G. (2000). Dibutyryl cAMP
delays neutrophil apoptosis using a PKA-independent mechanism. British Society for
Immunology Meeting, Harrogate, UK.
Martin M. C., Dransfield, I Haslett, C., Rossi, AG (2000) Regulation of granulocyte
apoptosis by cAMP. Cell and Molecular Biology of Apoptosis, Heriot Watt
University, Edinburgh 10-13 Sept, A44
Rossi, A.G., Ward, C., Murray, J., Martin, M. C., Fujihara, S., Dransfield, I., &
Haslett, C. Rossi, A.G., Ward, C., Murray, J., Martin, M. C., Fujihara, S.,
Dransfield, I., & Haslett, C.(1999). Transcriptional regulation of eosinophil
apoptosis. Eosinophil 99, Sweden pp 35-43.
A.G. Rossi., C. Ward., J. Murray., M. C. Martin., J. Cousin., E.R. Chilvers., I.
Dransfield., & C. Haslett. (1999) Signaling mechanisms underlying LPS-induced
inhibition of neutrophil apoptosis. Cold Spring Harbor Meeting: Programmed Cell
Death, pi95
209
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
REFERENCES
Abbinante-Nissen,J.M., Simpson,L.G., and Leikauf,G.D. (1995). Corticosteroids
increase secretory leukocyte protease inhibitor transcript levels in airway epithelial
cells. Am. J. Physiol 268, L601-L606.
Aharoni,D., Dantes,A., Oren,M., and Amsterdam,A. (1995). cAMP-mediated signals
as determinants for apoptosis in primary granulosa cells. Exp. Cell Res. 218, 271 -
282.
Ahmed,M.U., Hazeki,K., Hazeki,0., Katada,T., and Ui,M. (1995). Cyclic AMP-
increasing agents interfere with chemoattractant-induced respiratory burst in
neutrophils as a result of the inhibition ofphosphatidylinositol 3-kinase rather than
receptor-operated Ca2+ influx. J. Biol. Chem. 270, 23816-23822.
Akgul,C., Moulding,D.A., and Edwards,S.W. (2001). Molecular control of
neutrophil apoptosis. FEBS Lett. 487, 318-322.
Alderson,M.R., Tough,T.W., Braddy,S., Davis-Smith,T., Roux,E., Schooley,K.,
Miller,R.E., and Lynch,D.H. (1994). Regulation of apoptosis and T cell activation by
Fas-specific mAb. Int. Immunol. 6, 1799-1806.
Altman,L.C., Hill,J.S., Hairfield,W.M., and Mullarkey,M.F. (1981). Effects of
corticosteroids on eosinophil chemotaxis and adherence. J. Clin. Invest 67, 28-36.
Altschuler,D.L., Peterson,S.N., Ostrowski,M.C., and Lapetina,E.G. (1995). Cyclic
AMP-dependent activation ofRaplb. J. Biol. Chem. 270, 10373-10376.
Altschuler,D.L. and Ribeiro-Neto,F. (1998). Mitogenic and oncogenic properties of
the small G protein Raplb. Proc. Natl. Acad. Sci. U. S. A 95, 7475-7479.
Antakly,T., Thompson,E.B., and O'DonnelfD. (1989). Demonstration of the
intracellular localization and up-regulation of glucocorticoid receptor by in situ
hybridization and immunocytochemistry. Cancer Res. 49, 2230s-2234s.
Antonsson,B., Conti,F., Ciavatta,A., Montessuit,S., Lewis,S., Martinou,I.,
Bernasconi,L., Bernard,A., Mermod,J.J., Mazzei,G., Maundrell,K., Gambale,F.,
Sadoul,R., and Martinou,J.C. (1997). Inhibition of Bax channel-forming activity by
Bcl-2. Science 277, 370-372.
Antonsson,B., Montessuit,S., Lauper,S., Eskes,R., and Martinou,J.C. (2000). Bax
oligomerization is required for channel-forming activity in liposomes and to trigger
cytochrome c release from mitochondria. Biochem. J. 345 Pt 2, 271-278.
Antonsson,B., Montessuit,S., Sanchez,B., and Martinou,J.C. (2001). Bax is present
as a high molecular weight oligomer/complex in the mitochondrial membrane of
apoptotic cells. J. Biol. Chem. 276, 11615-11623.
210
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Aoshiba,K., Yasui,S., Hayashi,M., Tamaoki,J., and Nagai,A. (1999). Role ofp38-
mitogen-activated protein kinase in spontaneous apoptosis of human neutrophils. J.
Immunol. 162, 1692-1700.
Arends,M.J. and Wyllie,A.H. (1991). Apoptosis: mechanisms and roles in pathology.
Int. Rev. Exp. Pathol. 32, 223-254.
Arias,J., Alberts,A.S., Brindle,P., Claret,F.X., Smeal,T., Karin,M., Feramisco,J., and
Montminy,M. (1994). Activation of cAMP and mitogen responsive genes relies on a
common nuclear factor. Nature 370, 226-229.
Armstrong,R.A. (1995). Investigation of the inhibitory effects of PGE2 and selective
EP agonists on chemotaxis of human neutrophils. Br. J. Pharmacol. 116, 2903-2908.
Ashkenazi,A. and Dixit,V.M. (1998). Death receptors: signaling and modulation.
Science 281, 1305-1308.
Auphan,N., Didonato,J.A., Rosette,C., Helmberg,A., and Karin,M. (1995).
Immunosuppression by glucocorticoids: inhibition ofNFkB activity through
induction of IkB synthesis. Science 270, 286-290.
Bainton,D.F. (1975). Neutrophil granules. Br. J. Haematol. 29, 17-22.
Bamberger,C.M., Bamberger,A.M., de Castro,M., and Chrousos,G.P. (1995).
Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid
action in humans. J. Clin. Invest 95, 2435-2441.
Barnes,P.J. (1997). Molecular mechanisms of glucocorticoid action in asthma. Pulm.
Pharmacol. Ther. 10, 3-19.
Barnes,P.J. (1998). Anti-inflammatory actions of glucocorticoids: molecular
mechanisms. Clin. Sci. (Colch. ) 94, 557-572.
Barnes,P.J. (1999). Effect of beta-agonists on inflammatory cells. J. Allergy Clin.
Immunol. 104, S10-S17.
Barnes,P.J. and Adcock,I. (1993). Anti-inflammatory actions of steroids: molecular
mechanisms. Trends Pharmacol. Sci. 14, 436-441.
Bastian,L.S. and Nordeen,S.K. (1991). Concerted stimulation of transcription by
glucocorticoid receptors and basal transcription factors: limited transcriptional
synergism suggests mediation by coactivators/adaptors. Mol. Endocrinol. 5, 619-627.
Bauman,G.P., Bartik,M.M., Brooks,W.H., and Roszman,T.L. (1994). Induction of
cAMP-dependent protein kinase (PKA) activity in T cells after stimulation of the
prostaglandin E2 or the beta-adrenergic receptors: relationship between PKA activity
and inhibition of anti-CD3 monoclonal antibody-induced T cell proliferation. Cell
Immunol. 158, 182-194.
211
regulation of granulocyte apoptosis by glucocorticoids and cyclic amp
Bazzoni,F., Cassatella,M.A., Rossi,F., Ceska,M., Dewald,B., and Baggiolini,M.
(1991). Phagocytosing neutrophils produce and release high amounts of the
neutrophil-activating peptide 1/interleukin 8. J. Exp. Med. 173, 771-774.
Bazzoni,F., Giovedi,S., Kiefer,M.C., and Cassatella,M.A. (1999). Analysis of the
Bak protein expression in human polymorphonuclear neutrophils. Int. J. Clin. Lab
Res. 29, 41-45.
Beato,M., Candau,R., Chavez,S., Mows,C., and Truss,M. (1996). Interaction of
steroid hormone receptors with transcription factors involves chromatin remodelling.
J. Steroid Biochem. Mol. Biol. 56, 47-59.
Beato,M., Chalepakis,G., Schauer,M., and Slater,E.P. (1989). DNA regulatory
elements for steroid hormones. J. Steroid Biochem. 32,137-747.
Beauvais,F., Michel,L., and Dubertret,L. (1995). The nitric oxide donors, azide and
hydroxylamine, inhibit the programmed cell death of cytokine-deprived human
eosinophils. FEBS Lett. 361, 229-232.
Beebe,S.J. (1994). The cAMP-dependent protein kinases and cAMP signal
transduction. Semin. Cancer Biol. 5, 285-294.
Belvisi,M.G., Wicks,S.L., Battram,C.FL, Bottoms,S.E., Redford,J.E., Woodman,P.,
Brown,T.J., Webber,S.E., and Foster,M.L. (2001). Therapeutic benefit of a
dissociated glucocorticoid and the relevance of in vitro separation of transrepression
from transactivation activity. J. Immunol. 166, 1975-1982.
Berger,M., 0'Shea,J., Cross,A.S., Folks,T.M., Chused,T.M., Brown,E.J., and
Frank,M.M. (1984). Human neutrophils increase expression ofC3bi as well as C3b
receptors upon activation. J. Clin. Invest 74, 1566-1571.
Berkow,R.L. and Dodson,R.W. (1987). Functional analysis of the marginating pool
ofhuman polymorphonuclear leukocytes. Am. J. Hematol. 24, 47-54.
Betz,M. and Fox,B.S. (1991). Prostaglandin E2 inhibits production ofThl
lymphokines but not of Th2 lymphokines. J. Immunol. 146, 108-113.
Bicknell,S., van Eeden,S., Hayashi,S., Hards,J., English,D., and Hogg,J.C. (1994). A
non-radioisotopic method for tracing neutrophils in vivo using 5'- bromo-2'-
deoxyuridine. Am. J. Respir. Cell Mol. Biol. 10, 16-23.
Boland,M.P., Fitzgerald,K.A., and O'Neill,L.A. (2000). Topoisomerase II is required
for mitoxantrone to signal NFkB activation in HL60 cells. J. Biol. Chem. 275,
25231-25238.
Boldin,M.P., Mett,I.L., Varfolomeev,E.E., Chumakov,!., Shemer-Avni,Y.,
Camonis,J.H., and Wallach,D. (1995). Self-association of the "death domains" of the
p55 tumor necrosis factor (TNF) receptor and Fas/APOl prompts signaling for TNF
and Fas/APOl effects. J. Biol. Chem. 270, 387-391.
212
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Borger,P., Kauffman,H.F., Postma,D.S., and Vellenga,E. (1996). Interleukin-4 gene
expression in activated human T lymphocytes is regulated by the cyclic adenosine
monophosphate-dependent signaling pathway. Blood 87, 691-698.
Borregaard,N. (1985). The respiratory burst ofphagocytosis: biochemistry and
subcellular localization. Immunol. Lett. 11, 165-171.
Borregaard,N., Christensen,L., Bejerrum,O.W., Birgens,H.S., and Clemmensen,I.
(1990). Identification of a highly mobilizable subset ofhuman neutrophil
intracellular vesicles that contains tetranectin and latent alkaline phosphatase. J. Clin.
Invest 85, 408-416.
Borregaard,N. and Cowland,J.B. (1997). Granules of the human neutrophilic
polymorphonuclear leukocyte. Blood 89, 3503-3521.
Borregaard,N., Lollike,K., Kjeldsen,L., Sengelov,H., Bastholm,L., Nielsen,M.H., and
Bainton,D.F. (1993). Human neutrophil granules and secretory vesicles. Eur. J.
Haematol. 51, 187-198.
Bos,J.L. (1998). All in the family? New insights and questions regarding
interconnectivity ofRas, Rapl and Ral. EMBO J. 17, 6776-6782.
Bot,F.J., Dorssers,L., Wagemaker,G., and Lowenberg,B. (1988). Stimulating
spectrum ofhuman recombinant multi-CSF (IL-3) on human marrow precursors:
importance of accessory cells. Blood 71, 1609-1614.
Boucher,M.J., Duchesne,C., Laine,J., Morisset,J., and Rivard,N. (2001). cAMP
protection ofpancreatic cancer cells against apoptosis induced by ERK inhibition.
Biochem. Biophys. Res. Cornmun. 285, 207-216.
Boundy,V.A., Chen,J., and Nestler,E.J. (1998). Regulation of cAMP-dependent
protein kinase subunit expression in CATH.a and SH-SY5Y cells. J. Pharmacol. Exp.
Ther. 286, 1058-1065.
Bourgeois,S., Pfahl,M., and Baulieu,E.E. (1984). DNA binding properties of
glucocorticosteroid receptors bound to the steroid antagonist RU-486. EMBO J. 3,
751-755.
Bousquet,J., Chanez,P., Lacoste,J.Y., Barneon,G., Ghavanian,N., Enander,I.,
Venge,P., Ahlstedt,S., Simony-Lafontaine,J., Godard,P., and . (1990). Eosinophilic
inflammation in asthma. N. Engl. J. Med. 323, 1033-1039.
Boussiotis,V.A., Freeman,G.J., Berezovskaya,A., Barber,D.L., and Nadler,L.M.
(1997). Maintenance of human T cell anergy: blocking of IL-2 gene transcription by
activated Rapl. Science 278, 124-128.
Brach,M.A., deVos,S., Gruss,H.J., and Herrmann,F. (1992). Prolongation of survival
of human polymorphonuclear neutrophils by granulocyte-macrophage colony-
213
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
stimulating factor is caused by inhibition ofprogrammed cell death. Blood 80, 2920-
2924.
Bradley,B-L., Azzawi,M., Jacobson,M., Assoufi,B., Collins,J.V., Irani,A.M.,
Schwartz,L.B., Durham,S.R., Jeffery,P.K., and Kay,A.B. (1991). Eosinophils, T-
lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy
specimens from atopic subjects with asthma: comparison with biopsy specimens
from atopic subjects without asthma and normal control subjects and relationship to
bronchial hyperresponsiveness. J. Allergy Clin. Immunol. 88, 661-674.
Braun,R.K., Franchini,M., Erard,F., Rihs,S., De Vries,I.J., Blaser,K., Hansel,T.T.,
andWalker,C. (1993). Human peripheral blood eosinophils produce and release
interleukin-8 on stimulation with calcium ionophore. Eur. J. Immunol. 23, 956-960.
Breitschopf,K., Haendeler,J., Malchow,P., Zeiher,A.M., and Dimmeler,S. (2000).
Posttranslational modification of Bcl-2 facilitates its proteasome- dependent
degradation: molecular characterization of the involved signaling pathway. Mol. Cell
Biol. 20, 1886-1896.
Bresnick,E.H., Dalman,F.C., Sanchez,E.R., and Pratt,W.B. (1989). Evidence that the
90-kDa heat shock protein is necessary for the steroid binding conformation of the L
cell glucocorticoid receptor. J. Biol. Chem. 264, 4992-4997.
Bresnick,E.H., Sanchez,E.R., and Pratt,W.B. (1988). Relationship between
glucocorticoid receptor steroid-binding capacity and association of the Mr 90,000
heat shock protein with the unliganded receptor. J. Steroid Biochem. 30, 267-269.
Broide,D.H., Paine,M.M., and Firestein,G.S. (1992). Eosinophils express interleukin
5 and granulocyte macrophage-colony- stimulating factor mRNA at sites of allergic
inflammation in asthmatics. J. Clin. Invest 90, 1414-1424.
Brostjan,C., Anrather,J., Csizmadia,V., Stroka,D., Soares,M., Bach,F.H., and
Winkler,H. (1996). Glucocorticoid-mediated repression ofNFkB activity in
endothelial cells does not involve induction of IkappaBalpha synthesis. J. Biol.
Chem. 277, 19612-19616.
Brown,S.B., Bailey,K., and Savill,J. (1997). Actin is cleaved during constitutive
apoptosis. Biochem. J. 323 (Pt 1), 233-237.
Browning,J.L., Ward,M.P., Wallner,B.P., and Pepinsky,R.B. (1990). Studies on the
structural properties of lipocortin-1 and the regulation of its synthesis by steroids.
Prog. Clin. Biol. Res. 349, 27-45.
Bryan,S.A., O'Connor,B.J., Matti,S., Leckie,M.J., Kanabar,V., Khan,J.,
Warrington,S.J., Renzetti,L., Rames,A., Bock,J.A., Boyce,M.J., Hansel,T.T.,
Holgate,S.T., and Barnes,P.J. (2000). Effects of recombinant human interleukin-12
on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet
356, 2149-2153.
214
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Bryce,P.J., Dascombe,M.J., and Hutchinson,I.V. (1999). Immunomodulatory effects
ofpharmacological elevation of cyclic AMP in T lymphocytes proceed via a protein
kinase A independent mechanism. Immunopharmacology 41, 139-146.
Budihardjo,I., Oliver,H., Lutter,M., Luo,X., and Wang,X. (1999). Biochemical
pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15, 269-
290.
Buendia,B., Santa-Maria,A., and Courvalin,J.C. (1999). Caspase-dependent
proteolysis of integral and peripheral proteins of nuclear membranes and nuclear
pore complex proteins during apoptosis. J. Cell Sci. 112 (Pt 11), 1743-1753.
Burgering,B.M. and Coffer,P.J. (1995). Protein kinase B (c-Akt) in
phosphatidylinositol-3-OH kinase signal transduction. Nature 376, 599-602.
Busca,R., Abbe,P., Mantoux,F., Aberdam,E., Peyssonnaux,C., Eychene,A.,
Ortonne,J.P., and Ballotti,R. (2000). Ras mediates the cAMP-dependent activation of
extracellular signal- regulated kinases (ERKs) in melanocytes. EMBO J. 19, 2900-
2910.
Butterworth,A.E., Sturrock,R.F., Houba,V., Mahmoud,A.A., Sher,A., and Rees,P.H.
(1975). Eosinophils as mediators of antibody-dependent damage to schistosomula.
Nature 256, 727-729.
Cain,K., Brown,D.G., Langlais,C., and Cohen,G.M. (1999). Caspase activation
involves the formation of the aposome, a large (approximately 700 kDa) caspase-
activating complex. J. Biol. Chem. 274, 22686-22692.
Calafat,J., Kuijpers,T.W., Janssen,H., Borregaard,N., Verhoeven,A.J., and Roos,D.
(1993). Evidence for small intracellular vesicles in human blood phagocytes
containing cytochrome b558 and the adhesion molecule CD1 lb/CD18. Blood 81,
3122-3129.
Caldenhoven,E., Liden,J., Wissink,S., van de,S.A., Raaijmakers,J., Koenderman,L.,
Okret,S., Gustafsson,J.A., and van der Saag,P.T. (1995). Negative cross-talk between
RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory
action of glucocorticoids. Mol. Endocrinol. 9, 401-412.
Campbell,H.D., Tucker,W.Q., Hort,Y., Martinson,M.E., Mayo,G., Clutterbuck,E.J.,
Sanderson,C.J., and Young,I.G. (1987). Molecular cloning, nucleotide sequence, and
expression of the gene encoding human eosinophil differentiation factor (interleukin
5). Proc. Natl. Acad. Sci. U. S. A 84, 6629-6633.
Cannistra,S.A. and Griffin,J.D. (1988). Regulation of the production and function of
granulocytes and monocytes. Semin. Hematol. 25, 173-188.
Carlos,T.M. and Harlan,J.M. (1994). Leukocyte-endothelial adhesion molecules.
Blood 84, 2068-2101.
215
regulation of granulocyte apoptosis by glucocorticoids and cyclic amp
Carson-Jurica,M.A., Schrader,W.T., and 0'Malley,B.W. (1990). Steroid receptor
family: structure and functions. Endocr. Rev. 11, 201-220.
Casciola-Rosen,L.A., Anhalt,G.J., and Rosen,A. (1995). DNA-dependent protein
kinase is one of a subset of autoantigens specifically cleaved early during apoptosis.
J. Exp. Med. 182, 1625-1634.
Cass,L.A., Summers,S.A., Prendergast,G.V., Backer,J.M., Birnbaum,M.J., and
Meinkoth,J.L. (1999). Protein kinase A-dependent and -independent signaling
pathways contribute to cyclic AMP-stimulated proliferation. Mol. Cell Biol. 19,
5882-5891.
Cassatella,M.A., Bazzoni,F., Ceska,M., Ferro,I., Baggiolini,M., and Berton,G.
(1992). IL-8 production by human polymorphonuclear leukocytes. The
chemoattractant formyl-methionyl-leucyl-phenylalanine induces the gene expression
and release of IL-8 through a pertussis toxin-sensitive pathway. J. Immunol. 148,
3216-3220.
Chae,H.J., Chae,S.W., An,N.H., KimJ.H., Kim,C.W., Yoo,S.K., Kim,H.H.,
Lee,Z.H., and Kim,H.R. (2001). Cyclic-AMP inhibits nitric oxide-induced apoptosis
in human osteoblast: the regulation of caspase-3, -6, -9 and the release of cytochrome
c in nitric oxide-induced apoptosis by cAMP. Biol. Pharm. Bull. 24, 453-460.
Chang,H.S., Jeon,K.W., Kim,Y.H., Chung,I.Y., and Park,C.S. (2000). Role of
cAMP-dependent pathway in eosinophil apoptosis and survival. Cell Immunol. 203,
29-38.
Chao,D.T. and Korsmeyer,S.J. (1998). BCL-2 family: regulators of cell death. Annu.
Rev. Immunol. 16, 395-419.
Chapman,M.S., Askew,D.J., Kuscuoglu,U., and Miesfeld,R.L. (1996).
Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. Mol.
Endocrinol. 10, 967-978.
Chen,D. and Rothenberg,E.V. (1994). Interleukin 2 transcription factors as molecular
targets of cAMP inhibition: delayed inhibition kinetics and combinatorial
transcription roles. J. Exp. Med. 179, 931-942.
Chen,Z., Hagler,J., Palombella,V.J., Melandri,F., Scherer,D., Ballard,D., and
Maniatis,T. (1995). Signal-induced site-specific phosphorylation targets IkBcx to the
ubiquitin-proteasome pathway. Genes Dev. 9, 1586-1597.
Chertov,0., Yang,D., Howard,O.M., and Oppenheim,J.J. (2000). Leukocyte granule
proteins mobilize innate host defenses and adaptive immune responses. Immunol.
Rev. 777, 68-78.
Chijiwa,T., Mishima,A., Hagiwara,M., Sano,M., Hayashi,K., Inoue,T., Naito,K.,
Toshioka,T., and Hidaka,H. (1990). Inhibition of forskolin-induced neurite
outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of
216
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-
isoquinolinesulfonamide (H-89), ofPCI 2D pheochromocytoma cells. J. Biol. Chem.
265, 5267-5272.
Chinnaiyan,A.M., 0'Rourke,K., Tewari,M., and Dixit,V.M. (1995). FADD, a novel
death domain-containing protein, interacts with the death domain of Fas and initiates
apoptosis. Cell 81, 505-512.
Chuang,P.I., Yee,E., Karsan,A., Winn,R.K., and Harlan,J.M. (1998). A1 is a
constitutive and inducible Bcl-2 homologue in mature human neutrophils. Biochem.
Biophys. Res. Commun. 249, 361-365.
Cicco,N.A., Lindemann,A., Content,J., Vandenbussche,P., Lubbert,M., Gauss,J.,
Mertelsmann,R., and Herrmann,F. (1990). Inducible production of interleukin-6 by
human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-
stimulating factor and tumor necrosis factor-alpha. Blood 75, 2049-2052.
Cidlowski,J.A., Bellingham,D.L., Powell-Oliver,F.E., Lubahn,D.B., and Sar,M.
(1990). Novel antipeptide antibodies to the human glucocorticoid receptor:
recognition ofmultiple receptor forms in vitro and distinct localization of
cytoplasmic and nuclear receptors. Mol. Endocrinol. 4, 1427-1437.
Cikala,M., Wilm,B., Hobmayer,E., Bottger,A., and David,C.N. (1999). Identification
of caspases and apoptosis in the simple metazoan Hydra. Curr. Biol. 9, 959-962.
Clark,R.A., Gallin,J.I., and Fauci,A.S. (1979). Effects of in vivo prednisone on in
vitro eosinophil and neutrophil adherence and chemotaxis. Blood 53, 633-641.
Cohen,G.M. (1997). Caspases: the executioners of apoptosis. Biochem. J. 326 (Pt
1), 1-16.
Cohen,J.J. (1993). Apoptosis. Immunol. Today 14, 126-130.
Colotta,F., Re,F., Polentarutti,N., Sozzani,S., and Mantovani,A. (1992). Modulation
of granulocyte survival and programmed cell death by cytokines and bacterial
products. Blood 80, 2012-2020.
Condliffe,A.M., Kitchen,E., and Chilvers,E.R. (1998). Neutrophil priming:
pathophysiological consequences and underlying mechanisms. Clin. Sci. (Colch.)
94, 461-471.
Cook,S.J., Rubinfeld,B., Albert,I., and McCormick,F. (1993). RapV12 antagonizes
Ras-dependent activation ofERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts.
EMBO J. 12, 3475-3485.
Costa,J.J., Matossian,K., Resnick,M.B., Beil,W.J., Wong,D.T., Gordon,J.R.,
Dvorak,A.M., Weller,P.F., and Galli,S.J. (1993). Human eosinophils can express the
cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha.
J. Clin. Invest 91, 2673-2684.
217
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Cousin,J.M., Haslett,C., and Rossi,A.G. (1997). Regulation of granulocyte apoptosis
by PKC inhibition and elevation of [Ca2+]i. Biochem. Soc. Trans. 25, 243S.
Cox,G. (1995). Glucocorticoid treatment inhibits apoptosis in human neutrophils.
Separation of survival and activation outcomes. J. Immunol. 154, 4719-4725.
Cox,G. and Austin,R.C. (1997). Dexamethasone-induced suppression of apoptosis in
human neutrophils requires continuous stimulation of new protein synthesis. J.
Leukoc. Biol. 61, 224-230.
Cox,G., Crossley,J., and Xing,Z. (1995). Macrophage engulfment of apoptotic
neutrophils contributes to the resolution of acute pulmonary inflammation in vivo.
Am. J. Respir. Cell Mol. Biol. 12, 232-237.
Cox,G., Ohtoshi,T., Vancheri,C., Denburg,J.A., Dolovich,J., Gauldie,J., and
Jordana,M. (1991). Promotion of eosinophil survival by human bronchial epithelial
cells and its modulation by steroids. Am. J. Respir. Cell Mol. Biol. 4, 525-531.
Crompton,M. (1999). The mitochondrial permeability transition pore and its role in
cell death. Biochem. J. 341 (Pt 2), 233-249.
Cronstein,B.N., Kimmel,S.C., Levin,R.I., Martiniuk,F., and Weissmann,G. (1992). A
mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid
receptor regulates leukocyte adhesion to endothelial cells and expression of
endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1.
Proc. Natl. Acad. Sci. U. S. A 89, 9991-9995.
Cryns,V. and Yuan,J. (1998). Proteases to die for. Genes Dev. 12, 1551-1570.
D'Mello,S.R., Galli,C., Ciotti,T., and Calissano,P. (1993). Induction of apoptosis in
cerebellar granule neurons by low potassium: inhibition of death by insulin-like
growth factor I and cAMP. Proc. Natl. Acad. Sci. U. S. A 90, 10989-10993.
Dahinden,C.A., Geiser,T., Brunner,T., von,T., V, Caput,D., Ferrara,P., Minty,A., and
Baggiolini,M. (1994). Monocyte chemotactic protein 3 is a most effective baso. J.
Exp. Med. 179, 751-756.
Dahlman-Wright,K., Almlof,T., McEwan,I.J., Gustafsson,J.A., and Wright,A.P.
(1994). Delineation of a small region within the major transactivation domain of the
human glucocorticoid receptor that mediates transactivation of gene expression.
Proc. Natl. Acad. Sci. U. S. A 91, 1619-1623.
Dahlman-Wright,K., Baumann,H., McEwan,I.J., Almlof,T., Wright,A.P.,
Gustafsson,J.A., and Hard,T. (1995). Structural characterization of a minimal
functional transactivation domain from the human glucocorticoid receptor. Proc.
Natl. Acad. Sci. U. S. A 92, 1699-1703.
Dalman,F.C., Scherrer,L.C., Taylor,L.P., Akil,H., and Pratt,W.B. (1991).
Localization of the 90-kDa heat shock protein-binding site within the hormone-
218
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
binding domain of the glucocorticoid receptor by peptide competition. J. Biol. Chem.
266, 3482-3490.
Daniel,P.B., Walker,W.H., and Habener,J.F. (1998). Cyclic AMP signaling and gene
regulation. Annu. Rev. Nutr. 18, 353-383.
Danielian,P.S., White,R., Lees,J.A., and Parker,M.G. (1992). Identification of a
conserved region required for hormone dependent transcriptional activation by
steroid hormone receptors. EMBO J. 11, 1025-1033.
Daniels,R.H., Bird,I.N., Hill,M.E., and Finnen,M.J. (1993). Differential regulation of
early phase and late phase responses in human neutrophils by cAMP. Biochem.
Pharmacol. 45, 1613-1620.
Danielsen,M., Northrop,J.P., Jonklaas,J., and Ringold,G.M. (1987). Domains of the
glucocorticoid receptor involved in specific and nonspecific deoxyribonucleic acid
binding, hormone activation, and transcriptional enhancement. Mol. Endocrinol. 1,
816-822.
Danielsen,M., Northrop,J.P., and Ringold,G.M. (1986). The mouse glucocorticoid
receptor: mapping of functional domains by cloning, sequencing and expression of
wild-type and mutant receptor proteins. EMBO J. 5, 2513-2522.
Darwish,H.M., Burmester,J.K., Moss,V.E., and DeLuca,EI.F. (1993).
Phosphorylation is involved in transcriptional activation by the 1,25-
dihydroxyvitamin D3 receptor. Biochim. Biophys. Acta 1167, 29-36.
Datta,S.R., Dudek,H., Tao,X., Masters,S., Fu,H., Gotoh,Y., and Greenberg,M.E.
(1997). Akt phosphorylation ofBAD couples survival signals to the cell- intrinsic
death machinery. Cell 91, 231-241.
Davidsson,A., Anderson,T., and Hellquist,H.B. (2000). Apoptosis and phagocytosis
of tissue-dwelling eosinophils in sinonasal polyps. Laryngoscope 110, 111-116.
Davies,S.P., Reddy,H., Caivano,M., and Cohen,P. (2000). Specificity and
mechanism of action of some commonly used protein kinase inhibitors. Biochem. J.
357,95-105.
Davis,W.C. and Douglas,S.D. (1972). Defective granule formation and function in
the Chediak-Higashi syndrome in man and animals. Semin. Hematol. 9, 431-450.
De Bosscher,K., Vanden Berghe,W., and Haegeman,G. (2001). Glucocorticoid
repression ofAP-1 is not mediated by competition for nuclear coactivators. Mol.
Endocrinol. 75,219-227.
De Bosscher,K., Vanden Berghe,W., Vermeulen,L., Plaisance,S., Boone,E., and
Haegeman,G. (2000). Glucocorticoids repress NFicB-driven genes by disturbing the
interaction ofp65 with the basal transcription machinery, irrespective of coactivator
levels in the cell. Proc. Natl. Acad. Sci. U. S. A 97, 3919-3924.
219
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
de Castro,M., Elliot,S., Kino,T., Bamberger,C., Karl,M., Webster,E., and
Chrousos,G.P. (1996). The non-ligand binding beta-isoform of the human
glucocorticoid receptor (hGR beta): tissue levels, mechanism of action, and potential
physiologic role. Mol. Med. 2, 597-607.
de Rooij,J., Rehmann,H., van Triest,M., Cool,R.H., Wittinghofer,A., and Bos,J.L.
(2000). Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs.
J. Biol. Chem. 275, 20829-20836.
de Rooij,J., Zwartkruis,F.J., Verheijen,M.Fl., Cool,R.FL, Nijman,S.M.,
Wittinghofer,A., and Bos,J.L. (1998). Epac is a Rapl guanine-nucleotide-exchange
factor directly activated by cyclic AMP. Nature 396, 474-477.
De,A., Boyadjieva,N.I., Pastorcic,M., Reddy,B.V., and Sarkar,D.K. (1994). Cyclic
AMP and ethanol interact to control apoptosis and differentiation in hypothalamic
beta-endorphin neurons. J. Biol. Chem. 269, 26697-26705.
Deckwerth,T.L. and Johnson,E.M., Jr. (1993). Temporal analysis of events
associated with programmed cell death (apoptosis) of sympathetic neurons deprived
ofnerve growth factor. J. Cell Biol. 123, 1207-1222.
Degli-Esposti,M.A., Smolak,P.J., Walczak,H., Waugh,J., Huang,C.P., DuBose,R.F.,
Goodwin,R.G., and Smith,C.A. (1997). Cloning and characterization of TRAIL-R3,
a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186, 1165-
1170.
del Peso,L., Gonzalez-Garcia,M., Page,C., Herrera,R., and Nunez,G. (1997).
Interleukin-3-induced phosphorylation ofBAD through the protein kinase Akt.
Science 278, 687-689.
Delia,D., Aiello,A., Soligo,D., Fontanella,E., Melani,C., Pezzella,F., Pierotti,M.A.,
and Delia,P.G. (1992). bcl-2 proto-oncogene expression in normal and neoplastic
human myeloid cells. Blood 79, 1291-1298.
Dent,G. and Giembycz,M.A. (1996). Phosphodiesterase inhibitors: Lily the Pink's
medicinal compound for asthma? Thorax 51, 647-649.
Dent,G., Giembycz,M.A., Evans,P.M., Rabe,K.F., and Barnes,P.J. (1994).
Suppression ofhuman eosinophil respiratory burst and cyclic AMP hydrolysis by
inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor
agonist albuterol. J. Pharmacol. Exp. Ther. 271, 1167-1174.
Dent,G., Giembycz,M.A., Rabe,K.F., and Barnes,P.J. (1991). Inhibition of eosinophil
cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst
by 'type IV'-selective PDE inhibitors. Br. J. Pharmacol. 103, 1339-1346.
Detmers,P.A., Zhou,D., Powell,D., Lichenstein,H., Kelley,M., and Pironkova,R.
(1995). Endotoxin receptors (CD14) are found with CD16 (Fc gamma RIII) in an
220
regulation of granulocyte apoptosis by glucocorticoids and cyclic amp
intracellular compartment of neutrophils that contains alkaline phosphatase. J.
Immunol. 155, 2085-2095.
Devitt,A., Moffatt,O.D., Raykundalia,C., Capra,J.D., Simmons,D.L., and
Gregory,C.D. (1998). Human CD14 mediates recognition and phagocytosis of
apoptotic cells. Nature 392, 505-509.
Dewald,B., Bretz,U., and Baggiolini,M. (1982). Release of gelatinase from a novel
secretory compartment ofhuman neutrophils. J. Clin. Invest 70, 518-525.
Dewson,G., Cohen,G.M., and Wardlaw,A.J. (2001). Interleukin-5 inhibits
translocation ofBax to the mitochondria, cytochrome c release, and activation of
caspases in human eosinophils. Blood 98, 2239-2247.
Dibbert,B., Daigle,I., Braun,D., Schranz,C., Weber,M., Blaser,K., Zangemeister-
Wittke,U., Akbar,A.N., and Simon,H.U. (1998). Role for Bcl-xL in delayed
eosinophil apoptosis mediated by granulocyte- macrophage colony-stimulating factor
and interleukin-5. Blood 92, 778-783.
Distelhorst,C.W., Janiga,K.E., Howard,K.J., Strandjord,S.E., and Campbell,E.J.
(1987). Neutrophil elastase produces 52-kD and 30-kD glucocorticoid receptor
fragments in the cytosol of human leukemia cells. Blood 70, 860-868.
Djeu,J.Y., Serbousek,D., and Blanchard,D.K. (1990). Release of tumor necrosis
factor by human polymorphonuclear leukocytes. Blood 76, 1405-1409.
Djukanovic,R., Roche,W.R., Wilson,J.W., Beasley,C.R., Twentyman,O.P.,
Howarth,R.H., and Holgate,S.T. (1990). Mucosal inflammation in asthma. Am. Rev.
Respir. Dis. 142, 434-457.
Doerfler,M.E., Danner,R.L., Shelhamer,J.H., and Parrillo,J.E. (1989). Bacterial
lipopolysaccharides prime human neutrophils for enhanced production of leukotriene
B4. J. Clin. Invest 83, 970-977.
Doerfler,M.E., Weiss,J., Clark,J.D., and Elsbach,P. (1994). Bacterial
lipopolysaccharide primes human neutrophils for enhanced release of arachidonic
acid and causes phosphorylation of an 85-kD cytosolic phospholipase A2. J. Clin.
Invest 93, 1583-1591.
Doucas,V., Shi,Y., Miyamoto,S., West,A., Verma,I., and Evans,R.M. (2000).
Cytoplasmic catalytic subunit of protein kinase A mediates cross- repression by
NFkB and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U. S. A 97, 11893-
11898.
Dowd,D.R., MacDonald,P.N., Komm,B.S., Haussler,M.R., and Miesfeld,R.L.
(1992). Stable expression of the calbindin-D28K complementary DNA interferes
with the apoptotic pathway in lymphocytes. Mol. Endocrinol. 6, 1843-1848.
221
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Dransfield,I., Buckle,A.M., Savill,J.S., McDowall,A., Haslett,C., and Hogg,N.
(1994). Neutrophil apoptosis is associated with a reduction in CD 16 (FcyRIII)
expression. J. Immunol. 153, 1254-1263.
Druilhe,A., Arock,M., Le Goff,L., and Pretolani,M. (1998). Human eosinophils
express bcl-2 family proteins: modulation ofMcl-1 expression by IFNy. Am. J.
Respir. Cell Mol. Biol. 18, 315-322.
Dubravec,D.B., Spriggs,D.R., Mannick,J.A., and Rodrick,M.L. (1990). Circulating
human peripheral blood granulocytes synthesize and secrete tumor necrosis factor
alpha. Proc. Natl. Acad. Sci. U. S. A 87, 6758-6761.
Dubucquoi,S., Desreumaux,P., Janin,A., Klein,O., Goldman,M., Tavernier,J.,
Capron,A., and Capron,M. (1994). Interleukin 5 synthesis by eosinophils: association
with granules and immunoglobulin-dependent secretion. J. Exp. Med. 179, 703-708.
Dudley,D.T., Pang,L., Decker,S.J., Bridges,A.J., and Saltiel,A.R. (1995). A synthetic
inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. U. S.
A 92, 7686-7689.
Egesten,A., Alumets,J., von Mecklenburg,C., Palmegren,M., and 01sson,I. (1986).
Localization of eosinophil cationic protein, major basic protein, and eosinophil
peroxidase in human eosinophils by immunoelectron microscopic technique. J.
Histochem. Cytochem. 34, 1399-1403.
Ellis,R.E. and Horvitz,H.R. (1991). Two C. elegans genes control the programmed
deaths of specific cells in the pharynx. Development 112, 591-603.
Elwood,W., Sun,J., Barnes,P.J., Giembycz,M.A., and Chung,K.F. (1995). Inhibition
of allergen-induced lung eosinophilia by type-Ill and combined type III- and IV-
selective phosphodiesterase inhibitors in brown-Norway rats. Inflamm. Res. 44, 83-
86.
Enari,M., Sakahira,H., Yokoyama,H., Okawa,K., Iwamatsu,A., and Nagata,S.
(1998). A caspase-activated DNase that degrades DNA during apoptosis, and its
inhibitor ICAD. Nature 391, 43-50.
Encio,I.J. and Detera-Wadleigh,S.D. (1991). The genomic structure of the human
glucocorticoid receptor. J. Biol. Chem. 266, 7182-7188.
Erjefalt,J.S. and Persson,C.G. (2000). New aspects of degranulation and fates of
airway mucosal eosinophils. Am. J. Respir. Crit Care Med. 161, 2074-2085.
Errasfa,M., Rothhut,B., Fradin,A., Billardon,C., Junien,J.L., Bure,J., and Russo-
Marie,F. (1985). The presence of lipocortin in human embryonic skin fibroblasts and
its regulation by anti-inflammatory steroids. Biochim. Biophys. Acta 847, 247-254.
Eskes,R., Antonsson,B., Osen-Sand,A., Montessuit,S., Richter,C., Sadoul,R.,
Mazzei,G., Nichols,A., and Martinou,J.C. (1998). Bax-induced cytochrome C release
222
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
from mitochondria is independent of the permeability transition pore but highly
dependent on Mg2+ ions. J. Cell Biol. 143, 217-224.
Estes,G., Solomon,S.S., and Norton,W.L. (1971). Inhibition of lymphocyte
stimulation by cyclic and non-cyclic nucleotides. J. Immunol. 107, 1489-1492.
Fadok,V.A., Bratton,D.L., Konowal,A., Freed,P.W., Westcott,J.Y., and Henson,P.M.
(1998). Macrophages that have ingested apoptotic cells in vitro inhibit
proinflammatory cytokine production through autocrine/paracrine mechanisms
involving TGF-p, PGE2, and PAF. J. Clin. Invest 101, 890-898.
Fadok,V.A., Bratton,D.L., Rose,D.M., Pearson,A., Ezekewitz,R.A., and
Henson,P.M. (2000). A receptor for phosphatidylserine-specific clearance of
apoptotic cells. Nature 405, 85-90.
Fadok,V.A., Voelker,D.R., Campbell,P.A., Cohen,J.J., Bratton,D.L., and
Henson,P.M. (1992). Exposure of phosphatidylserine on the surface of apoptotic
lymphocytes triggers specific recognition and removal by macrophages. J. Immunol.
148,2201-2216.
Fecho,K. and Cohen,P.L. (1998). Fas ligand (gld)- and Fas (lpr)-deficient mice do
not show alterations in the extravasation or apoptosis of inflammatory neutrophils. J.
Leukoc. Biol. 64, 373-383.
Fenteany,G., Standaert,R.F., Lane,W.S., Choi,S., Corey,E.J., and Schreiber,S.L.
(1995). Inhibition of proteasome activities and subunit-specific amino-terminal
threonine modification by lactacystin. Science 268, 726-731.
Filep,J.G., Delalandre,A., Payette,Y., and Foldes-Filep,E. (1997). Glucocorticoid
receptor regulates expression of L-selectin and CD11/CD18 on human neutrophils.
Circulation 96, 295-301.
Fittschen,C., Sandhaus,R.A., Worthen,G.S., and Henson,P.M. (1988). Bacterial
lipopolysaccharide enhances chemoattractant-induced elastase secretion by human
neutrophils. J. Leukoc. Biol. 43, 547-556.
Folco,E.J. and Koren,G. (1997). Degradation of the inducible cAMP early repressor
(ICER) by the ubiquitin-proteasome pathway. Biochem. J. 328 (Pt 1), 37-43.
Fortenberry,J.D., Owens,M.L., and Brown,L.A. (1999). S-nitrosoglutathione
enhances neutrophil DNA fragmentation and cell death. Am. J. Physiol 276, L435-
L442.
Fortenberry,J.D., Owens,M.L., Brown,M.R., Atkinson,D., and Brown,L.A. (1998).
Exogenous nitric oxide enhances neutrophil cell death and DNA fragmentation. Am.
J. Respir. Cell Mol. Biol. 18, 421-428.
Fradin,A., Rothhut,B., Poincelot-Canton,B., Errasfa,M., and Russo-Marie,F. (1988).
Inhibition of eicosanoid and PAF formation by dexamethasone in rat inflammatory
223
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
polymorphonuclear neutrophils may implicate lipocortin's'. Biochim. Biophys. Acta
963, 248-257.
Franke,T.F. and Cantley,L.C. (1997). Apoptosis. A Bad kinase makes good. Nature
390, 116-117.
Franke,T.F., Yang,S.I., Chan,T.O., Datta,K., Kazlauskas,A., Morrison,D.K.,
Kaplan,D.R., and Tsichlis,P.N. (1995). The protein kinase encoded by the Akt proto-
oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81,
727-736.
Frasch,S.C., Nick,J.A., Fadok,V.A., Bratton,D.L., Worthen,G.S., and Henson,P.M.
(1998). p38 mitogen-activated protein kinase-dependent and -independent
intracellular signal transduction pathways leading to apoptosis in human neutrophils.
J. Biol. Chem. 273, 8389-8397.
Freedman,L.P., Luisi,B.F., Korszun,Z.R., Basavappa,R., Sigler,P.B., and
Yamamoto,K.R. (1988). The function and stmcture of the metal coordination sites
within the glucocorticoid receptor DNA binding domain. Nature 334, 543-546.
Fujisawa,T., Fukuda,S., Atsuta,J., Ichimi,R., Kamiya,H., and Sakurai,M. (1994).
Interferon-gamma induces interleukin-3 release from peripheral blood eosinophils.
Int. Arch. Allergy Immunol. 104 Suppl 1, 41-43.
Gajewski,T.F., Schell,S.R., and Fitch,F.W. (1990). Evidence implicating utilization
of different T cell receptor- associated signaling pathways by TH1 and TH2 clones.
J. Immunol. 144, 4110-4120.
Gerritsen,M.E., Williams,A.J., Neish,A.S., Moore,S., Shi,Y., and Collins,T. (1997).
CREB-binding protein/p300 are transcriptional coactivators of p65. Proc. Natl. Acad.
Sci. U. S. A 94, 2927-2932.
Giannopoulos,G. (1975). Glucocorticoid receptors in lung. Comparison between
nonactivated and activated forms of the cytoplasmic glucocorticoid binding protein
and their relationship to the nuclear binding protein of fetal rabbit lung. J. Biol.
Chem. 250, 2904-2910.
Giembycz,M.A. and Dent,G. (1992). Prospects for selective cyclic nucleotide
phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin. Exp. Allergy
22, 337-344.
Giguere,V., Hollenberg,S.M., Rosenfeld,M.G., and Evans,R.M. (1986). Functional
domains of the human glucocorticoid receptor. Cell 46, 645-652.
Gjertsen,B.T., Mellgren,G., Otten,A., Maronde,E., Genieser,H.G., Jastorff,B.,
Vintermyr,O.K., McKnight,G.S., and Doskeland,S.O. (1995). Novel (Rp)-cAMPS
analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase
activity modulates interleukin-1 beta action. J. Biol. Chem. 270, 20599-20607.
224
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Gleich,G.J. and Adolphson,C.R. (1986). The eosinophilic leukocyte: structure and
function. Adv. Immunol. 39, 177-253.
Gleich,G.J., Loegering,D.A., Mann,K.G., and Maldonado,J.E. (1976). Comparative
properties of the Charcot-Leyden crystal protein and the major basic protein from
human eosinophils. J. Clin. Invest 57, 633-640.
Goldman,P.S., Tran,V.K., and Goodman,R.H. (1997). The multifunctional role of the
co-activator CBP in transcriptional regulation. Recent Prog. Horm. Res. 52, 103-119.
Gonzalez-Amaro,R. and Sanchez-Madrid,F. (1999). Cell adhesion molecules:
selectins and integrins. Crit Rev. Immunol. 19, 389-429.
Goping,I.S., Gross,A., Lavoie,J.N., Nguyen,M., Jemmerson,R., Roth,K.,
Korsmeyer,S.J., and Shore,G.C. (1998). Regulated targeting ofBAX to
mitochondria. J. Cell Biol. 143, 207-215.
Granerus,M., Schofield,P., Bierke,P., and Engstrom,W. (1995). Growth factors and
apoptosis in development. The role of insulin like growth factor I and TGF(3l in
regulating cell growth and cell death in a human teratocarcinoma derived cell line.
Int. J. Dev. Biol. 39, 759-764.
Green,S., Kumar,V., Theulaz,I., Wahli,W., and Chambon,P. (1988). The N-terminal
DNA-binding 'zinc finger' of the oestrogen and glucocorticoid receptors determines
target gene specificity. EMBO J. 7, 3037-3044.
Griffiths-Johnson,D.A., Collins,P.D., Rossi,A.G., Jose,P.J., and Williams,T.J.
(1993). The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes
their accumulation into the lung in vivo. Biochem. Biophys. Res. Commun. 197,
1167-1172.
Grigg,J.M., SavilfJ.S., Sarraf,C., Haslett,C., and Silverman,M. (1991). Neutrophil
apoptosis and clearance from neonatal lungs. Lancet 338, 720-722.
Gronemeyer,H. (1992). Control of transcription activation by steroid hormone
receptors. FASEB J. 6, 2524-2529.
Gross,A., McDonnell,J.M., and Korsmeyer,S.J. (1999). BCL-2 family members and
the mitochondria in apoptosis. Genes Dev. 13, 1899-1911.
Guthrie,L.A., McPhail,L.C., Henson,P.M., and Johnston,R.B., Jr. (1984). Priming of
neutrophils for enhanced release of oxygen metabolites by bacterial
lipopolysaccharide. Evidence for increased activity of the superoxide-producing
enzyme. J. Exp. Med. 160, 1656-1671.
Hachicha,M., Rathanaswami,P., Naccache,P.H., and McColl,S.R. (1998). Regulation
of chemokine gene expression in human peripheral blood neutrophils phagocytosing
microbial pathogens. J. Immunol. 160, 449-454.
225
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Hachiya,0., Takeda,Y., Miyata,H., Watanabe,H., Yamashita,T., and Sendo,F.
(1995). Inhibition by bacterial lipopolysaccharide of spontaneous and TNFoc-
induced human neutrophil apoptosis in vitro. Microbiol. Immunol. 39, 715-723.
Hall,S.E., Savill,J.S., Henson,P.M., and Haslett,C. (1994). Apoptotic neutrophils are
phagocytosed by fibroblasts with participation of the fibroblast vitronectin receptor
and involvement of a mannose/fucose-specific lectin. J. Immunol. 153, 3218-3227.
Hallsworth,M.P., Giembycz,M.A., Barnes,P.J., and Lee,T.H. (1996). Cyclic AMP-
elevating agents prolong or inhibit eosinophil survival depending on prior exposure
to GM-CSF. Br. J. Pharmacol. 117, 79-86.
Hallsworth,M.P., Litchfield,T.M., and Lee,T.H. (1992). Glucocorticoids inhibit
granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in
vitro survival of human eosinophils. Immunology 75, 382-385.
Hallsworth,M.P., Twort,C.H., Lee,T.H., and Hirst,S.J. (2001). P(2)-adrenoceptor
agonists inhibit release of eosinophil-activating cytokines from human airway
smooth muscle cells. Br. J. Pharmacol. 132, 729-741.
Ham,E.A., Soderman,D.D., Zanetti,M.E., Dougherty,H.W., McCauley,E., and
Kuehl,F.A., Jr. (1983). Inhibition by prostaglandins of leukotriene B4 release from
activated neutrophils. Proc. Natl. Acad. Sci. U. S. A 80, 4349-4353.
Hamid,Q., Barkans,J., Meng,Q., Ying,S., Abrams,J.S., Kay,A.B., and Moqbel,R.
(1992). Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 80,
1496-1501.
Hannah,S., Cotter,T.G., Wyllie,A.H., and Haslett,C. (1994). The role of oncogene
products in neutrophil apoptosis. Biochem. Soc. Trans. 22, 253S.
Hannah,S., Mecklenburgh,K., Rahman,I., Bellingan,G.J., Greening,A., Haslett,C.,
and Chilvers,E.R. (1995). Hypoxia prolongs neutrophil survival in vitro. FEBS Lett.
372, 233-237.
Hanoune,J. and Defer,N. (2001). Regulation and role of adenylyl cyclase isoforms.
Annu. Rev. Pharmacol. Toxicol. 41, 145-174.
Harada,H., Becknell,B., Wilm,M., Mann,M., Huang,L.J., Taylor,S.S., Scott,J.D., and
Korsmeyer,S.J. (1999). Phosphorylation and inactivation ofBAD by mitochondria-
anchored protein kinase A. Mol. Cell 3, 413-422.
Hard,T., Dahlman,K., Carlstedt-Duke,J., Gustafsson,J.A., and Rigler,R. (1990).
Cooperativity and specificity in the interactions between DNA and the glucocorticoid
receptor DNA-binding domain. Biochemistry 29, 5358-5364.
Harvath,L., Robbins,J.D., Russell,A.A., and Seamon,K.B. (1991). cAMP and human
neutrophil chemotaxis. Elevation of cAMP differentially affects chemotactic
responsiveness. J. Immunol. 146, 224-232.
226
regulation of granulocyte apoptosis by glucocorticoids and cyclic amp
Harvey,N.L. and Kumar,S. (1998). The role of caspases in apoptosis. Adv. Biochem.
Eng Biotechnol. 62, 107-128.
Haslett,C. and Henson,P.M. (1988). The Molecular and Cellular Biology ofWound
Repair. (New York: Plenum Publishing Corporation).
Haslett,C., Guthrie,L.A., Kopaniak,M.M., Johnston,R.B., Jr., and Henson,P.M.
(1985). Modulation ofmultiple neutrophil functions by preparative methods or trace
concentrations of bacterial lipopolysaccharide. Am. J. Pathol. 119, 101-110.
Haslett,C., Lee,A., Savill,J.S., Meagher,L., and Whyte,M.K. (1991). Apoptosis
(programmed cell death) and functional changes in aging neutrophils. Modulation by
inflammatory mediators. Chest 99, 6S.
Haslett,C., Savill,J.S., and Meagher,L. (1989). The neutrophil. Curr. Opin. Immunol.
2, 10-18.
Heck,S., Bender,K., Kullmann,M., Gottlicher,M., Herrlich,P., and Cato,A.C. (1997).
iKB-a-independent downregulation ofNFkB activity by glucocorticoid receptor.
EMBO J. 16, 4698-4707.
Heck,S., Kullmann,M., Gast,A., Ponta,H., RahmsdorfH.J., Herrlich,P., and
Cato,A.C. (1994). A distinct modulating domain in glucocorticoid receptor
monomers in the repression ofactivity of the transcription factor AP-1. EMBO J. 13,
4087-4095.
Heinzelmann,M., Mercer-Jones,M.A., and Passmore,J.C. (1999). Neutrophils and
renal failure. Am. J. Kidney Dis. 34, 384-399.
Helmberg,A., Auphan,N., Caelles,C., and Karin,M. (1995). Glucocorticoid-induced
apoptosis of human leukemic cells is caused by the repressive function of the
glucocorticoid receptor. EMBO J. 14, 452-460.
Henderson,W.R., Jr. (1991). Eicosanoids and platelet-activating factor in allergic
respiratory diseases. Am. Rev. Respir. Dis. 143, S86-S90.
Hengartner,M.O. and Horvitz,H.R. (1994). Programmed cell death in Caenorhabditis
elegans. Curr. Opin. Genet. Dev. 4, 581-586.
Her,E., Frazer,J., Austen,K.F., and Owen,W.F., Jr. (1991). Eosinophil
hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and
glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned
medium. J. Clin. Invest 88, 1982-1987.
Hettmann,T., DiDonato,J., Karin,M., and Leiden,J.M. (1999). An essential role for
NFkB in promoting double positive thymocyte apoptosis. J. Exp. Med. 189, 145-158.
227
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Hochstrasser,K., Albrecht,G.J., Schonberger,O.L., Rasche,B., and Lempart,K.
(1981). An elastase-specific inhibitor from human bronchial mucus. Isolation and
characterization. Hoppe Seylers. Z. Physiol Chem. 362, 1369-1375.
Hofmann,K., Bucher,P., and Tschopp,J. (1997). The CARD domain: a new apoptotic
signalling motif. Trends Biochem. Sci. 22, 155-156.
Hohn,D.C. and Lehrer,R.I. (1975). NADPH oxidase deficiency in X-linked chronic
granulomatous disease. J. Clin. Invest 55, 707-713.
Hollenberg,S.M. and Evans,R.M. (1988). Multiple and cooperative trans-activation
domains of the human glucocorticoid receptor. Cell 55, 899-906.
Hollenberg,S.M., Weinberger,C., Ong,E.S., Cerelli,G., Oro,A., LeboJR.,
Thompson,E.B., Rosenfeld,M.G., and Evans,R.M. (1985). Primary structure and
expression of a functional human glucocorticoid receptor cDNA. Nature 318, 635-
641.
Hong,H., Kohli,K., Garabedian,M.J., and Stallcup,M.R. (1997). GRIP1, a
transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid,
retinoid, and vitamin D receptors. Mol. Cell Biol. 17, 2735-2744.
Houslay,M.D. and Milligan,G. (1997). Tailoring cAMP-signalling responses through
isoform multiplicity. Trends Biochem. Sci. 22, 217-224.
Hu,C.D., Kariya,K., Kotani,G., Shirouzu,M., Yokoyama,S., and Kataoka,T. (1997b).
Coassociation ofRap 1A and Ha-Ras with Raf-1 N-terminal region interferes with
ras-dependent activation ofRaf-1. J. Biol. Chem. 272, 11702-11705.
Hu,S., Vincenz,C., Ni,J., Gentz,R., and Dixit,V.M. (1997a). I-FLICE, a novel
inhibitor of tumor necrosis factor receptor-1- and CD- 95-induced apoptosis. J. Biol.
Chem. 272, 17255-17257.
Hu,Y., Benedict,M.A., Ding,L., and Nunez,G. (1999). Role of cytochrome c and
dATP/ATP hydrolysis in Apaf-1-mediated caspase- 9 activation and apoptosis.
EMBO J. 18, 3586-3595.
Hughes,J., Liu,Y., Van Damme,J., and SavilfJ. (1997). Human glomerular mesangial
cell phagocytosis of apoptotic neutrophils: mediation by a novel CD36-independent
vitronectin receptor/thrombospondin recognition mechanism that is uncoupled from
chemokine secretion. J. Immunol. 158, 4389-4397.
Hurley,J.V. (1983). Termination of inflammation. In Resolution in acute
inflammation, J.V.Hurley, ed. (London: Churchill Livingstone), p. 110.
Huston,E., Beard,M., McCallum,F., Pyne,N.J., Vandenabeele,P., Scotland,G., and
Houslay,M.D. (2000). The cAMP-specific phosphodiesterase PDE4A5 is cleaved
downstream of its SH3 interaction domain by caspase-3. Consequences for altered
intracellular distribution. J. Biol. Chem. 275, 28063-28074.
228
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Irmler,M., Thome,M., Hahne,M., Schneider,P., Hofmann,K., Steiner,V.,
Bodmer,J.L., Schroter,M., Burns,K., Mattmann,C., Rimoldi,D., French,L.E., and
Tschopp,J. (1997). Inhibition of death receptor signals by cellular FLIP. Nature 388,
190-195.
Ito,K., Barnes,P.J., and Adcock,I.M. (2000). Glucocorticoid receptor recruitment of
histone deacetylase 2 inhibits interleukin-l(3-induced histone H4 acetylation on
lysines 8 and 12. Mol. Cell Biol. 20, 6891-6903.
Ito,K., Jazwari,E., Cosio,B., Barnes,P.J., and Adcock,I.M. (2001). p65-activated
histone acetyltransferase activity is repressed by glucocorticoids: Mifepristone fails
to recruit FIDAC2 to the p65/HAT complex. J. Biol. Chem. 32, 30208-30215
Itoh,N. and Nagata,S. (1993). A novel protein domain required for apoptosis.
Mutational analysis of human Fas antigen. J. Biol. Chem. 268, 10932-10937.
Iwai,K., Miyawaki,T., Takizawa,T., Konno,A., Ohta,K., Yachie,A., Seki,H., and
Taniguchi,N. (1994). Differential expression ofbcl-2 and susceptibility to anti-Fas-
mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils.
Blood 84, 1201-1208.
Jordan,J.E., Zhao,Z.Q., and Vinten-Johansen,J. (1999). The role of neutrophils in
myocardial ischemia-reperfusion injury. Cardiovasc. Res. 43, 860-878.
Jung,E.Y., Ohshima,Y., Shintaku,N., Sumimoto,S., Heike,T., Katamura,K., and
Mayumi,M. (1994). Effects of cyclic AMP on expression of LFA-1, Mac-1, and
VLA-4 and eosinophilic differentiation of a human leukemia cell line, EoL-1. Eur. J.
Haematol. 53, 156-162.
Jurgensmeier,J.M., Xie,Z., Deveraux,Q., Ellerby,L., Bredesen,D., and Reed,J.C.
(1998). Bax directly induces release of cytochrome c from isolated mitochondria.
Proc. Natl. Acad. Sci. U. S. A 95, 4997-5002.
Kadin,M., ButmarcJ., Elovic,A., and Wong,D. (1993). Eosinophils are the major
source of transforming growth factor-(3 1 in nodular sclerosing Hodgkin's disease.
Am. J. Pathol. 142, 11-16.
Kamei,Y., Xu,L., Heinzel,T., Torchia,J., Kurokawa,R., Gloss,B., Lin,S.C.,
Heyman,R.A., Rose,D.W., Glass,C.K., and Rosenfeld,M.G. (1996). A CBP
integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear
receptors. Cell 85, 403-414.
Kameyoshi,Y., Dorschner,A., Mallet,A.I., Christophers,E., and Schroder,J.M.
(1992). Cytokine RANTES released by thrombin-stimulated platelets is a potent
attractant for human eosinophils. J. Exp. Med. 176, 587-592.
229
REGULATION Of GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Karin,M., Yang-Yen,H.F., Chambard,J.C., Deng,T., and Saatcioglu,F. (1993).
Various modes of gene regulation by nuclear receptors for steroid and thyroid
hormones. Eur. J. Clin. Pharmacol. 45 Suppl 1, S9-15.
Kato,T., Takeda,Y., Nakada,T., and Sendo,F. (1995). Inhibition by dexamethasone of
human neutrophil apoptosis in vitro. Nat. Immun. 14, 198-208.
Kawabori,S., Soda,K., Perdue,M.H., and Bienenstock,J. (1991). The dynamics of
intestinal eosinophil depletion in rats treated with dexamethasone. Lab Invest 64,
224-233.
Kawasaki,H., Springett,G.M., Mochizuki,N., Toki,S., Nakaya,M., Matsuda,M.,
Housman,D.E., and Graybiel,A.M. (1998). A family of cAMP-binding proteins that
directly activate Rapl. Science 282, 2275-2279.
Kay,A.B. (1991a). Eosinophils and asthma. N. Engl. J. Med. 324, 1514-1515.
Kay,A.B. (1991b). T lymphocytes and their products in atopic allergy and asthma.
Int. Arch. Allergy Appl. Immunol. 94, 189-193.
Kelekar,A. and Thompson,C.B. (1998). Bcl-2-family proteins: the role of the BH3
domain in apoptosis. Trends Cell Biol. 8, 324-330.
Kelso,A. and Munck,A. (1984). Glucocorticoid inhibition of lymphokine secretion
by alloreactive T lymphocyte clones. J. Immunol. 133, 784-791.
Kerner,B., Teichmann,B., and Welte,K. (1992). Dexamethasone inhibits tumor
necrosis factor-induced granulocyte colony- stimulating factor production in human
endothelial cells. Exp. Hematol. 20, 334-338.
Kettritz,R., Gaido,M.L., Haller,H., Luft,F.C., Jennette,C.J., and Falk,R.J. (1998).
Interleukin-8 delays spontaneous and tumor necrosis factor-a- mediated apoptosis of
human neutrophils. Kidney Int. 53, 84-91.
Khwaja,A. and Tatton,L. (1999). Caspase-mediated proteolysis and activation of
protein kinase C5 plays a central role in neutrophil apoptosis. Blood 94, 291-301.
Kips,J.C., Brusselle,G.J., Joos,G.F., Peleman,R.A., Tavernier,J.H., Devos,R.R., and
Pauwels,R.A. (1996). Interleukin-12 inhibits antigen-induced airway
hyperresponsiveness in mice. Am. J. Respir. Crit Care Med. 153, 535-539.
Kita,H., Abu-Ghazaleh,R., Sanderson,C.J., and Gleich,G.J. (1991c). Effect of
steroids on immunoglobulin-induced eosinophil degranulation. J. Allergy Clin.
Immunol. 87, 70-77.
Kita,H., Abu-Ghazaleh,R.I., Gleich,G.J., and Abraham,R.T. (1991b). Regulation of
Ig-induced eosinophil degranulation by adenosine 3',5'- cyclic monophosphate. J.
Immunol. 146, 2712-2718.
230
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Kita,H., Abu-Ghazaleh,R.I., Sur,S., and Gleich,G.J. (1995). Eosinophil major basic
protein induces degranulation and IL-8 production by human eosinophils. J.
Immunol. 154, 4749-4758.
Kita,H., Ohnishi,T., Okubo,Y., Weiler,D., Abrams,J.S., and Gleich,G.J. (1991a).
Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from
human peripheral blood eosinophils and neutrophils. J. Exp. Med. 174, 745-748.
Kitayama,H., Sugimoto,Y., Matsuzaki,T., Ikawa,Y., and Noda,M. (1989). A ras-
related gene with transformation suppressor activity. Cell 56, 77-84.
KlebanoffiS.J. (1975). Antimicrobial mechanisms in neutrophilic polymorphonuclear
leukocytes. Semin. Hematol. 12, 117-142.
Klebanoff,S.J. (1999). Myeloperoxidase. Proc. Assoc. Am. Physicians 111, 383-389.
Klein,J.B., Rane,M.J., Scherzer,J.A., Coxon,P.Y., Kettritz,R., Mathiesen,J.M.,
Buridi,A., and McLeish,K.R. (2000). Granulocyte-macrophage colony-stimulating
factor delays neutrophil constitutive apoptosis through phosphoinositide 3-kinase and
extracellular signal-regulated kinase pathways. J. Immunol. 164, 4286-4291.
Kluck,R.M., Martin,S.J., Hoffman,B.M., Zhou,J.S., Green,D.R., and Newmeyer,D.D.
(1997). Cytochrome c activation ofCPP32-like proteolysis plays a critical role in a
Xenopus cell-free apoptosis system. EMBO J. 16, 4639-4649.
Kodama,T., Matsuyama,T., Miyata,S., Nishimura,H., Nishioka,Y., Kitada,0., and
Sugita,M. (1998). Kinetics of apoptosis in the lung ofmice with allergic airway
inflammation. Clin. Exp. Allergy 25, 1435-1443.
Komiyama,T., Ray,C.A., Pickup,D.J., Howard,A.D., Thornberry,N.A., Peterson,E.P.,
and Salvesen,G. (1994). Inhibition of interleukin-1 [1 converting enzyme by the
cowpox virus serpin CrmA. An example of cross-class inhibition. J. Biol. Chem.
269, 19331-19337.
Kothakota,S., Azuma,T., Reinhard,C., Klippel,A., Tang,J., Chu,K., McGarry,T.J.,
Kirschner,M.W., Koths,K., Kwiatkowski,D.J., and Williams,L.T. (1997). Caspase-3-
generated fragment of gelsolin: effector ofmorphological change in apoptosis.
Science 275, 294-298.
Kroegel,C., Costabel,U., and Matthys,H. (1987). Mechanism ofmembrane damage
mediated by eosinophil major basic protein. Lancet 1, 1380-1381.
Kroemer,G., Zamzami,N., and Susin,S.A. (1997). Mitochondrial control of
apoptosis. Immunol. Today 18, 44-51.
Kuwana,T., Smith,J.J., Muzio,M., Dixit,V., Newmeyer,D.D., and Kornbluth,S.
(1998). Apoptosis induction by caspase-8 is amplified through the mitochondrial
release of cytochrome c. J. Biol. Chem. 273, 16589-16594.
231
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Kwon,O.J., Au,B.T., Collins,P.D., Baraniuk,J.N., Adcock,I.M., Chung,K.F., and
Barnes,P.J. (1994). Inhibition of interleukin-8 expression by dexamethasone in
human cultured airway epithelial cells. Immunology 81, 389-394.
Kwon,O.J., Jose,P.J., Robbins,R.A., Schall,T.J., Williams,T.J., and Barnes,P.J.
(1995). Glucocorticoid inhibition ofRANTES expression in human lung epithelial
cells. Am. J. Respir. Cell Mol. Biol. 12, 488-496.
Lacour,M., Arrighi,J.F., Muller,K.M., Carlberg,C., Saurat,J.H., and Hauser,C.
(1994). cAMP up-regulates IL-4 and IL-5 production from activated CD4+ T cells
while decreasing IL-2 release and NF-AT induction. Int. Immunol. 6, 1333-1343.
Lad,P.M., Goldberg,B.J., Smiley,P.A., and Olson,C.V. (1985). Receptor-specific
threshold effects of cyclic AMP are involved in the regulation of enzyme release and
superoxide production from human neutrophils. Biochim. Biophys. Acta 846, 286-
295.
Lamas,A.M., Leon,O.G., and Schleimer,R.P. (1991). Glucocorticoids inhibit
eosinophil responses to granulocyte-macrophage colony-stimulating factor. J.
Immunol. 147, 254-259.
Lanotte,M., Riviere,J.B., Hermouet,S., Houge,G., Vintermyr,O.K., Gjertsen,B.T.,
and Doskeland,S.O. (1991). Programmed cell death (apoptosis) is induced rapidly
and with positive cooperativity by activation of cyclic adenosine monophosphate-
kinase I in a myeloid leukemia cell line. J. Cell Physiol 146, 73-80.
Lawrence,M.B. and Springer,T.A. (1991). Leukocytes roll on a selectin at
physiologic flow rates: distinction from and prerequisite for adhesion through
integrins. Cell 65, 859-873.
Lawrence,M.B. and Springer,T.A. (1993). Neutrophils roll on E-selectin. J.
Immunol. 151, 6338-6346.
Lazebnik,Y.A., Kaufmann,S.H., Desnoyers,S., Poirier,G.G., and Earnshaw,W.C.
(1994). Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties
like ICE. Nature 371, 346-347.
Lazebnik,Y.A., Takahashi,A., Moir,R.D., Goldman,R.D., Poirier,G.G.,
Kaufmann,S.H., and Earnshaw,W.C. (1995). Studies of the lamin proteinase reveal
multiple parallel biochemical pathways during apoptotic execution. Proc. Natl. Acad.
Sci. U. S. A 92, 9042-9046.
Leckie,M.J., ten Brinke,A., Khan,J., Diamant,Z., O'Connor,B.J., Walls,C.M.,
Mathur,A.K., Cowley,H.C., Chung,K.F., Djukanovic,R., Hansel,T.T., Holgate,S.T.,
Sterk,P.J., and Barnes,P.J. (2000). Effects of an interleukin-5 blocking monoclonal
antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic
response. Lancet 356, 2144-2148.
232
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Lee,A., Whyte,M.K., and Haslett,C. (1993). Inhibition of apoptosis and prolongation
of neutrophil functional longevity by inflammatory mediators. J. Leukoc. Biol. 54,
283-288.
Lee,T., Lenihan,D.J., Malone,B., Roddy,L.L., and Wasserman,S.I. (1984). Increased
biosynthesis of platelet-activating factor in activated human eosinophils. J. Biol.
Chem. 259, 5526-5530.
Leonard,E.J., Skeel,A., Yoshimura,T., Noer,K., Kutvirt,S., and Van Epps,D. (1990).
Leukocyte specificity and binding of human neutrophil attractant/activation protein-
1. J. Immunol. 144, 1323-1330.
Lerner,E.C., Qian,Y., Hamilton,A.D., and Sebti,S.M. (1995). Disruption of
oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I
inhibitor. J. Biol. Chem. 270, 26770-26773.
Leuenroth,S., Lee,C., Grutkoski,P., Keeping,H., and Simms,H.H. (1998).
Interleukin-8-induced suppression of polymorphonuclear leukocyte apoptosis is
mediated by suppressing CD95 (Fas/Apo-1) Fas-1 interactions. Surgery 124, 409-
417.
Leuenroth,S.J., Grutkoski,P.S., Ayala,A., and Simms,H.H. (2000). Suppression of
PMN apoptosis by hypoxia is dependent on Mcl-1 and MAPK activity. Surgery 128,
171-177.
Levine,P.H., Hardin,J.C., Scoon,K.L., and Krinsky,N.I. (1981). Effect of
corticosteroids on the production of superoxide and hydrogen peroxide and the
appearance of chemiluminescence by phagocytosing polymorphonuclear leukocytes.
Inflammation 5, 19-27.
Levine,S.J., Benfield,T., and ShelhamerJ.H. (1996). Corticosteroids induce
intracellular interleukin-1 receptor antagonist type I expression by a human airway
epithelial cell line. Am. J. Respir. Cell Mol. Biol. 15, 245-251.
Levinson,B.B., Baxter,J.D., Rousseau,G.G., and Tomkins,G.M. (1972). Cellular site
of glucocorticoid-receptor complex formation. Science 175, 189-190.
Ley,K. (1992). Leukocyte adhesion to vascular endothelium. J. Reconstr. Microsurg.
8, 495-503.
Li,B. and Dou,Q.P. (2000). Bax degradation by the ubiquitin/proteasome-dependent
pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. U. S.
A 97, 3850-3855.
Li,H., Zhu,H., Xu,C.J., and Yuan,J. (1998). Cleavage ofBID by caspase 8 mediates
the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501.
Li,J., Yang,S., and Billiar,T.R. (2000b). Cyclic nucleotides suppress tumor necrosis
factor alpha-mediated apoptosis by inhibiting caspase activation and cytochrome c
233
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
release in primary hepatocytes via a mechanism independent ofAkt activation. J.
Biol. Chem. 275, 13026-13034.
Li,M., Wang,X., Meintzer,M.K., Laessig,T., Birnbaum,M.J., and Heidenreich,K.A.
(2000a). Cyclic AMP promotes neuronal survival by phosphorylation of glycogen
synthase kinase 3beta. Mol. Cell Biol. 20, 9356-9363.
Li,P., Nijhawan,D., Budihardjo,I., Srinivasula,S.M., Ahmad,M., Alnemri,E.S., and
Wang,X. (1997). Cytochrome c and dATP-dependent formation ofApaf-l/caspase-9
complex initiates an apoptotic protease cascade. Cell 91, 479-489.
Liles,W.C., Dale,D.C., and Klebanoff,S.J. (1995). Glucocorticoids inhibit apoptosis
of human neutrophils. Blood 86, 3181-3188.
Liles,W.C., Kiener,P.A., Ledbetter,J.A., Aruffo,A., and Klebanoff,S.J. (1996).
Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes:
implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184, 429-
440.
Lilly,C.M., Nakamura,H., Kesselman,H., Nagler-Anderson,C., Asano,K., Garcia-
Zepeda,E.A., Rothenberg,M.E., Drazen,J.M., and Luster,A.D. (1997). Expression of
eotaxin by human lung epithelial cells: induction by cytokines and inhibition by
glucocorticoids. J. Clin. Invest 99, 1767-1773.
Lim,K.G., Wan,H.C., Resnick,M., Wong,D.T., Cruikshank,W.W., Komfeld,H.,
Center,D.M., and Weller,P.F. (1995). Human eosinophils release the lymphocyte and
eosinophil active cytokines, RANTES and lymphocyte chemoattractant factor. Int.
Arch. Allergy Immunol. 107, 342.
Lindemann,A., Riedel,D., Oster,W., Meuer,S.C., Blohm,D., Mertelsmann,R.H., and
Herrmann,F. (1988). Granulocyte/macrophage colony-stimulating factor induces
interleukin 1 production by human polymorphonuclear neutrophils. J. Immunol. 140,
837-839.
Linden,M. and Brattsand,R. (1994). Effects of a corticosteroid, budesonide, on
alveolar macrophage and blood monocyte secretion of cytokines: differential
sensitivity ofGM- CSF, IL-lp, and IL-6. Pulm. Pharmacol. 7, 43-47.
Liu,J. and DeFranco,D.B. (1999). Chromatin recycling of glucocorticoid receptors:
implications for multiple roles of heat shock protein 90. Mol. Endocrinol. 13, 355-
365.
Liu,Y., Cousin,J.M., Hughes,J., Van Damme,J., Seckl,J.R., Haslett,C., Dransfield,I.,
Savill,J., and Rossi,A.G. (1999). Glucocorticoids promote nonphlogistic
phagocytosis of apoptotic leukocytes. J. Immunol. 162, 3639-3646.
234
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Liu,Z.G., Hsu,H., Goeddel,D.V., and Karin,M. (1996). Dissection ofTNF receptor 1
effector functions: JNK activation is not linked to apoptosis while NFkB activation
prevents cell death. Cell 87, 565-576.
Lorenz,J.J., Furdon,P.J., Taylor,J.D., Verghese,M.W., Chandra,G., Kost,T.A.,
Haneline,S.A., Roner,L.A., and Gray,J.G. (1995). A cyclic adenosine 3',5'-
monophosphate signal is required for the induction of IL-1 beta by TNF-a in human
monocytes. J. Immunol. 155, 836-844.
Luciani,M.F. and Chimini,G. (1996). The ATP binding cassette transporter ABC1, is
required for the engulfment of corpses generated by apoptotic cell death. EMBO J.
15, 226-235.
Luisi,B.F., Xu,W.X., Otwinowski,Z., Freedman,L.P., Yamamoto,K.R., and
Sigler,P.B. (1991). Crystallographic analysis of the interaction of the glucocorticoid
receptor with DNA. Nature 352, 497-505.
Luo,X., Budihardjo,I., Zou,FL, Slaughter,C., and Wang,X. (1998). Bid, a Bcl2
interacting protein, mediates cytochrome c release from mitochondria in response to
activation of cell surface death receptors. Cell 94, 481-490.
M'Rabet,L., Coffer,P., Zwartkruis,F., Franke,B., Segal,A.W., Koenderman,L., and
Bos,J.L. (1998). Activation of the small GTPase rapl in human neutrophils. Blood
92,2133-2140.
Mancini,M., Nicholson,D.W., Roy,S., Thornberry,N.A., Peterson,E.P., Casciola-
Rosen,L.A., and Rosen,A. (1998). The caspase-3 precursor has a cytosolic and
mitochondrial distribution: implications for apoptotic signaling. J. Cell Biol. 140,
1485-1495.
Marambaud,P., Wilk,S., and Checler,F. (1996). Protein kinase A phosphorylation of
the proteasome: a contribution to the alpha-secretase pathway in human cells. J.
Neurochem. 67, 2616-2619.
Marshansky,V., Wang,X., Bertrand,R., Luo,H., Duguid,W., Chinnadurai,G.,
Kanaan,N., Vu,M.D., and Wu,J. (2001). Proteasomes modulate balance among
proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning
of the electron transport chain in leukemic cells. J. Immunol. 166, 3130-3142.
Marsters,S.A., Sheridan,J.P., Pitti,R.M., Huang,A., Skubatch,M., Baldwin,D.,
Yuan,J., Gurney,A., Goddard,A.D., Godowski,P., and Ashkenazi,A. (1997). A novel
receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7, 1003-
1006.
Martin,L.B., Kita,H., Leiferman,K.M., and Gleich,G.J. (1996). Eosinophils in
allergy: role in disease, degranulation, and cytokines. Int. Arch. Allergy Immunol.
109, 207-215.
235
regulation of granulocyte apoptosis by glucocorticoids and cyclic amp
Martin,S.J. and Green,D.R. (1995). Protease activation during apoptosis: death by a
thousand cuts? Cell 82, 349-352.
Martinet,N., Vaillant,P., Charles,T., Lambert,J., and Martinet,Y. (1992).
Dexamethasone modulation of tumour necrosis factor-alpha (cachectin) release by
activated normal human alveolar macrophages. Eur. Respir. J. 5, 67-72.
Marzo,I., Brenner,C., Zamzami,N., Susin,S.A., Beutner,G., Brdiczka,D., Remy,R.,
Xie,Z.H., Reed,J.C., and Kroemer,G. (1998). The permeability transition pore
complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J.
Exp. Med. 187, 1261-1271.
Mayer,M.P. and Bukau,B. (1999). Molecular chaperones: the busy life ofHsp90.
Curr. Biol. 9, R322-R325.
McColl,S.R., Krump,E., Naccache,P.H., Poubelle,P.E., Braquet,P., Braquet,M., and
Borgeat,P. (1991). Granulocyte-macrophage colony-stimulating factor increases the
synthesis of leukotriene B4 by human neutrophils in response to platelet-activating
factor. Enhancement of both arachidonic acid availability and 5-lipoxygenase
activation. J. Immunol. 146, 1204-1211.
McConkey,D.J., Orrenius,S., and JondafM. (1990). Agents that elevate cAMP
stimulate DNA fragmentation in thymocytes. J. Immunol. 145, 1227-1230.
McDonald,P.P., Bald,A., and Cassatella,M.A. (1997). Activation of the NFkB
pathway by inflammatory stimuli in human neutrophils. Blood 89, 3421-3433.
McEwan,I.J., Almlof,T., Wikstrom,A.C., Dahlman-Wright,K., Wright,A.P., and
Gustafsson,J.A. (1994). The glucocorticoid receptor functions at multiple steps
during transcription initiation by RNA polymerase II. J. Biol. Chem. 269, 25629-
25636.
McEwan,I.J., Dahlman-Wright,K., Amlof,T., Ford,J., Wright,A.P., and
Gustafsson,J.A. (1995). Mechanisms of transcription activation by nuclear receptors:
studies on the human glucocorticoid receptor tau 1 transactivation domain. Mutat.
Res. 333, 15-22.
McGuire,W.W., Spragg,R.G., Cohen,A.B., and Cochrane,C.G. (1982). Studies on the
pathogenesis of the adult respiratory distress syndrome. J. Clin. Invest 69, 543-553.
Meagher,L.C., Cousin,J.M., Seckl,J.R., and Haslett,C. (1996). Opposing effects of
glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic
granulocytes. J. Immunol. 156, 4422-4428.
Meagher,L.C., Savill,J.S., Baker,A., Fuller,R.W., and Haslett,C. (1992).
Phagocytosis of apoptotic neutrophils does not induce macrophage release of
thromboxane B2. J. Leukoc. Biol. 52, 269-273.
236
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Mecklenburgh, K. Modulation of human neutrophil apoptosis by hypoxia. 1999.
University of Edinburgh.
RefType: Thesis/Dissertation
Melani,C., Mattia,G.F., Silvani,A., Care,A., Rivoltini,L., Parmiani,G., and
Colombo,M.P. (1993). Interleukin-6 expression in human neutrophil and eosinophil
peripheral blood granulocytes. Blood 81, 2744-2749.
Meng,L., Mohan,R., Kwok,B.H., Elofsson,M., Sin,N., and Crews,C.M. (1999).
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo
antiinflammatory activity. Proc. Natl. Acad. Sci. U. S. A 96, 10403-10408.
Metcalf,D., Begley,C.G., Johnson,G.R., Nicola,N.A., Vadas,M.A., Lopez,A.F.,
Williamson,D.J., Wong,G.G., Clark,S.C., and Wang,E.A. (1986). Biologic properties
in vitro of a recombinant human granulocyte- macrophage colony-stimulating factor.
Blood 67, 37-45.
Metcalf,D. and Nicola,N.A. (1983). Proliferative effects ofpurified granulocyte
colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells. J. Cell
Physiol 116, 198-206.
Minn,A.J., Velez,P., Schendel,S.L., Liang,H., Muchmore,S.W., Fesik,S.W., Fill,M.,
and Thompson,C.B. (1997). Bcl-x(L) forms an ion channel in synthetic lipid
membranes. Nature 385, 353-357.
Mittal,R., Kumar,K.U., Pater,A., and Pater,M.M. (1994). Differential regulation by
c-jun and c-fos protooncogenes of hormone response from composite glucocorticoid
response element in human papilloma vims type 16 regulatory region. Mol.
Endocrinol. 8, 1701-1708.
Miura,M., Zhu,H., Rotello,R., Hartwieg,E.A., and Yuan,J. (1993). Induction of
apoptosis in fibroblasts by IL-1 (3-converting enzyme, a mammalian homolog of the
C. elegans cell death gene ced-3. Cell 75, 653-660.
Mizuguchi,G., Vassilev,A., Tsukiyama,T., Nakatani,Y., and Wu,C. (2001). ATP-
dependent nucleosome remodeling and histone hyperacetylation synergistically
facilitate transcription of chromatin. J. Biol. Chem. 276, 14773-14783.
Moguilewsky,M. and Philibert,D. (1984). RU 38486: potent antiglucocorticoid
activity correlated with strong binding to the cytosolic glucocorticoid receptor
followed by an impaired activation. J. Steroid Biochem. 20, 271-276.
Moqbel,R., Ying,S., Barkans,J., Newman,T.M., Kimmitt,P., Wakelin,M., Taborda-
Barata,L., Meng,Q., Corrigan,C.J., Durham,S.R., and . (1995). Identification of
messenger RNA for IL-4 in human eosinophils with granule localization and release
of the translated product. J. Immunol. 155, 4939-4947.
Morishima,Y., Kanelakis,K.C., Silverstein,A.M., Dittmar,K.D., Estrada,L., and
Pratt,W.B. (2000a). The Hsp organizer protein hop enhances the rate of but is not
237
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
essential for glucocorticoid receptor folding by the multiprotein Hsp90-based
chaperone system. J. Biol. Chem. 275, 6894-6900.
Morishima,Y., Murphy,P.J., Li,D.P., Sanchez,E.R., and Pratt,W.B. (2000b).
Stepwise assembly of a glucocorticoid receptor.hsp90 heterocomplex resolves two
sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of
the steroid binding pocket. J. Biol. Chem. 275, 18054-18060.
Moulding,D.A., Akgul,C., Derouet,M., White,M.R., and Edwards,S.W. (2001).
BCL-2 family expression in human neutrophils during delayed and accelerated
apoptosis. J. Leukoc. Biol. 70, 783-792.
Moulding,D.A., Quayle,J.A., Hart,C.A., and Edwards,S.W. (1998). Mcl-1 expression
in human neutrophils: regulation by cytokines and correlation with cell survival.
Blood 92, 2495-2502.
Muchmore,S.W., Sattler,M., Liang,H., Meadows,R.P., Harlan,J.E., Yoon,H.S.,
Nettesheim,D., Chang,B.S., Thompson,C.B., Wong,S.L., Ng,S.L., and Fesik,S.W.
(1996). X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell
death. Nature 381, 335-341.
Mukaida,N., Morita,M., Ishikawa,Y., Rice,N., Okamoto,S., Kasahara,T., and
Matsushima,K. (1994b). Novel mechanism of glucocorticoid-mediated gene
repression. NFkB is target for glucocorticoid-mediated interleukin 8 gene repression.
J. Biol. Chem. 269, 13289-13295.
Mukaida,N., Okamoto,S., Ishikawa,Y., and Matsushima,K. (1994a). Molecular
mechanism of interleukin-8 gene expression. J. Leukoc. Biol. 56, 554-558.
Muller,M., Baniahmad,C., Kaltschmidt,C., and Renkawitz,R. (1991). Multiple
domains of the glucocorticoid receptor involved in synergism with the CACCC box
factor(s). Mol. Endocrinol. 5, 1498-1503.
Muller,W.A., Weigl,S.A., Deng,X., and Phillips,D.M. (1993). PECAM-1 is required
for transendothelial migration of leukocytes. J. Exp. Med. 178, 449-460.
Murphy,G., Bretz,U., Baggiolini,M., and Reynolds,J.J. (1980). The latent
collagenase and gelatinase of human polymorphonuclear neutrophil leucocytes.
Biochem. J. 192, 517-525.
Murray,J., Barbara,J.A., Dunkley,S.A., Lopez,A.F., Van,0., X, Condliffe,A.M.,
Dransfield,I., Haslett,C., and Chilvers,E.R. (1997). Regulation of neutrophil
apoptosis by tumor necrosis factor-alpha: requirement for TNFR55 and TNFR75 for
induction of apoptosis in vitro. Blood 90, 2772-2783.
Muzio,M„ Chinnaiyan,A.M., Kischkel,F.C., 0'Rourke,K., Shevchenko,A., Ni,J.,
Scaffidi,C., Bretz,J.D., Zhang,M., Gentz,R., Mann,M., Krammer,P.H., Peter,M.E.,
and Dixit,V.M. (1996). FLICE, a novel FADD-homologous ICE/CED-3-like
238
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
protease, is recruited to the CD95 (Fas/APO-1) death—inducing signaling complex.
Cell 85, 817-827.
Muzio,M., Stockwell,B.R., Stennicke,H.R., Salvesen,G.S., and Dixit,V.M. (1998).
An induced proximity model for caspase-8 activation. J. Biol. Chem. 273, 2926-
2930.
Narita,M., Shimizu,S., Ito,T., Chittenden,T., Lutz,R.J., Matsuda,H., and
Tsujimoto,Y. (1998). Bax interacts with the permeability transition pore to induce
permeability transition and cytochrome c release in isolated mitochondria. Proc. Natl.
Acad. Sci. U. S. A 95, 14681-14686.
Natoli,G., Costanzo,A., Ianni,A., Templeton,D.J., Woodgett,J.R., Balsano,C., and
Levrero,M. (1997). Activation of SAPK/JNK by TNF receptor 1 through a
noncytotoxic TRAF2- dependent pathway. Science 275, 200-203.
Neamati,N., Fernandez,A., Wright,S., Kiefer,J., and McConkey,D.J. (1995).
Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in
apoptotic thymocytes and isolated thymocyte nuclei. J. Immunol. 154, 3788-3795.
Nedachi,T., Akahori,M., Ariga,M., Sakamoto,H., Suzuki,N., Umesaki,K., Hakuno,F.,
and Takahashi,S.I. (2000). Tyrosine kinase and phosphatidylinositol 3-kinase
activation are required for cyclic adenosine 3',5'-monophosphate-dependent
potentiation of deoxyribonucleic acid synthesis induced by insulin-like growth
factor-I in FRTL-5 cells. Endocrinology 141, 2429-2438.
Newmeyer,D.D., Farschon,D.M., and Reed,J.C. (1994). Cell-free apoptosis in
Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction
enriched in mitochondria. Cell 79, 353-364.
Nicholson,C.D. and Shahid,M. (1994). Inhibitors of cyclic nucleotide
phosphodiesterase isoenzymes—their potential utility in the therapy of asthma. Pulm.
Pharmacol. 7, 1-17.
Nicholson,D.W. (1999). Caspase structure, proteolytic substrates, and function
during apoptotic cell death. Cell Death. Differ. 6, 1028-1042.
Niwa,M., Hara,A., Kanamori,Y., Matsuno,H., Kozawa,0., Yoshimi,N., Mori,H., and
Uematsu,T. (1999). Inhibition of tumor necrosis factor-alpha induced neutrophil
apoptosis by cyclic AMP: involvement of caspase cascade. Eur. J. Pharmacol. 371,
59-67.
Nolan,B., Duffy,A., Paquin,L., De,M., Collette,H., Graziano,C.M., and Bankey,P.
(1999). Mitogen-activated protein kinases signal inhibition of apoptosis in
lipopolysaccharide-stimulated neutrophils. Surgery 126, 406-412.
Nonaka,M., Nonaka,R., Woolley,K., Adelroth,E., Miura,K., Okhawara,Y.,
Glibetic,M., Nakano,K., 0'Byrne,P., Dolovich,J., and . (1995). Distinct
immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is
239
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
localized to eosinophils in vivo and is released by peripheral blood eosinophils. J.
Immunol. 155, 3234-3244.
Nourshargh,S. and Hoult,J.R. (1986). Inhibition of human neutrophil degranulation
by forskolin in the presence of phosphodiesterase inhibitors. Eur. J. Pharmacol. 122,
205-212.
Oakley,R.H., Jewell,C.M., Yudt,M.R., Bofetiado,D.M., and Cidlowski,J.A. (1999).
The dominant negative activity of the human glucocorticoid receptor beta isoform.
Specificity and mechanisms of action. J. Biol. Chem. 274, 27857-27866.
Oakley,R.H., Sar,M., and Cidlowski,J.A. (1996). The human glucocorticoid receptor
beta isoform. Expression, biochemical properties, and putative function. J. Biol.
Chem. 271, 9550-9559.
Ofek,I., Goldhar,J., Keisari,Y., and Sharon,N. (1995). Nonopsonic phagocytosis of
microorganisms. Annu. Rev. Microbiol. 49, 239-276.
Ogryzko,V.V., Schiltz,R.L., Russanova,V., Howard,B.H., and Nakatani,Y. (1996).
The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell
87, 953-959.
Ohno,I., Lea,R.G., Flanders,K.C., Clark,D.A., Banwatt,D., Dolovich,J., Denburg,J.,
Harley,C.B., Gauldie,J., and Jordana,M. (1992). Eosinophils in chronically inflamed
human upper airway tissues express transforming growth factor beta 1 gene (TGF
beta 1). J. Clin. Invest 89, 1662-1668.
Ohta,K., Yamashita,N., Tajima,M., Miyasaka,T., Kawashima,R., Nakano,J.,
Arioka,H., Ishii,A., Horiuchi,T., and Miyamoto,T. (2001). In vivo effects of
apoptosis in asthma examined by a murine model. Int. Arch. Allergy Immunol. 124,
259-261.
OlssonJ.L. and Breitman,T.R. (1982). Induction of differentiation of the human
histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3': 5'-
monophosphate- inducing agents. Cancer Res. 42, 3924-3927.
01tvai,Z.N., Milliman,C.L., and Korsmeyer,S.J. (1993). Bcl-2 heterodimerizes in
vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell
74, 609-619.
Orlowski,R.Z. (1999). The role of the ubiquitin-proteasome pathway in apoptosis.
Cell Death. Differ. 6, 303-313.
Orth,K., Chinnaiyan,A.M., Garg,M., Froelich,C.J., and Dixit,V.M. (1996). The CED-
3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death
substrate lamin A. J. Biol. Chem. 271, 16443-16446.
240
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Ottonello,L., Gonella,R., Dapino,P., Sacchetti,C., and Dallegri,F. (1998).
Prostaglandin E2 inhibits apoptosis in human neutrophilic polymorphonuclear
leukocytes: role of intracellular cyclic AMP levels. Exp. Hematol. 26, 895-902.
Pan,G., Ni,J., Wei,Y.F., Yu,G., Gentz,R., and Dixit,V.M. (1997). An antagonist
decoy receptor and a death domain-containing receptor for TRAIL. Science 277,
815-818.
Pandey,P., Saleh,A., Nakazawa,A., Kumar,S., Srinivasula,S.M., Kumar,V.,
Weichselbaum,R., Nalin,C., Alnemri,E.S., Kufe,D., and Kharbanda,S. (2000).
Negative regulation of cytochrome c-mediated oligomerization ofApaf-1 and
activation ofprocaspase-9 by heat shock protein 90. EMBO J. 19, 4310-4322.
Parvathenani,L.K., Buescher,E.S., Chacon-Cruz,E., and Beebe,S.J. (1998). Type I
cAMP-dependent protein kinase delays apoptosis in human neutrophils at a site
upstream of caspase-3. J. Biol. Chem. 273, 6736-6743.
Peachman,K.K., Lyles,D.S., and Bass,D.A. (2001). Mitochondria in eosinophils:
functional role in apoptosis but not respiration. Proc. Natl. Acad. Sci. U. S. A 98,
1717-1722.
Peacock,C.D., Misso,N.L., Watkins,D.N., and Thompson,P.J. (1999). PGE2and
dibutyryl cyclic adenosine monophosphate prolong eosinophil survival in vitro. J.
Allergy Clin. Immunol. 104, 153-162.
Peter,M.E. and Krammer,P.H. (1998). Mechanisms ofCD95 (APO-l/Fas)-mediated
apoptosis. Curr. Opin. Immunol. 10, 545-551.
Peters,A.M. (1998). Just how big is the pulmonary granulocyte pool? Clin. Sci.
(Colch.) 94, 7-19.
Peters,M.S., Rodriguez,M., and Gleich,G.J. (1986). Localization of human
eosinophil granule major basic protein, eosinophil cationic protein, and eosinophil-
derived neurotoxin by immunoelectron microscopy. Lab Invest 54, 656-662.
Peterson,A.P., Altman,L.C., Hill,J.S., Gosney,K., and Kadin,M.E. (1981).
Glucocorticoid receptors in normal human eosinophils: comparison with neutrophils.
J. Allergy Clin. Immunol. 68, 212-217.
Picard,D. and Yamamoto,K.R. (1987). Two signals mediate hormone-dependent
nuclear localization of the glucocorticoid receptor. EMBO J. 6, 3333-3340.
Picker,L.J., Warnock,R.A., Burns,A.R., Doerschuk,C.M., Berg,E.L., and
Butcher,E.C. (1991). The neutrophil selectin LECAM-1 presents carbohydrate
ligands to the vascular selectins ELAM-1 and GMP-140. Cell 66, 921-933.
Pitti,R.M., Marsters,S.A., Lawrence,D.A., Roy,M., Kischkel,F.C., Dowd,P.,
Huang,A., Donahue,C.J., Sherwood,S.W., Baldwin,D.T., Godowski,P.J., Wood,W.I.,
Gurney,A.L., Hillan,K.J., Cohen,R.L., Goddard,A.D., Botstein,D., and Ashkenazi,A.
241
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
(1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon
cancer. Nature 396, 699-703.
Pizon,V., Desjardins,M., Bucci,C., Parton,R.G., and Zerial,M. (1994). Association of
Rap la and Rap lb proteins with late endocytic/phagocytic compartments and Rap2a
with the Golgi complex. J. Cell Sci. 107 (Pt 6), 1661-1670.
Piatt,N., Suzuki,H., Kurihara,Y., Kodama,T., and Gordon,S. (1996). Role for the
class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes
in vitro. Proc. Natl. Acad. Sci. U. S. A 93, 12456-12460.
Platzer,C., Meisel,C., Vogt,K., Platzer,M., and Volk,H.D. (1995). Up-regulation of
monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int.
Immunol. 7, 517-523.
Ponath,P.D., Qin,S., Ringler,D.J., Clark-Lewis,I., Wang,J., Kassam,N., Smith,H.,
Shi,X., Gonzalo,J.A., Newman,W., Gutierrez-Ramos,J.C., and Mackay,C.R. (1996).
Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor
binding, and functional properties suggest a mechanism for the selective recruitment
of eosinophils. J. Clin. Invest 97, 604-612.
Pongracz,J., Webb,P., Wang,K., Deacon,E., Lunn,O.J., and Lord,J.M. (1999).
Spontaneous neutrophil apoptosis involves caspase 3-mediated activation of protein
kinase C-delta. J. Biol. Chem. 274, 37329-37334.
PopoffM.R., Chaves-01arte,E., Lemichez,E., Eichel-Streiber,C., Thelestam,M.,
Chardin,P., Cussac,D., Antonny,B., Chavrier,P., Flatau,G., Giry,M., de Gunzburg,J.,
and Boquet,P. (1996). Ras, Rap, and Rac small GTP-binding proteins are targets for
Clostridium sordellii lethal toxin glucosylation. J. Biol. Chem. 271, 10217-10224.
Pratt,W.B. (1998). The hsp90-based chaperone system: involvement in signal
transduction from a variety of hormone and growth factor receptors. Proc. Soc. Exp.
Biol. Med. 217, 420-434.
Pratt,W.B., Sanchez,E.R., Bresnick,E.H., Meshinchi,S., Scherrer,L.C., Dalman,F.C.,
and Welsh,M.J. (1989). Interaction of the glucocorticoid receptor with the Mr 90,000
heat shock protein: an evolving model of ligand-mediated receptor transformation
and translocation. Cancer Res. 49, 2222s-2229s.
Prodromou,C., Roe,S.M., O'Brien,R., Ladbury,J.E., Piper,P.W., and Pearl,L.H.
(1997). Identification and structural characterization of the ATP/ADP-binding site in
the Hsp90 molecular chaperone. Cell 90, 65-75.
Pryde,J.G., Walker,A., Rossi,A.G., Hannah,S., and Haslett,C. (2000). Temperature-
dependent arrest of neutrophil apoptosis. Failure of Bax insertion into mitochondria
at 15 degrees C prevents the release of cytochrome c. J. Biol. Chem. 275, 33574-
33584.
242
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Qian,T., Nieminen,A.L., Herman,B., and Lemasters,J.J. (1997). Mitochondrial
permeability transition in pH-dependent reperfusion injury to rat hepatocytes. Am. J.
Physiol 273, C1783-C1792.
Quilliam,L.A., Mueller,H., Bohl,B.P., Prossnitz,V., Sklar,L.A., Der,C.J., and
Bokoch,G.M. (1991). RaplA is a substrate for cyclic AMP-dependent protein kinase
in human neutrophils. J. Immunol. 147, 1628-1635.
Rajapandi,T., Greene,L.E., and Eisenberg,E. (2000). The molecular chaperones
Hsp90 and Hsc70 are both necessary and sufficient to activate hormone binding by
glucocorticoid receptor. J. Biol. Chem. 275, 22597-22604.
Rao,L., Perez,D., and White,E. (1996). Lamin proteolysis facilitates nuclear events
during apoptosis. J. Cell Biol. 135, 1441-1455.
Ray,A. and Prefontaine,K.E. (1994). Physical association and functional antagonism
between the p65 subunit of transcription factor NFkB and the glucocorticoid
receptor. Proc. Natl. Acad. Sci. U. S. A 91, 752-756.
Ray,C.A., Black,R.A., Kronheim,S.R., Greenstreet,T.A., Sleath,P.R., Salvesen,G.S.,
and Pickup,D.J. (1992). Viral inhibition of inflammation: cowpox virus encodes an
inhibitor of the interleukin-1 beta converting enzyme. Cell 69, 597-604.
Razani,B., Rubin,C.S., and Lisanti,M.P. (1999). Regulation of cAMP-mediated
signal transduction via interaction of caveolins with the catalytic subunit of protein
kinase A. J. Biol. Chem. 274, 26353-26360.
Reed,J.C. (1998). Bcl-2 family proteins. Oncogene 17, 3225-3236.
Reed,J.C., Zha,H., Aime-Sempe,C., Takayama,S., and Wang,H.G. (1996). Structure-
function analysis of Bcl-2 family proteins. Regulators ofprogrammed cell death.
Adv. Exp. Med. Biol. 406, 99-112.
Reers,M., Smith,T.W., and Chen,L.B. (1991). J-aggregate formation of a
carbocyanine as a quantitative fluorescent indicator ofmembrane potential.
Biochemistry 30, 4480-4486.
Reichardt,H.M., Kaestner,K.H., Tuckermann,J., Kretz,0., Wessely,0., Bock,R.,
Gass,P., Schmid,W., Herrlich,P., Angel,P., and Schutz,G. (1998). DNA binding of
the glucocorticoid receptor is not essential for survival. Cell 93, 531-541.
Reinhard,C., Shamoon,B., Shyamala,V., and Williams,L.T. (1997). Tumor necrosis
factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2.
EMBO J. 16, 1080-1092.
Renshaw,S.A., Timmons,S.J., Eaton,V., Usher,L.R., Akil,M., Bingle,C.D., and
Whyte,M.K. (2000). Inflammatory neutrophils retain susceptibility to apoptosis
mediated via the Fas death receptor. J. Leukoc. Biol. 67, 662-668.
243
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Resnick,M.B. and Weller,P.F. (1993). Mechanisms of eosinophil recruitment. Am. J.
Respir. Cell Mol. Biol. 8, 349-355.
Rock,K.L., Gramm,C., Rothstein,L., Clark,K., Stein,R., Dick,L., Hwang,D., and
Goldberg,A.L. (1994). Inhibitors of the proteasome block the degradation ofmost
cell proteins and the generation of peptides presented on MHC class I molecules.
Cell 78, 761-771.
Rodriguez,J. and Lazebnik,Y. (1999). Caspase-9 and APAF-1 form an active
holoenzyme. Genes Dev. 13, 3179-3184.
Roe,S.M., Prodromou,C., O'Brien,R., Ladbury,J.E., Piper,P.W., and Pearl,L.H.
(1999). Structural basis for inhibition of the Hsp90 molecular chaperone by the
antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42, 260-266.
Rossi,A.G., Cousin,J.M., Dransfield,I., Lawson,M.F., Chilvers,E.R., and Haslett,C.
(1995). Agents that elevate cAMP inhibit human neutrophil apoptosis. Biochem.
Biophys. Res. Commun. 217, 892-899.
Rossi,A.G., McCutcheon,J.C., Roy,N., Chilvers,E.R., Haslett,C., and Dransfield,I.
(1998). Regulation ofmacrophage phagocytosis of apoptotic cells by cAMP. J.
Immunol. 160, 3562-3568.
Rot,A., Krieger,M., Brunner,T., Bischoff,S.C., Schall,T.J., and Dahinden,C.A.
(1992). RANTES and macrophage inflammatory protein 1 alpha induce the
migration and activation ofnormal human eosinophil granulocytes. J. Exp. Med.
176, 1489-1495.
Rubin,C.S. (1994). A kinase anchor proteins and the intracellular targeting of signals
carried by cyclic AMP. Biochim. Biophys. Acta 1224, 467-479.
Sakai,D.D., Helms,S., Carlstedt-Duke,J., Gustafsson,J.A., Rottman,F.M., and
Yamamoto,K.R. (1988). Hormone-mediated repression: a negative glucocorticoid
response element from the bovine prolactin gene. Genes Dev. 2, 1144-1154.
Sallenave,J.M., Si-Ta,h.M., Cox,G., Chignard,M., and Gauldie,J. (1997). Secretory
leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human
neutrophils. J. Leukoc. Biol. 61, 695-702.
Salvesen,G.S. and Dixit,V.M. (1999). Caspase activation: the induced-proximity
model. Proc. Natl. Acad. Sci. U. S. A 96, 10964-10967.
Sassone-Corsi,P. (1995). Transcription factors responsive to cAMP. Annu. Rev. Cell
Dev. Biol. 11, 355-377.
Satriano,J. and Schlondorff,D. (1994). Activation and attenuation of transcription
factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis
factor-alpha, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate.
Evidence for involvement of reactive oxygen species. J. Clin. Invest 94, 1629-1636.
244
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Savill,J. (1992). Macrophage recognition of senescent neutrophils. Clin. Sci. (Colch)
83, 649-655.
Savill,J., Dransfield,I., Hogg,N., and Haslett,C. (1990). Vitronectin receptor-
mediated phagocytosis of cells undergoing apoptosis. Nature 343, 170-173.
Savill,J., Hogg,N., Ren,Y., and Haslett,C. (1992b). Thrombospondin cooperates with
CD36 and the vitronectin receptor in macrophage recognition ofneutrophils
undergoing apoptosis. J. Clin. Invest 90, 1513-1522.
Savill,J., Smith,J., SarrafC., Ren,Y., Abbott,F., and Rees,A. (1992a). Glomerular
mesangial cells and inflammatory macrophages ingest neutrophils undergoing
apoptosis. Kidney Int. 42, 924-936.
Savill,J.S., Wyllie,A.FI., Henson,J.E., Walport,M.J., Henson,P.M., and Haslett,C.
(1989). Macrophage phagocytosis of aging neutrophils in inflammation.
Programmed cell death in the neutrophil leads to its recognition by macrophages. J.
Clin. Invest 83, 865-875.
Scaffidi,C., Fulda,S., Srinivasan,A., Friesen,C., Li,F., Tomaselli,K.J., Debatin,K.M.,
Krammer,P.H., and Peter,M.E. (1998). Two CD95 (APO-l/Fas) signaling pathways.
EMBO J. 17, 1675-1687.
Scapini,P., Lapinet-Vera,J.A., Gasperini,S., Calzetti,F., Bazzoni,F., and
Cassatella,M.A. (2000). The neutrophil as a cellular source of chemokines. Immunol.
Rev. 177, 195-203.
Scheinman,R.I., Cogswell,P.C., Lofquist,A.K., and Baldwin,A.S., Jr. (1995a). Role
of transcriptional activation of IkBoc in mediation of immunosuppression by
glucocorticoids. Science 270, 283-286.
Scheinman,R.I., Gualberto,A., Jewell,C.M., Cidlowski,J.A., and Baldwin,A.S., Jr.
(1995b). Characterization ofmechanisms involved in transrepression ofNF-kB by
activated glucocorticoid receptors. Mol. Cell Biol. 15, 943-953.
Schendel,S.L., Xie,Z., Montal,M.O., Matsuyama,S., Montal,M., and Reed,J.C.
(1997). Channel formation by antiapoptotic protein Bcl-2. Proc. Natl. Acad. Sci. U.
S. A 94, 5113-5118.
Schleimer,R.P. (1990). Effects of glucocorticosteroids on inflammatory cells relevant
to their therapeutic applications in asthma. Am. Rev. Respir. Dis. 141, S59-S69.
Schleimer,R.P., Freeland,H.S., Peters,S.P., Brown,K.E., and Derse,C.P. (1989). An
assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to
vascular endothelium and formation of leukotriene B4 by purified human neutrophils.
J. Pharmacol. Exp. Ther. 250, 598-605.
245
regulation of granulocyte apoptosis by glucocorticoids and cyclic amp
Schlesinger,P.H., Gross,A., Yin,X.M., Yamamoto,K., Saito,M., Waksman,G., and
Korsmeyer,S.J. (1997). Comparison of the ion channel characteristics ofproapoptotic
BAX and antiapoptotic BCL-2. Proc. Natl. Acad. Sci. U. S. A 94, 11357-11362.
Schmitz,I., Kirchhoff,S., and Krammer,P.H. (2000). Regulation of death receptor-
mediated apoptosis pathways. Int. J. Biochem. Cell Biol. 32, 1123-1136.
Schudt,C., Winder,S., Forderkunz,S., Hatzelmann,A., and Ullrich,V. (1991).
Influence of selective phosphodiesterase inhibitors on human neutrophil functions
and levels of cAMP and Cai. Naunyn Schmiedebergs Arch. Pharmacol. 344, 682-
690.
Schwarze,J., Hamelmann,E., Cieslewicz,G., Tomkinson,A., Joetham,A., Bradley,K.,
and Gelfand,E.W. (1998). Local treatment with IL-12 is an effective inhibitor of
airway hyperresponsiveness and lung eosinophilia after airway challenge in
sensitized mice. J. Allergy Clin. Immunol. 102, 86-93.
Scott,J.D. and McCartney,S. (1994). Localization ofA-kinase through anchoring
proteins. Mol. Endocrinol. 8, 5-11.
Scribner,D.J. and Fahrney,D. (1976). Neutrophil receptors for IgG and complement:
their roles in the attachment and ingestion phases ofphagocytosis. J. Immunol. 116,
892-897.
Sengelov,H., Boulay,F., Kjeldsen,L., and Borregaard,N. (1994). Subcellular
localization and translocation of the receptor for N- formylmethionyl-leucyl-
phenylalanine in human neutrophils. Biochem. J. 299 (Pt 2), 473-479.
Shea,C. and Morse,E.D. (1978). Inhibition of human neutrophil chemotaxis by
corticosteroids. Ann. Clin. Lab Sci. 8, 30-33.
Sheldon,L.A., Becker,M., and Smith,C.L. (2001). Steroid hormone receptor-
mediated histone deacetylation and transcription at the mouse mammary tumor virus
promoter. J. Biol. Chem. 276, 32423-32426.
Sheppard,K.A., Phelps,K.M., Williams,A.J., Thanos,D., Glass,C.K., Rosenfeld,M.G.,
Gerritsen,M.E., and Collins,T. (1998). Nuclear integration of glucocorticoid receptor
and NFkB signaling by CREB-binding protein and steroid receptor coactivator-1. J.
Biol. Chem. 273, 29291-29294.
Sheridan,J.P., Marsters,S.A., Pitti,R.M., Gurney,A., Skubatch,M., Baldwin,D.,
Ramakrishnan,L., Gray,C.L., Baker,K., Wood,W.I., Goddard,A.D., Godowski,P.,
and Ashkenazi,A. (1997). Control of TRAIL-induced apoptosis by a family of
signaling and decoy receptors. Science 277, 818-821.
Shi,H.Z„ Li,C.Q„ Qin,S.M., Xie,Z.F., and Liu,Y. (1999). Effect of inhaled
interleukin-5 on number and activity of eosinophils in circulation from asthmatics.
Clin. Immunol. 91, 163-169.
246
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Shi,H.Z., Xiao,C.Q., Zhong,D., Qin,S.M., Liu,Y., Liang,G.R., Xu,H., Chen,Y.Q.,
Long,X.M., and Xie,Z.F. (1998). Effect of inhaled interleukin-5 on airway
hyperreactivity and eosinophilia in asthmatics. Am. J. Respir. Crit Care Med. 157,
204-209.
Shimizu,S., Ide,T., Yanagida,T., and Tsujimoto,Y. (2000). Electrophysiological
study of a novel large pore formed by Bax and the voltage-dependent anion channel
that is permeable to cytochrome c. J. Biol. Chem. 275, 12321-12325.
Shimizu,S., Narita,M., and Tsujimoto,Y. (1999). Bcl-2 family proteins regulate the
release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature
399, 483-487.
Simon,H.U. (2001). Regulation of eosinophil and neutrophil apoptosis—similarities
and differences. Immunol. Rev. 179, 156-162.
Skalhegg,B.S., Landmark,B.F., Doskeland,S.O., Hansson,V., Lea,T., and Jahnsen,T.
(1992). Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects
of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes.
J. Biol. Chem. 267, 15707-15714.
Slater,A.F., Kimland,M., Jiang,S.A., and Orrenius,S. (1995). Constitutive nuclear
NFicB/rel DNA-binding activity of rat thymocytes is increased by stimuli that
promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Biochem. J. 312
(Pt 3), 833-838.
Slee,E.A., Harte,M.T., Kluck,R.M., Wolf,B.B., Casiano,C.A., Newmeyer,D.D.,
Wang,H.G., Reed,J.C., Nicholson,D.W., Alnemri,E.S., Green,D.R., and Martin,S.J.
(1999). Ordering the cytochrome c-initiated caspase cascade: hierarchical activation
of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9- dependent manner. J. Cell Biol.
144, 281-292.
Smith,C.L., Onate,S.A., Tsai,M.J., and 0'Malley,B.W. (1996). CREB binding
protein acts synergistically with steroid receptor coactivator-1 to enhance steroid
receptor-dependent transcription. Proc. Natl. Acad. Sci. U. S. A 93, 8884-8888.
Smith,C.W., Marlin,S.D., Rothlein,R., Toman,C., and Anderson,D.C. (1989).
Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1
in facilitating adherence and transendothelial migration ofhuman neutrophils in
vitro. J. Clin. Invest 83, 2008-2017.
Smith,H. (1992). Asthma, inflammation, eosinophils and bronchial
hyperresponsiveness. Clin. Exp. Allergy 22, 187-197.
Snijdewint,F.G., Kalinski,P., Wierenga,E.A., Bos,J.D., and Kapsenberg,M.L. (1993).
Prostaglandin E2 differentially modulates cytokine secretion profiles of human T
helper lymphocytes. J. Immunol. 150, 5321-5329.
247
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Sokol,R.J., James,N.T., Wales,J., and Hudson,G. (1987). Morphometry of
eosinophils in human blood. Acta Anat. (Basel) 129, 211-213.
Sottile,A., Venza,I., Venza,M., Valenti,A., and Teti,D. (1996). PGE2-induced
immunoregulation mediated by cytokine production from cultures of human
peripheral T lymphocytes. Immunopharmacol. Immunotoxicol. 18, 27-36.
Spitznagel,J.K., Dalldorf,F.G., Leffell,M.S., Folds,J.D., Welsh,I.R., Cooney,M.H.,
and Martin,L.E. (1974). Character of azurophil and specific granules purified from
human polymorphonuclear leukocytes. Lab Invest 30, 774-785.
Springer,T.A. (1994). Traffic signals for lymphocyte recirculation and leukocyte
emigration: the multistep paradigm. Cell 76,301-314.
Srinivasula,S.M., Ahmad,M., Fernandes-Alnemri,T., Litwack,G., and Alnemri,E.S.
(1996). Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease
Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE- like cysteine
proteases. Proc. Natl. Acad. Sci. U. S. A 93, 14486-14491.
Stancato,L.F., Silverstein,A.M., Gitler,C., Groner,B., and Pratt,W.B. (1996). Use of
the thiol-specific derivatizing agent N-iodoacetyl-3- [125I]iodotyrosine to
demonstrate conformational differences between the unbound and hsp90-bound
glucocorticoid receptor hormone binding domain. J. Biol. Chem. 271, 8831-8836.
Staples,K.J., Bergmann,M., Tomita,K., Houslay,M.D., McPhee,I., Barnes,P.J.,
Giembycz,M.A., and Newton,R. (2001). Adenosine 3',5'-Cyclic Monophosphate
(cAMP)-Dependent Inhibition of IL- 5 from Human T Lymphocytes Is Not Mediated
by the cAMP-Dependent Protein Kinase A. J. Immunol. 167, 2074-2080.
Stennicke,H.R., Jurgensmeier,J.M., Shin,H., Deveraux,Q., Wolf,B.B., Yang,X.,
Zhou,Q., Ellerby,H.M., Ellerby,L.M., Bredesen,D., Green,D.R., Reed,J.C.,
Froelich,C.J., and Salvesen,G.S. (1998). Pro-caspase-3 is a major physiologic target
of caspase-8. J. Biol. Chem. 273, 27084-27090.
Stern,M., Meagher,L., Savill,J., and Haslett,C. (1992). Apoptosis in human
eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by
macrophages and is modulated by IL-5. J. Immunol. 148, 3543-3549.
Stocklin,E., Wissler,M., Gouilleux,F., and Groner,B. (1996). Functional interactions
between Stat5 and the glucocorticoid receptor. Nature 383, 726-728.
Strasser,A., O'Connor,L., and Dixit,V.M. (2000). Apoptosis signaling. Annu. Rev.
Biochem. 69, 217-245.
Strickland,I., Kisich,K., Hauk,P.J., Vottero,A., Chrousos,G.P., Klemm,D.J., and
Leung,D.Y. (2001). High constitutive glucocorticoid receptor beta in human
neutrophils enables them to reduce their spontaneous rate of cell death in response to
corticosteroids. J. Exp. Med. 193, 585-594.
248
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Susin,S.A., Zamzami,N., Castedo,M., Daugas,E., Wang,H.G., Geley,S., Fassy,F.,
Reed,J.C., and Kroemer,G. (1997). The central executioner of apoptosis: multiple
connections between protease activation and mitochondria in Fas/APO-1/. J. Exp.
Med. 186, 25-37.
Susin,S.A., Zamzami,N., Castedo,M., Hirsch,T., Marchetti,P., Macho,A., Daugas,E.,
Geuskens,M., and Kroemer,G. (1996). Bcl-2 inhibits the mitochondrial release of an
apoptogenic protease. J. Exp. Med. 184, 1331-1341.
Suzuki,K., Tadakuma,T., and Kizaki,H. (1991). Modulation of thymocyte apoptosis
by isoproterenol and prostaglandin E2. Cell Immunol. 134, 235-240.
Suzuki,Y., Nakabayashi,Y., and Takahashi,R. (2001). Ubiquitin-protein ligase
activity ofX-linked inhibitor of apoptosis protein promotes proteasomal degradation
of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc.
Natl. Acad. Sci. U. S. A 98, 8662-8667.
Tai,P.C., Sun,L., and Spry,C.J. (1991). Effects of IL-5, granulocyte/macrophage
colony-stimulating factor (GM- CSF) and IL-3 on the survival of human blood
eosinophils in vitro. Clin. Exp. Immunol. 85, 312-316.
Tartaglia,L.A., Ayres,T.M., Wong,G.H., and Goeddel,D.V. (1993). A novel domain
within the 55 kd TNF receptor signals cell death. Cell 74, 845-853.
Tenor,H., Hatzelmann,A., Church,M.K., Schudt,C., and Shute,J.K. (1996). Effects of
theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of
human eosinophils from normal and atopic subjects. Br. J. Pharmacol. 118, 1727-
1735.
Thome,M., Schneider,P., Hofmann,K., Fickenscher,H., Meinl,E., Neipel,F.,
Mattmann,C., Burns,K., Bodmer,J.L., Schroter,M., Scaffidi,C., Krammer,P.H.,
Peter,M.E., and Tschopp,J. (1997). Viral FLICE-inhibitory proteins (FLIPs) prevent
apoptosis induced by death receptors. Nature 386, 517-521.
Thornberry,N.A. (1997). The caspase family of cysteine proteases. Br. Med. Bull.
53, 478-490.
Thornberry,N.A., Bull,H.G., Calaycay,J.R., Chapman,K.T., Howard,A.D.,
Kostura,M.J., Miller,D.K., Molineaux,S.M., Weidner,J.R., Aunins,J., and . (1992). A
novel heterodimeric cysteine protease is required for interleukin-1 beta processing in
monocytes. Nature 356, 768-774.
Thornberry,N.A. and Lazebnik,Y. (1998). Caspases: enemies within. Science 281,
1312-1316.
Tiku,K., Tiku,M.L., and Skosey,J.L. (1986). Interleukin 1 production by human
polymorphonuclear neutrophils. J. Immunol. 136, 3677-3685.
249
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Ting,A.T., Pimentel-Muinos,F.X., and Seed,B. (1996). RIP mediates tumor necrosis
factor receptor 1 activation ofNFkB but not Fas/APO-l-initiated apoptosis. EMBO
J. 15, 6189-6196.
Tolone,G., Bonasera,L., and Tolone,C. (1977). PGE2 production by human
polymorphonuclear leukocytes. Boll. 1st. Sieroter. Milan 56, 399-400.
Torphy,T.J., Livi,G.P., Balcarek,J.M., White,J.R., Chilton,F.F1., and Undem,B.J.
(1992). Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in
the treatment of asthma. Adv. Second Messenger Phosphoprotein Res. 25, 289-305.
Tortorella,C., Piazzolla,G., Spaccavento,F., and Antonaci,S. (1998a). Effects of
granulocyte-macrophage colony-stimulating factor and cyclic AMP interaction on
human neutrophil apoptosis. Mediators. Inflamm. 7, 391-396.
Tortorella,C., Piazzolla,G., Spaccavento,F., Pece,S., Jirillo,E., and Antonaci,S.
(1998b). Spontaneous and Fas-induced apoptotic cell death in aged neutrophils. J.
Clin. Immunol. 18, 321-329.
Tosi,M.F. and Zakem,H. (1992). Surface expression of Fc gamma receptor III
(CD 16) on chemoattractant- stimulated neutrophils is determined by both surface
shedding and translocation from intracellular storage compartments. J. Clin. Invest
90, 462-470.
Tran,S.E., Holmstrom,T.H., Ahonen,M., Kahari,V.M., and Eriksson,J.E. (2001).
MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors.
J. Biol. Chem. 276, 16484-16490.
Trump,B.F., Berezesky,I.K., and Osornio-Vargas,A.R. (1981b). Cell Death and the
disease process. The role of calcium. In Cell Death in biology and pathology,
I.D.L.R.A.Bowen, ed. (London and New York: Chapman and Hall), pp. 209-242.
Trump,B.F., Berezesky,I.K., and Phelps,P.C. (1981a). Sodium and calcium
regulation and the role of the cytoskeleton in the pathogenesis of disease: a review
and hypothesis. Scan Electron Microsc. 435-54, 434.
Truss,M. and Beato,M. (1993). Steroid hormone receptors: interaction with
deoxyribonucleic acid and transcription factors. Endocr. Rev. 14, 459-479.
Tsai,M.J. and 0'Malley,B.W. (1994). Molecular mechanisms of action of
steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63, 451-486.
Tsai,S.Y., Carlstedt-Duke,J., Weigel,N.L., Dahlman,K., Gustafsson,J.A., Tsai,M.J.,
and 0'Malley,B.W. (1988). Molecular interactions of steroid hormone receptor with
its enhancer element: evidence for receptor dimer formation. Cell 55, 361-369.
Tschopp,J., Irmler,M., and Thome,M. (1998). Inhibition of fas death signals by
FLIPs. Curr. Opin. Immunol. 10, 552-558.
250
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Tsuyuki,S., Bertrand,C., Erard,F., Trifilieff,A., Tsuyuki,J., Wesp,M., Anderson,G.P.,
and Coyle,A.J. (1995). Activation of the Fas receptor on lung eosinophils leads to
apoptosis and the resolution of eosinophilic inflammation of the airways. J. Clin.
Invest 96, 2924-2931.
Uller,L., Persson,C.G., Kallstrom,L., and Erjefalt,J.S. (2001). Lung Tissue
Eosinophils May Be Cleared Through Luminal Entry Rather Than Apoptosis. Effects
of steroid treatment. Am. J. Respir. Crit Care Med. 164, 1948-1956.
Umeki,S. and Soejima,R. (1990). Hydrocortisone inhibits the respiratory burst
oxidase from human neutrophils in whole-cell and cell-free systems. Biochim.
Biophys. Acta 1052, 211-215.
Underwood,D.C., Osborn,R.R., Novak,L.B., Matthews,J.K., Newsholme,S.J.,
Undem,B.J., Hand,J.M., and Torphy,T.J. (1993). Inhibition of antigen-induced
bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-
specific phosphodiesterase inhibitor, rolipram. J. Pharmacol. Exp. Ther. 266, 306-
313.
Ura,K., Kurumizaka,H., Dimitrov,S., Almouzni,G., and Wolffe,A.P. (1997). Histone
acetylation: influence on transcription, nucleosome mobility and positioning, and
linker histone-dependent transcriptional repression. EMBO J. 16, 2096-2107.
van de,S.A., Caldenhoven,E., Raaijmakers,J.A., van der Saag,P.T., and
Koenderman,L. (1993). Glucocorticoid-mediated repression of intercellular adhesion
molecule-1 expression in human monocytic and bronchial epithelial cell lines. Am. J.
Respir. Cell Mol. Biol. 8, 340-347.
van Hooijdonk,C.A., Glade,C.P., and van Erp,P.E. (1994). TO-PRO-3 iodide: a
novel HeNe laser-excitable DNA stain as an alternative for propidium iodide in
multiparameter flow cytometry. Cytometry 17, 185-189.
Van Lint,C., Emiliani,S., and Verdin,E. (1996). The expression of a small fraction of
cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245-
253.
van Rensen,E.L., Stirling,R.G., Scheerens,J., Staples,K., Sterk,P.J., Barnes,P.J., and
Chung,K.F. (2001). Evidence for systemic rather than pulmonary effects of
interleukin-5 administration in asthma. Thorax 56, 935-940.
Vanden Berghe,W., Francesconi,E., De Bosscher,K., Resche-Rigon,M., and
Haegeman,G. (1999). Dissociated glucocorticoids with anti-inflammatory potential
repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent
mechanism. Mol. Pharmacol. 56, 797-806.
Vander Heiden,M.G., Chandel,N.S., Williamson,E.K., Schumacker,P.T., and
Thompson,C.B. (1997). Bcl-xL regulates the membrane potential and volume
homeostasis ofmitochondria. Cell 91, 627-637.
251
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Vaux,D.L., Haecker,G., and Strasser,A. (1994). An evolutionary perspective on
apoptosis. Cell 76, 777-779.
Vayssiere,B.M., Dupont,S., Choquart,A., Petit,F., Garcia,T., Marchandeau,C.,
Gronemeyer,H., and Resche-Rigon,M. (1997). Synthetic glucocorticoids that
dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity
in vivo. Mol. Endocrinol. 11, 1245-1255.
Verhagen,J., Bruynzeel,P.L., Koedam,J.A., Wassink,G.A., de Boer,M.,
Terpstra,G.K., Kreukniet,J., Veldink,G.A., and Vliegenthart,J.F. (1984). Specific
leukotriene formation by purified human eosinophils and neutrophils. FEBS Lett.
168, 23-28.
Vignola,A.M., Chanez,P., Chiappara,G., Siena,L., Merendino,A., Reina,C.,
Gagliardo,R., Profita,M., Bousquet,J., and Bonsignore,G. (1999). Evaluation of
apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy
specimens of patients with asthma and chronic bronchitis. J. Allergy Clin. Immunol.
703,563-573.
Villunger,A., O'Reilly,L.A., Holler,N., Adams,J., and Strasser,A. (2000). Fas ligand,
Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein
kinase: Regulators of distinct cell death and survival pathways in granulocytes. J.
Exp. Med. 192, 647-658.
Vlahos,C.J., Matter,W.F., Hui,K.Y., and Brown,R.F. (1994). A specific inhibitor of
phosphatidylinositol 3-kinase, 2-(4- morpholinyl)-8-phenyl-4H-l-benzopyran-4-one
(LY294002). J. Biol. Chem. 269, 5241-5248.
Voll,R.E., Herrmann,M., Roth,E.A., Stach,C., Kalden,J.R., and Girkontaite,I. (1997).
Immunosuppressive effects of apoptotic cells. Nature 390, 350-351.
Waage,A., Slupphaug,G., and Shalaby,R. (1990). Glucocorticoids inhibit the
production of IL6 from monocytes, endothelial cells and fibroblasts. Eur. J.
Immunol. 20, 2439-2443.
Wada,Y. (1989). Cyclic AMP inhibits chemotactic-peptide-induced but not Ca2+-
ionophore- or tetradecanoylphorbol-acetate-induced enzyme secretion in guinea pig
neutrophils. Int. Arch. Allergy Appl. Immunol. 90, 194-197.
Wallace,A.D. and Cidlowski,J.A. (2001). Proteasome-mediated Glucocorticoid
Receptor Degradation Restricts Transcriptional Signaling by Glucocorticoids. J. Biol.
Chem. 276, 42714-42721.
Wallen,N., Kita,H., Weiler,D., and Gleich,G.J. (1991). Glucocorticoids inhibit
cytokine-mediated eosinophil survival. J. Immunol. 147, 3490-3495.
Walsh,G.M. (2001). Eosinophil granule proteins and their role in disease. Curr. Opin.
Hematol. 8, 28-33.
252
regulation of granulocyte apoptosis by glucocorticoids and cyclic amp
Wang,J.H., Devalia,J.L., Xia,C., Sapsford,R.J., and Davies,R.J. (1996b). Expression
of RANTES by human bronchial epithelial cells in vitro and in vivo and the effect of
corticosteroids. Am. J. Respir. Cell Mol. Biol. 14, 27-35.
Wang,K., Yin,X.M., Chao,D.T., Milliman,C.L., and Korsmeyer,S.J. (1996a). BID: a
novel BH3 domain-only death agonist. Genes Dev. 10, 2859-2869.
Ward,C., Chilvers,E.R., Lawson,M.F., Pryde,J.G., Fujihara,S., Farrow,S.N.,
Haslett,C., and Rossi,A.G. (1999a). NFkB activation is a critical regulator of human
granulocyte apoptosis in vitro. J. Biol. Chem. 274, 4309-4318.
Ward,C., Wong,T.H., Murray,J., Rahman,I., Haslett,C., Chilvers,E.R., and
Rossi,A.G. (2000). Induction of human neutrophil apoptosis by nitric oxide donors:
evidence for a caspase-dependent, cyclic-GMP-independent, mechanism. Biochem.
Pharmacol. 59, 305-314.
Ward,C., Dransfield,I., Chilvers,E.R., Haslett,C., and Rossi,A.G. (1999b).
Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets.
Trends Pharmacol. Sci. 20, 503-509.
Wardlaw,A.J., Moqbel,R., and Kay,A.B. (1995). Eosinophils: biology and role in
disease. Adv. Immunol. 60, 151-266.
Webster,N.J., Green,S., Jin,J.R., and Chambon,P. (1988). The hormone-binding
domains of the estrogen and glucocorticoid receptors contain an inducible
transcription activation function. Cell 54, 199-207.
Wedi,B., Raap,U., Lewrick,H., and Kapp,A. (1997). Delayed eosinophil
programmed cell death in vitro: a common feature of inhalant allergy and extrinsic
and intrinsic atopic dermatitis. J. Allergy Clin. Immunol. 100, 536-543.
Weissmann,G. (1989). The role ofneutrophils in vascular injury: a summary of
signal transduction mechanisms in cell/cell interactions. Springer Semin.
Immunopathol. 11, 235-258.
Weissmann,G. and Korchak,H. (1984). Rheumatoid arthritis. The role of neutrophil
activation. Inflammation 8 Suppl, S3-14.
Weller,P.F. (1991). The immunobiology of eosinophils. N. Engl. J. Med. 324, 1110-
1118.
Weller,P.F. (1992). Roles of eosinophils in allergy. Curr. Opin. Immunol. 4, 782-
787.
Weller,P.F., Rand,T.H., Barrett,T., Elovic,A., Wong,D.T., and Finberg,R.W. (1993).
Accessory cell function of human eosinophils. HLA-DR-dependent, MHC- restricted
antigen-presentation and IL-la expression. J. Immunol. 150, 2554-2562.
253
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Weller,P.F., Rand,T.H., Goelz,S.E., Chi-Rosso,G., and Lobb,R.R. (1991). Human
eosinophil adherence to vascular endothelium mediated by binding to vascular cell
adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc. Natl.
Acad. Sci. U. S. A 88, 7430-7433.
Whyte,M.K., Meagher,L.C., MacDermotJ., and Haslett,C. (1993). Impairment of
function in aging neutrophils is associated with apoptosis. J. Immunol. 150, 5124-
5134.
Whyte,M.K., Savill,J., Meagher,L.C., Lee,A., and Haslett,C. (1997). Coupling of
neutrophil apoptosis to recognition by macrophages: coordinated acceleration by
protein synthesis inhibitors. J. Leukoc. Biol. 62, 195-202.
Wientjes,F.B. and Segal,A.W. (1995). NADPH oxidase and the respiratory burst.
Semin. Cell Biol. 6, 357-365.
Williams,G.T. (1991). Programmed cell death: apoptosis and oncogenesis. Cell 65,
1097-1098.
Wolffe,A.P. (1997). Chromatin remodeling regulated by steroid and nuclear
receptors. Cell Res. 7, 127-142.
Wolter,K.G., Hsu,Y.T., Smith,C.L., Nechushtan,A., Xi,X.G., and Youle,R.J. (1997).
Movement ofBax from the cytosol to mitochondria during apoptosis. J. Cell Biol.
139, 1281-1292.
Wong,D.T., Elovic,A., Matossian,K., Nagura,N., McBride,J., Chou,M.Y.,
Gordon,J.R., Rand,T.H., Galli,S.J., and Weller,P.F. (1991). Eosinophils from patients
with blood eosinophilia express transforming growth factor beta 1. Blood 78, 2702-
2707.
Woolley,K.L., Gibson,P.G., Carty,K., Wilson,A.J., Twaddell,S.H., and Woolley,M.J.
(1996). Eosinophil apoptosis and the resolution of airway inflammation in asthma.
Am. J. Respir. Crit Care Med. 154, 237-243.
Wyllie,A.H. (1980). Glucocorticoid-induced thymocyte apoptosis is associated with
endogenous endonuclease activation. Nature 284, 555-556.
Wyllie,A.H., Kerr,J.F., and Currie,A.R. (1980). Cell death: the significance of
apoptosis. Int. Rev. Cytol. 68, 251-306.
Xia,Z., Dickens,M., Raingeaud,J., Davis,R.J., and Greenberg,M.E. (1995). Opposing
effects ofERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331.
Yamaguchi,Y., Suda,T., Ohta,S., Tominaga,K., Miura,Y., and Kasahara,T. (1991).
Analysis of the survival ofmature human eosinophils: interleukin-5 prevents
apoptosis in mature human eosinophils. Blood 78, 2542-2547.
254
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Yang,J., Liu,X., Bhalla,K., Kim,C.N., Ibrado,A.M., Cai,J., Peng,T.I., Jones,D.P., and
Wang,X. (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from
mitochondria blocked. Science 275, 1129-1132.
Ying,S., Meng,Q., Taborda-Barata,L., and Kay,A.B. (1997). Association of apoptosis
of neutrophils and eosinophils and their ingestion by macrophages with resolution of
the allergen-induced cutaneous late-phase response in atopic human subjects. Proc.
Assoc. Am. Physicians 109, 42-50.
Yoon,P.S., Boxer,L.A., Mayo,L.A., Yang,A.Y., and Wicha,M.S. (1987). Human
neutrophil laminin receptors: activation-dependent receptor expression. J. Immunol.
138, 259-265.
York,R.D., Yao,H., Dillon,T., Ellig,C.L., Eckert,S.P., McCleskey,E.W., and
Stork,P.J. (1998). Rapl mediates sustained MAP kinase activation induced by nerve
growth factor. Nature 392, 622-626.
Yoshida,M., Kijima,M., Akita,M., and Beppu,T. (1990). Potent and specific
inhibition ofmammalian histone deacetylase both in vivo and in vitro by trichostatin
A. J. Biol. Chem. 265, 17174-17179.
Yuan,J., Shaham,S., Ledoux,S., Ellis,H.M., and Horvitz,H.R. (1993). The C. elegans
cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-
converting enzyme. Cell 75, 641-652.
Zainudin,B. (1997). Steroid therapy in obstructive airway diseases. Respirology. 2,
17-31.
Zajicek,G., Shohat,M., and Polliack,A. (1984). On the maturation rate of the
neutrophil. Anat. Rec. 209, 85-94.
Zamzami,N., Brenner,C., Marzo,I., Susin,S.A., and Kroemer,G. (1998). Subcellular
and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16,
2265-2282.
Zamzami,N., Marchetti,P., Castedo,M., Hirsch,T., Susin,S.A., Masse,B., and
Kroemer,G. (1996a). Inhibitors ofpermeability transition interfere with the
disruption of the mitochondrial transmembrane potential during apoptosis. FEBS
Lett. 384, 53-57.
Zamzami,N., Marchetti,P., Castedo,M., Zanin,C., Vayssiere,J.L., Petit,P.X., and
Kroemer,G. (1995). Reduction in mitochondrial potential constitutes an early
irreversible step ofprogrammed lymphocyte death in vivo. J. Exp. Med. 181, 1661 -
1672.
Zamzami,N., Susin,S.A., Marchetti,P., Hirsch,T., Gomez-Monterrey,I., Castedo,M.,
and Kroemer,G. (1996b). Mitochondrial control of nuclear apoptosis. J. Exp. Med.
183, 1533-1544.
255
REGULATION OF GRANULOCYTE APOPTOSIS BY GLUCOCORTICOIDS AND CYCLIC AMP
Zha,J., Harada,H., Osipov,K., Jockel,J., Waksman,G., and Korsmeyer,S.J. (1997).
BH3 domain ofBAD is required for heterodimerization with BCL-XL and pro-
apoptotic activity. J. Biol. Chem. 272, 24101-24104.
Zha,J., Harada,H., Yang,E., JockelJ., and Korsmeyer,S.J. (1996). Serine
phosphorylation of death agonist BAD in response to survival factor results in
binding to 14-3-3 not BCL-X(L). Cell 87, 619-628.
Zhang,J.J., Vinkemeier,U., Gu,W., Chakravarti,D., Horvath,C.M., and Darnell,J.E.,
Jr. (1996). Two contact regions between Statl and CBP/p300 in interferon gamma
signaling. Proc. Natl. Acad. Sci. U. S. A 93, 15092-15096.
Zheng,H., Crowley,J.J., Chan,J.C., and Raffin,T.A. (1991). Attenuation of LPS-
induced neutrophil thromboxane ba release and chemiluminescence. J. Cell Physiol
146, 264-269.
Zhong,H., SuYang,H., Erdjument-Bromage,H., Tempst,P., and Ghosh,S. (1997). The
transcriptional activity ofNF-kB is regulated by the IkB- associated PKAc subunit
through a cyclic AMP-independent mechanism. Cell 89, 413-424.
Zilliacus,J., Dahlman-Wright,K., Carlstedt-Duke,J., and Gustafsson,J.A. (1992). Zinc
coordination scheme for the C-terminal zinc binding site of nuclear hormone
receptors. J. Steroid Biochem. Mol. Biol. 42, 131-139.
Zou,H., Henzel,W.J., Liu,X., Lutschg,A., and Wang,X. (1997). Apaf-1, a human
protein homologous to C. elegans CED-4, participates in cytochrome c-dependent
activation of caspase-3. Cell 90, 405-413.
Zou,H., Li,Y., Liu,X., and Wang,X. (1999). An APAF-1.cytochrome c multimeric
complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274,
11549-11556.
Zwartkruis,F.J., Wolthuis,R.M., Nabben,N.M., Franke,B., and Bos,J.L. (1998).
Extracellular signal-regulated activation ofRap 1 fails to interfere in Ras effector
signalling. EMBO J. 17, 5905-5912.
256
The Journal of Biological Chemistry
© 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Vol. 276, No. 48, Issue of November 30, pp. 45041-45050, 2001
Printed in U.S.A.
Cyclic AMP Regulation of Neutrophil Apoptosis Occurs via a
Novel Protein Kinase A-independent Signaling Pathway*
Received for publication, June 6, 2001, and in revised form, August 29, 2001
Published, JBC Papers in Press, September 17, 2001, DOI 10.1074/jbc.M105197200
Morag C. Martint, Ian Dransfield, Christopher Haslett, and Adriano G. Rossi
From the Medical Research Council Centre for Inflammation Research, Respiratory Medicine Unit,
University of Edinburgh Medical School, Edinburgh EH8 9AG, United Kingdom
The second messenger molecule cyclic AMP dramati¬
cally modulates the apoptotic program in a wide variety
of cells, accelerating apoptosis in some and delaying the
rate ofapoptosis in others. Human neutrophil apoptosis,
a process that regulates the fate and numbers of these
potentially histotoxic cells in inflammatory sites, is pro¬
foundly delayed by the cell-permeable analog of cyclic
AMP, dibutyryl-cAMP. We have investigated the mecha¬
nisms underlying cyclic AMP-mediated delay of neutro¬
phil apoptosis, and we show that cyclic AMP inhibits
loss ofmitochondrial potential occurring during consti¬
tutive neutrophil apoptosis. Furthermore, we demon¬
strate that cyclic AMP also suppresses caspase activa¬
tion in these inflammatory cells. Despite increasing
protein kinase A activity, this kinase is unlikely to me¬
diate the effect of cyclic AMP on apoptosis because
blockade of protein kinase A activation did not influ¬
ence the survival effects of cyclic AMP. Further investi¬
gation of the signaling mechanism demonstrated that
the delay of apoptosis is independent of phosphoinosi-
tide 3-kinase and MAPK activation. Our results suggest
cyclic AMP delays neutrophil apoptosis via a novel, re¬
versible, and transcriptionally independent mechanism.
We show that proteasome activity in the neutrophil is
vitally involved in this process, and we suggest that a
balance of pro-apoptotic and anti-apoptotic proteins
plays a key role in the powerful ability of cyclic AMP to
delay neutrophil death.
The neutrophil is a terminally differentiated phagocytic cell
that plays a key role in first line defense against invading
bacteria. Neutrophils are rapidly recruited to inflamed sites in
response to infection and, following phagocytosis of the invad¬
ing organism, release a variety of toxic granule contents into
the phagolysosome containing the engulfed microorganisms (1,
2). The neutrophil normally has a short life span, and senescent
neutrophils must be prevented from releasing their cytotoxic
cell contents into the surrounding milieu because such libera¬
tion will lead to local tissue damage. To avoid this undesirable
and inappropriate response, the neutrophil undergoes a regu¬
lated process of programmed cell death or apoptosis (3-5),
allowing shutdown of secretory capacity (6) and phagocytic
removal of the intact effete cell by a mechanism that does not
incite an inflammatory response (7-9).
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The execution of the apoptotic program generally involves
the activation of a family of cysteine proteases, collectively
referred to as the caspases, that are ultimately responsible for
the structural dismantling of the cell (10, 11). In addition, the
mitochondria play a central role through their ability to inte¬
grate anti-apoptotic or pro-apoptotic signals from Bcl-2 family
members with coordinated activation of downstream caspases
and nucleases (12, 13). In many cell types it has been docu¬
mented that apoptosis is accompanied by an early dissipation
of the mitochondrial transmembrane potential (AI'm) with in¬
creased permeability of the outer mitochondrial membrane
allowing release of apoptosis-inducing factors such as cyto¬
chrome c (12-14). Neutrophils are thought to contain very few
mitochondria, and it has not yet been fully established whether
they have the capacity to play a functional role in regulation of
neutrophil apoptosis (15, 16).
Neutrophils undergo constitutive apoptosis during in vitro
culture and exhibit the classic changes associated with apo¬
ptosis including cytoplasmic condensation, internucleosomal
cleavage of DNA by endogenous endonucleases, and exposure
of phosphatidylserine on the outer leaflet of the plasmalemma
(3). Although the apoptotic program in neutrophils is an intrin¬
sic cell process, the rate of apoptosis can be altered dramati¬
cally by a number of agents (17). In particular, we and others
(18-20) have shown that elevated levels of the second messen¬
ger cyclic AMP can prolong neutrophil longevity by delaying
apoptosis.
The cyclic AMP-dependent signaling transduction pathway
is a multienzyme cascade that regulates a diverse array of
biological processes. Specific ligation of appropriate G-protein-
coupled receptors followed by adenylate cyclase activation
leads to the production of cyclic AMP. Cyclic AMP then binds to
cytoplasmic protein kinase A, a tetrameric structure composed
of two regulatory (R) and two catalytic (C) subunits, resulting
in dissociation of the C subunits and subsequent phosphoryla¬
tion of target proteins (21). Although most components of this
signaling cascade are well characterized, the molecular mech¬
anisms underlying cyclic AMP-mediated modulation of apopto¬
sis remain to be elucidated. The signaling mechanism(s) used
by cyclic AMP to control these events is (are) likely to be
complex and cell type-specific. For example, in contrast to the
profound delay in the engagement of the apoptotic process in
neutrophils (18-20), cyclic AMP elevation induces apoptosis in
thymocytes (22) and leukemic cell lines (23, 24). The signaling
mechanism determining this ability to differentially influence
apoptosis in diverse cell types remains to be elucidated.
In the present study we show that elevated cyclic AMP
inhibits activation of caspase-3 and loss in mitochondrial po¬
tential (ATOn) when neutrophils are aged in vitro, i.e. effects
that appear to be associative rather that causative. Although
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Fig. 1. Effect of cyclic AMP elevation on human neutrophil apoptosis. Human neutrophils (5 x 106/ml) were cultured at 37 °C in Iscove's
DMEM containing 10% autologous serum and treated with Bt2cAMP (dbcAMP) (0.2 mm) or PGE2 (10 /xm). After 20 h, the cells were incubated with
FITC-labeled recombinant human annexin V to determine phosphatidylserine expression. The cells were then assessed by flow cytometry on a
FACSCalibur and analyzed on associated CellQuest software. Data from a minimum of 5000 cells were analyzed for each condition. All values
represent mean ± S.E. ofn = 5-8 experiments, each performed in duplicate where significant difference from control is represented by *,p < 0.001,
and #, p < 0.05. Similar results were found by morphological assessment of apoptosis (data not shown).
we could demonstrate that cyclic AMP rapidly elevates endog¬
enous PKA1 activity in cultured neutrophils, blockade of PKA
activation did not influence the observed delay in neutrophil
apoptosis induced by cyclic AMP elevation. We also show that
cyclic AMP elevation delays neutrophil apoptosis via a tran¬
scriptionally independent and reversible pathway, which does
not require PI 3-kinase and MAPK activity. Together these
data point to a novel mode ofaction for the major retardation of
neutrophil apoptosis induced by cyclic AMP elevation.
1 The abbreviations used are: PKA, protein kinase A; B^cAMP, dibu-
tyryl cyclic AMP; DMEM, Dulbecco's modified Eagle's medium; GM-CSF,
granulocyte macrophage-colony-stimulating factor; JC-1 [5,5',6,6'-tetra-
chloro-l,l',3,3'-tetraethylbenzimidazocarbocyaniniodide; MAPK, mito-
gen-activated protein kinase; PI 3-kinase, phosphoinositide 3-kinase;
PBS, phosphate-buffered saline; PGE2, prostaglandin E2; FITC, fluores¬
cein isothiocyanate.
EXPERIMENTAL PROCEDURES
Granulocyte Isolation and Culture
Neutrophils were purified from the peripheral blood ofnormal donors
by dextran sedimentation (Sigma) followed by centrifugation on discon¬
tinuous Percoll™ (Amersham Pharmacia Biotech) gradients as de¬
scribed previously (25, 26). Only neutrophil preparations with a purity
of >98% were used. Cells were cultured in flat-bottomed Falcon flexible
wells (Becton Dickinson, Oxford, UK) at 37 °C in a 5% C02 atmosphere
at a concentration of 5 x 106/ml in Iscove's modified Dulbecco's medium
(Life Technologies, Inc.) supplemented with 100 units/ml penicillin/
streptomycin (Life Technologies, Inc.) and 10% (v/v) autologous serum.
As an index of necrosis, cell membrane integrity was assessed by the
ability of cells to exclude the vital dye trypan blue (Sigma). Under all
experimental conditions, greater than 99% of the cells consistently
excluded trypan blue.
Assessment ofGranulocyte Apoptosis
Morphology—Cells were cyto-centrifuged, fixed in methanol, stained
with Diff-Quik™ Gamidor Ltd. (Abingdon, Oxon, UK), and counted
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Fig. 2. Time course for the effect of
Bt2cAMP (dbcAMP) on caspase-3 ex¬
pression during human neutrophil
apoptosis. A, Western blot of cytoplas¬
mic extracts from neutrophils treated
with control buffer or Bt2cAMP (0.2 mM)
for the time points indicated. Cell lysates
were prepared and immunoblotted as de¬
scribed under "Experimental Proce¬
dures." Lysates were prepared from
equivalent numbers of cells and subjected
to SDS-polyacrylamide gel electrophore-
sis/immunoblot analysis using a rabbit
polyclonal antibody specific for caspase-3.
The caspase-3 antibody recognizes both
the 32-kDa pro-caspase-3 and the 17-kDa
subunit of active caspase-3. The 17-kDa
caspase-3 cleavage product is faintly vis¬
ible in control (con) lysates at 8 h becom¬
ing more apparent by 20 h. There appears
to be less active caspase-3 in Bt2cAMP
(dbcAMP)-treated cell lysates compared
with control cell lysates. The gel is repre¬
sentative of three experiments. B, human
neutrophils were treated with or without
Bt2cAMP (0.2 mM) for the time points in¬
dicated under equivalent culture condi¬
tions as the cells used for caspase-3 ex¬
pression assessment above. Cells were
assessed for apoptosis by measurement of
phosphatidylserine expression using an-
nexin V FITC. Data from a minimum of
5000 eels were analyzed for each condi¬
tion. All values represent mean ± S.E. of
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using oil immersion microscopy to determine the proportion of cells
with distinctive apoptotic morphology (3, 26). At least 500 cells were
counted per slide with the observer blinded to the experimental condi¬
tions. The results were expressed as the mean percent apoptosis ± S.E.
Annexin VBinding—A separate and independent assessment of apo¬
ptosis was performed by flow cytometry using annexin V binding (an¬
nexin V-FLUOS, Roche Molecular Biochemicals) to measure phosphati¬
dylserine exposure on the surface of apoptotic cells. A working solution
of annexin V-FLUOS was made from stock annexin V-FLUOS (0.1
/xg//x1) diluted 1:3000 in Hanks' balanced salt solution (Sigma) supple¬
mented with 2.5 mM CaCl2. Neutrophils (20 p,l of 5 X 106/ml) were
added to 200 /x1 of the working solution of annexin V-FLUOS before
being assessed by flow cytometry on a FACSCalibur (Becton Dickinson,
Oxford, UK) and analyzed on associated CellQuest (Becton Dickinson)
software. All experiments were performed at least three times unless
otherwise indicated.
Measurement of PKA Activity
PKA activity was measured using Promega's SignaTECT™ cAMP-
dependent Protein Kinase (PKA) Assay System, which utilizes biotiny-
lated Kemptide (LRRASLG), a peptide substrate derived from the in
vivo substrate pyruvate kinase. Neutrophils (5 X 106 cells) were prein-
cubated with control buffer or 10 pM H89 (Calbiochem) for 1 h in PBS
with Ca2+/Mg2+ (or for 19 h in DMEM Iscove's with 10% autologous
serum) at 37 °C before being stimulated with 0.2 mM Bt2cAMP or 1 pM
PGE2 (both from Sigma) for 30 min at 37 °C. Following one wash in
ice-cold PBS, neutrophils were resuspended in 0.5 ml of cold extraction
buffer (25 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 10 mM
/3-mercaptoethanol, 1 pg/ml leupeptin, 1 pg/ml aprotinin, 1 mM phen-
ylmethylsulfonyl fluoride, and 1% Triton X-100 (Sigma)). The lysates
were centrifuged (5 min at 4 °C; 14,000 x g) and the supernatants
retained. The PKA reaction mixture consisting of 5 pi of 5X PKA Assay
Buffer, 5 pi of cyclic AMP (0.025 mM), 5 pi of PKA-biotinylated peptide
substrate (0.5 mM), 5 pi of [y-33P]ATP mixture (5 pi of 0.5 mM ATP and
0.05 pi of [y-33P]ATP (3,000 Ci/mmol) 10 pCi/pl) was mixed gently and
preincubated at 30 °C for 5 min (Promega, Southampton, UK). A control
reaction without substrate was performed to determine background
counts. The PKA activity reaction was initiated by adding 5 pi of the
lysates to the reactants and incubated at 30 °C for 5 min. The reaction
was terminated by adding 12.5 pi of Termination Buffer to each sample
(Promega, Southampton, UK). Aliquots (10 pi) from each terminated
reaction sample were spotted onto prenumbered SAM2™ membrane
squares (Promega, Southampton, UK). The SAM2™ membrane squares
containing the spotted samples were then washed 1 time for 30 s with
200 ml of 2 M NaCl (Sigma) followed by 3 washes for 2 min with 200 ml
of 2 M NaCl and then 4 washes for 2 min with 200 ml of 2 m NaCl in 1%
H3P04. Finally the Membrane squares were quickly washed in deion-
ized water before being allowed to dry. PKA activity was measured by
scintillation counting.
Measurement ofMitochondrial Dissipation
Changes in mitochondrial potential were measured in neutrophils
following stimulation using JC-1 (5,5',6,6'-tetrachloro-l,l',3,3'-tetra-
ethylbenzimidazocarbocyaniniodide (Molecular Probes), a cationic dye
that exhibits potential dependent accumulation in mitochondria indi¬
cated by a fluorescence emission shift from green (525 nm) to red (590
nm) (27). Mitochondrial depolarization is therefore indicated by a de¬
crease in the red/green fluorescence intensity ratio. JC-1 (10 pg/ml) was
diluted in PBS from stock JC1 (5 mg/ml in Me2SO) and added to
neutrophils (1 X 106/ml) for 10 min at 37 °C. Neutrophil mitochondria
labeled with JC-1 were examined by confocal fluorescent microscopy
together with TO-PRO-3 (1 pM) (Molecular Probes) (28) to assess neu¬
trophils with necrotic morphology. Alternatively, neutrophils labeled
with JC-1 were assessed by flow cytometric analysis using FACSCali¬
bur (Becton Dickinson, Oxford, UK) and analyzed on associated
CellQuest (Becton Dickinson) software. Non-apoptotic neutrophils were
removed using immunomagnetic separation with sheep anti-mouse
IgG-Dynabeads (Dynabeads M-450, Dynal, Mersyside, UK) coated with
the murine anti-neutrophil antibody 3G8 (anti-CD16; a gift from Dr. J.
Unkeless, Mount Sinai Medical School, New York). Cells were mixed
with washed antibody-coated magnetic beads on a rotary mixer at 4 °C
for 20 min, and the beads removed magnetically by two 3-min station¬
ary magnetic contacts (Dynal Magnetic Particle Concentrator, MPC-1)
to yield an apoptotic neutrophil preparation. After purification, the
apoptotic neutrophils were labeled with JC-1 as described previously.
Western Blotting
Human neutrophils (5 X 106/ml) were cultured with or without
Bt2cAMP (0.2 mM) at 37 °C for various time points as detailed under
"Results." Cytoplasmic extracts were then prepared from equivalent
numbers of cells (10 X 106 cells). To minimize problems with proteoly¬
sis, lysates were prepared using methods normally used for electro-
phoretic mobility shift assay preparations (26, 29) with the addition of
1 mM phenylmethylsulfonyl fluoride. Samples were loaded onto a 12.5%
B
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Fig. 3. A, determination if neutrophils contain mitochondria. Human neutrophils (1 x 106/ml) were cultured at 37 °C in Iscove's DMEM
containing 10% autologous serum. Neutrophils were labeled with JC-1, a mitochondrial specific dye, and examined by confocal fluorescent
microscopy as described under "Experimental Procedures." Bottom panels show TO-PRO-3 staining for neutrophils with necrotic morphology
{blue). B, effect of Bt^cAMP (dbcAMP) on dissipation of mitochondrial transmembrane potential during human neutrophil apoptosis. Human
neutrophils (5 x 106/ml) were cultured for 20 h at 37 °C in Iscove's DMEM containing 10% autologous serum with or without Bt2cAMP (dbcAMP)
(0.2 mM). Cells were then labeled with the mitochondrial specific dye JC-1 as described under "Experimental Procedures" before flow cytometric
analysis of mitochondrial membrane potential using a FACSCalibur and associated CellQuest software. Non-apoptotic neutrophils (bottom right
panel) were removed by anti-CD16 immunodepletion before the remaining cells were labeled with JC-1. Shown is one representative experiment.
Tris-HCl polyacrylamide mini-gel under reducing conditions and trans¬
ferred to nitrocellulose membrane (Amersham Pharmacia Biotech) at
60 V for 1 h before overnight incubation at 4 °C with an antibody
specific to caspase-3 (catalog number 65906E, PharMingen). After
washing, blots were incubated with donkey anti-rabbit horseradish
peroxidase conjugate (Amersham Pharmacia Biotech) diluted 1:2000
and developed using a commercial chemiluminescence detection system
(ECL, Amersham Pharmacia Biotech).
Further Materials
Further specific materials were obtained as follows: (iy-S-Br-
cAMPS, PD98059, SB203580, and cycloheximide (Calbiochem); lacta-
cystin and epoxomicin (Affiniti, Mamhead, UK); and LY294002 (New
England Biolabs, Hertfordshire, UK).
Statistical Analysis
Statistical analysis was performed using the Student's t test or by
analysis of variance with comparisons between groups made using the
Newman-Keuls procedure. Differences were considered significant
when p < 0.05.
RESULTS
Elevation of Cyclic AMP Delays Neutrophil Apoptosis—To
examine the effects of cyclic AMP on apoptosis induction, neu¬
trophils were exposed to Bt2cAMP, a membrane-permeant cy¬
clic AMP analog and the receptor-directed stimulus PGE2, for
20 h. Both Bt2cAMP and PGE2 delay neutrophil apoptosis,
determined by standard morphological criteria (data not




control dbeAMP PGE2 H89 dbcAMP PGE2
-f H89 + H89
Fig. 4. Measurement of PKA activation by elevators of cyclic
AMP in human neutrophils. Human neutrophils (5 X 106/ml) were
preincubated with 10 /xm H89 for 1 h before being stimulated with
Bt2cAMP (dbcAMP) (0.2 mm) or PGE2 (1 /am) for 30 min at 37 °C. PKA
activity was measured as described under "Experimental Procedures."
All values represent mean ± S.E. of n = 3 experiments where signifi¬
cant difference from control values is represented by *, p < 0.05.
Significant difference from Bt2cAMP alone is represented by #, p <
0.001, and significant difference from PGE2 alone is represented by ±,
p < 0.001.
shown) and annexin V binding (Fig. 1). It is interesting to note
that maximal concentrations of Bt^cAMP (0.2 mM) were more
effective at delaying neutrophil apoptosis compared with max¬
imal concentrations of PGE2 (10 pM) (Fig. 1).
Bt.jcAMP Inhibits Caspase Activation but Is Unlikely to Act
Directly as an Inhibitor of Caspases—It is widely believed that
caspases act as the main executioners of apoptosis, with their
activation resulting in chromatin condensation and DNA frag¬
mentation. Whether cyclic AMP delays constitutive neutrophil
apoptosis by directly suppressing caspase activation in neutro¬
phils has not been examined. Therefore, we investigated the
effect of cyclic AMP on activation of caspase-3 during constitu¬
tive apoptosis by immunoblotting. Neutrophils were found to
express active caspase-3 (17 kDa) which closely correlates with
the exposure of phosphatidylserine during constitutive neutro¬
phil apoptosis (Fig. 2, A and B). By 20 h there is significant
caspase-3 activity (17 kDa) which can be inhibited by Bt2cAMP.
The appearance of some caspase-3 activity in the presence of
Bt2cAMP at 20 h probably reflects the presence of some apop-
totic cells in the population (Fig. 2B).
Apoptosis in Neutrophils Is Accompanied by Dissipation of
Mitochondrial Transmembrane Potential That Can Be Inhib¬
ited by Bt2cAMP—In many cell models, apoptosis is accompa¬
nied by an early dissipation of the mitochondrial transmem¬
brane potential (ATfti). Previous data (16) have indicated that
neutrophils do not respire, and it was thought unlikely that
they contained mitochondria. By using confocal microscopy and
flow cytometry, we have been able to demonstrate that neutro¬
phils do contain mitochondria (orange), which during overnight
culture exhibit loss of mitochondrial potential as indicated by
an increase in green fluorescence (Fig. 3A). Our studies also
reveal that Bt2cAMP inhibits changes in mitochondrial poten¬
tial occurring during constitutive neutrophil apoptosis (Fig.
3B). As the number of cells showing loss of mitochondrial
potential appeared to correlate with the number of apoptotic
cells measured by annexin V positivity in previous experiments
(Fig. 1), we examined directly if loss in mitochondrial potential
occurred in those neutrophils undergoing apoptosis. It is well
established that neutrophils lose cell surface expression of
CD 16 during the process of apoptosis (30). Immunodepletion of
control dbcAMP H89 1189 dbcAMP + dbcAMP+
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PGE2 PGE2 + H89
Fig. 5. The effect of pharmacological blockade of PKA activity
on Bt2cAMP-mediated delay of neutrophil apoptosis. A and B,
human neutrophils (5 X 10e/ml) cultured in Iscove's DMEM containing
10% autologous serum at 37 °C were preincubated for 30 min with H89
(10 pM) (A) or (l?p)-8-Br-cAMPS (100 pM) (B) before stimulation with
Bt2cAMP (dbcAMP) (0.2 mM). After a further 20 h in culture, the cells
were incubated with FITC-labeled recombinant human annexin V to
determine phosphatidylserine expression. The cells were then analyzed
by flow cytometry using a FACSCalibur and associated CellQuest soft¬
ware. Data from a minimum of 5000 cells were analyzed for each
condition. All values represent mean ± S.E. of n — 3 experiments, each
performed in duplicate. Similar results were found when cells were
assessed for apoptosis by morphological examination (data not shown).
C, human neutrophils (5 X 106/ml) cultured in Iscove's DMEM contain¬
ing 10% autologous serum at 37 °C were preincubated with 10 pM H89
for 19 h before being stimulated with PGE2 (1 pM) for 1 h at 37 °C. PKA
activity was measured as described under "Experimental Procedures."
All values represent mean ± S.E. of n = 5 experiments where signifi¬
cant difference from PGE2 alone is represented by **, p < 0.01.
non-apoptotic neutrophils using anti-CD 16 magnetic beads
demonstrated apoptotic neutrophils were indeed positive for
loss of mitochondrial potential (Fig. 3B) indicating that dissi¬
pation of mitochondrial membrane potential occurs in neutro¬
phils undergoing programmed cell death.
It has been shown previously (31) that inhibitors of the
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Fig. 6. Effect of PI 3-kinase and
MAPK inhibition on Bt2cAMP (db-
cAMP)-mediated delay of neutrophil
apoptosis. Human neutrophils (5 X 106/
ml) cultured in Iscove's DMEM contain¬
ing 10% autologous serum at 37 °C were
treated with LY294002 (LY, 10 /am) or
PD98059 (PD, 10 /am) for 30 min prior to
stimulation by Bt2cAMP (0.2 mm). After a
further 20 h in culture, the cells were
incubated with FITC-labeled recombi¬
nant human annexin V to determine
phosphatidylserine expression. The cells
were then analyzed by flow cytometry us¬
ing a FACSCalibur and associated
CellQuest software. Data from a mini¬
mum of 5000 cells were analyzed for each
condition. All values represent mean ±
S.E. ofn = 3 experiments, each performed
in duplicate where significant difference
from GM-CSF alone is represented by *,
p < 0.01. con, control.
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cycloheximide
0.1 0.3 0.5 1
cycloheximide +
dbcAMP
Fig. 7. Effect of protein synthesis
inhibition by cycloheximide on
Bt2cAMP idbeAMP) mediated delay
of neutrophil apoptosis. Human neu¬
trophils (5 X 106/ml) were cultured in
Iscove's DMEM containing 10% autolo¬
gous serum at 37 °C and treated with the
indicated concentrations of cycloheximide
(p-g/ml) with or without Bt2cAMP (0.2
mm). After 20 h, cells were harvested and
assessed morphologically for apoptosis.
All values represent mean ± S.E. of n =
10 experiments, each performed in tripli¬
cate. Similar results were found when
cells were assessed for apoptosis by an¬
nexin V binding (data not shown), con,
control.
mitochondrial respiratory chain do not affect constitutive neu¬
trophil apoptosis, raising the question of the source of their
ATm. It may be the case that the neutrophil maintains a
transmembrane gradient by a functional F^Fo-ATPase; how¬
ever, this needs to be investigated in more detail.
Cyclic AMP Elevation Stimulates PKA Activation in Neutro¬
phils, an Effect That Is Blocked by Pharmacological Inhibi¬
tors—To elucidate further the mechanism by which cyclic AMP
regulates neutrophil apoptosis, we examined its downstream
signaling pathway. The effects of cyclic AMP are thought to be
mediated through binding of cyclic AMP to the intracellular
kinase, PKA. This leads to the dissociation of PKA into regu¬
latory and catalytic subunits, which can consequently lead to
phosphorylation events of proteins such as the cyclic AMP-
response element-binding protein (21). To explore whether cy¬
clic AMP suppresses apoptosis and apoptotic signaling via ac¬
tivating the PKA pathway in neutrophils, we examined the
effects of Bt2cAMP on endogenous PKA activation (Fig. 4). We
found rapid activation of PKA when cells were treated with
both Bt2cAMP and PGE2 Furthermore, the activation of PKA
upon stimulation of neutrophils with cyclic AMP elevators
could be blocked by the pharmacological PKA inhibitor H89
(32) (Fig. 4).
Activation of the PKA Pathway Does Not Account for Cyclic
AMP-mediated Retardation of Apoptosis—To investigate
whether PKA activation by cyclic AMP was necessary for cyclic
AMP-mediated delay of apoptosis, neutrophils were incubated
with the PKA inhibitor H89 before being stimulated with
Bt2cAMP and assessed for apoptosis. Surprisingly, whereas
pre-treatment with H89 prevented activation of PKA, it did not
prevent the inhibition of apoptosis by Bt2cAMP (Fig. 5A). Ad¬
ditionally, the highly specific inhibitor of PKA, CRp)-8-Br-
cAMPS (100 p,m), also failed to block Bt2cAMP inhibition of
neutrophil apoptosis (Fig. 5B). This suggests that cyclic AMP
elevation stimulates PKA activity but PKA does not play a
major role in the anti-apoptotic effect of cyclic AMP elevation in
neutrophils.
The ability of H89 to block PKA activity, as shown by direct
measurement of kinase activity, suggests a lack of involvement
of PKA in the anti-apoptotic effect of cyclic AMP in neutrophils.
Most importantly, we investigated whether H89 could block
PKA activity for the full overnight culture period and under
identical culture conditions that we use for our apoptosis assay.
Neutrophils were therefore cultured in serum-supplemented
Iscove's DMEM for 19 h in the presence or absence of H89
before stimulation with PGE2 for 1 h. PKA activity was then
measured as described under "Experimental Procedures." We
found that H89 could still block PGE2-stimulated PKA activity
cAMP Regulator Neutrophil Apoptosis via a Novel Pathway 45047
Fig. 8. Loss of Bt2cAMP (dbcAMP)-
mediated delay of neutrophil apopto¬
sis by washing and rescue ofcultured
neutrophils from apoptosis by de¬
layed addition of Bt2cAMP. A, human
neutrophils (5 x 106/ml) cultured in
Iscove's DMEM containing 10% autolo¬
gous serum at 37 °C were treated with or
without Bt2cAMP (dbcAMP) (0.2 mm) for
the time points indicated before the cells
were washed 2 times in PBS to remove
Bt2cAMP and returned to culture. Cells
were cultured in Iscove's DMEM contain¬
ing 10% autologous serum until 20 h
when the cells were resuspended and in¬
cubated with FITC-labeled recombinant
human annexin V to determine phos-
phatidylserine expression. The cells were
then assessed by flow cytometry on a
FACSCalibur and analyzed on associated
CellQuest software. Data from a mini¬
mum of 5000 cells were analyzed for each
condition. All values represent mean ±
S.E. ofn = 3 experiments, each performed
in duplicate. B, human neutrophils (5 x
106/ml) cultured in Iscove's DMEM con¬
taining 10% autologous serum at 37 °C
for the time points indicated before addi¬
tion of Bt2cAMP (0.2 mm). At 20 h, cells
were resuspended and incubated with
FITC-labeled recombinant human an¬
nexin V to determine phosphatidylserine
expression. The cells were then assessed
by flow cytometry on a FACSCalibur and
analyzed on associated CellQuest soft¬
ware. Data from a minimum of 5000 cells
were analyzed for each condition. All val¬
ues represent mean ± S.E. of n = 3 ex¬
periments, each performed in duplicate.
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at 20 h (Fig. 5C). This is very important because it demon¬
strates that the inability of H89 to reverse cyclic AMP-medi-
ated delay of neutrophil apoptosis is not due to degradation of
H89 during the overnight culture period. Furthermore, it also
demonstrates that H89 is not inactivated by autologous serum
that is used in our apoptosis assay.
Activation ofAkt!PI 3-Kinase or Mitogen-activated Kinase
Pathways Does Not Account for the Bt^cAMP-mediated Delay of
Neutrophil Apoptosis—The phosphoinositide 3-kinase/Akt
pathway plays an essential role in cell survival in various cell
types (33) and may be involved in the cyclic AMP-signaling
cascade. For example, it has been reported that cyclic AMP
requires PI 3-kinase activation for DNA synthesis induced by
insulin-like growth factor I in FRTL-5 cells (34) and is involved
in the ability of cyclic AMP to attenuate chemoattractant-
induced respiratory burst in neutrophils (35). Therefore, we
examined whether PI 3-kinase is involved in the signaling
pathway mediating the protective effect of cyclic AMP on neu¬
trophil survival. Cells were preincubated with the specific PI
3-kinase inhibitor LY294002 (36) prior to exposing them to
Bt2cAMP or GM-CSF (Fig. 6). We found that the PI 3-kinase
inhibitor suppressed GM-CSF-mediated delay of neutrophil
apoptosis, which has been reported previously (37), yet had no
effect on suppression of apoptosis by Bt2cAMP.
We also investigated whether cyclic AMP could be acting
through the MAPK signaling pathway to delay neutrophil
apoptosis. Activation ofextracellular signal-regulated kinase has
been implicated in a number of systems to contribute as a nega¬
tive regulator ofapoptosis (38, 39). Elevation of cyclic AMP levels
is also known to either inhibit or activate MAPK in a cell type-
and stimulus-specific manner (40, 41). The protective effect of
cAMP-elevating agents does not appear to act through the MAPK
pathway in our system because the p42/p44 MAPK kinase inhib¬
itor PD98059 had no effect on the anti-apoptotic functions of
cyclic AMP in neutrophils, yet reversed the anti-apoptotic func¬
tions ofGM-CSF treatment in neutrophils (Fig. 6). Similarly the
p38 MAPK inhibitor SB203580 (42) did not reverse Bt2cAMP-
mediated delay of neutrophil apoptosis (data not shown).
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Retardation of Neutrophil Apoptosis by Bt.jcAMP Does Not
Require New Protein Synthesis—Our results suggest Bt2cAMP
suppresses neutrophil apoptosis via a previously uncharacter-
ized signaling mechanism. We therefore determined whether
Bt2cAMP stimulated a novel signaling pathway that would
require transcriptional activation to suppress neutrophil
apoptosis.
To block protein synthesis cycloheximide was titrated to low
concentrations to minimize the induction of neutrophil apopto¬
sis that has been reported by this compound (43). Apoptosis
was assessed by morphology and annexin V binding following
overnight culture of neutrophils with Bt2cAMP and cyclohexi¬
mide (Fig. 7). Cycloheximide failed to reverse the suppression
of apoptosis by cyclic AMP. It did however block glucocorticoid-
mediated suppression of neutrophil apoptosis at these concen¬
trations (Ref. 44 and data not shown), suggesting that gene
transcription is not necessary for the suppression of neutrophil
apoptosis by Bt2cAMP.
We next examined the possibility that Bt2cAMP might acti¬
vate a rapid and reversible signaling pathway rather than
stimulate new protein synthesis, which would occur over sev¬
eral hours. Cells were cultured in the presence ofBt2cAMP for
the time points indicated before Bt2cAMP was removed from
culture by gently washing in PBS and then returned to normal
culture conditions. Bt2cAMP was required to be continually
present in culture to suppress neutrophil apoptosis (Fig. 8A).
However, Bt2cAMP rescued neutrophils from apoptosis when
added at later time points (Fig. 8B). We are investigating
whether the effects of cyclic AMP occur when the rate of apo¬
ptosis is high (between 8 and 20 h). However, during constitu¬
tive apoptosis, cells at different stages of the apoptotic program
are present in the population at any one time point. We are
currently investigating whether synchronous apoptosis trig¬
gered by Fas ligation, tumor necrosis factor-a (26), or temper¬
ature shift (15) can be modulated by cyclic AMP. Taken to¬
gether, our results suggest that Bt2cAMP exerts a powerful
direct signaling mechanism, independent of new protein syn¬
thesis, to suppress neutrophil apoptosis, and this suppression
is rapidly lost when Bt2cAMP is removed from culture.
Proteasome Inhibitors Are Able to Reverse Retardation of
Neutrophil Apoptosis by RtwAMP—The ubiquitin/proteasome
system plays an important role in the degradation of cellular
proteins that regulate various cellular processes, including
apoptosis. The observations above reveal Bt2cAMP delays neu¬
trophil apoptosis independently of new protein synthesis, sug¬
gesting that Bt2cAMP is unlikely to stimulate the production of
a survival protein. Thus we examined whether alternatively
Bt2cAMP was accelerating the degradation or modification of
pro-death proteins within the neutrophil to increase survival.
Neutrophils were co-incubated with Bt2cAMP and the irrevers¬
ible proteasome inhibitors lactacystin (10 /xm) (45) and ep-
oxomicin (10 p.M) (46) for 20 h (Fig. 9, A and B). Both protea¬
some inhibitors eliminated the delay of neutrophil apoptosis
induced by Bt2cAMP.
DISCUSSION
Human neutrophils undergo apoptosis, a process that is cen¬
trally important in the resolution of inflammation. It has been
shown previously that cyclic AMP is an important regulator of
neutrophil apoptosis (18-20), yet little is known of the signal¬
ing mechanism by which by cyclic AMP controls neutrophil cell
death. The studies herein have established that cyclic AMP
acts upstream of caspase-3 activation to inhibit the apoptotic
pathway in neutrophils. For the first time, it was also demon¬
strated that neutrophils contain a small but significant number
of mitochondria, which exhibit a loss of membrane potential








Fig. 9. Effects of proteasome inhibitors on Bt2cAMP (db-
cAMP)-mediated delay of neutrophil apoptosis. Human neutro¬
phils (5 X 106/mi) were cultured in Iscove's DMEM containing 10%
autologous serum at 37 °C and treated with lactacystin (10 pM, A) or
epoxomicin (10 pM, B) with or without Bt2cAMP (0.2 mM). After 20 h in
culture, the cells were incubated with FITC-labeled recombinant hu¬
man annexin V to determine phosphatidylserine expression. The cells
were then analyzed by flow cytometry using a FACSCalibur and asso¬
ciated CellQuest software. Data from a minimum of 5000 cells were
analyzed for each condition. All values represent mean ± S.E. of n = 3
experiments, each performed in duplicate where significant difference
from control is represented by *p < 0.001. Significant difference from
Bt2cAMP alone represented by #p < 0.001 or ±p < 0.01.
AMP elevation. We are currently investigating whether loss of
mitochondrial membrane potential occurs before other indices
of apoptosis in neutrophils, such as phosphatidylserine expo¬
sure and nuclear condensation. This would help ascertain
whether loss ofmitochondrial potential during neutrophil apo¬
ptosis, shown to trigger apoptosis in other cell types, has a
similar function in neutrophils and whether Bt2cAMP can di¬
rectly affect loss of mitochondrial potential to delay neutrophil
apoptosis.
It has been suggested that PKA plays an important role in
cyclic AMP-mediated delay of neutrophil apoptosis (18-20). It
is known that cyclic AMP analogs, which selectively activate
type I PKA, attenuate neutrophil apoptosis, compared with
analogs that preferentially activate type II PKA suggesting
that that type I PKA is necessary and sufficient to mediate the
cyclic AMP-induced delay in human neutrophil apoptosis (19).
We suggest, alternatively, that PKA activation by cyclic AMP is
not responsible for the major apoptosis-retarding influences of
cyclic AMP in neutrophils. Indeed, we have demonstrated di¬
rectly that cyclic AMP elevation in neutrophils stimulates an
cAMP Regulator Neutrophil Apoptosis via a Novel Pathway 45049
increase in PKA activity, which is blocked by pharmacological
inhibitors. Importantly, however, blockade of PKA was not
sufficient to reverse the anti-apoptotic effect of cyclic AMP,
implying that this molecule has little or no role in the cyclic
AMP signaling pathway responsible for delay of neutrophil
apoptosis.
Previous publications (18, 19) have implicated a role for PKA
in cyclic AMP regulation of neutrophil apoptosis using concen¬
trations of H89 greater than 10 pM. The specificity of H89 at
these concentrations is questionable, and it has been published
(47) that H89 may inhibit several other kinases, some with
potency similar to or greater than that for PKA. We propose
that failure to directly measure PKA activity together with the
use of high and possibly nonspecific concentrations of H89
could have led to misinterpretation of previous data. We have
demonstrated that 10 /j.m H89 is sufficient to block PKA activ¬
ity for extended culture periods and is active in the presence of
autologous serum. The failure therefore of both H89 and (Rp)-
8-Br-cAMPS, a highly specific inhibitor of PKA, to reverse
cyclic AMP-mediated delay of neutrophil apoptosis points to a
novel signaling pathway used by cyclic AMP to inhibit neutro¬
phil apoptosis, which is independent of PKA activation.
There have been a few studies reporting PKA-independent
effects of cyclic AMP; however, little has been elucidated of the
alternative signaling pathways downstream of cyclic AMP.
Pharmacological blockade of the MAPK and PI 3-kinase signal¬
ing cascades in this study suggest that neither of these signal¬
ing pathways are likely to be important in the cyclic AMP-
mediated delay of neutrophil apoptosis. There has been
interest in the discovery that cyclic AMP can bind specifically
to and activate small guanine nucleotide exchange factors
which, when bound by cyclic AMP, activate the small Ras-like
GTPase, Rapl (48, 49). The biological function of Rapl is still
unclear, but it has been proposed that activation of this small
GTPase may feed into MAPK signaling pathways (50). As an
approach to establishing if Rapl has a role in cyclic AMP-
mediated delay of neutrophil apoptosis, we have blocked Rapl
activity using the Clostridium sordellii lethal toxin, which has
been reported to inhibit specifically the small GTPases Rapl,
Ras, and Rac (51). Furthermore, we have tested GGTI-286, a
geranylgeranyltransferase inhibitor, which blocks gera-
nylgeranylation required by Rapl to achieve its mature, bio¬
logically active form (52). Thus our preliminary experiments
suggest that Rapl is not involved in cyclic AMP-mediated delay
of neutrophil apoptosis (data not shown): however, this area of
research is still under investigation. Our studies are in accord
with a very recent publication that demonstrates that cyclic
AMP-dependent inhibition of interleukin-5 from human T lym¬
phocytes is not mediated by PKA or by the Rapl signaling
pathway (53).
Regulation of neutrophil apoptosis is thought to depend on
the balance between pro-apoptotic and anti-apoptotic death
factors expressed in the cell (17, 54). Neutrophils contain death
regulator proteins, including Bax and Bad, and also express
some members of the anti-apoptotic family such as Mcl-1 and
Bcl-xL but not Bcl-2 (17, 54). It has been proposed that neutro¬
phil longevity may be prolonged by the synthesis of anti-apo¬
ptotic proteins such as Mcl-1 (55). However, it is unlikely that
cyclic AMP effects are mediated by such a mechanism in the
retardation of neutrophil apoptosis since we have demon¬
strated that cyclic AMP-mediated delay ofneutrophil apoptosis
does not require gene transcription. Furthermore, "wash out"
experiments have revealed that retardation of neutrophil apo¬
ptosis is rapidly lost when Bt2cAMP is removed from culture,
even after incubation periods that should permit new protein
synthesis.
Together, these data suggest a mechanism whereby cyclic
AMP does not stimulate production of a survival protein but
may alternatively induce post-transitional modifications in the
neutrophil to promote survival. One potential mechanism for
cyclic AMP-mediated retardation of neutrophil apoptosis may
involve cyclic AMP specifically targeting a death protein(s) to
the proteasome for degradation. We have demonstrated that
blockade ofproteasome activity results in a dramatic loss of the
pro-survival effect of cyclic AMP. We speculate that cyclic AMP
may be involved in the post-translational modification of a
death protein, which targets the neutrophil proteasome. If cy¬
clic AMP stimulation is removed or proteasome activity is
blocked, then the accumulation of a death protein(s) would be
predicted to permit the constitutive death pathway of neutro¬
phils to be reconstituted. Further characterization of protea¬
some activity in this signaling pathway and possible death
protein targets ofcyclic AMP are currently under investigation.
In conclusion, cyclic AMP delays neutrophil apoptosis via a
novel, reversible, and transcriptionally independent mecha¬
nism. Our results contest the dogma that cyclic AMP exerts is
physiological functions almost entirely through activation of
PKA, and we are currently investigating the involvement of
novel downstream signaling pathways in cyclic AMP regula¬
tion of neutrophil cell death.
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